
<html lang="en"     class="pb-page"  data-request-id="a4a7b970-d05e-4848-8cda-b8bcf44c4580"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2016.59.issue-7;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.6b00276;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Synthesis of α,β-Unsaturated Carbonyl-Based Compounds, Oxime and Oxime Ether Analogs as Potential Anticancer Agents for Overcoming Cancer Multidrug Resistance by Modulation of Efflux Pumps in Tumor Cells" /></meta><meta name="dc.Creator" content="Hua-Li  Qin" /></meta><meta name="dc.Creator" content="Jing  Leng" /></meta><meta name="dc.Creator" content="Cheng-Pan  Zhang" /></meta><meta name="dc.Creator" content="Ibrahim  Jantan" /></meta><meta name="dc.Creator" content="Muhammad Wahab  Amjad" /></meta><meta name="dc.Creator" content="Muhammad  Sher" /></meta><meta name="dc.Creator" content="Muhammad  Naeem-ul-Hassan" /></meta><meta name="dc.Creator" content="Muhammad Ajaz  Hussain" /></meta><meta name="dc.Creator" content="Syed Nasir Abbas  Bukhari" /></meta><meta name="dc.Description" content="Sixty-nine novel α,β-unsaturated carbonyl based compounds, including cyclohexanone, tetralone, oxime, and oxime ether analogs, were synthesized. The antiproliferative activity determined by using s..." /></meta><meta name="Description" content="Sixty-nine novel α,β-unsaturated carbonyl based compounds, including cyclohexanone, tetralone, oxime, and oxime ether analogs, were synthesized. The antiproliferative activity determined by using s..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 4, 2016" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b00276" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2016 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00276" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b00276" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00276" /></link>
        
    
    

<title>Synthesis of α,β-Unsaturated Carbonyl-Based Compounds, Oxime and Oxime Ether Analogs as Potential Anticancer Agents for Overcoming Cancer Multidrug Resistance by Modulation of Efflux Pumps in Tumor Cells | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b00276" /></meta><meta property="og:title" content="Synthesis of α,β-Unsaturated Carbonyl-Based Compounds, Oxime and Oxime Ether Analogs as Potential Anticancer Agents for Overcoming Cancer Multidrug Resistance by Modulation of Efflux Pumps in Tumor Cells" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00276/20160414/images/large/jm-2016-00276j_0008.jpeg" /></meta><meta property="og:description" content="Sixty-nine novel α,β-unsaturated carbonyl based compounds, including cyclohexanone, tetralone, oxime, and oxime ether analogs, were synthesized. The antiproliferative activity determined by using seven different human cancer cell lines provided a structure–activity relationship. Compound 8ag exhibited high antiproliferative activity against Panc-1, PaCa-2, A-549, and PC-3 cell lines, with IC50 value of 0.02 μM, comparable to the positive control Erlotinib. The ten most active antiproliferative compounds were assessed for mechanistic effects on BRAFV600E, EGFR TK kinases, and tubulin polymerization, and were investigated in vitro to reverse efflux-mediated resistance developed by cancer cells. Compound 8af exhibited the most potent BRAFV600E inhibitory activity with an IC50 value of 0.9 μM. Oxime analog 7o displayed the most potent EGFR TK inhibitory activity with an IC50 of 0.07 μM, which was analogous to the positive control. Some analogs including 7f, 8af, and 8ag showed a dual role as anticancer and MDR reversal agents." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b00276"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b00276">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b00276&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b00276&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b00276&amp;href=/doi/10.1021/acs.jmedchem.6b00276" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 7</span><span class="cit-fg-pageRange">, 3549-3561</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/7" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b00213" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.5b01828" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Synthesis of α,β-Unsaturated Carbonyl-Based Compounds, Oxime and Oxime Ether Analogs as Potential Anticancer Agents for Overcoming Cancer Multidrug Resistance by Modulation of Efflux Pumps in Tumor Cells</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hua-Li++Qin">Hua-Li Qin</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jing++Leng">Jing Leng</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Cheng-Pan++Zhang">Cheng-Pan Zhang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ibrahim++Jantan">Ibrahim Jantan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Muhammad+Wahab++Amjad">Muhammad Wahab Amjad</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Muhammad++Sher">Muhammad Sher</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Muhammad++Naeem-ul-Hassan">Muhammad Naeem-ul-Hassan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Muhammad+Ajaz++Hussain">Muhammad Ajaz Hussain</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Syed+Nasir+Abbas++Bukhari">Syed Nasir Abbas Bukhari</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Department of Pharmaceutical Engineering, School of Chemistry, Chemical Engineering and Life Science, Wuhan University of Technology, 205 Luoshi Road, Wuhan 430070, P.R. China</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Drug and Herbal Research Centre, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300 Kuala Lumpur, Malaysia</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Department of Chemistry, University of Sargodha, Sargodha 40100, Pakistan</span></div><div class="corresp-info"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#58293136302d393431182f302d2c763d3c2d763b36"><span class="__cf_email__" data-cfemail="14657d7a7c6175787d54637c61603a7170613a777a">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#88fbe6e9eac8fde3e5a6edecfda6e5f1"><span class="__cf_email__" data-cfemail="d3a0bdb2b193a6b8befdb6b7a6fdbeaa">[email protected]</span></a>; <a href="/cdn-cgi/l/email-protection#bccfd2dddeccd4d8fcc5ddd4d3d392dfd3d1"><span class="__cf_email__" data-cfemail="74071a1516041c10340d151c1b1b5a171b19">[email protected]</span></a>. Tel: +6-01123695295. Fax: +6-0326983271.</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00276&amp;href=/doi/10.1021%2Facs.jmedchem.6b00276" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 7</span><span class="cit-pageRange">, 3549–3561</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 24, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>20 February 2016</li><li><span class="item_label"><b>Published</b> online</span>4 April 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 April 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b00276" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00276</a></div><div class="article_header-article-copyright"><strong>Copyright © 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D3549%26pageCount%3D13%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DHua-Li%2BQin%252C%2BJing%2BLeng%252C%2BCheng-Pan%2BZhang%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D7%26contentID%3Dacs.jmedchem.6b00276%26title%3DSynthesis%2Bof%2B%25CE%25B1%252C%25CE%25B2-Unsaturated%2BCarbonyl-Based%2BCompounds%252C%2BOxime%2Band%2BOxime%2BEther%2BAnalogs%2Bas%2BPotential%2BAnticancer%2BAgents%2Bfor%2BOvercoming%2BCancer%2BMultidrug%2BResistance%2Bby%2BModulation%2Bof%2BEfflux%2BPumps%2Bin%2BTumor%2BCells%26numPages%3D13%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D3561%26publicationDate%3DApril%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b00276"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1438</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">51</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b00276" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Synthesis of α,β-Unsaturated Carbonyl-Based Compounds, Oxime and Oxime Ether Analogs as Potential Anticancer Agents for Overcoming Cancer Multidrug Resistance by Modulation of Efflux Pumps in Tumor Cells&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Hua-Li&quot;,&quot;last_name&quot;:&quot;Qin&quot;},{&quot;first_name&quot;:&quot;Jing&quot;,&quot;last_name&quot;:&quot;Leng&quot;},{&quot;first_name&quot;:&quot;Cheng-Pan&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Ibrahim&quot;,&quot;last_name&quot;:&quot;Jantan&quot;},{&quot;first_name&quot;:&quot;Muhammad&quot;,&quot;last_name&quot;:&quot;Wahab Amjad&quot;},{&quot;first_name&quot;:&quot;Muhammad&quot;,&quot;last_name&quot;:&quot;Sher&quot;},{&quot;first_name&quot;:&quot;Muhammad&quot;,&quot;last_name&quot;:&quot;Naeem-ul-Hassan&quot;},{&quot;first_name&quot;:&quot;Muhammad&quot;,&quot;last_name&quot;:&quot;Ajaz Hussain&quot;},{&quot;first_name&quot;:&quot;Syed&quot;,&quot;last_name&quot;:&quot;Nasir Abbas Bukhari&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;04&quot;,&quot;issue&quot;:&quot;7&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;3549-3561&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b00276&quot;},&quot;abstract&quot;:&quot;Sixty-nine novel α,β-unsaturated carbonyl based compounds, including cyclohexanone, tetralone, oxime, and oxime ether analogs, were synthesized. The antiproliferative activity determined by using seven different human cancer cell lines provided a structure–activity relationship. Compound 8ag exhibited high antiproliferative activity against Panc-1, PaCa-2, A-549, and PC-3 cell lines, with IC50 value of 0.02 μM, comparable to the positive control Erlotinib. The ten most active antiproliferative compounds were assessed for mechanistic effects on BRAFV600E, EGFR TK kinases, and tubulin polymerization, and were investigated in vitro to reverse efflux-mediated resistance developed by cancer cells. Compound 8af exhibited the most potent BRAFV600E inhibitory activity with an IC50 value of 0.9 μM. Oxime analog 7o displayed the most potent EGFR TK inhibitory activity with an IC50 of 0.07 μM, which was analogous to the positive control. Some analogs including 7f, 8af, and 8ag showed a dual role as anticancer and MDR re&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00276&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00276" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00276&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00276" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00276&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00276" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00276&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00276&amp;href=/doi/10.1021/acs.jmedchem.6b00276" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b00276" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b00276" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (1 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b00276%26sid%3Dliteratum%253Aachs%26pmid%3D27010345%26genre%3Darticle%26aulast%3DQin%26date%3D2016%26atitle%3DSynthesis%2Bof%2B%25CE%25B1%252C%25CE%25B2-Unsaturated%2BCarbonyl-Based%2BCompounds%252C%2BOxime%2Band%2BOxime%2BEther%2BAnalogs%2Bas%2BPotential%2BAnticancer%2BAgents%2Bfor%2BOvercoming%2BCancer%2BMultidrug%2BResistance%2Bby%2BModulation%2Bof%2BEfflux%2BPumps%2Bin%2BTumor%2BCells%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D7%26spage%3D3549%26epage%3D3561%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292227" title="Drug resistance">Drug resistance</a>,</li><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/7" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/jmcmar.2016.59.issue-7/20160414-01/jmcmar.2016.59.issue-7.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00276/20160414/images/medium/jm-2016-00276j_0008.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00276/20160414/images/large/jm-2016-00276j_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00276&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Sixty-nine novel α,β-unsaturated carbonyl based compounds, including cyclohexanone, tetralone, oxime, and oxime ether analogs, were synthesized. The antiproliferative activity determined by using seven different human cancer cell lines provided a structure–activity relationship. Compound <b>8ag</b> exhibited high antiproliferative activity against Panc-1, PaCa-2, A-549, and PC-3 cell lines, with IC<sub>50</sub> value of 0.02 μM, comparable to the positive control Erlotinib. The ten most active antiproliferative compounds were assessed for mechanistic effects on BRAF<sup>V600E</sup>, EGFR TK kinases, and tubulin polymerization, and were investigated <i>in vitro</i> to reverse efflux-mediated resistance developed by cancer cells. Compound <b>8af</b> exhibited the most potent BRAF<sup>V600E</sup> inhibitory activity with an IC<sub>50</sub> value of 0.9 μM. Oxime analog <b>7o</b> displayed the most potent EGFR TK inhibitory activity with an IC<sub>50</sub> of 0.07 μM, which was analogous to the positive control. Some analogs including <b>7f</b>, <b>8af</b>, and <b>8ag</b> showed a dual role as anticancer and MDR reversal agents.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76112" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76112" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">A sophisticated system of signaling pathways in multicellular organisms regulates cellular behavior and ensures that cells multiply only when they are needed by the body as a whole throughout healing or development. A defect in these signaling mechanisms leads to the breakdown of normal growth regulation, resulting in cancer. Multiple pathways and processes by which cancer arises from normal cells and tissues make it very challenging to develop anticancer agents possessing effects on all receptors, pathways, and signaling mechanisms. Moreover, the tumor cells adapt themselves, enhancing their resistance against chemotherapy to escape programmed death by activating antiapoptotic pathways, after recurrent treatment with anticancer chemotherapeutic agents.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4 ref5 ref6">(1-6)</a> In spite of the combination of chemotherapeutic agents used to prevent drug resistance, the cancer cells adapt and develop one or more drug resistance pathways eventually leading to failure in the treatment of cancer.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7, 8)</a> Some key targets for treatment of cancer and multidrug resistance (MDR) in cancer cells are described below.</div><div class="NLM_p">A transmembrane glycoprotein, epidermal growth factor receptor (EGFR), belongs to the erbB family of closely linked cell membrane receptors that includes EGFR (erbB-1 or HER1), erbB-2 (HER2), erbB-3 (HER3), and erbB-4 (HER4).<a onclick="showRef(event, 'ref9 ref10 ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11 ref12 ref13">(9-13)</a> Many human solid tumors, including head and neck, colorectal, nonsmall cell lung (NSCLC), ovarian, and breast cancers exhibit the expression, overexpression, or dysregulation of EGFR.<a onclick="showRef(event, 'ref14 ref15 ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16 ref17 ref18">(14-18)</a> The activation of EGFR might support the growth of a tumor by increasing motility, cell proliferation,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> invasive capacity, and adhesion,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> and by inhibiting apoptosis.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> The importance of controlling EGFR signaling as a cancer treatment strategy has been demonstrated recently by the wide-ranging collection of molecular inhibitors that have been developed and are undergoing clinical trials.</div><div class="NLM_p">The RAS-RAF-MEK-ERK is a rapidly activated downstream pathway of receptor tyrosine kinases (RTK) which controls a number of cell responses to extracellular signals.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> The pathway constitutively activates in cancer (particularly melanoma) and triggers propagation, survival, and tumor development. A total of 3 <i>RAF</i> (<i>ARAF</i>, <i>BRAF</i>, and <i>CRAF)</i> and 3 <i>RAS</i> (<i>NRAS, KRAS</i>, and <i>HRAS</i>) genes are found in humans, and critically, <i>BRAF, KRAS</i>, and <i>NRAS</i> are mutated in 45%, 2%, and 20% of the melanomas, respectively.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> The cancer-cell proliferation and survival are stimulated by <i>BRAF</i><sup><i>V600E</i></sup> via signaling through the mitogen-activated protein kinase (MAPK) pathway.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> The development of oncogenic BRAF inhibitors, specifically type I BRAF inhibitors, that block the active conformation of BRAF kinase, has resulted in a great degree of objective tumor responses and enhancement in overall survival, in contrast to standard chemotherapy.<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25, 26)</a></div><div class="NLM_p">Chemotherapy is among the most vital approaches for the treatment of cancers. However, successful cancer chemotherapy is hindered by MDR in cancer cells.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> The mechanism behind the development of resistance to anticancer drugs by cancer cells is complex. Up until now, the best categorized mechanism of MDR comprises the overexpression of ATP-binding cassette (ABC) transporter Pgp (also referred to as ABCB1, MDR1) on cell membranes of tumor cells. A wide range of structurally different anticancer drugs can be effluxed out of the cell by Pgp, thus lowering their intracellular levels and therapeutic efficacy.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> MDR can be reversed by the inhibition of this efflux mechanism. The complications in chemotherapy can be overcome by the development of pharmacological modulators or agents of MDR efflux pumps that reverse multidrug resistance.</div><div class="NLM_p">Several natural and synthetic α,β-unsaturated carbonyl based compounds including chalcones, curcumin, and their synthetic analogs are recognized to show antitumor activities.<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29, 30)</a> The ketone functional group of these compounds has been postulated to work in cancer chemotherapy by thiol alkylation without any reactivity toward cellular hydroxyl or amino groups, and thus, due to this reactivity, enones may have potential benefit over conventional alkylators as these compounds are predicted to have fewer genotoxic effects, related with many anticancer drugs.<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31, 32)</a> Furthermore, the antitumor activity of enone containing materials is associated with numerous effects such as inhibition of NF-kappaB (NF-kB)<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> and mitochondrial mediated pathways,<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> triggering of death receptors (DRS) of tumor necrosis factor (TFN),<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> inhibition of cyclin-dependent kinases<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> or DNA topoisomerase II,<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> and so on. Therefore, the synthesis of novel α,β-unsaturated ketones is presently of high importance. Most of the research on α,β-unsaturated carbonyl based compounds as chalcones and curcumin analogs is focused on the evaluation against cancer, and comparatively less is known of their capability to reverse MDR. More information is required to explain whether the lack of a β-diketone group affects the capability of these compounds to inhibit ABC transporters and if these compounds can be better chemotherapeutic agents possessing dual properties as anticancer and efficient MDR reversal agents.</div><div class="NLM_p last">In the current study, we extended our formerly reported work<a onclick="showRef(event, 'ref30 ref38'); return false;" href="javascript:void(0);" class="ref ref30 ref38">(30, 38)</a> by synthesizing 54 new α,β-unsaturated carbonyl based compounds and evaluating their anticancer potential on human cancer cell lines. Among these compounds, the 10 most active were designated as precursors for further synthesis to their oxime derivatives. The anticancer activity of all new oxime derivatives was evaluated and the 5 most active oxime analogs were then selected for additional synthesis as oxime ether analogs. From all 69 new compounds, the 10 most potent were selected for anticancer mechanistic studies, for their effects on BRAF<sup>V600E</sup>, EGFR TK kinases, and tubulin polymerization, and were tested <i>in vitro</i> to reverse efflux mediated resistance developed by cancer cells.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48408" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48408" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Chemistry</h3><div class="NLM_p">Sixty-nine novel compounds of four different types including cyclohexanone, tetralone, oxime, and oxime ether backbone were synthesized in the current study as reported previously<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> (<a class="ref internalNav" href="#tbl1" aria-label="Tables 1">Tables 1</a>, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>, and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). To synthesize the desired α,β-unsaturated carbonyl based compounds, Claisene Schmidt condensation was used between different ketones and suitable aryl aldehydes at a molar ratio 1:2 for cyclohexanone derivatives (<b>4a</b>–<b>u</b>) and at a molar ratio 1:1 for tetralone derivatives (<b>5a</b>–<b>ag</b>) (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). All synthesized compounds were characterized by using various analytical techniques and characterization data of compounds including melting point (MP), <sup>1</sup>H NMR, <sup>13</sup>C NMR, HRMS, microanalysis (CHNS) is provided in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>. All compounds have a purity grade ≥95%.</div><figure id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00276/20160414/images/medium/jm-2016-00276j_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00276/20160414/images/large/jm-2016-00276j_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis Scheme of α,β-Unsaturated Carbonyl Based Compounds, Oxime, and Oxime Ether Analogs<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00276/20160414/images/large/jm-2016-00276j_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00276&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) NaOH, EtOH, room temperature; (ii) NH<sub>2</sub>OH.HCl, pyridine, ethanol, anhyd., reflux; (iii) haloalkylamine (<b>9</b>), K<sub>2</sub>CO<sub>3</sub>, acetone/DMF, anhyd., reflux.</p></p></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Structures of New Synthetic α,β-Unsaturated Carbonyl Based Compounds (Cyclohexanone Derivatives)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00276/20160414/images/medium/jm-2016-00276j_0004.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00276/20160414/images/medium/jm-2016-00276j_0005.gif" alt="" id="fx2" /></img><div></div></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Structures of New Synthetic α,β-Unsaturated Carbonyl Based Compounds (Tetralone Derivatives)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00276/20160414/images/medium/jm-2016-00276j_0006.gif" alt="" id="fx3" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">no.</th><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center">R<sub>1</sub></th><th class="colsep0 rowsep0" align="center">R<sub>2</sub></th><th class="colsep0 rowsep0" align="center">R<sub>3</sub></th><th class="colsep0 rowsep0" align="center">R<sub>4</sub></th><th class="colsep0 rowsep0" align="center">R<sub>5</sub></th><th class="colsep0 rowsep0" align="center">R′<sub>3</sub></th><th class="colsep0 rowsep0" align="center">R′<sub>4</sub></th><th class="colsep0 rowsep0" align="center">R′<sub>6</sub></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">22.</td><td class="colsep0 rowsep0" align="left"><b>5a</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cl</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">23.</td><td class="colsep0 rowsep0" align="left"><b>5b</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">Cl</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">24.</td><td class="colsep0 rowsep0" align="left"><b>5c</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">Br</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">25.</td><td class="colsep0 rowsep0" align="left"><b>5d</b></td><td class="colsep0 rowsep0" align="left">CH–CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cl</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">26.</td><td class="colsep0 rowsep0" align="left"><b>5e</b></td><td class="colsep0 rowsep0" align="left">CH–CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">Cl</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">27.</td><td class="colsep0 rowsep0" align="left"><b>5f</b></td><td class="colsep0 rowsep0" align="left">CH–CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">Br</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">28.</td><td class="colsep0 rowsep0" align="left"><b>5g</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cl</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">29.</td><td class="colsep0 rowsep0" align="left"><b>5h</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">Cl</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">30.</td><td class="colsep0 rowsep0" align="left"><b>5i</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">Br</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">31.</td><td class="colsep0 rowsep0" align="left"><b>5j</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cl</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">32.</td><td class="colsep0 rowsep0" align="left"><b>5k</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">Cl</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">33.</td><td class="colsep0 rowsep0" align="left"><b>5l</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">Br</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">34.</td><td class="colsep0 rowsep0" align="left"><b>5m</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cl</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">35.</td><td class="colsep0 rowsep0" align="left"><b>5n</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">Cl</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">36.</td><td class="colsep0 rowsep0" align="left"><b>5o</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">Br</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">37.</td><td class="colsep0 rowsep0" align="left"><b>5p</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cl</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">38.</td><td class="colsep0 rowsep0" align="left"><b>5q</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">Cl</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">39.</td><td class="colsep0 rowsep0" align="left"><b>5r</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">Br</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">40.</td><td class="colsep0 rowsep0" align="left"><b>5s</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cl</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">41.</td><td class="colsep0 rowsep0" align="left"><b>5t</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">Cl</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">42.</td><td class="colsep0 rowsep0" align="left"><b>5u</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">Br</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">43.</td><td class="colsep0 rowsep0" align="left"><b>5v</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cl</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">44.</td><td class="colsep0 rowsep0" align="left"><b>5w</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">Cl</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">45.</td><td class="colsep0 rowsep0" align="left"><b>5x</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">Br</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">46.</td><td class="colsep0 rowsep0" align="left"><b>5y</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Br</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cl</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">47.</td><td class="colsep0 rowsep0" align="left"><b>5z</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Br</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">Cl</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">48.</td><td class="colsep0 rowsep0" align="left"><b>5aa</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Br</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">Br</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">49.</td><td class="colsep0 rowsep0" align="left"><b>5ab</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cl</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">50.</td><td class="colsep0 rowsep0" align="left"><b>5ac</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">Cl</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">51.</td><td class="colsep0 rowsep0" align="left"><b>5ad</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">Br</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">52.</td><td class="colsep0 rowsep0" align="left"><b>5ae</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">NO<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cl</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">53.</td><td class="colsep0 rowsep0" align="left"><b>5af</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">NO<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">Cl</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">54.</td><td class="colsep0 rowsep0" align="left"><b>5ag</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">NO<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">Br</td></tr></tbody></table></div></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Structures of New Synthetic Oxime and Oxime Ether Analogs</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00276/20160414/images/medium/jm-2016-00276j_0007.gif" alt="" id="fx4" /></img><div></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Cell Viability Assay</h3><div class="NLM_p">Human mammary gland epithelial cell line (MCF-10A) was used to perform the cell viability assay. The MCF-10A cells were treated with the synthesized compounds for 4 days and a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to measure the viability of cells. The findings are presented according to the toxicity percentage (<a class="ref internalNav" href="#tbl4" aria-label="Tables 4">Tables 4</a>, <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>, and <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>). All compounds were discovered to be nontoxic with most of them exhibiting more than 90% cell viability.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Inhibitory Effects of Synthetic Cyclohexanone Derivatives on the Growth of Normal (MCF-10A) Mammary Epithelial Cells (Cell Viability) And Different Types of Human Cancer Cells<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="7" align="center" char="±">antiproliferative activity IC<sub>50</sub>  ± SEM (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center">cell viability %</th><th class="colsep0 rowsep0" align="center" char="±">Panc-1</th><th class="colsep0 rowsep0" align="center" char="±">PaCa-2</th><th class="colsep0 rowsep0" align="center" char="±">MCF-7</th><th class="colsep0 rowsep0" align="center" char="±">A-549</th><th class="colsep0 rowsep0" align="center" char="±">HT-29</th><th class="colsep0 rowsep0" align="center" char="±">H-460</th><th class="colsep0 rowsep0" align="center" char="±">PC-3</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4a</b></td><td class="colsep0 rowsep0" align="left">90</td><td class="colsep0 rowsep0" align="char" char="±">6.9 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">7.2 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">6.5 ± 2.1</td><td class="colsep0 rowsep0" align="char" char="±">8.1 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">6.1 ± 2.9</td><td class="colsep0 rowsep0" align="char" char="±">5.4 ± 2.7</td><td class="colsep0 rowsep0" align="char" char="±">6.4 ± 0.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4b</b></td><td class="colsep0 rowsep0" align="left">90</td><td class="colsep0 rowsep0" align="char" char="±">4.2 ± 2.1</td><td class="colsep0 rowsep0" align="char" char="±">4.2 ± 1.6</td><td class="colsep0 rowsep0" align="char" char="±">4.7 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">3.9 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">3.7 ± 1.9</td><td class="colsep0 rowsep0" align="char" char="±">4.1 ± 6.5</td><td class="colsep0 rowsep0" align="char" char="±">5.2 ± 0.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4c</b></td><td class="colsep0 rowsep0" align="left">89</td><td class="colsep0 rowsep0" align="char" char="±">2.4 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">2.6 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">3.1 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">2.6 ± 1.7</td><td class="colsep0 rowsep0" align="char" char="±">2.0 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">2.6 ± 4.4</td><td class="colsep0 rowsep0" align="char" char="±">2.9 ± 1.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4d</b></td><td class="colsep0 rowsep0" align="left">93</td><td class="colsep0 rowsep0" align="char" char="±">3.3 ± 2.9</td><td class="colsep0 rowsep0" align="char" char="±">2.9 ± 2.6</td><td class="colsep0 rowsep0" align="char" char="±">2.8 ± 2.2</td><td class="colsep0 rowsep0" align="char" char="±">3.1 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">3.4 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">4.2 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">3.9 ± 0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4e</b></td><td class="colsep0 rowsep0" align="left">94</td><td class="colsep0 rowsep0" align="char" char="±">3.2 ± 1.7</td><td class="colsep0 rowsep0" align="char" char="±">3.0 ± 1.1</td><td class="colsep0 rowsep0" align="char" char="±">3.2 ± 2.8</td><td class="colsep0 rowsep0" align="char" char="±">4.4 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">2.9 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">2.9 ± 0.7</td><td class="colsep0 rowsep0" align="char" char="±">3.7 ± 2.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4f</b></td><td class="colsep0 rowsep0" align="left">91</td><td class="colsep0 rowsep0" align="char" char="±">1.6 ± 0.7</td><td class="colsep0 rowsep0" align="char" char="±">1.4 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">1.3 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">1.8 ± 2.2</td><td class="colsep0 rowsep0" align="char" char="±">1.8 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">1.2 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">1.1 ± 1.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4g</b></td><td class="colsep0 rowsep0" align="left">93</td><td class="colsep0 rowsep0" align="char" char="±">14.5 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">16.7 ± 0.7</td><td class="colsep0 rowsep0" align="char" char="±">15.2 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">13.4 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">12.1 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">13.9 ± 1.8</td><td class="colsep0 rowsep0" align="char" char="±">14.1 ± 2.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4h</b></td><td class="colsep0 rowsep0" align="left">87</td><td class="colsep0 rowsep0" align="char" char="±">12.2 ± 1.3</td><td class="colsep0 rowsep0" align="char" char="±">11.8 ± 1.1</td><td class="colsep0 rowsep0" align="char" char="±">11.9 ± 2.2</td><td class="colsep0 rowsep0" align="char" char="±">12.9 ± 2.1</td><td class="colsep0 rowsep0" align="char" char="±">13.2 ± 1.0</td><td class="colsep0 rowsep0" align="char" char="±">15.3 ± 2.3</td><td class="colsep0 rowsep0" align="char" char="±">12.6 ± 1.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4i</b></td><td class="colsep0 rowsep0" align="left">89</td><td class="colsep0 rowsep0" align="char" char="±">7.2 ± 2.2</td><td class="colsep0 rowsep0" align="char" char="±">7.5 ± 2.9</td><td class="colsep0 rowsep0" align="char" char="±">8.1 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">7.6 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">6.7 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">7.4 ± 2.3</td><td class="colsep0 rowsep0" align="char" char="±">7.2 ± 1.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4j</b></td><td class="colsep0 rowsep0" align="left">94</td><td class="colsep0 rowsep0" align="char" char="±">7.5 ± 1.1</td><td class="colsep0 rowsep0" align="char" char="±">7.7 ± 1.9</td><td class="colsep0 rowsep0" align="char" char="±">8.4 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">7.3 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">7.4 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">7.3 ± 4.1</td><td class="colsep0 rowsep0" align="char" char="±">7.6 ± 1.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4k</b></td><td class="colsep0 rowsep0" align="left">92</td><td class="colsep0 rowsep0" align="char" char="±">6.5 ± 1.6</td><td class="colsep0 rowsep0" align="char" char="±">6.2 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">6.4 ± 1.6</td><td class="colsep0 rowsep0" align="char" char="±">7.5 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">6.6 ± 1.7</td><td class="colsep0 rowsep0" align="char" char="±">7.2 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">7.0 ± 0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4l</b></td><td class="colsep0 rowsep0" align="left">96</td><td class="colsep0 rowsep0" align="char" char="±">4.2 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">4.3 ± 1.1</td><td class="colsep0 rowsep0" align="char" char="±">4.0 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">4.4 ± 1.7</td><td class="colsep0 rowsep0" align="char" char="±">4.5 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">4.9 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">4.8 ± 1.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4m</b></td><td class="colsep0 rowsep0" align="left">91</td><td class="colsep0 rowsep0" align="char" char="±">4.2 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">4.6 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">4.4 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">4.0 ± 2.2</td><td class="colsep0 rowsep0" align="char" char="±">4.4 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">4.0 ± 0.7</td><td class="colsep0 rowsep0" align="char" char="±">4.9 ± 1.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4n</b></td><td class="colsep0 rowsep0" align="left">90</td><td class="colsep0 rowsep0" align="char" char="±">3.4 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">3.2 ± 1.1</td><td class="colsep0 rowsep0" align="char" char="±">3.3 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">3.9 ± 1.8</td><td class="colsep0 rowsep0" align="char" char="±">3.8 ± 2.9</td><td class="colsep0 rowsep0" align="char" char="±">3.5 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">3.3 ± 1.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4o</b></td><td class="colsep0 rowsep0" align="left">92</td><td class="colsep0 rowsep0" align="char" char="±">1.8 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">1.9 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">1.9 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">1.3 ± 0.7</td><td class="colsep0 rowsep0" align="char" char="±">1.1 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">1.8 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">1.6 ± 0.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4p</b></td><td class="colsep0 rowsep0" align="left">89</td><td class="colsep0 rowsep0" align="char" char="±">17.5 ± 3.7</td><td class="colsep0 rowsep0" align="char" char="±">17.0 ± 1.1</td><td class="colsep0 rowsep0" align="char" char="±">17.6 ± 2.9</td><td class="colsep0 rowsep0" align="char" char="±">15.4 ± 2.2</td><td class="colsep0 rowsep0" align="char" char="±">15.9 ± 3.7</td><td class="colsep0 rowsep0" align="char" char="±">14.1 ± 3.9</td><td class="colsep0 rowsep0" align="char" char="±">18.7 ± 4.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4q</b></td><td class="colsep0 rowsep0" align="left">89</td><td class="colsep0 rowsep0" align="char" char="±">15.6 ± 1.7</td><td class="colsep0 rowsep0" align="char" char="±">15.5 ± 4.2</td><td class="colsep0 rowsep0" align="char" char="±">15.4 ± 4.9</td><td class="colsep0 rowsep0" align="char" char="±">16.2 ± 1.9</td><td class="colsep0 rowsep0" align="char" char="±">10.3 ± 2.4</td><td class="colsep0 rowsep0" align="char" char="±">13.9 ± 4.6</td><td class="colsep0 rowsep0" align="char" char="±">15.7 ± 5.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4r</b></td><td class="colsep0 rowsep0" align="left">91</td><td class="colsep0 rowsep0" align="char" char="±">12.2 ± 2.1</td><td class="colsep0 rowsep0" align="char" char="±">11.9 ± 2.4</td><td class="colsep0 rowsep0" align="char" char="±">12.8 ± 3.2</td><td class="colsep0 rowsep0" align="char" char="±">11.1 ± 3.8</td><td class="colsep0 rowsep0" align="char" char="±">12.0 ± 6.2</td><td class="colsep0 rowsep0" align="char" char="±">12.3 ± 1.8</td><td class="colsep0 rowsep0" align="char" char="±">14.6 ± 2.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4s</b></td><td class="colsep0 rowsep0" align="left">88</td><td class="colsep0 rowsep0" align="char" char="±">8.9 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">8.7 ± 2.2</td><td class="colsep0 rowsep0" align="char" char="±">7.3 ± 2.1</td><td class="colsep0 rowsep0" align="char" char="±">8.4 ± 2.9</td><td class="colsep0 rowsep0" align="char" char="±">8.8 ± 2.5</td><td class="colsep0 rowsep0" align="char" char="±">7.4 ± 1.6</td><td class="colsep0 rowsep0" align="char" char="±">8.3 ± 2.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4t</b></td><td class="colsep0 rowsep0" align="left">89</td><td class="colsep0 rowsep0" align="char" char="±">5.8 ± 1.3</td><td class="colsep0 rowsep0" align="char" char="±">5.2 ± 2.3</td><td class="colsep0 rowsep0" align="char" char="±">5.6 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">5.8 ± 3.2</td><td class="colsep0 rowsep0" align="char" char="±">5.1 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">5.3 ± 1.3</td><td class="colsep0 rowsep0" align="char" char="±">5.1 ± 1.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4u</b></td><td class="colsep0 rowsep0" align="left">92</td><td class="colsep0 rowsep0" align="char" char="±">4.9 ± 1.7</td><td class="colsep0 rowsep0" align="char" char="±">4.6 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">4.3 ± 1.9</td><td class="colsep0 rowsep0" align="char" char="±">4.1 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">4.2 ± 1.8</td><td class="colsep0 rowsep0" align="char" char="±">5.0 ± 2.3</td><td class="colsep0 rowsep0" align="char" char="±">4.6 ± 1.5</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">Panc-1 (pancreas cancer cell line), PaCa-2 (pancreatic carcinoma cell line), MCF-7 (breast cancer cell line), A-549 (epithelial), HT-29 (colon cancer cell line), H-460 (lung cancer cell line), PC-3 (prostate cancer cell line).</p></div></div></div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Inhibitory Effects of Synthetic Tetralone Derivatives on the Growth of Normal (MCF-10A) Mammary Epithelial Cells (Cell Viability) And Different Types of Human Cancer Cells<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="7" align="center" char="±">antiproliferative activity IC<sub>50</sub>  ± SEM (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center">cell viability %</th><th class="colsep0 rowsep0" align="center" char="±">Panc-1</th><th class="colsep0 rowsep0" align="center" char="±">PaCa-2</th><th class="colsep0 rowsep0" align="center" char="±">MCF-7</th><th class="colsep0 rowsep0" align="center" char="±">A-549</th><th class="colsep0 rowsep0" align="center" char="±">HT-29</th><th class="colsep0 rowsep0" align="center" char="±">H-460</th><th class="colsep0 rowsep0" align="center" char="±">PC-3</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5a</b></td><td class="colsep0 rowsep0" align="left">92</td><td class="colsep0 rowsep0" align="char" char="±">27.5 ± 1.8</td><td class="colsep0 rowsep0" align="char" char="±">27.9 ± 2.7</td><td class="colsep0 rowsep0" align="char" char="±">26.7 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">25.1 ± 3.9</td><td class="colsep0 rowsep0" align="char" char="±">28.2 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">25.1 ± 2.5</td><td class="colsep0 rowsep0" align="char" char="±">28.5 ± 3.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5b</b></td><td class="colsep0 rowsep0" align="left">96</td><td class="colsep0 rowsep0" align="char" char="±">24.5 ± 2.4</td><td class="colsep0 rowsep0" align="char" char="±">23.2 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">20.5 ± 1.7</td><td class="colsep0 rowsep0" align="char" char="±">23.3 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">26.5 ± 3.2</td><td class="colsep0 rowsep0" align="char" char="±">22.9 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">23.4 ± 2.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5c</b></td><td class="colsep0 rowsep0" align="left">94</td><td class="colsep0 rowsep0" align="char" char="±">21.3 ± 1.9</td><td class="colsep0 rowsep0" align="char" char="±">23.7 ± 1.9</td><td class="colsep0 rowsep0" align="char" char="±">20.4 ± 4.2</td><td class="colsep0 rowsep0" align="char" char="±">22.6 ± 1.0</td><td class="colsep0 rowsep0" align="char" char="±">21.2 ± 2.6</td><td class="colsep0 rowsep0" align="char" char="±">22.2 ± 5.6</td><td class="colsep0 rowsep0" align="char" char="±">22.0 ± 4.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5d</b></td><td class="colsep0 rowsep0" align="left">98</td><td class="colsep0 rowsep0" align="char" char="±">8.3 ± 2.4</td><td class="colsep0 rowsep0" align="char" char="±">9.8 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">8.8 ± 2.9</td><td class="colsep0 rowsep0" align="char" char="±">8.7 ± 1.3</td><td class="colsep0 rowsep0" align="char" char="±">8.4 ± 2.1</td><td class="colsep0 rowsep0" align="char" char="±">9.6 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">9.9 ± 1.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5e</b></td><td class="colsep0 rowsep0" align="left">99</td><td class="colsep0 rowsep0" align="char" char="±">7.5 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">7.2 ± 2.5</td><td class="colsep0 rowsep0" align="char" char="±">7.2 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">7.7 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">7.2 ± 2.5</td><td class="colsep0 rowsep0" align="char" char="±">7.9 ± 2.6</td><td class="colsep0 rowsep0" align="char" char="±">7.3 ± 1.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5f</b></td><td class="colsep0 rowsep0" align="left">92</td><td class="colsep0 rowsep0" align="char" char="±">2.4 ± 1.6</td><td class="colsep0 rowsep0" align="char" char="±">2.3 ± 3.5</td><td class="colsep0 rowsep0" align="char" char="±">2.1 ± 2.2</td><td class="colsep0 rowsep0" align="char" char="±">2.6 ± 1.8</td><td class="colsep0 rowsep0" align="char" char="±">2.9 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">2.2 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">2.4 ± 0.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5g</b></td><td class="colsep0 rowsep0" align="left">96</td><td class="colsep0 rowsep0" align="char" char="±">4.2 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">4.9 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">4.4 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">4.4 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">5.1 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">4.9 ± 1.8</td><td class="colsep0 rowsep0" align="char" char="±">5.2 ± 0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5h</b></td><td class="colsep0 rowsep0" align="left">91</td><td class="colsep0 rowsep0" align="char" char="±">3.6 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">3.2 ± 4.4</td><td class="colsep0 rowsep0" align="char" char="±">3.1 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">3.3 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">3.0 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">3.8 ± 2.5</td><td class="colsep0 rowsep0" align="char" char="±">3.5 ± 0.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5i</b></td><td class="colsep0 rowsep0" align="left">93</td><td class="colsep0 rowsep0" align="char" char="±">1.9 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">1.9 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">1.8 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">1.6 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">1.9 ± 1.6</td><td class="colsep0 rowsep0" align="char" char="±">1.9 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">2.2 ± 1.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5j</b></td><td class="colsep0 rowsep0" align="left">94</td><td class="colsep0 rowsep0" align="char" char="±">12.4 ± 1.8</td><td class="colsep0 rowsep0" align="char" char="±">12.8 ± 2.5</td><td class="colsep0 rowsep0" align="char" char="±">14.1 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">13.3 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">12.6 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">13.3 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">13.7 ± 0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5k</b></td><td class="colsep0 rowsep0" align="left">94</td><td class="colsep0 rowsep0" align="char" char="±">10.5 ± 3.1</td><td class="colsep0 rowsep0" align="char" char="±">9.5 ± 0.7</td><td class="colsep0 rowsep0" align="char" char="±">9.1 ± 2.1</td><td class="colsep0 rowsep0" align="char" char="±">10.7 ± 2.9</td><td class="colsep0 rowsep0" align="char" char="±">10.9 ± 4.6</td><td class="colsep0 rowsep0" align="char" char="±">10.6 ± 3.7</td><td class="colsep0 rowsep0" align="char" char="±">10.8 ± 2.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5l</b></td><td class="colsep0 rowsep0" align="left">90</td><td class="colsep0 rowsep0" align="char" char="±">10.2 ± 2.5</td><td class="colsep0 rowsep0" align="char" char="±">10.4 ± 2.4</td><td class="colsep0 rowsep0" align="char" char="±">12.9 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">10.7 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">9.9 ± 1.1</td><td class="colsep0 rowsep0" align="char" char="±">10.7 ± 1.7</td><td class="colsep0 rowsep0" align="char" char="±">10.2 ± 1.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5m</b></td><td class="colsep0 rowsep0" align="left">95</td><td class="colsep0 rowsep0" align="char" char="±">4.5 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">4.0 ± 2.1</td><td class="colsep0 rowsep0" align="char" char="±">5.1 ± 1.6</td><td class="colsep0 rowsep0" align="char" char="±">4.6 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">4.4 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">4.7 ± 0.7</td><td class="colsep0 rowsep0" align="char" char="±">4.7 ± 1.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5n</b></td><td class="colsep0 rowsep0" align="left">89</td><td class="colsep0 rowsep0" align="char" char="±">2.1 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">2.3 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">2.6 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">2.9 ± 2.6</td><td class="colsep0 rowsep0" align="char" char="±">2.7 ± 0.7</td><td class="colsep0 rowsep0" align="char" char="±">2.6 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">2.0 ± 1.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5o</b></td><td class="colsep0 rowsep0" align="left">90</td><td class="colsep0 rowsep0" align="char" char="±">1.4 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">1.6 ± 0.7</td><td class="colsep0 rowsep0" align="char" char="±">1.9 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">1.9 ± 1.1</td><td class="colsep0 rowsep0" align="char" char="±">1.5 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">1.9 ± 2.6</td><td class="colsep0 rowsep0" align="char" char="±">1.5 ± 1.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5p</b></td><td class="colsep0 rowsep0" align="left">93</td><td class="colsep0 rowsep0" align="char" char="±">8.5 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">8.7 ± 1.8</td><td class="colsep0 rowsep0" align="char" char="±">9.0 ± 1.1</td><td class="colsep0 rowsep0" align="char" char="±">6.4 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">8.4 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">9.0 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">8.4 ± 3.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5q</b></td><td class="colsep0 rowsep0" align="left">95</td><td class="colsep0 rowsep0" align="char" char="±">6.9 ± 2.4</td><td class="colsep0 rowsep0" align="char" char="±">6.7 ± 2.7</td><td class="colsep0 rowsep0" align="char" char="±">6.4 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">6.7 ± 4.2</td><td class="colsep0 rowsep0" align="char" char="±">6.7 ± 3.5</td><td class="colsep0 rowsep0" align="char" char="±">6.4 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">7.2 ± 1.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5r</b></td><td class="colsep0 rowsep0" align="left">94</td><td class="colsep0 rowsep0" align="char" char="±">4.2 ± 1.3</td><td class="colsep0 rowsep0" align="char" char="±">4.6 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">5.7 ± 2.2</td><td class="colsep0 rowsep0" align="char" char="±">4.5 ± 3.2</td><td class="colsep0 rowsep0" align="char" char="±">3.9 ± 2.8</td><td class="colsep0 rowsep0" align="char" char="±">4.7 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">3.9 ± 1.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5s</b></td><td class="colsep0 rowsep0" align="left">91</td><td class="colsep0 rowsep0" align="char" char="±">9.5 ± 2.1</td><td class="colsep0 rowsep0" align="char" char="±">9.9 ± 2.6</td><td class="colsep0 rowsep0" align="char" char="±">10.5 ± 4.9</td><td class="colsep0 rowsep0" align="char" char="±">9.2 ± 2.8</td><td class="colsep0 rowsep0" align="char" char="±">10.4 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">9.2 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">9.2 ± 1.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5t</b></td><td class="colsep0 rowsep0" align="left">97</td><td class="colsep0 rowsep0" align="char" char="±">5.4 ± 2.4</td><td class="colsep0 rowsep0" align="char" char="±">5.0 ± 1.1</td><td class="colsep0 rowsep0" align="char" char="±">5.4 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">5.4 ± 3.2</td><td class="colsep0 rowsep0" align="char" char="±">5.2 ± 1.6</td><td class="colsep0 rowsep0" align="char" char="±">5.8 ± 1.0</td><td class="colsep0 rowsep0" align="char" char="±">5.2 ± 2.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5u</b></td><td class="colsep0 rowsep0" align="left">98</td><td class="colsep0 rowsep0" align="char" char="±">2.6 ± 1.7</td><td class="colsep0 rowsep0" align="char" char="±">2.4 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">2.8 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">2.2 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">2.8 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">2.2 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">2.0 ± 0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5v</b></td><td class="colsep0 rowsep0" align="left">98</td><td class="colsep0 rowsep0" align="char" char="±">7.4 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">6.7 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">7.2 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">8.8 ± 1.7</td><td class="colsep0 rowsep0" align="char" char="±">7.10 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">7.9 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">7.2 ± 2.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5w</b></td><td class="colsep0 rowsep0" align="left">90</td><td class="colsep0 rowsep0" align="char" char="±">4.3 ± 1.8</td><td class="colsep0 rowsep0" align="char" char="±">3.9 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">4.1 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">4.3 ± 2.1</td><td class="colsep0 rowsep0" align="char" char="±">4.0 ± 1.7</td><td class="colsep0 rowsep0" align="char" char="±">3.8 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">4.5 ± 2.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5x</b></td><td class="colsep0 rowsep0" align="left">91</td><td class="colsep0 rowsep0" align="char" char="±">2.5 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">2.2 ± 1.7</td><td class="colsep0 rowsep0" align="char" char="±">2.4 ± 1.6</td><td class="colsep0 rowsep0" align="char" char="±">2.6 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">1.9 ± 1.6</td><td class="colsep0 rowsep0" align="char" char="±">2.1 ± 3.5</td><td class="colsep0 rowsep0" align="char" char="±">2.2 ± 1.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5y</b></td><td class="colsep0 rowsep0" align="left">94</td><td class="colsep0 rowsep0" align="char" char="±">13.4 ± 1.6</td><td class="colsep0 rowsep0" align="char" char="±">12.8 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">14.1 ± 2.6</td><td class="colsep0 rowsep0" align="char" char="±">13.3 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">14.0 ± 2.5</td><td class="colsep0 rowsep0" align="char" char="±">12.9 ± 1.3</td><td class="colsep0 rowsep0" align="char" char="±">13.7 ± 1.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5z</b></td><td class="colsep0 rowsep0" align="left">92</td><td class="colsep0 rowsep0" align="char" char="±">10.8 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">10.6 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">11.1 ± 2.1</td><td class="colsep0 rowsep0" align="char" char="±">10.3 ± 4.2</td><td class="colsep0 rowsep0" align="char" char="±">10.5 ± 2.6</td><td class="colsep0 rowsep0" align="char" char="±">11.1 ± 2.1</td><td class="colsep0 rowsep0" align="char" char="±">10.4 ± 0.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5aa</b></td><td class="colsep0 rowsep0" align="left">92</td><td class="colsep0 rowsep0" align="char" char="±">9.9 ± 1.6</td><td class="colsep0 rowsep0" align="char" char="±">9.0 ± 1.0</td><td class="colsep0 rowsep0" align="char" char="±">10.9 ± 1.6</td><td class="colsep0 rowsep0" align="char" char="±">9.1 ± 1.3</td><td class="colsep0 rowsep0" align="char" char="±">9.2 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">10.9 ± 5.6</td><td class="colsep0 rowsep0" align="char" char="±">9.3 ± 2.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5ab</b></td><td class="colsep0 rowsep0" align="left">90</td><td class="colsep0 rowsep0" align="char" char="±">12.4 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">15.2 ± 5.6</td><td class="colsep0 rowsep0" align="char" char="±">12.9 ± 1.8</td><td class="colsep0 rowsep0" align="char" char="±">11.1 ± 2.1</td><td class="colsep0 rowsep0" align="char" char="±">12.9 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">15.2 ± 4.6</td><td class="colsep0 rowsep0" align="char" char="±">12.6 ± 2.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5ac</b></td><td class="colsep0 rowsep0" align="left">95</td><td class="colsep0 rowsep0" align="char" char="±">9.8 ± 3.2</td><td class="colsep0 rowsep0" align="char" char="±">9.6 ± 2.5</td><td class="colsep0 rowsep0" align="char" char="±">9.8 ± 2.5</td><td class="colsep0 rowsep0" align="char" char="±">10.9 ± 1.6</td><td class="colsep0 rowsep0" align="char" char="±">9.4 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">10.6 ± 4.5</td><td class="colsep0 rowsep0" align="char" char="±">9.3 ± 2.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5ad</b></td><td class="colsep0 rowsep0" align="left">93</td><td class="colsep0 rowsep0" align="char" char="±">8.5 ± 1.7</td><td class="colsep0 rowsep0" align="char" char="±">8.9 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">10.1 ± 3.5</td><td class="colsep0 rowsep0" align="char" char="±">8.2 ± 1.6</td><td class="colsep0 rowsep0" align="char" char="±">9.6 ± 2.3</td><td class="colsep0 rowsep0" align="char" char="±">8.9 ± 2.6</td><td class="colsep0 rowsep0" align="char" char="±">10.3 ± 2.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5ae</b></td><td class="colsep0 rowsep0" align="left">95</td><td class="colsep0 rowsep0" align="char" char="±">3.5 ± 0.7</td><td class="colsep0 rowsep0" align="char" char="±">3.4 ± 1.1</td><td class="colsep0 rowsep0" align="char" char="±">3.3 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">3.6 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">3.5 ± 1.7</td><td class="colsep0 rowsep0" align="char" char="±">3.1 ± 2.8</td><td class="colsep0 rowsep0" align="char" char="±">3.1 ± 3.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5af</b></td><td class="colsep0 rowsep0" align="left">90</td><td class="colsep0 rowsep0" align="char" char="±">1.9 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">1.7 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">2.3 ± 1.3</td><td class="colsep0 rowsep0" align="char" char="±">1.9 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">1.9 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">1.8 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">1.6 ± 0.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5ag</b></td><td class="colsep0 rowsep0" align="left">88</td><td class="colsep0 rowsep0" align="char" char="±">1.2 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">1.5 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">1.4 ± 2.2</td><td class="colsep0 rowsep0" align="char" char="±">1.3 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">1.4 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">1.3 ± 0.7</td><td class="colsep0 rowsep0" align="char" char="±">1.4 ± 0.8</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Panc-1 (pancreas cancer cell line), PaCa-2 (pancreatic carcinoma cell line), MCF-7 (breast cancer cell line), A-549 (epithelial), HT-29 (colon cancer cell line), H-460 (lung cancer cell line), PC-3 (prostate cancer cell line).</p></div></div></div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Inhibitory Effects of Synthetic Compounds on the Growth of Normal (MCF-10A) Mammary Epithelial Cells (Cell Viability) And Different Types of Human Cancer Cells<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="7" align="center" char="±">antiproliferative activity IC<sub>50</sub>  ± SEM (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center">cell viability %</th><th class="colsep0 rowsep0" align="center" char="±">Panc-1</th><th class="colsep0 rowsep0" align="center" char="±">PaCa-2</th><th class="colsep0 rowsep0" align="center" char="±">MCF-7</th><th class="colsep0 rowsep0" align="center" char="±">A-549</th><th class="colsep0 rowsep0" align="center" char="±">HT-29</th><th class="colsep0 rowsep0" align="center" char="±">H-460</th><th class="colsep0 rowsep0" align="center" char="±">PC-3</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7c</b></td><td class="colsep0 rowsep0" align="left">95</td><td class="colsep0 rowsep0" align="char" char="±">2.2 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">2.6 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">2.9 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">2.6 ± 1.7</td><td class="colsep0 rowsep0" align="char" char="±">2.1 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">2.5 ± 0.7</td><td class="colsep0 rowsep0" align="char" char="±">2.5 ± 0.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7f</b></td><td class="colsep0 rowsep0" align="left">98</td><td class="colsep0 rowsep0" align="char" char="±">0.2 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">0.7 ± 1.3</td><td class="colsep0 rowsep0" align="char" char="±">0.4 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">0.3 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">0.4 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">0.4 ± 0.7</td><td class="colsep0 rowsep0" align="char" char="±">0.4 ± 0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7o</b></td><td class="colsep0 rowsep0" align="left">96</td><td class="colsep0 rowsep0" align="char" char="±">0.09 ± 0.01</td><td class="colsep0 rowsep0" align="char" char="±">0.07 ± 0.09</td><td class="colsep0 rowsep0" align="char" char="±">0.06 ± 0.03</td><td class="colsep0 rowsep0" align="char" char="±">0.06 ± 0.04</td><td class="colsep0 rowsep0" align="char" char="±">0.07 ± 0.05</td><td class="colsep0 rowsep0" align="char" char="±">0.08 ± 0.04</td><td class="colsep0 rowsep0" align="char" char="±">0.09 ± 0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8f</b></td><td class="colsep0 rowsep0" align="left">98</td><td class="colsep0 rowsep0" align="char" char="±">2.0 ± 1.0</td><td class="colsep0 rowsep0" align="char" char="±">2.6 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">2.5 ± 1.7</td><td class="colsep0 rowsep0" align="char" char="±">2.2 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">2.1 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">1.9 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">1.9 ± 1.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8i</b></td><td class="colsep0 rowsep0" align="left">90</td><td class="colsep0 rowsep0" align="char" char="±">1.5 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">1.2 ± 2.6</td><td class="colsep0 rowsep0" align="char" char="±">1.4 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">2.0 ± 0.7</td><td class="colsep0 rowsep0" align="char" char="±">1.1 ± 1.6</td><td class="colsep0 rowsep0" align="char" char="±">1.3 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">2.3 ± 2.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8o</b></td><td class="colsep0 rowsep0" align="left">92</td><td class="colsep0 rowsep0" align="char" char="±">1.0 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">1.2 ± 2.0</td><td class="colsep0 rowsep0" align="char" char="±">0.8 ± 1.1</td><td class="colsep0 rowsep0" align="char" char="±">1.2 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">1.7 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">1.1 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">1.4 ± 0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8u</b></td><td class="colsep0 rowsep0" align="left">92</td><td class="colsep0 rowsep0" align="char" char="±">2.1 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">2.9 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">2.2 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">1.9 ± 0.7</td><td class="colsep0 rowsep0" align="char" char="±">2.2 ± 1.6</td><td class="colsep0 rowsep0" align="char" char="±">2.6 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">2.2 ± 0.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8x</b></td><td class="colsep0 rowsep0" align="left">89</td><td class="colsep0 rowsep0" align="char" char="±">0.7 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">0.6 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">0.5 ± 0.7</td><td class="colsep0 rowsep0" align="char" char="±">0.4 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">0.6 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">0.6 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">0.7 ± 1.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8af</b></td><td class="colsep0 rowsep0" align="left">93</td><td class="colsep0 rowsep0" align="char" char="±">0.09 ± 0.03</td><td class="colsep0 rowsep0" align="char" char="±">0.09 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">0.07 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">0.08 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">0.09 ± 0.06</td><td class="colsep0 rowsep0" align="char" char="±">0.08 ± 0.01</td><td class="colsep0 rowsep0" align="char" char="±">0.02 ± 0.04</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8ag</b></td><td class="colsep0 rowsep0" align="left">96</td><td class="colsep0 rowsep0" align="char" char="±">0.02 ± 0.08</td><td class="colsep0 rowsep0" align="char" char="±">0.02 ± 0.07</td><td class="colsep0 rowsep0" align="char" char="±">0.09 ± 0.04</td><td class="colsep0 rowsep0" align="char" char="±">0.02 ± 0.08</td><td class="colsep0 rowsep0" align="char" char="±">0.03 ± 0.07</td><td class="colsep0 rowsep0" align="char" char="±">0.04 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">0.02 ± 0.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10f</b></td><td class="colsep0 rowsep0" align="left">94</td><td class="colsep0 rowsep0" align="char" char="±">4.2 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">4.9 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">4.1 ± 1.1</td><td class="colsep0 rowsep0" align="char" char="±">4.1 ± 3.2</td><td class="colsep0 rowsep0" align="char" char="±">4.5 ± 2.4</td><td class="colsep0 rowsep0" align="char" char="±">4.1 ± 1.7</td><td class="colsep0 rowsep0" align="char" char="±">4.7 ± 1.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10o</b></td><td class="colsep0 rowsep0" align="left">95</td><td class="colsep0 rowsep0" align="char" char="±">0.09 ± 0.01</td><td class="colsep0 rowsep0" align="char" char="±">0.08 ± 0.01</td><td class="colsep0 rowsep0" align="char" char="±">0.09 ± 0.08</td><td class="colsep0 rowsep0" align="char" char="±">0.07 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">0.09 ± 0.05</td><td class="colsep0 rowsep0" align="char" char="±">0.07 ± 0.01</td><td class="colsep0 rowsep0" align="char" char="±">0.08 ± 0.07</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11x</b></td><td class="colsep0 rowsep0" align="left">95</td><td class="colsep0 rowsep0" align="char" char="±">2.7 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">2.1 ± 2.5</td><td class="colsep0 rowsep0" align="char" char="±">2.2 ± 1.6</td><td class="colsep0 rowsep0" align="char" char="±">2.1 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">2.9 ± 1.8</td><td class="colsep0 rowsep0" align="char" char="±">2.9 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">2.2 ± 2.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11af</b></td><td class="colsep0 rowsep0" align="left">94</td><td class="colsep0 rowsep0" align="char" char="±">6.9 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">6.6 ± 1.9</td><td class="colsep0 rowsep0" align="char" char="±">6.6 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">7.1 ± 2.1</td><td class="colsep0 rowsep0" align="char" char="±">7.0 ± 2.1</td><td class="colsep0 rowsep0" align="char" char="±">7.2 ± 2.8</td><td class="colsep0 rowsep0" align="char" char="±">6.4 ± 2.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11ag</b></td><td class="colsep0 rowsep0" align="left">97</td><td class="colsep0 rowsep0" align="char" char="±">4.2 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">4.0 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">4.9 ± 2.6</td><td class="colsep0 rowsep0" align="char" char="±">4.3 ± 2.0</td><td class="colsep0 rowsep0" align="char" char="±">4.5 ± 3.2</td><td class="colsep0 rowsep0" align="char" char="±">4.6 ± 2.9</td><td class="colsep0 rowsep0" align="char" char="±">4.4 ± 2.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>Erlotinib</b></td><td class="colsep0 rowsep0" align="left">-</td><td class="colsep0 rowsep0" align="char" char="±">0.02 ± 0.01</td><td class="colsep0 rowsep0" align="char" char="±">0.03 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">0.02 ± 0.001</td><td class="colsep0 rowsep0" align="char" char="±">0.02 ± 0.01</td><td class="colsep0 rowsep0" align="char" char="±">0.03 ± 0.01</td><td class="colsep0 rowsep0" align="char" char="±">0.04 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">0.02 ± 0.05</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">Panc-1 (pancreas cancer cell line), PaCa-2 (pancreatic carcinoma cell line), MCF-7 (breast cancer cell line), A-549 (epithelial), HT-29 (colon cancer cell line), H-460 (lung cancer cell line), PC-3 (prostate cancer cell line).</p></div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Effects on Human Cancer Cell Lines</h3><div class="NLM_p">The antiproliferative activity of all synthetic compounds on human prostate cancer cells (PC-3), colon cancer cells (HT-29), breast cancer cells (MCF-7), lung cancer cells (H-460), epithelial cancer cells (A-549), pancreatic carcinoma cells (PaCa-2), and pancreas cancer cell line (Panc-1) was investigated using the propidium iodide (PI) fluorescence assay. Generally, investigated compounds showed almost similar antiproliferative activity against different cancer cells and the average variance in their inhibitory activities was less than 8% against all types of cancer cells. GraphPad Prism software (GraphPad Software, San Diego, CA, USA) was used to calculate the median inhibition concentration (IC<sub>50</sub>) for all compounds. On the basis of IC<sub>50</sub>, a significant association was witnessed between the analogs in terms of their structural features.</div><div class="NLM_p">The three most active compounds (<b>4c</b>, <b>4f</b>, <b>4o</b>) among cyclohexanone derivatives or α,β-unsaturated carbonyl-based compounds exhibited potent inhibition of cancer cells growth (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). Compounds <b>4f</b> and <b>4o</b> showed nearly comparable and maximum anticancer activity against all cancer cell lines with IC<sub>50</sub> ranging from 1.1 ± 0.2 to 1.9 ± 0.8 μM. Moreover, compound <b>4c</b> also displayed strong activity with an IC<sub>50</sub> of 2.0 ± 1.5 μM for the HT-29 cell line. The findings of these compounds (<b>4c</b>, <b>4f</b>, <b>4o</b>) were similar against all seven cancer cell lines.</div><div class="NLM_p">Seven compounds such as <b>5</b>(<b>f</b>, <b>i</b>, <b>o</b>, <b>u</b>, <b>x</b>, <b>af</b>, and <b>ag</b>) from new tetralone derivatives (<b>5a</b>–<b>5ag</b>) showed potent growth inhibition of all cell lines (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). The compound <b>5ag</b> displayed the highest anticancer potential with IC<sub>50</sub> 1.2 ± 0.9 μM for Panc-1. After <b>5ag</b>, the compound <b>5o</b> exhibited significant anticancer activity with IC<sub>50</sub> 1.4 ± 0.5 μM. The derivatives <b>5i</b>, <b>5af</b>, <b>5f</b>, <b>5u</b>, <b>5x</b> also exhibited noteworthy inhibition of cancer cells. These findings of the anticancer assay motivated us to extend our synthesis work. In doing so, ten new oxime analogs were synthesized by taking the three most active cyclohexanone derivatives <b>4</b>(<b>c</b>, <b>f</b>, <b>o</b>) and seven most active tetralone derivatives <b>5</b>(<b>f</b>, <b>i</b>, <b>o</b>, <b>u</b>, <b>x</b>, <b>af</b>, and <b>ag</b>) as bases. The newly synthesized oxime analogs were then subjected to the antiproliferative assay using seven cancer cell lines. In contrast to parent α,β-unsaturated carbonyl-based compounds, all analogs showed potent antiproliferative activity against seven cell lines with IC<sub>50</sub> ranging from 0.02 ± 0.08 to 2.9 ± 0.2 μM (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>).</div><div class="NLM_p last">The most potent oxime analogs were screened for subsequent synthesis as oxime ether analogs, and the resultant analogs were also assessed for antiproliferative activity (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>). In contrast to the parent oximes, all oxime ether analogs exhibited less inhibition of cancer cells. Following the antiproliferative assay, all 4 series including tetralones (33 compounds), cyclohexanones (21 compounds), oximes (10 compounds), and oxime ethers (5 compounds) were subjected to an overall comparison. The 10 most potent compounds among the series mentioned above were selected for anticancer mechanistic experiments including their effect on tubulin polymerization, EGFR-TK and BRAF<sup>V600E</sup>, and were also assessed <i>in vitro</i> to reverse multidrug resistance developed by cancer cells.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Effects on Tubulin Polymerization</h3><div class="NLM_p">The effect of all ten selected synthetic compounds on tubulin polymerization has been summarized in <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>. A significant influence on tubulin assembly was exhibited by most compounds; where compounds <b>7f</b> and <b>8f</b> inhibited tubulin assembly strongly. According to the propidium iodide fluorescence assay, just two compounds (<b>7o</b> and <b>10o</b>) did not exhibit tubulin assembly inhibition which suggests a different process for the witnessed cytotoxicity than inhibition of tubulin. No synthetic compound exhibited microtubule-stabilizing action comparable to recognized antimitotic chemotherapeutic drug docetaxel.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></div><figure id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00276/20160414/images/medium/jm-2016-00276j_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00276/20160414/images/large/jm-2016-00276j_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Effect of selected synthetic compounds on tubulin polymerization activity at concentration of 25 μM. Results are the mean values of three experiments, <i>n</i> = 3. While vincristine and docetaxel (3 μM) were used as reference compounds. All compounds showed the inhibition of tubulin as below the horizontal line indicate tubulin inhibition; only docetaxel is above the horizontal line indicating tubulin stabilization and compounds (<b>7o</b> and <b>10o</b>) close to the horizontal line are considered to be inactive. The <i>y</i>-axis demonstrates tubulin polymerization activity measured at 15 min (arbitrary units) in the growth phase of the tubulin polymerization curve.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00276/20160414/images/large/jm-2016-00276j_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00276&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> EGFR Inhibitory Activity</h3><div class="NLM_p">An EGFR-TK assay was performed to assess the EGFR inhibitory strength of new compounds and the results are presented in <a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>. The results from this assay complement the findings of the cancer cell-based assays. All investigated compounds exhibited strong inhibition of EGFR with IC<sub>50</sub> ranging from 0.07 ± 0.03 to 8.4 ± 0.2 μM. According to <a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>, compounds <b>7o</b> and <b>10o</b> were found to be most potent (IC<sub>50</sub> = 0.07 ± 0.03 μM and 0.1 ± 0.05 μM for EGFR), and their EGFR inhibitory activities were similar to the positive control erlotinib (IC<sub>50</sub> = 0.05 ± 0.02 μM). This experiment shows that α,β-unsaturated carbonyl based oxime compounds and their ether analogs are potent EGFR inhibitors and can possibly be used as anticancer agents.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Effects of Selected Synthetic Compounds on EGFR, BRAF<sup>V600E</sup>, and MDR</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center" char="±">EGFR inhibition IC<sub>50</sub>  ± SEM (μM)</th><th class="colsep0 rowsep0" align="center" char="±">BRAF inhibition IC<sub>50</sub>  ± SEM (μM)</th><th class="colsep0 rowsep0" align="center" char=".">fluorescence activity ratio (FAR)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7f</b></td><td class="colsep0 rowsep0" align="char" char="±">0.5 ± 0.05</td><td class="colsep0 rowsep0" align="char" char="±">2.7 ± 0.8</td><td class="colsep0 rowsep0" align="char" char=".">15.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7o</b></td><td class="colsep0 rowsep0" align="char" char="±">0.07 ± 0.05</td><td class="colsep0 rowsep0" align="char" char="±">1.6 ± 0.3</td><td class="colsep0 rowsep0" align="char" char=".">27.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8f</b></td><td class="colsep0 rowsep0" align="char" char="±">3.2 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">2.4 ± 0.5</td><td class="colsep0 rowsep0" align="char" char=".">44.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8i</b></td><td class="colsep0 rowsep0" align="char" char="±">4.6 ± 2.9</td><td class="colsep0 rowsep0" align="char" char="±">1.7 ± 1.2</td><td class="colsep0 rowsep0" align="char" char=".">41.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8o</b></td><td class="colsep0 rowsep0" align="char" char="±">2.1 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">1.9 ± 1.1</td><td class="colsep0 rowsep0" align="char" char=".">37.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8u</b></td><td class="colsep0 rowsep0" align="char" char="±">8.4 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">6.3 ± 1.5</td><td class="colsep0 rowsep0" align="char" char=".">51.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8x</b></td><td class="colsep0 rowsep0" align="char" char="±">4.2 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">1.8 ± 0.4</td><td class="colsep0 rowsep0" align="char" char=".">52.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8af</b></td><td class="colsep0 rowsep0" align="char" char="±">2.0 ± 1.0</td><td class="colsep0 rowsep0" align="char" char="±">0.9 ± 0.4</td><td class="colsep0 rowsep0" align="char" char=".">42.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8ag</b></td><td class="colsep0 rowsep0" align="char" char="±">1.9 ± 1.8</td><td class="colsep0 rowsep0" align="char" char="±">1.0 ± 0.6</td><td class="colsep0 rowsep0" align="char" char=".">40.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10o</b></td><td class="colsep0 rowsep0" align="char" char="±">0.1 ± 0.05</td><td class="colsep0 rowsep0" align="char" char="±">3.2 ± 1.1</td><td class="colsep0 rowsep0" align="char" char=".">17.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>Erlotinib</b></td><td class="colsep0 rowsep0" align="char" char="±">0.05 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">0.08 ± 0.02</td><td class="colsep0 rowsep0" align="char" char=".">25.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>Verapamil</b></td><td class="colsep0 rowsep0" align="char" char="±">-</td><td class="colsep0 rowsep0" align="char" char="±">-</td><td class="colsep0 rowsep0" align="char" char=".">12.8</td></tr></tbody></table></div></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> BRAF<sup>V600E</sup> Inhibitory Activity</h3><div class="NLM_p last">As compared to standard chemotherapy, the development of oncogenic BRAF inhibitors has caused a high percentage of objective tumor responses and improvement in general survival. Therefore, small molecule inhibitors which target V600E mutant BRAF protein kinase are being developed for the treatment of cancer. An <i>in vitro</i> assay was performed to investigate the BRAF<sup>V600E</sup> inhibitory potential of the ten most active synthesized compounds. According to <a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>, all investigated compounds showed IC<sub>50</sub> in the range of 0.9 ± 0.4 to 6.3 ± 0.4 μM. All investigated synthetic α,β-unsaturated carbonyl based oxime compounds were discovered to be strong BRAF<sup>V600E</sup> inhibitors. Interestingly, two of them (<b>8af</b> and <b>8ag</b>) displayed nearly the same BRAF inhibitory potential and were also found to be potent against the proliferation of cancer cells. These findings show that the investigated compounds are prospective anticancer agents and also effectively inhibit BRAF enzyme.</div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> MDR Reversal Activity</h3><div class="NLM_p last">A Rhodamine accumulation test was performed to study the effect of the synthesized compounds (at nontoxic concentrations) on the drug accumulation of MDR cancer cells (<a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>). A Trypan blue experiment was used to investigate the toxic effects of these compounds. During a short incubation period, the compounds (at 50 μg/mL concentration) exhibited no apparent toxicity on cells. At 5 μg/mL concentration, most of compounds were ineffective on R123 accumulation. Nonetheless, the multidrug resistance on the mouse lypmhoma cells was reversed by the compounds at 50 μg/mL concentration and an incubation time of 30 min. Verapamil served as a positive control in the experiment. <a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a> shows the findings related to MDR. The oxime analogs based on tetralone series <b>8</b> (<b>f</b>, <b>i</b>, <b>o</b>, <b>u</b>, <b>x</b>, <b>af</b>, and <b>ag</b>) were discovered to be most effective whereas compounds <b>7f</b>, <b>7o</b>, and <b>10o</b> were almost ineffective. No compound was found to be inactive against human mdr1 gene-transfected mouse lymphoma cells. A combination of traditional chemotherapeutics and resistance modifiers can be used to treat MDR cancer cells. So, compounds possessing dual characteristics as strong anticancer agents as well as MDR modulators can be prospective contenders for cancer treatment.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67135" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67135" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">A broad range of structurally correlated α,β-unsaturated carbonyl-based compounds such as tetralone, cyclohexanone, and their oxime analogs were synthesized and investigated for anticancer activity against numerous cancer cell lines. Some of the synthesized compounds exhibited anticancer activity against certain cancer cell lines. The most active of these compounds were screened for mechanistic experiments and assessed for their effects on BRAF<sup>V600E</sup>, EGFR-TK, and tubulin polymerization, in addition to an <i>in vitro</i> investigation of the reversal of efflux-mediated resistance developed by cancer cells.</div><div class="NLM_p">The most complex challenge encountered by drug candidates from the design to the development phase is the rule of three (activity-exposure-toxicity). To regulate the balance of characteristics vital to convert lead compounds into drugs that are both safe and effective, absorption, distribution, metabolism, and excretion (ADME) studies are widely used in drug discovery.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Therefore, human mammary gland epithelial cell line (MCF-10A) was used to perform an <i>in vitro</i> cell viability assay. All compounds were discovered to be safe with most of them exhibiting cell viability of more than 90%. Hence, the synthesized compounds were discovered to be biologically safe and might be used as potential therapeutic agents for future drug discovery experiments.</div><div class="NLM_p">Based on the assessments among the antiproliferative activities of tetralone and cyclohexanone derivatives, the subsequent structure–activity relationships can be witnessed: (1) On assessment, it was found that oxime analogs (series 7 and 8) exhibited maximum antiproliferative activity against cancer cell lines in comparison to tetralone, cyclohexanone and oxime ether analogs. As compared to cyclohexanone, tetralone derivatives were discovered to be more promising. Nonetheless, some cyclohexanone derivatives (<b>4c</b>, <b>4f</b>, and <b>4o</b>) displayed potent antiproliferative activity. In comparison to their parent oxime analogs, oxime ether analogs were found to be less active. (2) A remarkable structure–activity relationship was witnessed among cyclohexanone derivatives. R<sub>1</sub> position substitution in the cyclohexanone ring played a vital part in the activities of these types of compounds. A similar phenomenon was also observed for these types of compounds in our previously reported experiments for anti-inflammatory activities.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> The compounds <b>4</b>(<b>a</b>, <b>b</b>, and <b>c</b>) showed good activity without R<sub>1</sub> substitution, However, the presence of a N–CH<sub>3</sub> at R<sub>1</sub> exhibited the greatest activity. Methyl substitution also showed significant effects on antiproliferative activity and it was also found that the methoxy group’s occurrence improved the antiproliferative activity. The methoxy group was present at position 5 in all compounds. However, substitution patterns at R<sub>3</sub>, R<sub>4</sub>, and R<sub>6</sub> differed between the compounds and the occurrence of methoxy group at position 4 improved the activities. Cyclohexanone derivatives possessing three methoxy groups at positions 3, 4, and 5 were discovered to be more active in comparison to those having two methoxy groups at positions 4 and 5. All compounds contained halogens (Cl or Br) at position 6 on the benzene ring. The influence of halogens on the activity of compounds could not be recognized, as no compound was halogen-free. The most potent compounds in the cyclohexanone series (<b>4c</b>, <b>4f</b>, and <b>4o</b>) possessed Br at R<sub>6</sub> and three methoxy groups at positions 3, 4, and 5, respectively. (3) The same substitution pattern as the cyclohexanone derivatives was present for all tetralone derivatives as similar aldehydes were used to synthesize tetralone derivatives. Remarkably, our structure–activity relationship as mentioned above for cyclohexanone derivatives was verified and maintained by the antiproliferative activity of tetralone derivatives. In comparison to those bearing two methoxy groups at positions R′4 and R′5, all compounds possessing three methoxy groups at R′<sub>3</sub>, R′<sub>4</sub>, and R′<sub>5</sub> were discovered to be more potent. As compared to cyclohexanone derivatives, another substitution configuration on the linked phenyl ring of the tetralone moiety is present in tetralone derivatives designated as R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, and R<sub>5</sub>. Compounds (<b>5af</b> and <b>5ag</b>) having nitro group substitution at R<sub>3</sub> were found to be most potent. As compared to <b>5af</b>, tetralone derivative <b>5ag</b> proved to be a stronger antiproliferative agent, therefore verifying that three methoxy groups at positions R′<sub>3</sub>, R′<sub>4</sub>, and R′<sub>5</sub> added more antiproliferative activity compared with two methoxy groups at R′<sub>4</sub> and R′<sub>5</sub>. The three most active tetralone derivatives <b>5</b>(<b>o</b>, <b>u</b>, and <b>x</b>) possessed similar functional groups on the phenyl contributed by the aldehyde; however, in comparison to <b>5u</b> and <b>5x</b>, <b>5o</b> was found to be more active due to a different substitution arrangement on the phenyl group of the tetralone moiety. Hence, the activities of these three compounds show that the methoxy group substitution at position R<sub>4</sub> is more effective in comparison to methoxy groups at R<sub>2</sub> and R<sub>5</sub> or at position R<sub>3</sub> and R<sub>4</sub> of the tetralone moiety.</div><div class="NLM_p">The polymerization activity of the ten most active antiproliferative compounds was investigated. The findings showed that compounds <b>7f</b>, <b>8i</b>, <b>8o</b>, <b>8u</b>, <b>8x</b>, and <b>8af</b> exhibited slight to moderate inhibition of microtubule assembly, while the microtubules were best destabilized by compounds <b>7f</b> and <b>8f</b> in comparison to both positive control drugs (docetaxel as microtubule stabilizing agent and vincristine as microtubule destabilizing agent).<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> The R<sub>1</sub> position in the cyclohexanone of the tetralone moiety of the most potent oxime analogs (<b>7f</b> and <b>8f</b>) contained methyl substitutions. Tubulin assembly has been previously reported to be inhibited by the methyl substitutions at the R<sub>1</sub> position in the cyclohexanone ring.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> The two most inactive compounds (<b>7o</b> and <b>10o</b>) possessed N–CH<sub>3</sub> substitution at R<sub>1</sub> in the cyclohexanone of the tetralone moiety.</div><div class="NLM_p">An important target for the development of melanoma drugs is BRAF. The persistent MAPK activity is promoted by BRAF<sup>V600E</sup> resulting in an enhanced survival and proliferation. Cell cycle arrest can occur due to the acute inhibition of BRAF<sup>V600E</sup> by kinase inhibitors or genetic depletion and in some cases, apoptosis in melanomas addicted to this oncogene.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Among ten selected compounds, two (<b>8af</b> and <b>8ag</b>) having oxime moiety and nitro substitution at position R<sub>3</sub> were discovered to be potent BRAF inhibitors. According to Li et al., para-nitro substitutions on phenyl ring showed better inhibition of BRAF<sup>V600E</sup> activity.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a></div><div class="NLM_p">The understanding of the significance of EGFR signaling pathway in cancer has resulted in the development of numerous anti-EGFR drugs, such as reversible first generation tyrosine kinase inhibitors (TKIs) including erlotinib and gefitinib, together with monoclonal antibodies such as panitumumab and cetuximab. The EGFR inhibitory activities of the ten most potent antiproliferative oxime and oxime ether analogs have been presented in <a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>. The N–CH<sub>3</sub> substitution at the R<sub>1</sub> position in the cyclohexanone of tetralone moiety enhanced the potency of the compounds (<b>7o</b> and <b>10o</b>). These compounds did not affect tubulin polymerization but were discovered to be strong EGFR inhibitors. Methoxy group substitution at position R<sub>3</sub> of thetetralone moiety (compound <b>8u</b>) considerably decreased the potency of EGFR (IC<sub>50</sub> = 8.4 μM).</div><div class="NLM_p">The cell efflux pump can be considered as an enzyme with exceptionally broad substrate specificity, and it involves ABC transporters. To overcome MDR, the ABC transporter inhibition of tumor cells can be a capable prospect. The ten most active anticancer compounds were selected and assessed as MDR modulators using multidrug-resistant mouse lymphoma cells. All investigated compounds were discovered to be potent MDR reversing agents. The oxime ether analog (<b>10o</b>) did not exhibit significant activity. The compounds with a fluorescence activity ratio (FAR) of 1 or more indicated the reversal of MDR. The modulators of MDR attach to the transmembrane domains of Pgp, thus bringing a structural change in Pgp, which in turn prevents the ABC transporter activity.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Compounds (<b>8af</b> and <b>8ag</b>) possessing nitro substitution exhibited the same potency of MDR reversal. Among two oxime analogs (<b>8o</b> and <b>8u</b>) with identical aldehyde substitutions on the phenyl ring, <b>8u</b> showed maximum MDR reversal activity while the activity of <b>8o</b> was 15% less. The enhanced MDR reversal activity of <b>8u</b> may be attributed to the additional methoxy group at position R<sub>3</sub> of the tetralone moiety.</div><div class="NLM_p last">In summary, a series of α,β-unsaturated tetralone and cyclohexanone derivatives with various substitutions were synthesized and assessed <i>in vitro</i> for their antiproliferative activities using human cancer cell lines. The compounds which exhibited the most potent antiproliferative activities were selected for subsequent synthesis as oxime and oxime ether analogs followed by assessment through mechanistic experiments. This study has revealed some new oxime analogs as EGFR-TK, BRAF<sup>V600E</sup>, and tubulin polymerization inhibitors. Most of these compounds also exhibited MDR reversal activity. The compounds <b>8af</b> and <b>8ag</b> were found to be extremely active in all experiments. Hence, we have recognized active anticancer agents exhibiting a dual role as anticancer and MDR reversal agents, and have compiled some valuable SAR information that might prove useful in synthesizing more MDR reversal agents with intrinsic antitumor activity.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36366" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36366" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Chemistry General Information</h3><div class="NLM_p last">All chemicals and reagents used in this project were procured from Sigma-Aldrich, Merck, and Acros Organics. The reagents were of analytical grade and were used as supplied. A typical experiment consisted of brine washing and desiccating the organic layer with magnesium sulfate prior to concentration in vacuum. JEOL ECP spectrometer was used to record the <sup>1</sup>H and <sup>13</sup>C NMR spectra operating at 500 MHz, with Me<sub>4</sub>Si as internal standard and dimethyl sulfoxide (DMSO-<i>d</i><sub>6</sub>) and CDCl<sub>3</sub> as the solvents. MicroTOF-Q mass spectrometer (Bruker) was used to record the high-resolution mass spectra (HRMS). The microanalyses data were obtained using Fison EA 1108 elemental analyzer. Precoated silica plates (kiesel gel 60 F<sub>254</sub>, BDH) were used to perform thin layer chromatography (TLC) while flash column chromatography was carried out using silica gel 60 (230–400 mesh) (Merck). Electrothermal instrumentation was used to determine the melting points of the compounds. The synthesized compounds were observed under ultraviolet (UV) light (254 nm) or by using vanillin stain successively burning on a hot plate. Analytical HPLC were recorded for purity determination of new compounds with Beckmann system Gold HPLC using a linear gradient from 0% to 100% solvent B (60% acetonitrile/40% water/0.1% TFA) and a Kinetex C<sub>18</sub> Coloumn (250 mm × mm, 5 μm) was used for this system. Purity values for all tested compounds were found to be above 95%.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Synthesis of α,β-Unsaturated Carbonyl Based Compounds</h3><div class="NLM_p">New α,β-unsaturated carbonyl based compounds (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>) were synthesized by using a direct coupling method<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). The reaction was performed via base-catalyzed Claisen-Schmidt condensation, by reacting 10 various kinds of ketones with a suitable aromatic aldehyde at molar feed ratio of 2:1 for the synthesis of 21 compounds (<b>4a</b>–<b>4u</b>), and at 1:1 for synthesizing 33 compounds (<b>5a</b>–<b>5ag</b>). A synthetic route for α,β-unsaturated carbonyl based compounds is shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Concisely, ketone (10 mmol, 1 equiv) and particular aromatic aldehyde (20 mmol, 2 equiv) were mixed and dissolved in 15 mL ethanol in a round-bottom flask, and stirred for few min at 5 °C. For several minutes, a 40% NaOH solution (in ethanol) was added dropwise into the above solution. The resultant mixture was stirred at 27 °C for 1–24 h. A change in color of the reaction mixture and appearance of precipitate indicated the formation of product. The reaction was monitored using TLC and acidified ice was added to the mixture to stop the reaction upon completion. The compounds were isolated by recrystallization and/or column chromatography.</div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 2,6-Bis(2-bromo-3,4,5-trimethoxy-benzylidene)-cyclohexanone (<b>4c</b>)</h4><div class="NLM_p last">Yield: 74%; mp: 102–103 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 7.82 (s, 2H), 6.89 (s, 2H), 3.75 (s, 18H), 2.32 (t, <i>J</i> = 8.0 Hz, 4H), 1.82 (m, 2H); <sup>13</sup>C NMR (500 MHz, CDCl<sub>3</sub>) δ: 185.4, 151.2, 146.5, 144.2, 144.9, 135.9, 130.5, 108.4, 98.6, 56.5, 56.1, 55.5, 28.5, 27.3; HRMS (ESI) <i>m</i>/<i>z</i>: 613.32 [M + H]<sup>+</sup>, Microanalysis calculated for C<sub>26</sub>H<sub>28</sub>Br<sub>2</sub>O<sub>7</sub> (612.30), C: 51.00%, H: 4.61%. Found C: 51.22%, H: 4.59%.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 2,6-Bis(2-bromo-3,4,5-trimethoxy-benzylidene)-4-methyl-cyclohexanone (<b>4f</b>)</h4><div class="NLM_p last">Yield: 69%; Mp: 105–106 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 7.84 (s, 2H), 6.87 (s, 2H), 3.79 (s, 18H), 2.02 (d, <i>J</i> = 8.5 Hz, 4H), 1.72 (m, H); 1.16 (d, <i>J</i> = 8.5 Hz, 3H); <sup>13</sup>C NMR (500 MHz, CDCl<sub>3</sub>) δ: 185.6, 150.8, 146.9, 146.4, 145.9, 134.8, 130.6, 107.5, 99.8, 56.8, 56.5, 56.0, 31.5, 29.3, 22.5; HRMS (ESI) <i>m</i>/<i>z</i>: 627.65 [M + H]<sup>+</sup>, Microanalysis calculated for C<sub>27</sub>H<sub>30</sub>Br<sub>2</sub>O<sub>7</sub> (626.33), C: 51.78%, H: 4.83%. Found C: 51.92%, H: 4.99%.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 3,5-Bis(2-bromo-3,4,5-trimethoxy-benzylidene)-1-methyl-piperidin-4-one (<b>4o</b>)</h4><div class="NLM_p last">Yield: 55%; Mp: 140–141 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 7.81 (s, 2H), 6.84 (s, 2H), 3.81 (s, 18H), 2.72 (s, 4H), 2.16 (s, 3H); <sup>13</sup>C NMR (500 MHz, CDCl<sub>3</sub>) δ: 184.9, 150.6, 147.5, 145.2, 144.9, 135.3, 131.8, 106.2, 99.5, 56.7, 56.1, 55.9, 41.5, 16.5; HRMS (ESI) <i>m</i>/<i>z</i>: 628.32 [M + H]<sup>+</sup>, Microanalysis calculated for C<sub>26</sub>H<sub>29</sub>Br<sub>2</sub>NO<sub>7</sub> (627.32), C: 49.78%, H: 4.66%, N: 2.23%. Found C: 49.91%, H: 4.86%, N: 2.12%.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 2-(2-Bromo-3,4,5-trimethoxy-benzylidene)-4-methyl-tetralone (<b>5f</b>)</h4><div class="NLM_p last">Yield: 69%; Mp: 90–91 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 7.69 (s, H), 7.27 (d, <i>J</i> = 7.5 Hz, H), 7.19 (d, <i>J</i> = 7.5 Hz, H), 7.07 (t, <i>J</i> = 7.5 Hz, H), 6.91 (t, <i>J</i> = 7.0 Hz, H), 6.47 (s, H), 3.56 (s, 9H), 2.19 (d, <i>J</i> = 8.5 Hz, 2H), 1.79 (m, H); 1.19 (d, <i>J</i> = 8.5 Hz, 3H); <sup>13</sup>C NMR (500 MHz, CDCl<sub>3</sub>) δ: 184.5, 150.7, 149.1, 147.1, 146.8, 145.2, 137.3, 134.5, 134.0, 130.2, 127.3, 125.5, 124.8, 106.9, 98.7, 56.9, 56.1, 55.8, 30.4, 29.7, 21.8; HRMS (ESI) <i>m</i>/<i>z</i>: 418.32 [M + H]<sup>+</sup>, Microanalysis calculated for C<sub>21</sub>H<sub>21</sub>BrO<sub>4</sub> (417.29), C: 60.44%, H: 5.07%. Found C: 60.52%, H: 5.15%.</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 2-(2-Bromo-3,4,5-trimethoxy-benzylidene)-5-hydroxy-tetralone (<b>5i</b>)</h4><div class="NLM_p last">Yield: 72%; Mp: 94–95 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 7.68 (s, H), 7.15 (d, <i>J</i> = 7.5 Hz, H), 7.02 (t, <i>J</i> = 7.0 Hz, H), 6.90 (d, <i>J</i> = 7.5 Hz, H), 6.42 (s, H), 5.81 (s, H), 3.52 (s, 9H), 2.52 (t, <i>J</i> = 8.0 Hz, 2H), 2.13 (t, <i>J</i> = 8.0 Hz, 2H); <sup>13</sup>C NMR (500 MHz, CDCl<sub>3</sub>) δ: 184.9, 159.6, 149.2, 147.2, 146.1, 140.2, 137.8, 134.4, 134.0, 130.5, 126.2, 122.4, 120.2, 105.5, 96.1, 56.8, 56.0, 55.8, 31.2, 27.8; HRMS (ESI) <i>m</i>/<i>z</i>: 420.46 [M + H]<sup>+</sup>, Microanalysis calculated for C<sub>20</sub>H<sub>19</sub>BrO<sub>5</sub> (419.27), C: 57.29%, H: 4.57%. Found C: 57.52%, H: 4.65%.</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 2-(2-Bromo-3,4,5-trimethoxy-benzylidene)-7-methoxy-tetralone (<b>5o</b>)</h4><div class="NLM_p last">Yield: 76%; Mp: 92–93 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 7.80 (s, H), 7.21 (d, <i>J</i> = 8.0 Hz, H), 7.02 (s, H), 6.85 (d, <i>J</i> = 8.0 Hz, H), 6.55 (s, H), 3.59 (s, 3H), 3.50 (s, 9H), 2.50 (t, <i>J</i> = 8.0 Hz, 2H), 2.18 (t, <i>J</i> = 8.0 Hz, 2H); <sup>13</sup>C NMR (500 MHz, CDCl<sub>3</sub>) δ: 185.3, 159.9, 148.9, 147.4, 146.3, 141.0, 137.2, 134.5, 134.2, 130.5, 126.5, 123.0, 119.1, 102.7, 99.4, 56.8, 56.2, 56.0, 55.8, 30.6, 25.9; HRMS (ESI) <i>m</i>/<i>z</i>: 456.62 [M + Na]<sup>+</sup>, Microanalysis calculated for C<sub>21</sub>H<sub>21</sub>BrO<sub>5</sub> (433.29), C: 58.21%, H: 4.89%. Found C: 58.51%, H: 4.91%.</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 2-(2-Bromo-3,4,5-trimethoxy-benzylidene)-7,8-dimethoxy-tetralone (<b>5u</b>)</h4><div class="NLM_p last">Yield: 72%; Mp: 98–99 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 7.89 (s, H), 7.12 (s, H), 6.75 (s, H), 6.25 (s, H), 3.58 (s, 6H), 3.64 (s, 9H), 2.54 (t, <i>J</i> = 8.0 Hz, 2H), 2.18 (t, <i>J</i> = 8.5 Hz, 2H); <sup>13</sup>C NMR (500 MHz, CDCl<sub>3</sub>) δ: 186.5, 152.7, 148.3, 147.2, 146.0, 140.6, 135.9, 134.9, 134.4, 131.2, 125.2, 122.6, 119.6, 102.2, 93.2, 56.1, 55.9, 55.5, 55.3, 55.0, 29.4, 21.2; HRMS (ESI) <i>m</i>/<i>z</i>: 464.72 [M + H]<sup>+</sup>, Microanalysis calculated for C<sub>22</sub>H<sub>23</sub>BrO<sub>6</sub> (463.32), C: 57.03%, H: 5.00%. Found C: 57.25%, H: 5.15%.</div></div><div id="sec4_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 2-(2-Bromo-3,4,5-trimethoxy-benzylidene)-6,9-dimethoxy-tetralone (<b>5x</b>)</h4><div class="NLM_p last">Yield: 69%; Mp: 98–99 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 7.85 (s, H), 7.05 (d, <i>J</i> = 7.5 Hz, H), 6.82 (d, <i>J</i> = 7.5 Hz, H), 6.24 (s, H), 3.72 (s, 15H), 2.52 (t, <i>J</i> = 8.0 Hz, 2H), 2.10 (t, <i>J</i> = 8.0 Hz, 2H); <sup>13</sup>C NMR (500 MHz, CDCl<sub>3</sub>) δ: 186.2, 151.9, 148.5, 147.4, 146.0, 140.4, 136.2, 134.6, 134.3, 131.0, 125.4, 123.1, 119.5, 102.5, 94.0, 56.2, 55.9, 55.4, 55.2, 55.0, 29.8, 21.6; HRMS (ESI) <i>m</i>/<i>z</i>: 464.36 [M + H]<sup>+</sup>, Microanalysis calculated for C<sub>22</sub>H<sub>23</sub>BrO<sub>6</sub> (463.32), C: 57.03%, H: 5.00%. Found C: 57.24%, H: 5.12%.</div></div><div id="sec4_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 2-(2-Chloro-3,4-dimethoxy-benzylidene)-8-nitro-tetralone (<b>5af</b>)</h4><div class="NLM_p last">Yield: 62%; Mp: 94–95 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 7.96 (s, H), 7.64 (d, <i>J</i> = 8 Hz, H), 7.32 (d, <i>J</i> = 8 Hz, H), 7.12 (d, <i>J</i> = 7.5 Hz, H), 6.92 (d, <i>J</i> = 7.5 Hz, H), 6.52 (s, H), 3.89 (s, 6H), 2.82 (t, <i>J</i> = 8.0 Hz, 2H), 2.24 (t, <i>J</i> = 8.0 Hz, 2H); <sup>13</sup>C NMR (500 MHz, CDCl<sub>3</sub>) δ: 190.2, 154.5, 149.5, 147.1, 146.6, 138.5, 132.1, 130.5, 129.3, 127.5, 125.2, 124.6, 120.8, 100.6, 94.4, 56.8, 56.6, 27.3, 19.4; HRMS (ESI) <i>m</i>/<i>z</i>: 374.80 [M + H]<sup>+</sup>, Microanalysis calculated for C<sub>19</sub>H<sub>16</sub>ClNO<sub>5</sub> (373.79), C: 61.05%, H: 4.31%, N: 3.75%. Found C: 61.46%, H: 4.49%, N: 3.54%.</div></div><div id="sec4_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 2-(2-Bromo-3,4,5-trimethoxy-benzylidene)-8-nitro-tetralone (<b>5ag</b>)</h4><div class="NLM_p last">Yield: 54%; Mp: 98–99 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 7.92 (s, H), 7.66 (d, <i>J</i> = 8 Hz, H), 7.14 (s, H), 6.89 (d, <i>J</i> = 7.5 Hz, H), 6.58 (s, H), 3.81 (s, 9H), 2.88 (t, <i>J</i> = 8.0 Hz, 2H), 2.19 (t, <i>J</i> = 8.0 Hz, 2H); <sup>13</sup>C NMR (500 MHz, CDCl<sub>3</sub>) δ: 191.0, 154.2, 148.6, 147.4, 146.2, 137.2, 132.6, 130.1, 128.8, 127.1, 125.3, 124.6, 121.2, 99.4, 95.5, 56.9, 56.6, 55.8, 25.4, 20.2; HRMS (ESI) <i>m</i>/<i>z</i>: 449.50 [M + H]<sup>+</sup>, Microanalysis calculated for C<sub>20</sub>H<sub>18</sub>BrNO<sub>6</sub> (448.26), C: 53.59%, H: 4.05%, N: 3.12%. Found C: 53.64%, H: 4.22%, N: 3.06%.</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Synthesis of Oxime Analogs</h3><div class="NLM_p">Particular α,β-unsaturated carbonyl based compounds acted as precursors for the synthesis of oxime analogs. Hydroxylamine hydrochloride (2 mmol) was reacted with each selected compound (1 mmol) in 10 mL ethanol to yield the respective oxime (<b>7c</b>, <b>7f</b>, <b>7o</b>, <b>8f</b>, <b>8i</b>, <b>8o</b>, <b>8u</b>, <b>8x</b>, <b>8af</b>, and <b>8ag</b>). The average completion time of a reaction was around 6–8 h, as determined by TLC. The mixture was filtered and the solvent was evaporated using rotary evaporator after the completion of reaction. To extract organic compounds, dichloromethane (15 mL × 3) and distilled water (15 mL) were added to the mixture. Anhydrous MgSO<sub>4</sub> was used to dry the organic extracts, followed by their filtration and concentration under reduced pressure. The purity of the product was determined by using TLC. The product was recrystallized from ethyl acetate to yield solid powder. Column chromatography using ethyl acetate:hexane (70:30 v/v) as eluent was used to purify certain products.</div><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 2,6-Bis(2-bromo-3,4,5-trimethoxy-benzylidene)-cyclohexanone oxime (<b>7c</b>)</h4><div class="NLM_p last">Yield: 55%; Mp: 105–106 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 8.39 (s, H), 7.14 (s, 2H), 6.21 (s, 2H), 3.75 (s, 18H), 2.10 (d, <i>J</i> = 8.5 Hz, 4H), 1.81 (m, 2H); <sup>13</sup>C NMR (500 MHz, CDCl<sub>3</sub>) δ: 164.5, 148.6, 146.5, 145.4, 142.2, 134.5, 130.1, 105.2, 98.8, 56.9, 56.5, 56.0, 29.2, 28.1; HRMS (ESI) <i>m</i>/<i>z</i>: 628.35 [M + H]<sup>+</sup>, Microanalysis calculated for C<sub>26</sub>H<sub>29</sub>Br<sub>2</sub>NO<sub>7</sub> (627.32), C: 49.78%, H: 4.66%, N: 2.23%. Found C: 49.92%, H: 4.72%, N: 2.19%.</div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 2,6-Bis(2-bromo-3,4,5-trimethoxy-benzylidene)-4-methyl-cyclohexanone oxime (<b>7f</b>)</h4><div class="NLM_p last">Yield: 49%; Mp: 108–109 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 8.42 (s, H), 7.12 (s, 2H), 6.27 (s, 2H), 3.72 (s, 18H), 2.12 (d, <i>J</i> = 8.5 Hz, 4H), 1.75 (m, H); 1.24 (d, <i>J</i> = 8.5 Hz, 3H); <sup>13</sup>C NMR (500 MHz, CDCl<sub>3</sub>) δ: 162.2, 148.8, 146.4, 145.4, 141.6, 134.6, 130.7, 107.4, 98.2, 56.4, 56.2, 56.0, 30.2, 28.4, 22.2; HRMS (ESI) <i>m</i>/<i>z</i>: 642.37 [M + H]<sup>+</sup>, Microanalysis calculated for C<sub>27</sub>H<sub>31</sub>Br<sub>2</sub>NO<sub>7</sub> (641.35), C: 50.56%, H: 4.87%, N: 2.18%. Found C: 50.92%, H: 4.92%, N: 2.10%.</div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 3,5-Bis(2-bromo-3,4,5-trimethoxy-benzylidene)-1-methyl-piperidin-4-one oxime (<b>7o</b>)</h4><div class="NLM_p last">Yield: 42%; Mp: 132–133 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 8.38 (s, H), 7.14 (s, 2H), 6.29 (s, 2H), 3.75 (s, 18H), 2.61 (s, 4H), 2.14 (s, 3H); <sup>13</sup>C NMR (500 MHz, CDCl<sub>3</sub>) δ: 164.1, 150.2, 147.3, 145.5, 142.2, 135.5, 131.6, 105.9, 99.1, 56.7, 56.3, 56.1, 42.0, 16.2; HRMS (ESI) <i>m</i>/<i>z</i>: 643.14 [M + H]<sup>+</sup>, Microanalysis calculated for C<sub>26</sub>H<sub>30</sub>Br<sub>2</sub>N<sub>2</sub>O<sub>7</sub> (642.33), C: 48.62%, H: 4.71%, N: 4.36%. Found C: 48.85%, H: 4.79%, N: 4.25%.</div></div><div id="sec4_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 2-(2-Bromo-3,4,5-trimethoxy-benzylidene)-4-methyl-tetralone oxime (<b>8f</b>)</h4><div class="NLM_p last">Yield: 50%; Mp: 114–115 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 8.29 (s, H), 7.42 (s, H), 6.85 (t, <i>J</i> = 7 Hz, H), 6.79 (t, <i>J</i> = 7 Hz, H), 6.44 (d, <i>J</i> = 7.5 Hz, H), 6.35 (d, <i>J</i> = 7.5 Hz, H), 6.28 (s, H), 3.71 (s, 9H), 2.51 (d, <i>J</i> = 7 Hz, 2H), 2.0 (m, H); 1.25 (d, <i>J</i> = 8.5 Hz, 3H); <sup>13</sup>C NMR (500 MHz, CDCl<sub>3</sub>) δ: 167.2, 151.9, 148.6, 146.5, 144.5, 139.5, 135.7, 134.1, 132.5, 131.2, 125.5, 122.2, 118.5, 99.8, 92.5, 56.8, 56.2, 55.5, 29.6, 24.5, 22.5; HRMS (ESI) <i>m</i>/<i>z</i>: 433.31 [M + H]<sup>+</sup>, Microanalysis calculated for C<sub>21</sub>H<sub>22</sub>BrNO<sub>4</sub> (432.31), C: 58.34%, H: 5.13%, N: 3.24%. Found C: 58.55%, H: 5.29%, N: 3.12%.</div></div><div id="sec4_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 2-(2-Bromo-3,4,5-trimethoxy-benzylidene)-6-hydroxy-tetralone oxime (<b>8i</b>)</h4><div class="NLM_p last">Yield: 57%; Mp: 119–120 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 8.32 (s, H), 7.46 (s, H), 6.82 (t, <i>J</i> = 7 Hz, H), 6.70 (d, <i>J</i> = 7.5 Hz, H), 6.38 (d, <i>J</i> = 7.5 Hz, H), 6.22 (s, H), 4.09 (s, H), 3.75 (s, 9H), 2.57 (t, <i>J</i> = 7 Hz, 2H), 1.98 (t, <i>J</i> = 7.5 Hz, 2H); <sup>13</sup>C NMR (500 MHz, CDCl<sub>3</sub>) δ: 167.5, 152.2, 148.4, 146.1, 143.9, 139.7, 134.9, 133.8, 132.5, 131.1, 124.9, 121.6, 118.7, 99.2, 92.7, 56.9, 56.1, 55.8, 29.2, 24.1; HRMS (ESI) <i>m</i>/<i>z</i>: 435.29 [M + H]<sup>+</sup>, Microanalysis calculated for C<sub>20</sub>H<sub>20</sub>BrNO<sub>5</sub> (434.28), C: 55.31%, H: 4.64%, N: 3.23%. Found C: 55.52%, H: 4.68%, N: 3.20%.</div></div><div id="sec4_3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 2-(2-Bromo-3,4,5-trimethoxy-benzylidene)-7-methoxy-tetralone oxime (<b>8o</b>)</h4><div class="NLM_p last">Yield: 55%; Mp: 117–118 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 8.28 (s, H), 7.42 (s, H), 6.81 (d, <i>J</i> = 7 Hz, H), 6.76 (d, <i>J</i> = 7.5 Hz, H), 6.42 (s, H), 6.25 (s, H), 3.78 (s, 12H), 2.55 (t, <i>J</i> = 7 Hz, 2H), 1.99 (t, <i>J</i> = 7.5 Hz, 2H); <sup>13</sup>C NMR (500 MHz, CDCl<sub>3</sub>) δ: 168.2, 152.8, 148.1, 146.5, 142.1, 139.6, 134.2, 133.9, 132.4, 130.2, 124.6, 120.8, 118.2, 99.1, 92.5, 57.5, 56.8, 56.2, 55.7, 29.5, 25.1; HRMS (ESI) <i>m</i>/<i>z</i>: 449.35 [M + H]<sup>+</sup>, Microanalysis calculated for C<sub>21</sub>H<sub>22</sub>BrNO<sub>5</sub> (448.31), C: 56.26%, H: 4.95%, N: 3.12%. Found C: 56.29%, H: 4.99%, N: 3.09%.</div></div><div id="sec4_3_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 2-(2-Bromo-3,4,5-trimethoxy-benzylidene)-7,8-dimethoxy-tetralone oxime (<b>8u</b>)</h4><div class="NLM_p last">Yield: 59%; Mp: 111–112 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 8.29 (s, H), 7.45 (s, H), 6.75 (s, H), 6.42 (s, H), 6.25 (s, H), 3.78 (s, 15H), 2.52 (t, <i>J</i> = 7 Hz, 2H), 1.97 (t, <i>J</i> = 7.5 Hz, 2H); <sup>13</sup>C NMR (500 MHz, CDCl<sub>3</sub>) δ: 168.9, 152.4, 147.6, 146.2, 141.9, 139.5, 134.3, 132.4, 131.9, 130.0, 124.2, 120.9, 118.7, 98.8, 92.4, 57.5, 56.9, 56.2, 55.7, 55.2, 29.4, 25.8; HRMS (ESI) <i>m</i>/<i>z</i>: 479.35 [M + H]<sup>+</sup>, Microanalysis calculated for C<sub>22</sub>H<sub>24</sub>BrNO<sub>6</sub> (478.33), C: 55.24%, H: 5.06%, N: 2.93%. Found C: 55.29%, H: 5.10%, N: 2.88%.</div></div><div id="sec4_3_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 2-(2-Bromo-3,4,5-trimethoxy-benzylidene)-6,9-dimethoxy-tetralone oxime (<b>8x</b>)</h4><div class="NLM_p last">Yield: 52%; Mp: 112–114 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 8.39 (s, H), 7.15 (s, H), 6.43 (d, <i>J</i> = 7.2 Hz, H), 6.38 (d, <i>J</i> = 7.4 Hz, H), 6.29 (s, H), 3.68 (s, 15H), 2.51 (t, <i>J</i> = 6.8 Hz, 2H), 1.99 (t, <i>J</i> = 7.5 Hz, 2H); <sup>13</sup>C NMR (500 MHz, CDCl<sub>3</sub>) δ: 166.5, 151.3, 148.1, 146.2, 145.0, 139.2, 136.7, 134.2, 133.9, 131.5, 124.8, 123.5, 117.2, 100.1, 94.6, 56.7, 56.4, 56.2, 55.9, 55.5, 29.6, 21.5; HRMS (ESI) <i>m</i>/<i>z</i>: 479.45 [M + H]<sup>+</sup>, Microanalysis calculated for C<sub>22</sub>H<sub>24</sub>BrNO<sub>6</sub> (478.33), C: 55.24%, H: 5.06%, N: 2.93%. Found C: 55.29%, H: 5.18%, N: 2.91%.</div></div><div id="sec4_3_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 2-(2-Chloro-3,4-dimethoxy-benzylidene)-8-nitro-tetralone oxime (<b>8af</b>)</h4><div class="NLM_p last">Yield: 57%; Mp: 124–125 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 8.47 (s, H), 7.26 (s, H), 7.14 (d, <i>J</i> = 8.4 Hz, H), 7.04 (d, <i>J</i> = 7.4 Hz, H), 6.87 (d, <i>J</i> = 7.2 Hz, H), 6.65 (d, <i>J</i> = 7.5 Hz, H), 6.50 (s, H), 3.74 (s, 6H), 2.75 (t, <i>J</i> = 8.2 Hz, 2H), 2.14 (t, <i>J</i> = 8.2 Hz, 2H); <sup>13</sup>C NMR (500 MHz, CDCl<sub>3</sub>) δ: 164.5, 152.3, 149.2, 147.8, 145.2, 138.6, 132.9, 130.1, 128.7, 127.1, 125.2, 124.1, 121.3, 99.9, 93.7, 57.1, 56.8, 28.8, 19.1; HRMS (ESI) <i>m</i>/<i>z</i>: 389.80 [M + H]<sup>+</sup>, Microanalysis calculated for C<sub>19</sub>H<sub>17</sub>ClN<sub>2</sub>O<sub>5</sub> (388.80), C: 58.69%, H: 4.41%, N: 7.21%. Found C: 58.72%, H: 4.49%, N: 7.25%.</div></div><div id="sec4_3_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 2-(2-Bromo-3,4,5-trimethoxy-benzylidene)-8-nitro-tetralone oxime (<b>8ag</b>)</h4><div class="NLM_p last">Yield: 54%; Mp: 98–99 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 8.45 (s, H), 7.32 (s, H), 7.22 (d, <i>J</i> = 8.2 Hz, H), 7.10 (s, H), 6.75 (d, <i>J</i> = 8.2 Hz, H), 6.48 (s, H), 3.72 (s, 9H), 2.81 (t, <i>J</i> = 8.0 Hz, 2H), 2.09 (t, <i>J</i> = 8.0 Hz, 2H); <sup>13</sup>C NMR (500 MHz, CDCl<sub>3</sub>) δ: 167.9, 154.6, 148.4, 146.5, 145.1, 137.6, 131.9, 130.0, 128.5, 126.9, 125.1, 124.7, 120.8, 98.8, 95.2, 56.8, 56.5, 56.0, 25.2, 19.7; HRMS (ESI) <i>m</i>/<i>z</i>: 449.50 [M + H]<sup>+</sup>, Microanalysis calculated for C<sub>20</sub>H<sub>19</sub>BrN<sub>2</sub>O<sub>6</sub> (463.28), C: 51.85%, H: 4.13%, N: 6.05%. Found C: 51.59%, H: 4.29%, N: 6.14%.</div></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> Synthesis of oxime ether analogs</h3><div class="NLM_p">Dry acetone (10.0 mL), baked K<sub>2</sub>CO<sub>3</sub> (5 mmol), haloalkylamine hydrochloride (1.2 mmol) and respective oxime analog (1 mmol) were taken in a round-bottom flask and refluxed for 8 h under anhydrous conditions. TLC was used to monitor the reaction (silica gel plate as stationary phase while 5% methanol in chloroform as mobile phase). Once the reaction was completed, K<sub>2</sub>CO<sub>3</sub> was filtered off from the mixture followed by washing with acetone (3 × 10 mL). The filtrate was concentrated and purification of crude product was carried out using distilled hexane-based basic alumina column chromatography.</div><div id="sec4_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 3,5-Bis(2-bromo-3,4,5-trimethoxy-benzylidene)-1-methyl-cyclohexanone-O-(2-diethylamino-ethyl)-oxime (<b>10f</b>)</h4><div class="NLM_p last">Yield: 62%; Mp: 106–107 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 7.12 (s, 2H), 6.87 (s, 2H), 4.51 (m, 2H), 3.81 (s, 18H), 2.60 (m, 4H), 2.51 (m, 2H), 2.14 (d, <i>J</i> = 8.5 Hz, 4H), 1.76 (m, H); 1.70 (t, <i>J</i> = 7.0 Hz, 6H); 1.25 (d, <i>J</i> = 8.5 Hz, 3H);<sup>13</sup>C NMR (500 MHz, CDCl<sub>3</sub>) δ: 164.5, 152.5, 147.5, 145.1, 140.8, 135.9, 132.4, 104.1, 98.9, 72.1, 56.9, 56.2, 55.8, 52.1, 48.2, 42.5,30.9, 17.5, 14.9; HRMS (ESI) <i>m</i>/<i>z</i>: 741.52 [M + H]<sup>+</sup>, Microanalysis calculated for C<sub>32</sub>H<sub>44</sub>Br<sub>2</sub>N<sub>2</sub>O<sub>7</sub> (740.52), C: 53.52%, H: 5.99%, N: 3.78%. Found C: 53.54%, H: 6.12%, N: 3.62%.</div></div><div id="sec4_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 3,5-Bis(2-bromo-3,4,5-trimethoxy-benzylidene)-1-methyl-piperidin-4-one-<i>O</i>-(2-diethylamino-ethyl)-oxime (<b>10o</b>)</h4><div class="NLM_p last">Yield: 50%; Mp: 111–113 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 7.10 (s, 2H), 6.89 (s, 2H), 4.52 (m, 2H), 3.78 (s, 18H), 2.62 (s, 4H), 2.55 (m, 2H), 2.42 (m, 4H), 2.19 (s, 3H), 1.75 (t, <i>J</i> = 7.0 Hz, 6H); <sup>13</sup>C NMR (500 MHz, CDCl<sub>3</sub>) δ: 164.7, 151.3, 147.8, 145.5, 141.4, 135.9, 132.0, 104.7, 99.6, 72.2, 56.8, 56.6, 56.2, 52.0, 48.4, 42.1, 17.7, 14.4; HRMS (ESI) <i>m</i>/<i>z</i>: 742.55 [M + H]<sup>+</sup>, Microanalysis calculated for C<sub>32</sub>H<sub>43</sub>Br<sub>2</sub>N<sub>3</sub>O<sub>7</sub> (741.51), C: 51.83%, H: 5.85%, N: 5.67%. Found C: 51.89%, H: 5.92%, N: 5.52%.</div></div><div id="sec4_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 2-(2-Bromo-3,4,5-trimethoxy-benzylidene)-8-nitro-tetralone-<i>O</i>-(2-diethylamino-ethyl)-oxime (<b>11x</b>)</h4><div class="NLM_p last">Yield: 49%; Mp: 121–122 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 7.25 (s, H), 7.02 (d, <i>J</i> = 8.0 Hz, H), 6.91 (s, H), 6.65 (d, <i>J</i> = 8.0 Hz, H), 4.50 (m, 2H), 3.68 (s, 15H), 2.87 (t, <i>J</i> = 8.0 Hz, 2H), 2.55 (m, 2H), 2.40 (m, 4H), 2.08 (t, <i>J</i> = 8.0 Hz, 2H); 1.70 (t, <i>J</i> = 7.0 Hz, 6H); <sup>13</sup>C NMR (500 MHz, CDCl<sub>3</sub>) δ: 170.2, 153.5, 148.7, 146.1, 145.2, 135.6, 131.0, 129.5, 127.2, 126.2, 125.0, 124.1, 118.4, 98.2, 95.1, 72.5, 56.8, 56.2, 56.0, 55.5, 55.2, 52.4, 48.8, 25.1, 19.9, 14.2; HRMS (ESI) <i>m</i>/<i>z</i>: 578.55 [M + H]<sup>+</sup>, Microanalysis calculated for C<sub>28</sub>H<sub>37</sub>BrN<sub>2</sub>O<sub>6</sub> (577.51), C: 58.23%, H: 6.46%, N: 4.85%. Found C: 58.25%, H: 6.72%, N: 4.75%.</div></div><div id="sec4_4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 2-(2-Chloro-4,5-dimethoxy-benzylidene)-8-nitro-tetralone-<i>O</i>-(2-diethylamino-ethyl)-oxime (<b>11af</b>)</h4><div class="NLM_p last">Yield: 47%; Mp: 117–118 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 7.29 (s, H), 6.99 (d, <i>J</i> = 8.0 Hz, H), 6.89 (d, <i>J</i> = 8.0 Hz, H), 6.72 (d, <i>J</i> = 8.0 Hz, H), 6.58 (d, <i>J</i> = 8.0 Hz, H), 6.40 (s, H), 4.55 (m, 2H), 3.68 (s, 6H), 3.10 (t, <i>J</i> = 8.4 Hz, 2H), 2.52 (m, 2H), 2.43 (m, 4H), 2.12 (t, <i>J</i> = 8.2, 2H), 1.75 (t, <i>J</i> = 7.0 Hz, 6H); <sup>13</sup>C NMR (500 MHz, CDCl<sub>3</sub>) δ: 169.5, 154.5, 148.0, 146.9, 145.1, 136.8, 132.0, 129.2, 128.5, 125.5, 124.9, 124.1, 118.9, 98.9, 95.2, 72.5, 56.9, 56.1, 52.0, 48.2, 25.5, 20.6, 15.1; HRMS (ESI) <i>m</i>/<i>z</i>: 488.98 [M + H]<sup>+</sup>, Microanalysis calculated for C<sub>25</sub>H<sub>30</sub>ClN<sub>3</sub>O<sub>5</sub> (487.98), C: 61.53%, H: 6.20%, N: 8.61%. Found C: 61.55%, H: 6.25%, N: 8.55%.</div></div><div id="sec4_4_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 2-(2-Bromo-3,4,5-trimethoxy-benzylidene)-8-nitro-tetralone-<i>O</i>-(2-diethylamino-ethyl)-oxime (<b>11ag</b>)</h4><div class="NLM_p last">Yield: 42%; Mp: 119–120 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 7.24 (s, H), 7.05 (d, <i>J</i> = 8.0 Hz, H), 6.90 (s, H), 6.68 (d, <i>J</i> = 8.0 Hz, H), 6.42 (s, H), 4.59 (m, 2H), 3.64 (s, 9H), 3.12 (t, <i>J</i> = 8.4 Hz, 2H), 2.58 (m, 2H), 2.41 (m, 4H), 2.10 (t, <i>J</i> = 8.2, 2H), 1.72 (t, <i>J</i> = 7.0 Hz, 6H); <sup>13</sup>C NMR (500 MHz, CDCl<sub>3</sub>) δ: 169.9, 153.5, 148.2, 146.8, 145.9, 136.2, 131.3, 129.9, 128.4, 126.5, 125.2, 124.0, 119.1, 98.5, 94.0, 72.4, 56.9, 56.4, 56.0, 52.1, 48.1, 25.7, 20.2, 14.9; HRMS (ESI) <i>m</i>/<i>z</i>: 563.44 [M + H]<sup>+</sup>, Microanalysis calculated for C<sub>26</sub>H<sub>32</sub>BrN<sub>3</sub>O<sub>6</sub> (562.45), C: 55.52%, H: 5.73%, N: 7.47%. Found C: 55.59%, H: 5.92%, N: 7.62%.</div></div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> MTT Assay</h3><div class="NLM_p last">To investigate the effect of synthesized compounds on mammary epithelial cells (MCF-10A), MTT assay was performed.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> The cells were propagated in medium consisting of Ham’s F-12 medium/Dulbecco’s modified Eagle’s medium (DMEM) (1:1) supplemented with 10% fetal calf serum, 2 mM glutamine, insulin (10 μg/mL), hydrocortisone (500 ng/mL), and epidermal growth factor (20 ng/mL). Trypsin ethylenediamine tetra acetic acid (EDTA) was used to passage the cells after every 2–3 days. 96-well flat-bottomed cell culture plates were used to seed the cells at a density of 10<sup>4</sup> cells mL<sup>–1</sup>. The medium was aspirated from all the wells of culture plates after 24 h followed by the addition of synthesized compounds (in 200 μL medium to yield a final concentration of 0.1% (v/v) dimethyl sulfoxide) into individual wells of the plates. Four wells were designated to a single compound. The plates were allowed to incubate at 37 °C for 96 h. Afterward, the medium was aspirated and 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) (0.4 mg/mL) in medium was added to each well and subsequently incubated for 3 h. The medium was aspirated and 150 μL dimethyl sulfoxide (DMSO) was added to each well. The plates were vortexed followed by the measurement of absorbance at 540 nm on a microplate reader. The results were presented as inhibition (%) of proliferation in contrast to controls comprising 0.1% DMSO.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> Assay for Antiproliferative Effect</h3><div class="NLM_p last">Propidium iodide fluorescence assay<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> was carried out on Panc-1 (pancreas cancer), PaCa-2 (pancreatic carcinoma), MCF-7 (breast cancer): A-549 (epithelial): HT-29 (colon cancer), H-460 (lung cancer), and PC-3 (prostate cancer) cell lines to investigate the antiproliferative activity of compounds. Propidium iodide is a fluorescence dye which possesses ability to attach with DNA, therefore providing a precise and quick method for the calculation of total nuclear DNA. PI is incapable of crossing the plasma membrane and its fluorescence signal intensity is directly proportional to the amount of cellular DNA. Thus, cells with damaged plasma membranes or altered permeability are totaled as dead ones. To perform the assay, cells were seeded in 96-well flat-bottomed culture plates at a density of 3000–7500 cells/well in 200 μL medium and incubated at 37 °C for 24 h in humidified 5% CO<sub>2</sub>/95% air atmosphere. Later, the compounds at 10 μM concentrations (in 0.1% DMSO) were added in triplicate wells while 0.1% DMSO served as control, followed by a 48 h incubation of plates. The medium was removed and 25 μL PI (50 μg/mL in water/medium) was added in each well. The plates were then frozen at −80 °C for 24 h, followed by thawing and equilibration to 25 °C. The readings were recorded at excitation and emission wavelengths of 530 and 620 nm using a fluorometer (Polar-Star BMG Tech). The following formula was used to calculate the cytotoxicity (%) of compounds:<span class="NLM_disp-formula" id="ueq1"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00276/20160414/images/jm-2016-00276j_m001.gif" alt="" /></img></span>where <i>A</i><sub>C</sub> = Absorbance of control and <i>A</i><sub>TC</sub> = Absorbance of treated cells. To equate the results, erlotinib was used as positive control.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> Tubulin Polymerization Assay</h3><div class="NLM_p last">The activity of compounds on tubulin polymerization was investigated by Tubulin Polymerization Assay Kit (Cytoskeleton Inc., Denver, CO, USA), which works via fluorescent reporter enhancement.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> The fluorescence of compounds (dissolved in DMSO at 5 and 25 μM concentration) was recorded in triplicates using FLUO star OPTIMA. Docetaxel and vincristine (Apoteket AB, Sweden) served as positive stabilizing and destabilizing controls. Both were used at 3 μM concentration in PBS.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a></div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> EGFR Inhibitory Assay</h3><div class="NLM_p">Baculoviral expression vectors such as pFASTBacHTc and pBlueBacHis2B were separately used to clone 1.6 kb cDNA encoding for EGFR cytoplasmic domain (EGFR-CD, amino acids 645–1186) separately. 5′ upstream from the EGFR sequence was a sequence that encodes (His)<sub>6</sub>. For protein expression, Sf-9 cells were infected for 3 days. Sf-9 cell pellets were solubilized at pH 7.4 at 0 °C for 20 min in a buffer comprising 16 μg/mL benzamidine HCl, 10 μg/mL pepstatin, 10 μg/mL leupeptin, 10 μg/mL aprotinin, 100 μM sodium vanadate, 10 μM ammonium molybdate, 1% Triton, 10 mM NaCl, and 50 mM HEPES, followed by 20 min centrifugation. Using an equilibrated Ni-NTA superflow packed column, the crude extract supernatant was passed through and washed first with 10 mM and later with 100 mM imidazole for the elimination of nonspecifically bound material. Histidine-tagged proteins were eluted first with 250 and later with 500 mM imidazole followed by dialysis against 10% glycerol, 20 mM HEPES, 50 mM NaCl, and 1 μg/mL each of pepstatin, leupeptin, and aprotinin for 2 h. This purification was carried out either on ice or at 4 °C. On the basis of DELFIA/Time-Resolved Fluorometry, EGFR kinase assay was performed to measure the level of autophosphorylation. DMSO (100%) was used to dissolve the compounds, followed by dilution to suitable concentrations using 25 mM HEPES at pH 7.4. In every well, 10 μL (5 ng for EGFR) recombinant enzyme (1:80 dilution in 100 mM HEPES) was incubated with 10 μL compound at 25 °C for 10 min, followed by addition of 10 μL 5X buffer (containing 1 mM DTT, 100 μM Na<sub>3</sub>VO<sub>4</sub>, 2 mM MnCl<sub>2</sub>, and 20 mM HEPES) and 20 μL 0.1 mM ATP-50 mM MgCl<sub>2</sub> for 1 h. By incubating the enzyme with or without ATP-MgCl<sub>2</sub>, positive and negative controls were included in every plate. After incubation, liquid was removed, and wash buffer was used to wash the plates thrice. Each well of plate was added with 75 μL (400 ng) europium-labeled antiphosphotyrosine antibody for another 1 h, followed by washing. After adding the enhancement solution, the signal was detected (with excitation and emission at 340 at 615 nm, respectively) using Victor (Wallac Inc.). The following equation was used to calculate the autophosphorylation inhibition (%) by the compounds:<span class="NLM_disp-formula" id="ueq2"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00276/20160414/images/jm-2016-00276j_m002.gif" alt="" /></img></span></div><div class="NLM_p last">The IC<sub>50</sub> was calculated using the curves of inhibition (%) with eight concentrations of compound. Most of the signal detected by antiphosphotyrosine antibody is from EGFR, as the impurities in the enzyme preparation are quite low.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> BRAF Kinase Assay</h3><div class="NLM_p last">Each compound in this study was subjected to V600E mutant BRAF kinase assay in triplicate. 1 μL drug and 4 μL assay dilution buffer were preincubated with 7.5 ng mouse full-length GST-tagged BRAF<sup>V600E</sup> (Invitrogen, PV3849) at 25 °C for 1 h. The assay was started by adding 5 μL solution comprising 200 ng recombinant human full length, <i>N</i>-terminal His-tagged MEK1 (Invitrogen), 30 mM MgCl<sub>2</sub>, and 200 μM ATP in assay dilution buffer, followed by continuation at 25 °C for 25 min. Using 5× protein denaturing buffer (LDS) solution (5 μL), the assay was quenched. Further denaturing of protein was performed by heating at 70 °C for 5 min. Electrophoresis was performed at 200 V by loading 10 μL of each reaction into a 15-well 4–12% precast NuPage gel plate (Invitrogen). Once the electrophoresis was finished, the front (containing additional hot ATP) was cut from the gel and subsequently discarded. A phosphor screen was used to develop the dried gel. A reaction containing no inhibitor was used as positive control whereas a reaction without active enzyme served as negative control. ELISA kits (Invitrogen) were used per manufacturer’s protocol to investigate the effect of compounds on cell based pERK1/2 activity in cancer cells.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> MDR-Reversal Assay</h3><div class="NLM_p last">PHa MDR1/A retrovirus (20) was used to transfect L5178 mouse T-cell lymphoma cells (ATCC, USA). To maintain the expression of MDR phenotype, the <i>mdr1</i>-expressing cell line was cultured with 60 ng/mL colchicine. McCoy’s 5A medium (supplemented with antibiotics, <span class="smallcaps smallerCapital">l</span>-glutamine, and 10% heat-inactivated horse serum) was used to culture L5178 (parental) mouse T-cell lymphoma cells and the human <i>mdr1</i>-transfected subline at 37 °C in a 5% CO<sub>2</sub> atmosphere. At a density of 2 × 10<sup>6</sup>/mL, the cells were resuspended in serum-free McCoy’s 5A medium and 0.5 mL aliquots were transferred into eppendorf tubes. The compounds were added in the tubes at various concentrations (ranging from 4.0 and 40 μg/mL), followed by incubation at 25 °C for 10 min. 10 μL rhodamine 123 (5.2 μM final concentration) was added to the tubes, incubated again at 37 °C for 20 min, washed twice, followed by resuspension in 0.5 mL PBS. Using a flow cytometer, the fluorescence of cell population was measured. In rhodamine 123 exclusion study, verapamil served as positive control. The fluorescence intensity (%) was recorded for the parental and treated MDR cell lines in comparison with untreated cells. Using the following equation, the activity ratio (<i>R</i>) was calculated, based on the recorded fluorescence readings:<span class="NLM_disp-formula" id="ueq3"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00276/20160414/images/jm-2016-00276j_m003.gif" alt="" /></img></span></div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> Statistical Analysis</h3><div class="NLM_p last">All the experiments were performed in triplicate and data presented as the mean ± standard error of mean (SEM). The IC<sub>50</sub> values were calculated by using Graph Pad Prism 5 software. Data was analyzed using a one-way analysis of variance (ANOVA) for multiple comparisons.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i56"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00276">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51651" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51651" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b00276" class="ext-link">10.1021/acs.jmedchem.6b00276</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">HPLC analytical chromatograms of respective most active purified compounds (<b>7f</b>, <b>7o</b>, <b>8af</b>, and <b>8ag</b>) (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00276/suppl_file/jm6b00276_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00276/suppl_file/jm6b00276_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00276/suppl_file/jm6b00276_si_001.pdf">jm6b00276_si_001.pdf (491.04 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00276/suppl_file/jm6b00276_si_002.csv">jm6b00276_si_002.csv (1.76 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.6b00276" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25011" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25011" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hua-Li Qin</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Engineering, School of Chemistry, Chemical Engineering
and Life Science, Wuhan University of Technology, 205 Luoshi Road, Wuhan 430070, P.R. China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#b1c0d8dfd9c4d0ddd8f1c6d9c4c59fd4d5c49fd2df"><span class="__cf_email__" data-cfemail="acddc5c2c4d9cdc0c5ecdbc4d9d882c9c8d982cfc2">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Syed Nasir Abbas Bukhari</span> - <span class="hlFld-Affiliation affiliation">Drug
and Herbal Research Centre, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300 Kuala Lumpur, Malaysia</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#6c1f020d0e2c190701420908194201154c1f020d0e1c04082c150d040303420f0301"><span class="__cf_email__" data-cfemail="b8cbd6d9daf8cdd3d596dddccd96d5c1">[email protected]</span> <span class="__cf_email__" data-cfemail="abd8c5cac9dbc3cfebd2cac3c4c485c8c4c6">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jing Leng</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Engineering, School of Chemistry, Chemical Engineering
and Life Science, Wuhan University of Technology, 205 Luoshi Road, Wuhan 430070, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cheng-Pan Zhang</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Engineering, School of Chemistry, Chemical Engineering
and Life Science, Wuhan University of Technology, 205 Luoshi Road, Wuhan 430070, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ibrahim Jantan</span> - <span class="hlFld-Affiliation affiliation">Drug
and Herbal Research Centre, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300 Kuala Lumpur, Malaysia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Muhammad Wahab Amjad</span> - <span class="hlFld-Affiliation affiliation">Drug
and Herbal Research Centre, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300 Kuala Lumpur, Malaysia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Muhammad Sher</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry, University of Sargodha, Sargodha 40100, Pakistan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Muhammad Naeem-ul-Hassan</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry, University of Sargodha, Sargodha 40100, Pakistan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Muhammad Ajaz Hussain</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry, University of Sargodha, Sargodha 40100, Pakistan</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>These authors contributed equally. The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d3116e7091-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i58">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43176" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43176" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by the Research Incentive Fund of Universiti Kebangsaan Malaysia Arus Perdana grant (AP-2014-023). H.Q. is grateful to Wuhan University of Technology for financial support.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i59" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i59"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i60" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i60"> Abbreviations</h2><tr><td class="NLM_term">MDR</td><td class="NLM_def"><p class="first last">multidrug resistance</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">nonsmall cell lung</p></td></tr><tr><td class="NLM_term">RTK</td><td class="NLM_def"><p class="first last">receptor tyrosine kinases</p></td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">ABC</td><td class="NLM_def"><p class="first last">ATP-binding cassette</p></td></tr><tr><td class="NLM_term">NF-kB</td><td class="NLM_def"><p class="first last">NF-kappaB</p></td></tr><tr><td class="NLM_term">DRS</td><td class="NLM_def"><p class="first last">death receptors</p></td></tr><tr><td class="NLM_term">TFN</td><td class="NLM_def"><p class="first last">tumor necrosis factor</p></td></tr><tr><td class="NLM_term">PI</td><td class="NLM_def"><p class="first last">propidium iodide</p></td></tr><tr><td class="NLM_term">TKIs</td><td class="NLM_def"><p class="first last">tyrosine kinase inhibitors</p></td></tr><tr><td class="NLM_term">FAR</td><td class="NLM_def"><p class="first last">fluorescence activity ratio</p></td></tr><tr><td class="NLM_term">HRMS</td><td class="NLM_def"><p class="first last">high resolution mass spectra</p></td></tr><tr><td class="NLM_term">TLC</td><td class="NLM_def"><p class="first last">thin layer chromatography</p></td></tr><tr><td class="NLM_term">UV</td><td class="NLM_def"><p class="first last">ultraviolet</p></td></tr><tr><td class="NLM_term">DMEM</td><td class="NLM_def"><p class="first last">Dulbecco’s modified Eagle’s medium</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i61">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11146" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11146" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 48 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Kelland, L.</span><span> </span><span class="NLM_article-title">The resurgence of platinum-based cancer chemotherapy</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">573</span><span class="NLM_x">–</span> <span class="NLM_lpage">84</span><span class="refDoi"> DOI: 10.1038/nrc2167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1038%2Fnrc2167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=17625587" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotVKru7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=573-84&author=L.+Kelland&title=The+resurgence+of+platinum-based+cancer+chemotherapy&doi=10.1038%2Fnrc2167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The resurgence of platinum-based cancer chemotherapy</span></div><div class="casAuthors">Kelland, Lloyd</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">573-584</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The accidental discovery of the anticancer properties of cisplatin and its clin. introduction in the 1970s represent a major landmark in the history of successful anticancer drugs.  Although carboplatin - a second-generation analog that is safer but shows a similar spectrum of activity to cisplatin - was introduced in the 1980s, the pace of further improvements slowed for many years.  However, in the past several years interest in platinum drugs has increased.  Key developments include the elucidation of mechanisms of tumor resistance to these drugs, the introduction of new platinum-based agents (oxaliplatin, satraplatin and picoplatin), and clin. combination studies using platinum drugs with resistance modulators or new molecularly targeted drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTEI4HRCjxQrVg90H21EOLACvtfcHk0lhQ-fiQOp78Pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotVKru7c%253D&md5=9d55f600a83a19d7836a2524de20efbf</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc2167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2167%26sid%3Dliteratum%253Aachs%26aulast%3DKelland%26aufirst%3DL.%26atitle%3DThe%2520resurgence%2520of%2520platinum-based%2520cancer%2520chemotherapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D573%26epage%3D84%26doi%3D10.1038%2Fnrc2167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Lowery, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowery, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnett, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Acevedo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Secord, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Havrilesky, L.</span><span> </span><span class="NLM_article-title">Cost-effectiveness of early palliative care intervention in recurrent platinum-resistant ovarian cancer</span> <span class="citation_source-journal">Gynecol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">130</span><span class="NLM_x">, </span> <span class="NLM_fpage">426</span><span class="NLM_x">–</span> <span class="NLM_lpage">430</span><span class="refDoi"> DOI: 10.1016/j.ygyno.2013.06.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1016%2Fj.ygyno.2013.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=23769759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A280%3ADC%252BC3sjivVOrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2013&pages=426-430&author=W.+J.+Loweryauthor=A.+W.+Loweryauthor=J.+C.+Barnettauthor=M.+Lopez-Acevedoauthor=P.+S.+Leeauthor=A.+A.+Secordauthor=L.+Havrilesky&title=Cost-effectiveness+of+early+palliative+care+intervention+in+recurrent+platinum-resistant+ovarian+cancer&doi=10.1016%2Fj.ygyno.2013.06.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Cost-effectiveness of early palliative care intervention in recurrent platinum-resistant ovarian cancer</span></div><div class="casAuthors">Lowery William J; Lowery Ashlei W; Barnett Jason C; Lopez-Acevedo Micael; Lee Paula S; Secord Angeles Alvarez; Havrilesky Laura</div><div class="citationInfo"><span class="NLM_cas:title">Gynecologic oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">426-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  To determine if early palliative care intervention in patients with recurrent, platinum-resistant ovarian cancer is potentially cost saving or cost-effective.  METHODS:  A decision model with a 6 month time horizon evaluated routine care versus routine care plus early referral to a palliative medicine specialist (EPC) for recurrent platinum-resistant ovarian cancer.  Model parameters included rates of inpatient admissions, emergency department (ED) visits, chemotherapy administration, and quality of life (QOL).  From published ovarian cancer data, we assumed baseline rates over the final 6 months: hospitalization 70%, chemotherapy 60%, and ED visit 30%.  Published data from a randomized trial evaluating EPC in metastatic lung cancer were used to model odds ratios (ORs) for potential reductions in hospitalization (OR 0.69), chemotherapy (OR 0.77), and emergency department care (OR 0.74) and improvement in QOL (OR 1.07).  The costs of hospitalization, ED visit, chemotherapy, and EPC were based on published data.  Ranges were used for sensitivity analysis.  Effectiveness was quantified in quality adjusted life years (QALYs); survival was assumed equivalent between strategies.  RESULTS:  EPC was associated with a cost savings of $1285 per patient over routine care.  In sensitivity analysis incorporating QOL, EPC was either dominant or cost-effective, with an incremental cost-effectiveness ratio (ICER) <$50,000/QALY, unless the cost of outpatient EPC exceeded $2400.  Assuming no clinical benefit other than QOL (no change in chemotherapy administration, hospitalizations or ED visits), EPC remained highly cost-effective with ICER $37,440/QALY.  CONCLUSION:  Early palliative care intervention has the potential to reduce costs associated with end of life care in patients with ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQe47xmG1f2pJ6KlWarZTAzfW6udTcc2ebWPuYCKTjgVbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sjivVOrtw%253D%253D&md5=b697aa90be16e33df917a6f43864214e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.ygyno.2013.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ygyno.2013.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DLowery%26aufirst%3DW.%2BJ.%26aulast%3DLowery%26aufirst%3DA.%2BW.%26aulast%3DBarnett%26aufirst%3DJ.%2BC.%26aulast%3DLopez-Acevedo%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DP.%2BS.%26aulast%3DSecord%26aufirst%3DA.%2BA.%26aulast%3DHavrilesky%26aufirst%3DL.%26atitle%3DCost-effectiveness%2520of%2520early%2520palliative%2520care%2520intervention%2520in%2520recurrent%2520platinum-resistant%2520ovarian%2520cancer%26jtitle%3DGynecol.%2520Oncol.%26date%3D2013%26volume%3D130%26spage%3D426%26epage%3D430%26doi%3D10.1016%2Fj.ygyno.2013.06.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Galluzzi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senovilla, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vitale, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michels, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martins, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kepp, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castedo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroemer, G.</span><span> </span><span class="NLM_article-title">Molecular mechanisms of cisplatin resistance</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">1869</span><span class="NLM_x">–</span> <span class="NLM_lpage">1883</span><span class="refDoi"> DOI: 10.1038/onc.2011.384</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1038%2Fonc.2011.384" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=21892204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFWrsr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2012&pages=1869-1883&author=L.+Galluzziauthor=L.+Senovillaauthor=I.+Vitaleauthor=J.+Michelsauthor=I.+Martinsauthor=O.+Keppauthor=M.+Castedoauthor=G.+Kroemer&title=Molecular+mechanisms+of+cisplatin+resistance&doi=10.1038%2Fonc.2011.384"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms of cisplatin resistance</span></div><div class="casAuthors">Galluzzi, L.; Senovilla, L.; Vitale, I.; Michels, J.; Martins, I.; Kepp, O.; Castedo, M.; Kroemer, G.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1869-1883</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Platinum-based drugs, and in particular cis-diamminedichloroplatinum(II) (best known as cisplatin), are employed for the treatment of a wide array of solid malignancies, including testicular, ovarian, head and neck, colorectal, bladder and lung cancers.  Cisplatin exerts anticancer effects via multiple mechanisms, yet its most prominent (and best understood) mode of action involves the generation of DNA lesions followed by the activation of the DNA damage response and the induction of mitochondrial apoptosis.  Despite a consistent rate of initial responses, cisplatin treatment often results in the development of chemoresistance, leading to therapeutic failure.  An intense research has been conducted during the past 30 years and several mechanisms that account for the cisplatin-resistant phenotype of tumor cells have been described.  Here, we provide a systematic discussion of these mechanism by classifying them in alterations (1) that involve steps preceding the binding of cisplatin to DNA (pre-target resistance), (2) that directly relate to DNA-cisplatin adducts (on-target resistance), (3) concerning the lethal signaling pathway(s) elicited by cisplatin-mediated DNA damage (post-target resistance) and (4) affecting mol. circuitries that do not present obvious links with cisplatin-elicited signals (off-target resistance).  As in some clin. settings cisplatin constitutes the major therapeutic option, the development of chemosensitization strategies constitute a goal with important clin. implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxTrgUhh4V17Vg90H21EOLACvtfcHk0ljfz0W7NgSiJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFWrsr7E&md5=4f947e6d5b834673b819e88b06309a53</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fonc.2011.384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2011.384%26sid%3Dliteratum%253Aachs%26aulast%3DGalluzzi%26aufirst%3DL.%26aulast%3DSenovilla%26aufirst%3DL.%26aulast%3DVitale%26aufirst%3DI.%26aulast%3DMichels%26aufirst%3DJ.%26aulast%3DMartins%26aufirst%3DI.%26aulast%3DKepp%26aufirst%3DO.%26aulast%3DCastedo%26aufirst%3DM.%26aulast%3DKroemer%26aufirst%3DG.%26atitle%3DMolecular%2520mechanisms%2520of%2520cisplatin%2520resistance%26jtitle%3DOncogene%26date%3D2012%26volume%3D31%26spage%3D1869%26epage%3D1883%26doi%3D10.1038%2Fonc.2011.384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Siddik, Z. H.</span><span> </span><span class="NLM_article-title">Cisplatin: mode of cytotoxic action and molecular basis of resistance</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">7265</span><span class="NLM_x">–</span> <span class="NLM_lpage">79</span><span class="refDoi"> DOI: 10.1038/sj.onc.1206933</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1038%2Fsj.onc.1206933" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=14576837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotlajtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2003&pages=7265-79&author=Z.+H.+Siddik&title=Cisplatin%3A+mode+of+cytotoxic+action+and+molecular+basis+of+resistance&doi=10.1038%2Fsj.onc.1206933"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Cisplatin: mode of cytotoxic action and molecular basis of resistance</span></div><div class="casAuthors">Siddik, Zahid H.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">7265-7279</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cisplatin is one of the most potent antitumor agents known, displaying clin. activity against a wide variety of solid tumors.  Its cytotoxic mode of action is mediated by its interaction with DNA to form DNA adducts, primarily intrastrand crosslink adducts, which activate several signal transduction pathways, including those involving ATR, p53, p73, and MAPK, and culminate in the activation of apoptosis.  DNA damage-mediated apoptotic signals, however, can be attenuated, and the resistance that ensues is a major limitation of cisplatin-based chemotherapy.  The mechanisms responsible for cisplatin resistance are several, and contribute to the multifactorial nature of the problem.  Resistance mechanisms that limit the extent of DNA damage include reduced drug uptake, increased drug inactivation, and increased DNA adduct repair.  Origins of these pharmacol.-based mechanisms, however, are at the mol. level.  Mechanisms that inhibit propagation of the DNA damage signal to the apoptotic machinery include loss of damage recognition, overexpression of HER-2/neu, activation of the PI3-K/Akt (also known as PI3-K/PKB) pathway, loss of p53 function, overexpression of antiapoptotic bcl-2, and interference in caspase activation.  The mol. signature defining the resistant phenotype varies between tumors, and the no. of resistance mechanisms activated in response to selection pressures dictates the overall extent of cisplatin resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3k2Fki_ax2rVg90H21EOLACvtfcHk0ljfz0W7NgSiJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotlajtbY%253D&md5=8520a82f029717c4352d23e4bd7166fe</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1206933&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1206933%26sid%3Dliteratum%253Aachs%26aulast%3DSiddik%26aufirst%3DZ.%2BH.%26atitle%3DCisplatin%253A%2520mode%2520of%2520cytotoxic%2520action%2520and%2520molecular%2520basis%2520of%2520resistance%26jtitle%3DOncogene%26date%3D2003%26volume%3D22%26spage%3D7265%26epage%3D79%26doi%3D10.1038%2Fsj.onc.1206933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Igney, F. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krammer, P. H.</span><span> </span><span class="NLM_article-title">Death and anti-death: tumour resistance to apoptosis</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">277</span><span class="NLM_x">–</span> <span class="NLM_lpage">88</span><span class="refDoi"> DOI: 10.1038/nrc776</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1038%2Fnrc776" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=12001989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BD38XivFGqt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=277-88&author=F.+H.+Igneyauthor=P.+H.+Krammer&title=Death+and+anti-death%3A+tumour+resistance+to+apoptosis&doi=10.1038%2Fnrc776"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Death and anti-death: tumor resistance to apoptosis</span></div><div class="casAuthors">Igney, Frederik H.; Krammer, Peter H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">277-288</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with refs.  Every cell in a multicellular organism has the potential to die by apoptosis, but tumor cells often have faulty apoptotic pathways.  These defects not only increase tumor mass, but also render the tumor resistant to therapy.  So, what are the mol. mechanisms of tumor resistance to apoptosis and how can we use this knowledge to resensitize tumor cells to cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLYsKdE8S_srVg90H21EOLACvtfcHk0ljfz0W7NgSiJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XivFGqt7s%253D&md5=fa59ba8c08307cbbe71ae34f3f118222</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrc776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc776%26sid%3Dliteratum%253Aachs%26aulast%3DIgney%26aufirst%3DF.%2BH.%26aulast%3DKrammer%26aufirst%3DP.%2BH.%26atitle%3DDeath%2520and%2520anti-death%253A%2520tumour%2520resistance%2520to%2520apoptosis%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2002%26volume%3D2%26spage%3D277%26epage%3D88%26doi%3D10.1038%2Fnrc776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Holohan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Schaeybroeck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longley, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, P. G.</span><span> </span><span class="NLM_article-title">Cancer drug resistance: an evolving paradigm</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">714</span><span class="NLM_x">–</span> <span class="NLM_lpage">726</span><span class="refDoi"> DOI: 10.1038/nrc3599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1038%2Fnrc3599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=24060863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVyqurnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=714-726&author=C.+Holohanauthor=S.+Van+Schaeybroeckauthor=D.+B.+Longleyauthor=P.+G.+Johnston&title=Cancer+drug+resistance%3A+an+evolving+paradigm&doi=10.1038%2Fnrc3599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer drug resistance: an evolving paradigm</span></div><div class="casAuthors">Holohan, Caitriona; Van Schaeybroeck, Sandra; Longley, Daniel B.; Johnston, Patrick G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">714-726</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Resistance to chemotherapy and molecularly targeted therapies is a major problem facing current cancer research.  The mechanisms of resistance to 'classical' cytotoxic chemotherapeutics and to therapies that are designed to be selective for specific mol. targets share many features, such as alterations in the drug target, activation of prosurvival pathways and ineffective induction of cell death.  With the increasing arsenal of anticancer agents, improving preclin. models and the advent of powerful high-throughput screening techniques, there are now unprecedented opportunities to understand and overcome drug resistance through the clin. assessment of rational therapeutic drug combinations and the use of predictive biomarkers to enable patient stratification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrykBEUSgvv7Vg90H21EOLACvtfcHk0lihxWqEDL4lhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVyqurnE&md5=b497a823bbd968904ce1591b918d0679</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrc3599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3599%26sid%3Dliteratum%253Aachs%26aulast%3DHolohan%26aufirst%3DC.%26aulast%3DVan%2BSchaeybroeck%26aufirst%3DS.%26aulast%3DLongley%26aufirst%3DD.%2BB.%26aulast%3DJohnston%26aufirst%3DP.%2BG.%26atitle%3DCancer%2520drug%2520resistance%253A%2520an%2520evolving%2520paradigm%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2013%26volume%3D13%26spage%3D714%26epage%3D726%26doi%3D10.1038%2Fnrc3599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, L.</span><span> </span><span class="NLM_article-title">Nanoparticle delivery of pooled siRNA for effective treatment of non-small cell lung cancer</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">2280</span><span class="NLM_x">–</span> <span class="NLM_lpage">9</span><span class="refDoi"> DOI: 10.1021/mp300152v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp300152v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BC38Xotlemsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=2280-9&author=Y.+Yangauthor=Y.+Huauthor=Y.+Wangauthor=J.+Liauthor=F.+Liuauthor=L.+Huang&title=Nanoparticle+delivery+of+pooled+siRNA+for+effective+treatment+of+non-small+cell+lung+cancer&doi=10.1021%2Fmp300152v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Nanoparticle Delivery of Pooled siRNA for Effective Treatment of Non-Small Cell Lung Caner</span></div><div class="casAuthors">Yang, Yang; Hu, Yunxia; Wang, Yuhua; Li, Jun; Liu, Feng; Huang, Leaf</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2280-2289</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death.  To explore the potential of small interfering RNA (siRNA) therapy for NSCLC, we have developed anisamide-targeted LCP to efficiently deliver siRNA into the cytoplasm of sigma receptor-expressing NSCLC cells.  Targeted LCP demonstrated a 9-fold higher siRNA delivery efficiency compared to nontargeted LCP in A549 cells in vitro.  To simultaneously target multiple oncogenic mechanisms, we coformulated three siRNA sequences targeting HDM2, c-myc and VEGF oncogenes, and investigated their efficacy of cell-killing in A549 and H460 cells in vitro.  The results indicated that the pooled siRNA codelivered by the targeted LCP could effectively and simultaneously knock down HDM2, c-myc and VEGF expressions and significantly inhibit tumor cell growth.  After iv injection of mice bearing A549 xenografted tumor with Texas Red-labeled siRNA formulated in the targeted LCP, siRNA was successfully delivered to and concd. in the tumor cells.  Repeated i.v. injections of mice with pooled siRNA formulated in the targeted LCP significantly impaired NSCLC growth in vivo (p < 0.01) for both A549 and H460 tumors, demonstrating an ED50 for the treatment of ∼0.2 mg/kg in A549 tumors.  The enhanced antitumor activity is due to the fact that the silencing of HDM2/c-myc/VEGF could inhibit tumor proliferation and angiogenesis and also simultaneously induce tumor apoptosis.  Our results demonstrate that the targeted LCP is a promising vector to deliver pooled siRNA into tumors and to achieve multiple target blocking.  This is potentially a valid therapeutic modality in the gene therapy of human NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprsiDWU5lLu7Vg90H21EOLACvtfcHk0lihxWqEDL4lhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xotlemsbk%253D&md5=1d2fbf4cab7e645ba7fd9013c2020799</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fmp300152v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp300152v%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DHuang%26aufirst%3DL.%26atitle%3DNanoparticle%2520delivery%2520of%2520pooled%2520siRNA%2520for%2520effective%2520treatment%2520of%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2012%26volume%3D9%26spage%3D2280%26epage%3D9%26doi%3D10.1021%2Fmp300152v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Agarwal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, S. B.</span><span> </span><span class="NLM_article-title">Ovarian cancer: strategies for overcoming resistance to chemotherapy</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">502</span><span class="NLM_x">–</span> <span class="NLM_lpage">16</span><span class="refDoi"> DOI: 10.1038/nrc1123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1038%2Fnrc1123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=12835670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BD3sXltVSqtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=502-16&author=R.+Agarwalauthor=S.+B.+Kaye&title=Ovarian+cancer%3A+strategies+for+overcoming+resistance+to+chemotherapy&doi=10.1038%2Fnrc1123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Ovarian cancer: strategies for overcoming resistance to chemotherapy</span></div><div class="casAuthors">Agarwal, Roshan; Kaye, Stan B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">502-516</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Ovarian cancer is responsible for 4% of the deaths from cancer in women.  Treatment comprises a combination of surgery and chemotherapy, but patients typically experience disease relapse within 2 yr of the initial treatment.  Further treatment can extend survival, although relapse eventually occurs again.  A better understanding of the mechanisms that underlie this drug resistance should allow treatment to be optimized, so that substantial improvements in the outlook for women with this disease can be achieved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrU40u5eHTnk7Vg90H21EOLACvtfcHk0ljfG5AqT8WFnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXltVSqtr0%253D&md5=8063243f9f19e30d7a867f225efbb265</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrc1123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1123%26sid%3Dliteratum%253Aachs%26aulast%3DAgarwal%26aufirst%3DR.%26aulast%3DKaye%26aufirst%3DS.%2BB.%26atitle%3DOvarian%2520cancer%253A%2520strategies%2520for%2520overcoming%2520resistance%2520to%2520chemotherapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2003%26volume%3D3%26spage%3D502%26epage%3D16%26doi%3D10.1038%2Fnrc1123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Garofalo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosa, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bianco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tortora, G.</span><span> </span><span class="NLM_article-title">EGFR-targeting agents in oncology</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">889</span><span class="NLM_x">–</span> <span class="NLM_lpage">901</span><span class="refDoi"> DOI: 10.1517/13543776.18.8.889</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1517%2F13543776.18.8.889" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptlagsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=889-901&author=S.+Garofaloauthor=R.+Rosaauthor=R.+Biancoauthor=G.+Tortora&title=EGFR-targeting+agents+in+oncology&doi=10.1517%2F13543776.18.8.889"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR-targeting agents in oncology</span></div><div class="casAuthors">Garofalo, Sonia; Rosa, Roberta; Bianco, Roberto; Tortora, Giampaolo</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">889-901</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: The targeted therapy' has been defined as an innovative therapy designed to interfere with mol. targets playing a crit. role in tumor growth or progression.  The epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor mediating the effect of growth factors both in physiol. and pathol. conditions; aberrations in the EGFR may result in the development of a tumor phenotype.  Objective: To summarize the current state of the development of anti-EGFR drugs.  Methods: Patent literature and preclin./clin. studies about EGFR inhibitors are analyzed.  Conclusion: Some monoclonal antibodies and small-mol. tyrosine kinase inhibitors have been approved in several countries for the treatment of various human cancer types; moreover, more than ten EGFR-targeting agents are actually in advanced clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ_vZH0bm4s7Vg90H21EOLACvtfcHk0ljfG5AqT8WFnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptlagsbw%253D&md5=cfb4f50c4044eb45636be7999fe8a140</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1517%2F13543776.18.8.889&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.18.8.889%26sid%3Dliteratum%253Aachs%26aulast%3DGarofalo%26aufirst%3DS.%26aulast%3DRosa%26aufirst%3DR.%26aulast%3DBianco%26aufirst%3DR.%26aulast%3DTortora%26aufirst%3DG.%26atitle%3DEGFR-targeting%2520agents%2520in%2520oncology%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2008%26volume%3D18%26spage%3D889%26epage%3D901%26doi%3D10.1517%2F13543776.18.8.889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Madhusudan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganesan, T. S.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors in cancer therapy</span> <span class="citation_source-journal">Clin. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">618</span><span class="NLM_x">–</span> <span class="NLM_lpage">635</span><span class="refDoi"> DOI: 10.1016/j.clinbiochem.2004.05.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1016%2Fj.clinbiochem.2004.05.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=15234243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BD2cXltl2gtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2004&pages=618-635&author=S.+Madhusudanauthor=T.+S.+Ganesan&title=Tyrosine+kinase+inhibitors+in+cancer+therapy&doi=10.1016%2Fj.clinbiochem.2004.05.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinase inhibitors in cancer therapy</span></div><div class="casAuthors">Madhusudan, Srinivasan; Ganesan, Trivadi S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Biochemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">618-635</span>CODEN:
                <span class="NLM_cas:coden">CLBIAS</span>;
        ISSN:<span class="NLM_cas:issn">0009-9120</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Cancer is the second leading cause of death in the western world.  Despite advances in diagnosis and treatment, overall survival of patients remains poor.  Scientific advances in recent years have enhanced our understanding of the biol. of cancer.  Human protein tyrosine kinases (PTKs) play a central role in human carcinogenesis and have emerged as the promising new targets.  Several approaches to inhibit tyrosine kinase have been developed.  These agents have shown impressive anticancer effects in preclin. studies and are emerging as promising agents in the clinic.  The remarkable success of BCR-ABL tyrosine kinase inhibitor imatinib (STI571) in the treatment of chronic myeloid leukemia has particularly stimulated intense research in this field.  At least 30 inhibitors are in various stages of clin. development in cancer, and about 120 clin. trials are ongoing worldwide.  In this review, we focus on the role of tyrosine kinases in cancer and the development of specific small mol. inhibitors for therapy.  We also provide a crit. anal. of the current data on tyrosine kinase inhibitors and highlight areas for future research.  Issues with regards to the design of clin. trials with such agents are also discussed.  Innovative approaches are needed to fully evaluate the potential of these agents, and a concerted international effort will hopefully help to integrate these inhibitors in cancer therapy in the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2J3dyMJZEE7Vg90H21EOLACvtfcHk0ljfG5AqT8WFnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXltl2gtbY%253D&md5=ff308cde1b8cb3d2d868c8740d7422b7</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.clinbiochem.2004.05.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clinbiochem.2004.05.006%26sid%3Dliteratum%253Aachs%26aulast%3DMadhusudan%26aufirst%3DS.%26aulast%3DGanesan%26aufirst%3DT.%2BS.%26atitle%3DTyrosine%2520kinase%2520inhibitors%2520in%2520cancer%2520therapy%26jtitle%3DClin.%2520Biochem.%26date%3D2004%26volume%3D37%26spage%3D618%26epage%3D635%26doi%3D10.1016%2Fj.clinbiochem.2004.05.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Cockerill, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackey, K. E.</span><span> </span><span class="NLM_article-title">Small molecule inhibitors of the class 1 receptor tyrosine kinase family</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1001</span><span class="NLM_x">–</span> <span class="NLM_lpage">10</span><span class="refDoi"> DOI: 10.2174/1568026023393309</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.2174%2F1568026023393309" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=12171567" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BD38XmtVOitb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=1001-10&author=G.+S.+Cockerillauthor=K.+E.+Lackey&title=Small+molecule+inhibitors+of+the+class+1+receptor+tyrosine+kinase+family&doi=10.2174%2F1568026023393309"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule inhibitors of the class 1 receptor tyrosine kinase family</span></div><div class="casAuthors">Cockerill, G. Stuart; Lackey, Karen E.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Hilversum, Netherlands)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1001-1010</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  This review covers literature describing research progress in erbB family tyrosine kinase inhibition over the last year.  Excellent recent reviews are available, thus we have focussed on current developments of leading small mol. drug candidates as well as their erbB family inhibition profile.  The most advanced erbB family tyrosine kinase (TK) inhibitors are demonstrating promising anti-cancer activity in clin. trials and are discussed.  Several inhibition strategies are emerging: EGFR TK selective, irreversible TK inhibition and dual EGFR/erbB2 TK inhibitors.  While small structural differences are seen in the leading compds., the variations in their inhibition profiles and compd. properties suggest that biol. systems judge structural diversity differently.  The readers' attention is drawn to common issues of selectivity and potency generally encountered with kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBco-X2q4LCbVg90H21EOLACvtfcHk0ljiAS0_yGkhVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmtVOitb0%253D&md5=795d41584fee8792e7ca03705b73c6e3</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.2174%2F1568026023393309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026023393309%26sid%3Dliteratum%253Aachs%26aulast%3DCockerill%26aufirst%3DG.%2BS.%26aulast%3DLackey%26aufirst%3DK.%2BE.%26atitle%3DSmall%2520molecule%2520inhibitors%2520of%2520the%2520class%25201%2520receptor%2520tyrosine%2520kinase%2520family%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2002%26volume%3D2%26spage%3D1001%26epage%3D10%26doi%3D10.2174%2F1568026023393309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Yarden, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span> </span><span class="NLM_article-title">Untangling the ErbB signalling network</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">37</span><span class="refDoi"> DOI: 10.1038/35052073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1038%2F35052073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=11252954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivVWnt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=127-37&author=Y.+Yardenauthor=M.+X.+Sliwkowski&title=Untangling+the+ErbB+signalling+network&doi=10.1038%2F35052073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Untangling the ErbB signalling network</span></div><div class="casAuthors">Yarden, Yosef; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">127-137</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review, with 112 refs.  When epidermal growth factor and its relatives bind the ErbB family of receptors, they trigger a rich network of signaling pathways, culminating in responses ranging from cell division to death, motility to adhesion.  The network is often dysregulated in cancer and lends credence to the mantra that mol. understanding yields clin. benefit: over 25,000 women with breast cancer have now been treated with Herceptin, a recombinant antibody designed to block the receptor ErbB2.  Likewise, small-mol. enzyme inhibitors and monoclonal antibodies to ErbB1 are in advanced phases of clin. testing.  What can this pathway teach us about translating basic science into clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovhWL1HObvNrVg90H21EOLACvtfcHk0ljiAS0_yGkhVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivVWnt7k%253D&md5=1561a9666f77fce888be821399870cd6</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2F35052073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35052073%26sid%3Dliteratum%253Aachs%26aulast%3DYarden%26aufirst%3DY.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DUntangling%2520the%2520ErbB%2520signalling%2520network%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2001%26volume%3D2%26spage%3D127%26epage%3D37%26doi%3D10.1038%2F35052073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Han, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, H. W.</span><span> </span><span class="NLM_article-title">Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">318</span><span class="NLM_x">, </span> <span class="NLM_fpage">124</span><span class="NLM_x">–</span> <span class="NLM_lpage">34</span><span class="refDoi"> DOI: 10.1016/j.canlet.2012.01.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1016%2Fj.canlet.2012.01.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=22261334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVGns7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=318&publication_year=2012&pages=124-34&author=W.+Hanauthor=H.+W.+Lo&title=Landscape+of+EGFR+signaling+network+in+human+cancers%3A+biology+and+therapeutic+response+in+relation+to+receptor+subcellular+locations&doi=10.1016%2Fj.canlet.2012.01.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Landscape of EGFR signaling network in human cancers: Biology and therapeutic response in relation to receptor subcellular locations</span></div><div class="casAuthors">Han, Woody; Lo, Hui-Wen</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">318</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">124-134</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The epidermal growth factor receptor (EGFR) pathway is one of the most dysregulated mol. pathways in human cancers.  Despite its well-established importance in tumor growth, progression and drug-resistant phenotype over the past several decades, targeted therapy designed to circumvent EGFR has yielded only modest clin. success in cancer patients, except those with non-small cell lung cancer (NSCLC) carrying EGFR activation mutations.  However, almost all of these NSCLC patients eventually developed resistance to small mol. EGFR kinase inhibitors.  These disappointing outcomes are, in part, due to the high complexity and the interactive nature of the EGFR signaling network.  More recent compelling evidence further indicates that EGFR functionality can be dependent on its subcellular location.  In this regard, EGFR undergoes translocation into different organelles where it elicits distinctly different functions than its best known activity as a plasma membrane-bound receptor tyrosine kinase.  EGFR can be shuttled into the cell nucleus and mitochondrion upon ligand binding, radiation, EGFR-targeted therapy and other stimuli.  Nuclear EGFR behaves as transcriptional regulator, tyrosine kinase, and mediator of other physiol. processes.  The role of mitochondrial EGFR remains poorly understood but it appears to regulate apoptosis and autophagy.  While studies using patient tumors have shown nuclear EGFR to be an indicator for poor clin. outcomes in cancer patients, the impact of mitochondrial EGFR on tumor behavior and patient prognosis remains to be defined.  Most recently, several lines of evidence suggest that mislocated EGFR may regulate tumor response to therapy and that plasma membrane-bound EGFR elicits survival signals independent of its kinase activity.  In light of these recent progresses and discoveries, we will outline in this minireview an emerging line of research that uncovers and functionally characterizes several novel modes of EGFR signaling that take center stage in the cell nucleus, mitochondrion and other subcellular compartments.  We will also discuss the clin. implications of these findings in the rationale design for therapeutic strategy that overcomes tumor drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgDjdRcHam3bVg90H21EOLACvtfcHk0lgd6bF75Sl2Vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVGns7c%253D&md5=e29390cd4a03e2c6d3eae1fd99202268</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2012.01.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2012.01.011%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DW.%26aulast%3DLo%26aufirst%3DH.%2BW.%26atitle%3DLandscape%2520of%2520EGFR%2520signaling%2520network%2520in%2520human%2520cancers%253A%2520biology%2520and%2520therapeutic%2520response%2520in%2520relation%2520to%2520receptor%2520subcellular%2520locations%26jtitle%3DCancer%2520Lett.%26date%3D2012%26volume%3D318%26spage%3D124%26epage%3D34%26doi%3D10.1016%2Fj.canlet.2012.01.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Barlesi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tchouhadjian, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doddoli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villani, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greillier, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleisbauer, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Astoul, P.</span><span> </span><span class="NLM_article-title">Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective</span> <span class="citation_source-journal">Fundam. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">385</span><span class="NLM_x">–</span> <span class="NLM_lpage">93</span><span class="refDoi"> DOI: 10.1111/j.1472-8206.2005.00323.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1111%2Fj.1472-8206.2005.00323.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=15910663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltFagtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2005&pages=385-93&author=F.+Barlesiauthor=C.+Tchouhadjianauthor=C.+Doddoliauthor=P.+Villaniauthor=L.+Greillierauthor=J.+P.+Kleisbauerauthor=P.+Thomasauthor=P.+Astoul&title=Gefitinib+%28ZD1839%2C+Iressa%29+in+non-small-cell+lung+cancer%3A+a+review+of+clinical+trials+from+a+daily+practice+perspective&doi=10.1111%2Fj.1472-8206.2005.00323.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: A review of clinical trials from a daily practice perspective</span></div><div class="casAuthors">Barlesi, Fabrice; Tchouhadjian, Cecile; Doddoli, Christophe; Villani, Patrick; Greillier, Laurent; Kleisbauer, Jean-Pierre; Thomas, Pascal; Astoul, Philippe</div><div class="citationInfo"><span class="NLM_cas:title">Fundamental & Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">385-393</span>CODEN:
                <span class="NLM_cas:coden">FCPHEZ</span>;
        ISSN:<span class="NLM_cas:issn">0767-3981</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Gefitinib (ZD1839) is the most widely studied targeting agent in the area of non-small-cell lung cancer (NSCLC).  Gefitinib is an orally active epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor.  In order to assess the role of gefitinib in the management of NSCLC patients, we systematically reviewed published clin. trials from a daily practice perspective.  A systematic research was made in the international medical literature.  Gefitinib demonstrated a good tolerance and an encouraging efficacy in pretreated NSCLC patients in preclin. studies.  These results were then confirmed in two phase II trials (IDEAL 1 and 2) involving more than 400 patients mostly pretreated with a platinum-contg. regimen and docetaxel.  All these results were reinforced by those of retrospective studies on patients enrolled in a compassionate use program.  Thus, two phase III trials in chemo-naive patients were initiated (INTACT 1 and 2).  Unfortunately, the use of gefitinib with std. combination chemotherapy provided no survival benefit nor response rate or progression-free survival improvement over placebo.  Furthermore, we also reviewed the results of studies interested in the characterization of predictive clin. or biol. markers for response to gefitinib and discussed the results obtained with other EGFR inhibitors.  The efficacy of gefitinib in the first-line setting of each stage of NSCLC has to be further studied through clin. trials.  Furthermore, translational studies characterizing the mol. features involved in the response to anti-EGFR-targeted therapies are needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtJIQKGI8dq7Vg90H21EOLACvtfcHk0lgd6bF75Sl2Vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltFagtLw%253D&md5=40fe698dd434655696d8222111e218e1</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1111%2Fj.1472-8206.2005.00323.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1472-8206.2005.00323.x%26sid%3Dliteratum%253Aachs%26aulast%3DBarlesi%26aufirst%3DF.%26aulast%3DTchouhadjian%26aufirst%3DC.%26aulast%3DDoddoli%26aufirst%3DC.%26aulast%3DVillani%26aufirst%3DP.%26aulast%3DGreillier%26aufirst%3DL.%26aulast%3DKleisbauer%26aufirst%3DJ.%2BP.%26aulast%3DThomas%26aufirst%3DP.%26aulast%3DAstoul%26aufirst%3DP.%26atitle%3DGefitinib%2520%2528ZD1839%252C%2520Iressa%2529%2520in%2520non-small-cell%2520lung%2520cancer%253A%2520a%2520review%2520of%2520clinical%2520trials%2520from%2520a%2520daily%2520practice%2520perspective%26jtitle%3DFundam.%2520Clin.%2520Pharmacol.%26date%3D2005%26volume%3D19%26spage%3D385%26epage%3D93%26doi%3D10.1111%2Fj.1472-8206.2005.00323.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Arteaga, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, D. H.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors-ZD1839 (Iressa)</span> <span class="citation_source-journal">Curr. Opin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">491</span><span class="NLM_x">–</span> <span class="NLM_lpage">8</span><span class="refDoi"> DOI: 10.1097/00001622-200111000-00012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1097%2F00001622-200111000-00012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=11673690" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BD3MXos1Oqs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2001&pages=491-8&author=C.+L.+Arteagaauthor=D.+H.+Johnson&title=Tyrosine+kinase+inhibitors-ZD1839+%28Iressa%29&doi=10.1097%2F00001622-200111000-00012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinase inhibitors-ZD1839 (Iressa)</span></div><div class="casAuthors">Arteaga, Carlos L.; Johnson, David H.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Oncology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">491-498</span>CODEN:
                <span class="NLM_cas:coden">CUOOE8</span>;
        ISSN:<span class="NLM_cas:issn">1040-8746</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Several epithelial tumors display epidermal growth factor receptor (EGFR) overexpression (with or without EGFR gene amplification) that is often assocd. with increased prodn. of EGFR ligands.  This permits the activation of endogenous tumor EGFR via autocrine mechanisms, resulting in cellular proliferation and tumor growth.  Interruption of receptor signaling with bivalent EGFR antibodies or with small mol. inhibitors of the EGFR tyrosine kinase results in inhibition of tumor cell proliferation or viability in vitro and in vivo.  One small mol. currently undergoing preclin. and clin. investigation is ZD1839 (Iressa), a synthetic anilinoquinazoline capable of inhibiting EGFR tyrosine kinase in vitro.  The early results of clin. trials indicate this drug possesses antitumor activity in certain malignancies of the upper aerodigestive tract.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUp52ELUA8HLVg90H21EOLACvtfcHk0lgd6bF75Sl2Vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXos1Oqs7k%253D&md5=ed22721cbb3560ac54e438d363f8a59e</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1097%2F00001622-200111000-00012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00001622-200111000-00012%26sid%3Dliteratum%253Aachs%26aulast%3DArteaga%26aufirst%3DC.%2BL.%26aulast%3DJohnson%26aufirst%3DD.%2BH.%26atitle%3DTyrosine%2520kinase%2520inhibitors-ZD1839%2520%2528Iressa%2529%26jtitle%3DCurr.%2520Opin.%2520Oncol.%26date%3D2001%26volume%3D13%26spage%3D491%26epage%3D8%26doi%3D10.1097%2F00001622-200111000-00012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Barker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grundy, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godfrey, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barlow, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Healy, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodburn, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarlett, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henthorn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richards, L.</span><span> </span><span class="NLM_article-title">Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1911</span><span class="NLM_x">–</span> <span class="NLM_lpage">4</span><span class="refDoi"> DOI: 10.1016/S0960-894X(01)00344-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1016%2FS0960-894X%2801%2900344-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=11459659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltFylsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=1911-4&author=A.+J.+Barkerauthor=K.+H.+Gibsonauthor=W.+Grundyauthor=A.+A.+Godfreyauthor=J.+J.+Barlowauthor=M.+P.+Healyauthor=J.+R.+Woodburnauthor=S.+E.+Ashtonauthor=B.+J.+Curryauthor=L.+Scarlettauthor=L.+Henthornauthor=L.+Richards&title=Studies+leading+to+the+identification+of+ZD1839+%28IRESSA%29%3A+an+orally+active%2C+selective+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitor+targeted+to+the+treatment+of+cancer&doi=10.1016%2FS0960-894X%2801%2900344-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Studies leading to the identification of ZD1839 (iressa): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer</span></div><div class="casAuthors">Barker, A. J.; Gibson, K. H.; Grundy, W.; Godfrey, A. A.; Barlow, J. J.; Healy, M. P.; Woodburn, J. R.; Ashton, S. E.; Curry, B. J.; Scarlett, L.; Henthorn, L.; Richards, L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1911-1914</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">This paper describes the development of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 from a lead series of 4-anilinoquinazoline compds.  ZD1839 has suitable properties for use as a clin. effective drug and shows activity against human tumors.  In particular, the use of pharmacokinetic data in the development of ZD1839 is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvsJ1FTqEwvbVg90H21EOLACvtfcHk0lgFJgsbGjLoQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltFylsLo%253D&md5=ebb210453ade246e43de9fd07ae1d581</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900344-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900344-4%26sid%3Dliteratum%253Aachs%26aulast%3DBarker%26aufirst%3DA.%2BJ.%26aulast%3DGibson%26aufirst%3DK.%2BH.%26aulast%3DGrundy%26aufirst%3DW.%26aulast%3DGodfrey%26aufirst%3DA.%2BA.%26aulast%3DBarlow%26aufirst%3DJ.%2BJ.%26aulast%3DHealy%26aufirst%3DM.%2BP.%26aulast%3DWoodburn%26aufirst%3DJ.%2BR.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DCurry%26aufirst%3DB.%2BJ.%26aulast%3DScarlett%26aufirst%3DL.%26aulast%3DHenthorn%26aufirst%3DL.%26aulast%3DRichards%26aufirst%3DL.%26atitle%3DStudies%2520leading%2520to%2520the%2520identification%2520of%2520ZD1839%2520%2528IRESSA%2529%253A%2520an%2520orally%2520active%252C%2520selective%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitor%2520targeted%2520to%2520the%2520treatment%2520of%2520cancer%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26spage%3D1911%26epage%3D4%26doi%3D10.1016%2FS0960-894X%2801%2900344-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Ganjoo, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakelee, H.</span><span> </span><span class="NLM_article-title">Review of erlotinib in the treatment of advanced non-small cell lung cancer</span> <span class="citation_source-journal">Biol.: Targets Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">335</span><span class="NLM_x">–</span> <span class="NLM_lpage">346</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=19707304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtVygsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2007&pages=335-346&author=K.+N.+Ganjooauthor=H.+Wakelee&title=Review+of+erlotinib+in+the+treatment+of+advanced+non-small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Review of erlotinib in the treatment of advanced non-small cell lung cancer</span></div><div class="casAuthors">Ganjoo, Kristen N.; Wakelee, Heather</div><div class="citationInfo"><span class="NLM_cas:title">Biologics: Targets & Therapy</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">335-346</span>CODEN:
                <span class="NLM_cas:coden">BTTICT</span>;
        ISSN:<span class="NLM_cas:issn">1177-5475</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press (NZ) Ltd.</span>)
        </div><div class="casAbstract">A review.  Epidermal growth factor receptor (EGFR) is a transmembrane receptor with a cytoplasmic tyrosine kinase (TK) domain present on many solid tumors including non-small cell lung cancer (NSCLC).  Once stimulated by ligand, the downstream pathway is activated leading to cell growth, survival, and carcinogenesis.  There are several methods of EGFR inhibition including monoclonal antibodies directed against the external region and small mol. inhibitors of TK domain.  Erlotinib and gefitinib are orally available small mol. EGFR TK inhibitors, with proven efficacy in NSCLC.  The most common side effects are skin toxicity and diarrhea.  Erlotinib has been shown to improve survival compared to placebo in second or third-line therapy for NSCLC.  However, erlotinib in combination with chemotherapy failed to show a survival advantage in two first-line studies which could be due to the timing of chemotherapy administration.  In general, patients with adenocarcinoma histol., female gender, Asian ethnicity, and never smokers have a better response when treated with erlotinib.  This could be related to the presence of EGFR mutations, lack of KRAS mutations, or overexpression of EGFR as measured by fluorescent in-situ hybridization (FISH) anal.  Future studies should conc. on further development of predictors of clin. benefit with erlotinib, overcoming resistance to erlotinib that develops in initial responders, as well as more effective sequencing of erlotinib with chemotherapy and combinations of the drug with other "targeted" therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkIh360NygIrVg90H21EOLACvtfcHk0lgFJgsbGjLoQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtVygsb8%253D&md5=4980eda401551fcba54e6f9ac8da7ae9</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGanjoo%26aufirst%3DK.%2BN.%26aulast%3DWakelee%26aufirst%3DH.%26atitle%3DReview%2520of%2520erlotinib%2520in%2520the%2520treatment%2520of%2520advanced%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DBiol.%253A%2520Targets%2520Ther.%26date%3D2007%26volume%3D1%26spage%3D335%26epage%3D346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Kopper, L.</span><span> </span><span class="NLM_article-title">Lapatinib: a sword with two edges</span> <span class="citation_source-journal">Pathol. Oncol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">8</span><span class="refDoi"> DOI: 10.1007/s12253-008-9018-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1007%2Fs12253-008-9018-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=18409020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpvFyis78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=1-8&author=L.+Kopper&title=Lapatinib%3A+a+sword+with+two+edges&doi=10.1007%2Fs12253-008-9018-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Lapatinib: a sword with two edges</span></div><div class="casAuthors">Kopper, Laszlo</div><div class="citationInfo"><span class="NLM_cas:title">Pathology & Oncology Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-8</span>CODEN:
                <span class="NLM_cas:coden">POREFR</span>;
        ISSN:<span class="NLM_cas:issn">1219-4956</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Lapatinib is an oral dual tyrosine kinase inhibitor targeting EGFR1 and EGFR2 (HER2).  Phase I trials have shown that lapatinib is well tolerated, with mild diarrhea and skin rush as common adverse effects, and low cardiotoxicity.  Phase II and III trials provided evidences on clin. effectiveness in advanced or metastatic breast cancer and potential against brain metastases.  Lapatinib is active in combination with trastuzumab and in trastuzumab-resistant patients, moreover it has synergistic action with capecitabine.  Several clin. trials are in progress to explore the effectiveness of lapatinib in other combinations and against several tumor types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrf0_JyTqFmPLVg90H21EOLACvtfcHk0lg8LKDGObmH3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpvFyis78%253D&md5=f8b3ac8f8b01092355de4b2759c1d773</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1007%2Fs12253-008-9018-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12253-008-9018-z%26sid%3Dliteratum%253Aachs%26aulast%3DKopper%26aufirst%3DL.%26atitle%3DLapatinib%253A%2520a%2520sword%2520with%2520two%2520edges%26jtitle%3DPathol.%2520Oncol.%2520Res.%26date%3D2008%26volume%3D14%26spage%3D1%26epage%3D8%26doi%3D10.1007%2Fs12253-008-9018-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Lu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blume-Jensen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, T.</span><span> </span><span class="NLM_article-title">Epidermal Growth Factor-Induced Tumor Cell Invasion and Metastasis Initiated by Dephosphorylation and Downregulation of Focal Adhesion Kinase</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">4016</span><span class="NLM_x">–</span> <span class="NLM_lpage">4031</span><span class="refDoi"> DOI: 10.1128/MCB.21.12.4016-4031.2001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1128%2FMCB.21.12.4016-4031.2001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=11359909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BD3MXktFWgtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2001&pages=4016-4031&author=Z.+Luauthor=G.+Jiangauthor=P.+Blume-Jensenauthor=T.+Hunter&title=Epidermal+Growth+Factor-Induced+Tumor+Cell+Invasion+and+Metastasis+Initiated+by+Dephosphorylation+and+Downregulation+of+Focal+Adhesion+Kinase&doi=10.1128%2FMCB.21.12.4016-4031.2001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase</span></div><div class="casAuthors">Lu, Zhimin; Jiang, Guoqiang; Blume-Jensen, Peter; Hunter, Tony</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4016-4031</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Upregulated epidermal growth factor (EGF) receptor (EGFR) expression and EGFR-induced signaling have been correlated with progression to invasion and metastasis in a wide variety of carcinomas, but the mechanism behind this is not well understood.  We show here that, in various human carcinoma cells that overexpress EGFR, EGF treatment induced rapid tyrosine dephosphorylation of focal adhesion kinase (FAK) assocd. with downregulation of its kinase activity.  The downregulation of FAK activity was both required and sufficient for EGF-induced refractile morphol. changes, detachment of cells from the extracellular matrix, and increased tumor cell motility, invasion, and metastasis.  Tumor cells with downregulated FAK activity became less adherent to the extracellular matrix.  However, once cells started reattaching, FAK activity was restored by activated integrin signaling.  Moreover, this process of readhesion and spreading could not be abrogated by further EGF stimulation.  Interruption of transforming growth factor alpha-EGFR autocrine regulation with an EGFR tyrosine kinase inhibitor led to a substantial increase in FAK tyrosine phosphorylation and inhibition of tumor cell invasion in vitro.  Consistent with this, FAK tyrosine phosphorylation was reduced in cells from tumors growing in transplanted, athymic, nude mice, which have an intact autocrine regulation of the EGFR.  We suggest that the dynamic regulation of FAK activity, initiated by EGF-induced downregulation of FAK leading to cell detachment and increased motility and invasion, followed by integrin-dependent reactivation during readhesion, plays a role in EGF-assocd. tumor invasion and metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcrBC-34ss5bVg90H21EOLACvtfcHk0lg8LKDGObmH3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXktFWgtLw%253D&md5=1d7c09f65ed896b2dac4cb252bbce373</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1128%2FMCB.21.12.4016-4031.2001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.21.12.4016-4031.2001%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DG.%26aulast%3DBlume-Jensen%26aufirst%3DP.%26aulast%3DHunter%26aufirst%3DT.%26atitle%3DEpidermal%2520Growth%2520Factor-Induced%2520Tumor%2520Cell%2520Invasion%2520and%2520Metastasis%2520Initiated%2520by%2520Dephosphorylation%2520and%2520Downregulation%2520of%2520Focal%2520Adhesion%2520Kinase%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2001%26volume%3D21%26spage%3D4016%26epage%3D4031%26doi%3D10.1128%2FMCB.21.12.4016-4031.2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Cáceres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerrero, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martínez, J.</span><span> </span><span class="NLM_article-title">Overexpression of RhoA-GTP induces activation of the Epidermal Growth Factor Receptor, dephosphorylation of focal adhesion kinase and increased motility in breast cancer cells</span> <span class="citation_source-journal">Exp. Cell Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">309</span><span class="NLM_x">, </span> <span class="NLM_fpage">229</span><span class="NLM_x">–</span> <span class="NLM_lpage">238</span><span class="refDoi"> DOI: 10.1016/j.yexcr.2005.05.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1016%2Fj.yexcr.2005.05.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=15963982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpt1ektL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=309&publication_year=2005&pages=229-238&author=M.+C%C3%A1ceresauthor=J.+Guerreroauthor=J.+Mart%C3%ADnez&title=Overexpression+of+RhoA-GTP+induces+activation+of+the+Epidermal+Growth+Factor+Receptor%2C+dephosphorylation+of+focal+adhesion+kinase+and+increased+motility+in+breast+cancer+cells&doi=10.1016%2Fj.yexcr.2005.05.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of RhoA-GTP induces activation of the epidermal growth factor receptor, dephosphorylation of focal adhesion kinase and increased motility in breast cancer cells</span></div><div class="casAuthors">Caceres, Monica; Guerrero, Javier; Martinez, Jorge</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Cell Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">309</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">229-238</span>CODEN:
                <span class="NLM_cas:coden">ECREAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-4827</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Rho GTPases are overexpressed in human tumors and are involved in a variety of cellular processes such as organization of the actin cytoskeleton, cell-cell contact and malignant transformation.  EGFR activation plays a key role in the acquisition of motile properties in carcinoma cells, and it has been proposed that downregulation of FAK activity is one of its most relevant consequences.  In the present study, using mammary MCF-7 cells, we demonstrated that overexpression of the active form of the small GTPase RhoA induced the activation of EGFR by a phenomenon that depends on the activity of a metalloproteinase (MMP), which presumably cleaves a membrane-bound EGFR ligand.  The EGFR tyrosine phosphorylation correlates with ERK1,2 activation and the stimulation of urokinase prodn.  An aggressive mammary cell line (MDA-MB-231) that overexpresses both RhoA and EGFR in their active forms also displayed an MMP-dependent activation mechanism of EGFR.  RhoA-GTP-transfected cells showed a cortical array of F-actin, rounded morphol., reduced spreading potential and a dephosphorylation of FAK that was released by integrin-dependent fibronectin adhesion and a specific EGFR tyrosine kinase inhibitor.  Our results suggest that the MMP-dependent EGFR activation obsd. in V14 RhoA cells represents the starting point of a signaling route that promotes cell motility by activation of ERK1,2 and further enhancement of proteases prodn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohkNr-cQ1MAbVg90H21EOLACvtfcHk0lg_3tfceWW8YQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpt1ektL0%253D&md5=11166ddda07b50ac8021f01127304e36</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.yexcr.2005.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yexcr.2005.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DC%25C3%25A1ceres%26aufirst%3DM.%26aulast%3DGuerrero%26aufirst%3DJ.%26aulast%3DMart%25C3%25ADnez%26aufirst%3DJ.%26atitle%3DOverexpression%2520of%2520RhoA-GTP%2520induces%2520activation%2520of%2520the%2520Epidermal%2520Growth%2520Factor%2520Receptor%252C%2520dephosphorylation%2520of%2520focal%2520adhesion%2520kinase%2520and%2520increased%2520motility%2520in%2520breast%2520cancer%2520cells%26jtitle%3DExp.%2520Cell%2520Res.%26date%3D2005%26volume%3D309%26spage%3D229%26epage%3D238%26doi%3D10.1016%2Fj.yexcr.2005.05.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Sengupta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smitha, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santhoshkumar, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devi, S. K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sreejalekshmi, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajasekharan, K. N.</span><span> </span><span class="NLM_article-title">4-Amino-5-benzoyl-2-(4-methoxyphenylamino)thiazole (DAT1): a cytotoxic agent towards cancer cells and a probe for tubulin-microtubule system</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">145</span><span class="NLM_x">, </span> <span class="NLM_fpage">1076</span><span class="NLM_x">–</span> <span class="NLM_lpage">1083</span><span class="refDoi"> DOI: 10.1038/sj.bjp.0706276</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1038%2Fsj.bjp.0706276" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=15951833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BD2MXns1Wrsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=145&publication_year=2005&pages=1076-1083&author=S.+Senguptaauthor=S.+L.+Smithaauthor=N.+E.+Thomasauthor=T.+R.+Santhoshkumarauthor=S.+K.+C.+Deviauthor=K.+G.+Sreejalekshmiauthor=K.+N.+Rajasekharan&title=4-Amino-5-benzoyl-2-%284-methoxyphenylamino%29thiazole+%28DAT1%29%3A+a+cytotoxic+agent+towards+cancer+cells+and+a+probe+for+tubulin-microtubule+system&doi=10.1038%2Fsj.bjp.0706276"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">4-Amino-5-benzoyl-2-(4-methoxyphenylamino)thiazole (DAT1): a cytotoxic agent towards cancer cells and a probe for tubulin-microtubule system</span></div><div class="casAuthors">Sengupta, Suparna; Smitha, Sasidharan L.; Thomas, Nisha E.; Santhoshkumar, Thankaiyyan R.; Devi, Satyabhama K. C.; Sreejalekshmi, Kumaran G.; Rajasekharan, Kallikat N.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">145</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1076-1083</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Microtubule binding drugs are of special interest as they have important roles in the modulation of cellular functions and many of them act as anticancer agents.  4-Amino-5-benzoyl-2-(4-methoxyphenylamino)thiazole (DAT1) was identified as one of the active compds. from a series of diaminoketothiazoles in a cell-based screening assay to discover cytotoxic compds.  DAT1 shows cytotoxicity with GI50 values ranging from 0.05 to 1 μM in different malignant cell lines with an av. value of 0.35 μM.  It blocks mitosis in the prometaphase and metaphase stages.  In HeLa cells, DAT1 blocks the spindle function by disturbing spindle microtubule and chromosome organization.  The drug also inhibits assembly of brain microtubules and binds tubulin specifically at a single site with induction of fluorescence.  The dissocn. const. of DAT1 binding to tubulin was detd. as 2.9±1 μM at 24°.  The binding site of DAT1 on tubulin overlaps with that of the conventional colchicine-binding site.  DAT1 can thus be considered as a lead compd. of a new class of small mols. and this study can be used as a step to develop potent antimitotic agents for the control of cytoskeletal functions and cell proliferation.  It would also be an interesting probe for the structure-function studies of tubulin-microtubule system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_lBzdf_bEtbVg90H21EOLACvtfcHk0lg_3tfceWW8YQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXns1Wrsbk%253D&md5=d3bb0e7a3049cbf8a9d2a57fbdad0282</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0706276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0706276%26sid%3Dliteratum%253Aachs%26aulast%3DSengupta%26aufirst%3DS.%26aulast%3DSmitha%26aufirst%3DS.%2BL.%26aulast%3DThomas%26aufirst%3DN.%2BE.%26aulast%3DSanthoshkumar%26aufirst%3DT.%2BR.%26aulast%3DDevi%26aufirst%3DS.%2BK.%2BC.%26aulast%3DSreejalekshmi%26aufirst%3DK.%2BG.%26aulast%3DRajasekharan%26aufirst%3DK.%2BN.%26atitle%3D4-Amino-5-benzoyl-2-%25284-methoxyphenylamino%2529thiazole%2520%2528DAT1%2529%253A%2520a%2520cytotoxic%2520agent%2520towards%2520cancer%2520cells%2520and%2520a%2520probe%2520for%2520tubulin-microtubule%2520system%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2005%26volume%3D145%26spage%3D1076%26epage%3D1083%26doi%3D10.1038%2Fsj.bjp.0706276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Gray-Schopfer, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wellbrock, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span> </span><span class="NLM_article-title">Melanoma biology and new targeted therapy</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">445</span><span class="NLM_x">, </span> <span class="NLM_fpage">851</span><span class="NLM_x">–</span> <span class="NLM_lpage">857</span><span class="refDoi"> DOI: 10.1038/nature05661</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1038%2Fnature05661" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=17314971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvFGiu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=445&publication_year=2007&pages=851-857&author=V.+Gray-Schopferauthor=C.+Wellbrockauthor=R.+Marais&title=Melanoma+biology+and+new+targeted+therapy&doi=10.1038%2Fnature05661"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Melanoma biology and new targeted therapy</span></div><div class="casAuthors">Gray-Schopfer, Vanessa; Wellbrock, Claudia; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">445</span>
        (<span class="NLM_cas:issue">7130</span>),
    <span class="NLM_cas:pages">851-857</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Melanoma is a cancer that arises from melanocytes, specialized pigmented cells that are found predominantly in the skin.  The incidence of melanoma is rising steadily in western populations - the no. of cases worldwide has doubled in the past 20 years.  In its early stages malignant melanoma can be cured by surgical resection, but once it has progressed to the metastatic stage it is extremely difficult to treat and does not respond to current therapies.  Recent discoveries in cell signalling have provided greater understanding of the biol. that underlies melanoma, and these advances are being exploited to provide targeted drugs and new therapeutic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXWnhlx-AzCbVg90H21EOLACvtfcHk0lgk_R1lPf6Ung"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvFGiu7g%253D&md5=a898105964c68ba64eca76489a703e8d</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnature05661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05661%26sid%3Dliteratum%253Aachs%26aulast%3DGray-Schopfer%26aufirst%3DV.%26aulast%3DWellbrock%26aufirst%3DC.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DMelanoma%2520biology%2520and%2520new%2520targeted%2520therapy%26jtitle%3DNature%26date%3D2007%26volume%3D445%26spage%3D851%26epage%3D857%26doi%3D10.1038%2Fnature05661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Davies, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bignell, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edkins, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clegg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teague, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woffendin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garnett, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bottomley, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dicks, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ewing, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosmidou, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menzies, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mould, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hooper, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayatilake, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gusterson, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shipley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hargrave, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard-Jones, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maitland, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chenevix-Trench, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riggins, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bigner, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmieri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cossu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, J. W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seigler, H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darrow, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paterson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wooster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratton, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Futreal, P. A.</span><span> </span><span class="NLM_article-title">Mutations of the BRAF gene in human cancer</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">417</span><span class="NLM_x">, </span> <span class="NLM_fpage">949</span><span class="NLM_x">–</span> <span class="NLM_lpage">954</span><span class="refDoi"> DOI: 10.1038/nature00766</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1038%2Fnature00766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=12068308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvVagsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=417&publication_year=2002&pages=949-954&author=H.+Daviesauthor=G.+R.+Bignellauthor=C.+Coxauthor=P.+Stephensauthor=S.+Edkinsauthor=S.+Cleggauthor=J.+Teagueauthor=H.+Woffendinauthor=M.+J.+Garnettauthor=W.+Bottomleyauthor=N.+Davisauthor=E.+Dicksauthor=R.+Ewingauthor=Y.+Floydauthor=K.+Grayauthor=S.+Hallauthor=R.+Hawesauthor=J.+Hughesauthor=V.+Kosmidouauthor=A.+Menziesauthor=C.+Mouldauthor=A.+Parkerauthor=C.+Stevensauthor=S.+Wattauthor=S.+Hooperauthor=R.+Wilsonauthor=H.+Jayatilakeauthor=B.+A.+Gustersonauthor=C.+Cooperauthor=J.+Shipleyauthor=D.+Hargraveauthor=K.+Pritchard-Jonesauthor=N.+Maitlandauthor=G.+Chenevix-Trenchauthor=G.+J.+Rigginsauthor=D.+D.+Bignerauthor=G.+Palmieriauthor=A.+Cossuauthor=A.+Flanaganauthor=A.+Nicholsonauthor=J.+W.+C.+Hoauthor=S.+Y.+Leungauthor=S.+T.+Yuenauthor=B.+L.+Weberauthor=H.+F.+Seiglerauthor=T.+L.+Darrowauthor=H.+Patersonauthor=R.+Maraisauthor=C.+J.+Marshallauthor=R.+Woosterauthor=M.+R.+Strattonauthor=P.+A.+Futreal&title=Mutations+of+the+BRAF+gene+in+human+cancer&doi=10.1038%2Fnature00766"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations of the BRAF gene in human cancer</span></div><div class="casAuthors">Davies, Helen; Bignell, Graham R.; Cox, Charles; Stephens, Philip; Edkins, Sarah; Clegg, Sheila; Teague, Jon; Woffendin, Hayley; Garnett, Mathew J.; Bottomley, William; Davis, Neil; Dicks, Ed; Ewing, Rebecca; Floyd, Yvonne; Gray, Kristian; Hall, Sarah; Hawes, Rachel; Hughes, Jaime; Kosmidou, Vivian; Menzies, Andrew; Mould, Catherine; Parker, Adrian; Stevens, Claire; Watt, Stephen; Hooper, Steven; Wilson, Rebecca; Jayatilake, Hiran; Gusterson, Barry A.; Cooper, Colin; Shipley, Janet; Hargrave, Darren; Pritchard-Jones, Katherine; Maitland, Norman; Chenevix-Trench, Georgia; Riggins, Gregory J.; Bigner, Darell D.; Palmieri, Giuseppe; Cossu, Antonio; Flanagan, Adrienne; Nicholson, Andrew; Ho, Judy W. C.; Leung, Suet Y.; Yuen, Siu T.; Weber, Barbara L.; Seigler, Hilliard F.; Darrow, Timothy L.; Paterson, Hugh; Marais, Richard; Marshall, Christopher J.; Wooster, Richard; Stratton, Michael R.; Futreal, P. Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">417</span>
        (<span class="NLM_cas:issue">6892</span>),
    <span class="NLM_cas:pages">949-954</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cancers arise owing to the accumulation of mutations in crit. genes that alter normal programs of cell proliferation, differentiation and death.  As the first stage of a systematic genome-wide screen for these genes, we have prioritized for anal. signalling pathways in which at least one gene is mutated in human cancer.  The RAS-RAF-MEK-ERK-MAP kinase pathway mediates cellular responses to growth signals.  RAS is mutated to an oncogenic form in about 15% of human cancer.  The three RAF genes code for cytoplasmic serine/threonine kinases that are regulated by binding RAS.  Here we report BRAF somatic missense mutations in 66% of malignant melanomas and at lower frequency in a wide range of human cancers.  All mutations are within the kinase domain, with a single substitution (V599E) accounting for 80%.  Mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells.  Furthermore, RAS function is not required for the growth of cancer cell lines with the V599E mutation.  As BRAF is a serine/threonine kinase that is commonly activated by somatic point mutation in human cancer, it may provide new therapeutic opportunities in malignant melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPBmhJC0GAjrVg90H21EOLACvtfcHk0lgk_R1lPf6Ung"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvVagsLo%253D&md5=4625be53ad9a382d51b6ee753d0c17e8</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnature00766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature00766%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DH.%26aulast%3DBignell%26aufirst%3DG.%2BR.%26aulast%3DCox%26aufirst%3DC.%26aulast%3DStephens%26aufirst%3DP.%26aulast%3DEdkins%26aufirst%3DS.%26aulast%3DClegg%26aufirst%3DS.%26aulast%3DTeague%26aufirst%3DJ.%26aulast%3DWoffendin%26aufirst%3DH.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DBottomley%26aufirst%3DW.%26aulast%3DDavis%26aufirst%3DN.%26aulast%3DDicks%26aufirst%3DE.%26aulast%3DEwing%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DK.%26aulast%3DHall%26aufirst%3DS.%26aulast%3DHawes%26aufirst%3DR.%26aulast%3DHughes%26aufirst%3DJ.%26aulast%3DKosmidou%26aufirst%3DV.%26aulast%3DMenzies%26aufirst%3DA.%26aulast%3DMould%26aufirst%3DC.%26aulast%3DParker%26aufirst%3DA.%26aulast%3DStevens%26aufirst%3DC.%26aulast%3DWatt%26aufirst%3DS.%26aulast%3DHooper%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DJayatilake%26aufirst%3DH.%26aulast%3DGusterson%26aufirst%3DB.%2BA.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DShipley%26aufirst%3DJ.%26aulast%3DHargrave%26aufirst%3DD.%26aulast%3DPritchard-Jones%26aufirst%3DK.%26aulast%3DMaitland%26aufirst%3DN.%26aulast%3DChenevix-Trench%26aufirst%3DG.%26aulast%3DRiggins%26aufirst%3DG.%2BJ.%26aulast%3DBigner%26aufirst%3DD.%2BD.%26aulast%3DPalmieri%26aufirst%3DG.%26aulast%3DCossu%26aufirst%3DA.%26aulast%3DFlanagan%26aufirst%3DA.%26aulast%3DNicholson%26aufirst%3DA.%26aulast%3DHo%26aufirst%3DJ.%2BW.%2BC.%26aulast%3DLeung%26aufirst%3DS.%2BY.%26aulast%3DYuen%26aufirst%3DS.%2BT.%26aulast%3DWeber%26aufirst%3DB.%2BL.%26aulast%3DSeigler%26aufirst%3DH.%2BF.%26aulast%3DDarrow%26aufirst%3DT.%2BL.%26aulast%3DPaterson%26aufirst%3DH.%26aulast%3DMarais%26aufirst%3DR.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26aulast%3DWooster%26aufirst%3DR.%26aulast%3DStratton%26aufirst%3DM.%2BR.%26aulast%3DFutreal%26aufirst%3DP.%2BA.%26atitle%3DMutations%2520of%2520the%2520BRAF%2520gene%2520in%2520human%2520cancer%26jtitle%3DNature%26date%3D2002%26volume%3D417%26spage%3D949%26epage%3D954%26doi%3D10.1038%2Fnature00766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Wan, P. T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garnett, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roe, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niculescu-Duvaz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Project, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barford, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span> </span><span class="NLM_article-title">Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">855</span><span class="NLM_x">–</span> <span class="NLM_lpage">867</span><span class="refDoi"> DOI: 10.1016/S0092-8674(04)00215-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1016%2FS0092-8674%2804%2900215-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=15035987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivVyksLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2004&pages=855-867&author=P.+T.+C.+Wanauthor=M.+J.+Garnettauthor=S.+M.+Roeauthor=S.+Leeauthor=D.+Niculescu-Duvazauthor=V.+M.+Goodauthor=C.+G.+Projectauthor=C.+M.+Jonesauthor=C.+J.+Marshallauthor=C.+J.+Springerauthor=D.+Barfordauthor=R.+Marais&title=Mechanism+of+Activation+of+the+RAF-ERK+Signaling+Pathway+by+Oncogenic+Mutations+of+B-RAF&doi=10.1016%2FS0092-8674%2804%2900215-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF</span></div><div class="casAuthors">Wan, Paul T. C.; Garnett, Mathew J.; Roe, S. Mark; Lee, Sharlene; Niculescu-Duvaz, Dan; Good, Valerie M.; Project, Cancer Genome; Jones, C. Michael; Marshall, Christopher J.; Springer, Caroline J.; Barford, David; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">855-867</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Over 30 mutations of the B-RAF gene assocd. with human cancers have been identified, the majority of which are located within the kinase domain.  Here the authors show that of 22 B-RAF mutants analyzed, 18 have elevated kinase activity and signal to ERK in vivo.  Surprisingly, three mutants have reduced kinase activity towards MEK in vitro but, by activating C-RAF in vivo, signal to ERK in cells.  The structures of wild type and oncogenic V599EB-RAF kinase domains in complex with the RAF inhibitor BAY43-9006 show that the activation segment is held in an inactive conformation by assocn. with the P loop.  The clustering of most mutations to these two regions suggests that disruption of this interaction converts B-RAF into its active conformation.  The high activity mutants signal to ERK by directly phosphorylating MEK, whereas the impaired activity mutants stimulate MEK by activating endogenous C-RAF, possibly via an allosteric or transphosphorylation mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYiQicwc1xVLVg90H21EOLACvtfcHk0lgLO-SEt69Smw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivVyksLw%253D&md5=4cc020056c64e514286c000666da1972</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2804%2900215-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252804%252900215-6%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DP.%2BT.%2BC.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DRoe%26aufirst%3DS.%2BM.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DGood%26aufirst%3DV.%2BM.%26aulast%3DProject%26aufirst%3DC.%2BG.%26aulast%3DJones%26aufirst%3DC.%2BM.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26aulast%3DBarford%26aufirst%3DD.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DMechanism%2520of%2520Activation%2520of%2520the%2520RAF-ERK%2520Signaling%2520Pathway%2520by%2520Oncogenic%2520Mutations%2520of%2520B-RAF%26jtitle%3DCell%26date%3D2004%26volume%3D116%26spage%3D855%26epage%3D867%26doi%3D10.1016%2FS0092-8674%2804%2900215-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puzanov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Dwyer, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grippo, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span> </span><span class="NLM_article-title">Inhibition of Mutated, Activated BRAF in Metastatic Melanoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">809</span><span class="NLM_x">–</span> <span class="NLM_lpage">819</span><span class="refDoi"> DOI: 10.1056/NEJMoa1002011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1056%2FNEJMoa1002011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=20818844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVyksb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=809-819&author=K.+T.+Flahertyauthor=I.+Puzanovauthor=K.+B.+Kimauthor=A.+Ribasauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=P.+J.+O%E2%80%99Dwyerauthor=R.+J.+Leeauthor=J.+F.+Grippoauthor=K.+Nolopauthor=P.+B.+Chapman&title=Inhibition+of+Mutated%2C+Activated+BRAF+in+Metastatic+Melanoma&doi=10.1056%2FNEJMoa1002011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of mutated, activated BRAF in metastatic melanoma</span></div><div class="casAuthors">Flaherty, Keith T.; Puzanov, Igor; Kim, Kevin B.; Ribas, Antoni; McArthur, Grant A.; Sosman, Jeffrey A.; O'dwyer, Peter J.; Lee, Richard J.; Grippo, Joseph F.; Nolop, Keith; Chapman, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">809-819</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: The identification of somatic mutations in the gene encoding the serine-threonine protein kinase B-RAF (BRAF) in the majority of melanomas offers an opportunity to test oncogene-targeted therapy for this disease.  Methods: We conducted a multicenter, phase 1, dose-escalation trial of PLX4032 (also known as RG7204), an orally available inhibitor of mutated BRAF, followed by an extension phase involving the max. dose that could be administered without adverse effects (the recommended phase 2 dose).  Patients received PLX4032 twice daily until they had disease progression.  Pharmacokinetic anal. and tumor-response assessments were conducted in all patients.  In selected patients, tumor biopsy was performed before and during treatment to validate BRAF inhibition.  Results: A total of 55 patients (49 of whom had melanoma) were enrolled in the dose-escalation phase, and 32 addnl. patients with metastatic melanoma who had BRAF with the V600E mutation were enrolled in the extension phase.  The recommended phase 2 dose was 960 mg twice daily, with increases in the dose limited by grade 2 or 3 rash, fatigue, and arthralgia.  In the dose-escalation cohort, among the 16 patients with melanoma whose tumors carried the V600E BRAF mutation and who were receiving 240 mg or more of PLX4032 twice daily, 10 had a partial response and 1 had a complete response.  Among the 32 patients in the extension cohort, 24 had a partial response and 2 had a complete response.  The estd. median progression-free survival among all patients was more than 7 mo.  Conclusions: Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwq1fkvEjfyLVg90H21EOLACvtfcHk0lgLO-SEt69Smw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVyksb3M&md5=80f70df0ac490828a42e6c7c0b40067f</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1002011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1002011%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DP.%2BJ.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DGrippo%26aufirst%3DJ.%2BF.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26atitle%3DInhibition%2520of%2520Mutated%252C%2520Activated%2520BRAF%2520in%2520Metastatic%2520Melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D809%26epage%3D819%26doi%3D10.1056%2FNEJMoa1002011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Chapman, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauschild, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haanen, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ascierto, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larkin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dummer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Testori, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorigan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jouary, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schadendorf, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Day, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkwood, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eggermont, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreno, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span> </span><span class="NLM_article-title">Improved survival with vemurafenib in melanoma with BRAF V600E mutation</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">2507</span><span class="NLM_x">–</span> <span class="NLM_lpage">16</span><span class="refDoi"> DOI: 10.1056/NEJMoa1103782</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1056%2FNEJMoa1103782" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=21639808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosVeitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=2507-16&author=P.+B.+Chapmanauthor=A.+Hauschildauthor=C.+Robertauthor=J.+B.+Haanenauthor=P.+Asciertoauthor=J.+Larkinauthor=R.+Dummerauthor=C.+Garbeauthor=A.+Testoriauthor=M.+Maioauthor=D.+Hoggauthor=P.+Loriganauthor=C.+Lebbeauthor=T.+Jouaryauthor=D.+Schadendorfauthor=A.+Ribasauthor=S.+J.+O%E2%80%99Dayauthor=J.+A.+Sosmanauthor=J.+M.+Kirkwoodauthor=A.+M.+Eggermontauthor=B.+Drenoauthor=K.+Nolopauthor=J.+Liauthor=B.+Nelsonauthor=J.+Houauthor=R.+J.+Leeauthor=K.+T.+Flahertyauthor=G.+A.+McArthur&title=Improved+survival+with+vemurafenib+in+melanoma+with+BRAF+V600E+mutation&doi=10.1056%2FNEJMoa1103782"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Improved survival with vemurafenib in melanoma with BRAF V600E mutation</span></div><div class="casAuthors">Chapman, Paul B.; Hauschild, Axel; Robert, Caroline; Haanen, John B.; Ascierto, Paolo; Larkin, James; Dummer, Reinhard; Garbe, Claus; Testori, Alessandro; Maio, Michele; Hogg, David; Lorigan, Paul; Lebbe, Celeste; Jouary, Thomas; Schadendorf, Dirk; Ribas, Antoni; O'Day, Steven J.; Sosman, Jeffrey A.; Kirkwood, John M.; Eggermont, Alexander M. M.; Dreno, Brigitte; Nolop, Keith; Li, Jiang; Nelson, Betty; Hou, Jeannie; Lee, Richard J.; Flaherty, Keith T.; McArthur, Grant A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2507-2516</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Phase 1 and 2 clin. trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation.  METHODS: We conducted a phase 3 randomized clin. trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation.  Patients were randomly assigned to receive either vemurafenib (960 mg orally twice daily) or dacarbazine (1000 mg per square meter of body-surface area i.v. every 3 wk).  Coprimary end points were rates of overall and progression-free survival.  Secondary end points included the response rate, response duration, and safety.  A final anal. was planned after 196 deaths and an interim anal. after 98 deaths.  RESULTS: At 6 mo, overall survival was 840/ (95% confidence interval [CI], 78 to 89) in the vemurafenib group and 64% (95% CI, 56 to 73) in the dacarbazine group.  In the interim anal. for overall survival and final anal. for progression-free survival, vemurafenib was assocd. with a relative redn. of 63% in the risk of death and of 74% in the risk of either death or disease progression, as compared with dacarbazine (P < 0.001 for both comparisons).  After review of the interim anal. by an independent data and safety monitoring board, crossover from dacarbazine to vemurafenib was recommended.  Response rates were 48% for vemurafenib and 5% for dacarbazine.  Common adverse events assocd. with vemurafenib were arthralgia, rash, fatigue, alopecia, keratoacanthoma or squamous-cell carcinoma, photosensitivity, nausea, and diarrhea; 38% of patients required dose modification because of toxic effects.  CONCLUSIONS: Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4NFxmTaDz97Vg90H21EOLACvtfcHk0lgS1bfD-0VsRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosVeitbs%253D&md5=1a4b4f963221888dc63f620e87408070</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1103782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1103782%26sid%3Dliteratum%253Aachs%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DHaanen%26aufirst%3DJ.%2BB.%26aulast%3DAscierto%26aufirst%3DP.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DTestori%26aufirst%3DA.%26aulast%3DMaio%26aufirst%3DM.%26aulast%3DHogg%26aufirst%3DD.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DLebbe%26aufirst%3DC.%26aulast%3DJouary%26aufirst%3DT.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Day%26aufirst%3DS.%2BJ.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DKirkwood%26aufirst%3DJ.%2BM.%26aulast%3DEggermont%26aufirst%3DA.%2BM.%26aulast%3DDreno%26aufirst%3DB.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DNelson%26aufirst%3DB.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26atitle%3DImproved%2520survival%2520with%2520vemurafenib%2520in%2520melanoma%2520with%2520BRAF%2520V600E%2520mutation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D2507%26epage%3D16%26doi%3D10.1056%2FNEJMoa1103782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Lehnert, M.</span><span> </span><span class="NLM_article-title">Multidrug resistance in human cancer</span> <span class="citation_source-journal">J. Neuro-Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">239</span><span class="NLM_x">–</span> <span class="NLM_lpage">43</span><span class="refDoi"> DOI: 10.1007/BF01052927</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1007%2FBF01052927" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=7760101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A280%3ADyaK2M3otVSmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1994&pages=239-43&author=M.+Lehnert&title=Multidrug+resistance+in+human+cancer&doi=10.1007%2FBF01052927"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Multidrug resistance in human cancer</span></div><div class="casAuthors">Lehnert M</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neuro-oncology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">239-43</span>
        ISSN:<span class="NLM_cas:issn">0167-594X</span>.
    </div><div class="casAbstract">Resistance to cytotoxic chemotherapy continues to be a major obstacle to more effective treatment of human cancers.  A particular problem in clinical cancer chemotherapy is the phenomenon of simultaneous resistance of cancers to a variety of unrelated cytotoxic agents.  Such resistance to multiple drugs is observed much more often than resistance to individual compounds.  A similar experimental phenomenon has been termed multidrug resistance or MDR.  Much has been learned in recent years about molecular mechanisms which can lead to MDR in cancer cells and a number of studies has been performed to evaluate the clinical relevance of such mechanisms.  In particular, P-glycoprotein-associated MDR (MDR1) has received a lot of attention.  This review will discuss (i) some principal aspects of drug resistance in cancer with particular emphasis on MDR1; (ii) available data on drug resistance mechanisms in brain tumors; and (iii) our current knowledge on the putative role of P-glycoprotein in the blood-brain barrier.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR51BMNng4S_ty3lHz94U-GfW6udTcc2eb1FRniW_4GGLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2M3otVSmtw%253D%253D&md5=b8ef6c87aa932a1be90be81e1f230b1e</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1007%2FBF01052927&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF01052927%26sid%3Dliteratum%253Aachs%26aulast%3DLehnert%26aufirst%3DM.%26atitle%3DMultidrug%2520resistance%2520in%2520human%2520cancer%26jtitle%3DJ.%2520Neuro-Oncol.%26date%3D1994%26volume%3D22%26spage%3D239%26epage%3D43%26doi%3D10.1007%2FBF01052927" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Gottesman, M. M.</span><span> </span><span class="NLM_article-title">How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal Foundation Award Lecture</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">747</span><span class="NLM_x">–</span> <span class="NLM_lpage">54</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1993&pages=747-54&author=M.+M.+Gottesman&title=How+cancer+cells+evade+chemotherapy%3A+sixteenth+Richard+and+Hinda+Rosenthal+Foundation+Award+Lecture"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26atitle%3DHow%2520cancer%2520cells%2520evade%2520chemotherapy%253A%2520sixteenth%2520Richard%2520and%2520Hinda%2520Rosenthal%2520Foundation%2520Award%2520Lecture%26jtitle%3DCancer%2520Res.%26date%3D1993%26volume%3D53%26spage%3D747%26epage%3D54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Sahu, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balbhadra, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choudhary, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohli, D. V.</span><span> </span><span class="NLM_article-title">Exploring pharmacological significance of chalcone scaffold: a review</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">209</span><span class="NLM_x">–</span> <span class="NLM_lpage">25</span><span class="refDoi"> DOI: 10.2174/092986712803414132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.2174%2F092986712803414132" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=22320299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1ygtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=209-25&author=N.+K.+Sahuauthor=S.+S.+Balbhadraauthor=J.+Choudharyauthor=D.+V.+Kohli&title=Exploring+pharmacological+significance+of+chalcone+scaffold%3A+a+review&doi=10.2174%2F092986712803414132"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring pharmacological significance of chalcone scaffold: a review</span></div><div class="casAuthors">Sahu, N. K.; Balbhadra, S. S.; Choudhary, J.; Kohli, D. V.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-225</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Chalcones (1,3-diaryl-2-propen-1-ones) and their heterocyclic analogs, belong to the flavonoid family, which possess a no. of interesting biol. properties such as antioxidant, cytotoxic, anticancer, antimicrobial, antiprotozoal, antiulcer, antihistaminic and anti-inflammatory activities.  Several pure chalcones have been approved for clin. use or tested in humans.  Clin. trials have shown that these compds. reached reasonable plasma concn. and are well-tolerated.  For this reason they are an object of continuously growing interest amongst the scientists.  However, much of the pharmacol. potential of chalcones is still not utilized.  The purpose of this review is to provide an overview of the pharmacol. activity of naturally occurring and synthetic chalcones.  This review highlights more recent pharmacol. screening of these compds., their mechanisms of action and relevant structure-activity relationships.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxOy69N3sXULVg90H21EOLACvtfcHk0ljKZ95tu-opyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1ygtbo%253D&md5=65b8fd77d6156b5de7bcc8f46740ff70</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.2174%2F092986712803414132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986712803414132%26sid%3Dliteratum%253Aachs%26aulast%3DSahu%26aufirst%3DN.%2BK.%26aulast%3DBalbhadra%26aufirst%3DS.%2BS.%26aulast%3DChoudhary%26aufirst%3DJ.%26aulast%3DKohli%26aufirst%3DD.%2BV.%26atitle%3DExploring%2520pharmacological%2520significance%2520of%2520chalcone%2520scaffold%253A%2520a%2520review%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2012%26volume%3D19%26spage%3D209%26epage%3D25%26doi%3D10.2174%2F092986712803414132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Bukhari, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jantan, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unsal Tan, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sher, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naeem-Ul-Hassan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, H. L.</span><span> </span><span class="NLM_article-title">Biological activity and molecular docking studies of curcumin-related alpha,beta-unsaturated carbonyl-based synthetic compounds as anticancer agents and mushroom tyrosinase inhibitors</span> <span class="citation_source-journal">J. Agric. Food Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">5538</span><span class="NLM_x">–</span> <span class="NLM_lpage">47</span><span class="refDoi"> DOI: 10.1021/jf501145b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jf501145b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2014&pages=5538-47&author=S.+N.+Bukhariauthor=I.+Jantanauthor=O.+Unsal+Tanauthor=M.+Sherauthor=M.+Naeem-Ul-Hassanauthor=H.+L.+Qin&title=Biological+activity+and+molecular+docking+studies+of+curcumin-related+alpha%2Cbeta-unsaturated+carbonyl-based+synthetic+compounds+as+anticancer+agents+and+mushroom+tyrosinase+inhibitors&doi=10.1021%2Fjf501145b"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjf501145b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjf501145b%26sid%3Dliteratum%253Aachs%26aulast%3DBukhari%26aufirst%3DS.%2BN.%26aulast%3DJantan%26aufirst%3DI.%26aulast%3DUnsal%2BTan%26aufirst%3DO.%26aulast%3DSher%26aufirst%3DM.%26aulast%3DNaeem-Ul-Hassan%26aufirst%3DM.%26aulast%3DQin%26aufirst%3DH.%2BL.%26atitle%3DBiological%2520activity%2520and%2520molecular%2520docking%2520studies%2520of%2520curcumin-related%2520alpha%252Cbeta-unsaturated%2520carbonyl-based%2520synthetic%2520compounds%2520as%2520anticancer%2520agents%2520and%2520mushroom%2520tyrosinase%2520inhibitors%26jtitle%3DJ.%2520Agric.%2520Food%2520Chem.%26date%3D2014%26volume%3D62%26spage%3D5538%26epage%3D47%26doi%3D10.1021%2Fjf501145b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Pati, H. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimmock, J. R.</span><span> </span><span class="NLM_article-title">Cytotoxic thiol alkylators</span> <span class="citation_source-journal">Mini-Rev. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">131</span><span class="NLM_x">–</span> <span class="NLM_lpage">9</span><span class="refDoi"> DOI: 10.2174/138955707779802642</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.2174%2F138955707779802642" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=131-9&author=H.+N.+Patiauthor=U.+Dasauthor=R.+K.+Sharmaauthor=J.+R.+Dimmock&title=Cytotoxic+thiol+alkylators&doi=10.2174%2F138955707779802642"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.2174%2F138955707779802642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955707779802642%26sid%3Dliteratum%253Aachs%26aulast%3DPati%26aufirst%3DH.%2BN.%26aulast%3DDas%26aufirst%3DU.%26aulast%3DSharma%26aufirst%3DR.%2BK.%26aulast%3DDimmock%26aufirst%3DJ.%2BR.%26atitle%3DCytotoxic%2520thiol%2520alkylators%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26spage%3D131%26epage%3D9%26doi%3D10.2174%2F138955707779802642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Maydt, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Spirt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muschelknautz, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahl, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, T. J.</span><span> </span><span class="NLM_article-title">Chemical reactivity and biological activity of chalcones and other alpha,beta-unsaturated carbonyl compounds</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">711</span><span class="NLM_x">–</span> <span class="NLM_lpage">8</span><span class="refDoi"> DOI: 10.3109/00498254.2012.754112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.3109%2F00498254.2012.754112" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2013&pages=711-8&author=D.+Maydtauthor=S.+De+Spirtauthor=C.+Muschelknautzauthor=W.+Stahlauthor=T.+J.+Muller&title=Chemical+reactivity+and+biological+activity+of+chalcones+and+other+alpha%2Cbeta-unsaturated+carbonyl+compounds&doi=10.3109%2F00498254.2012.754112"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.3109%2F00498254.2012.754112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F00498254.2012.754112%26sid%3Dliteratum%253Aachs%26aulast%3DMaydt%26aufirst%3DD.%26aulast%3DDe%2BSpirt%26aufirst%3DS.%26aulast%3DMuschelknautz%26aufirst%3DC.%26aulast%3DStahl%26aufirst%3DW.%26aulast%3DMuller%26aufirst%3DT.%2BJ.%26atitle%3DChemical%2520reactivity%2520and%2520biological%2520activity%2520of%2520chalcones%2520and%2520other%2520alpha%252Cbeta-unsaturated%2520carbonyl%2520compounds%26jtitle%3DXenobiotica%26date%3D2013%26volume%3D43%26spage%3D711%26epage%3D8%26doi%3D10.3109%2F00498254.2012.754112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Peng, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span> </span><span class="NLM_article-title">Characterization of a novel curcumin analog P1 as potent inhibitor of the NF-kappaB signaling pathway with distinct mechanisms</span> <span class="citation_source-journal">Acta Pharmacol. Sin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">939</span><span class="NLM_x">–</span> <span class="NLM_lpage">50</span><span class="refDoi"> DOI: 10.1038/aps.2013.2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1038%2Faps.2013.2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=23603982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVGktrjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=939-50&author=Y.+M.+Pengauthor=J.+B.+Zhengauthor=Y.+B.+Zhouauthor=J.+Li&title=Characterization+of+a+novel+curcumin+analog+P1+as+potent+inhibitor+of+the+NF-kappaB+signaling+pathway+with+distinct+mechanisms&doi=10.1038%2Faps.2013.2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of a novel curcumin analog P1 as potent inhibitor of the NF-κB signaling pathway with distinct mechanisms</span></div><div class="casAuthors">Peng, Yan-min; Zheng, Jian-bin; Zhou, Yu-bo; Li, Jia</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">939-950</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Aim: Curcumin has shown promising anticancer activity, which relies on its inhibition on NF-κB pathway.  In this study, we characterized the pharmacol. profile of a novel curcumin analog P1 and elucidate the related mechanisms.  Methods: HEK293/NF-κB cells, stably transfected with an NF-κB-responsive luciferase reporter plasmid, were generated for high-throughput screen (HTS).  Eight cancer cell lines, including PC3, COLO 205, HeLa cells etc. were tested.  Cell viability was assessed using the sulforhodamine B (SRB) assays.  Cell apoptosis was evaluated using FACS, immunocytochem., and Western blotting.  H2-DCFDA and MitoSOX Red were used to detect cellular and mitochondrial reactive oxygen species (ROS).  The mitochondrial function was evaluated using mitochondrial oxygen consumption assay.  Results: P1, a tropinone curcumin, was found in HTS targeting the NF-κB pathway.  Its IC50 value in inhibition of TNF-α-induced NF-κB activation was 0.8 μmol/L, whereas its IC50 values in inhibiting the growth of A549 and HeLa cells were 1.24 and 0.69 μmol/L, resp., which was 20- to 30-fold more potent than curcumin.  The inhibition of P1 on the NF-κB pathway was further addressed in HeLa cells.  The compd. up to 10 μmol/L did not affect the binding of NF-κB to DNA, but markedly inhibited NF-κB nuclear translocation, IκB degrdn. and IκB kinase phosphorylation.  The compd. (1 and 3 μmol/L) concn.-dependently induced ROS generation, whereas curcumin up to 20 μmol/L had no effect.  P1-induced ROS generation was mainly localized in mitochondria, and reversed by NAC.  Moreover, the compd. significantly enhanced TNF-α-induced apoptosis.  Conclusion: P1 is a novel curcumin analog with potent anticancer activities, which exerts a distinct inhibition on the NF-κB pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrACH-zytJoj7Vg90H21EOLACvtfcHk0lizl4WG6A5_wA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVGktrjI&md5=92649400225e5c44217954fcf4203923</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Faps.2013.2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Faps.2013.2%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DY.%2BM.%26aulast%3DZheng%26aufirst%3DJ.%2BB.%26aulast%3DZhou%26aufirst%3DY.%2BB.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DCharacterization%2520of%2520a%2520novel%2520curcumin%2520analog%2520P1%2520as%2520potent%2520inhibitor%2520of%2520the%2520NF-kappaB%2520signaling%2520pathway%2520with%2520distinct%2520mechanisms%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2013%26volume%3D34%26spage%3D939%26epage%3D50%26doi%3D10.1038%2Faps.2013.2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Jung, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, H.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, W.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, K.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. H. Y.</span><span> </span><span class="NLM_article-title">Isoliquiritigenin induces apoptosis by depolarizing mitochondrial membranes in prostate cancer cells</span> <span class="citation_source-journal">J. Nutr. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">689</span><span class="NLM_x">–</span> <span class="NLM_lpage">696</span><span class="refDoi"> DOI: 10.1016/j.jnutbio.2005.11.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1016%2Fj.jnutbio.2005.11.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=16517140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BD28XpvFGisr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2006&pages=689-696&author=J.+I.+Jungauthor=S.+S.+Limauthor=H.+J.+Choiauthor=H.+J.+Choauthor=H.-K.+Shinauthor=E.+J.+Kimauthor=W.-Y.+Chungauthor=K.-K.+Parkauthor=J.+H.+Y.+Park&title=Isoliquiritigenin+induces+apoptosis+by+depolarizing+mitochondrial+membranes+in+prostate+cancer+cells&doi=10.1016%2Fj.jnutbio.2005.11.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Isoliquiritigenin induces apoptosis by depolarizing mitochondrial membranes in prostate cancer cells</span></div><div class="casAuthors">Jung, Jae In; Lim, Soon Sung; Choi, Hyun Ju; Cho, Han Jin; Shin, Hyun-Kyung; Kim, Eun Ji; Chung, Won-Yoon; Park, Kwang-Kyun; Park, Jung Han Yoon</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nutritional Biochemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">689-696</span>CODEN:
                <span class="NLM_cas:coden">JNBIEL</span>;
        ISSN:<span class="NLM_cas:issn">0955-2863</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Isoliquiritigenin (ISL), a simple chalcone deriv., 4,2',4'-trihydroxychalcone, found in licorice, shallot and bean sprouts, has been reported to have chemoprotective effects.  To examine the effects of ISL on the growth of prostate cancer cells, we cultured MAT-LyLu (MLL) rat and DU145 human prostate cancer cells with various concns. (0-20 μmol/L) of ISL.  Treatment of the cells with increasing concns. of ISL led to dose-dependent decreases in the viable cell nos. in both DU145 and MLL cells (P<.05).  Hoechst 33258 dye staining of condensed nuclei and annexin V binding to surface phosphatidylserine revealed increased nos. of apoptotic cells after ISL treatment.  Western blot anal. revealed that ISL increased the levels of membrane-bound Fas ligand (FasL), Fas, cleaved caspase-8, truncated Bid (tBid), Bax and Bad in DU145 cells (P<.05).  Isoliquiritigenin increased the percentage of cells with depolarized mitochondrial membranes, in a concn.-dependent manner (P<.05).  Isoliquiritigenin induced the release of cytochrome c and Smac/Diablo from the mitochondria into the cytoplasm (P<.05).  Isoliquiritigenin dose-dependently increased the levels of cleaved caspase-9, caspase-7, caspase-3 and poly(ADP-ribose) polymerase (P<.05).  The present results indicate that ISL inhibits prostate cancer cell growth by the induction of apoptosis, which is mediated through mitochondrial events, which are assocd. with an evident disruption of the mitochondrial membrane potential, and the release of cytochrome c and Smac/Diablo, and the activation of caspase-9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomeWjZMwPxxrVg90H21EOLACvtfcHk0lizl4WG6A5_wA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpvFGisr0%253D&md5=3649aa6519f562bce7b93c69664ab032</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.jnutbio.2005.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jnutbio.2005.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DJung%26aufirst%3DJ.%2BI.%26aulast%3DLim%26aufirst%3DS.%2BS.%26aulast%3DChoi%26aufirst%3DH.%2BJ.%26aulast%3DCho%26aufirst%3DH.%2BJ.%26aulast%3DShin%26aufirst%3DH.-K.%26aulast%3DKim%26aufirst%3DE.%2BJ.%26aulast%3DChung%26aufirst%3DW.-Y.%26aulast%3DPark%26aufirst%3DK.-K.%26aulast%3DPark%26aufirst%3DJ.%2BH.%2BY.%26atitle%3DIsoliquiritigenin%2520induces%2520apoptosis%2520by%2520depolarizing%2520mitochondrial%2520membranes%2520in%2520prostate%2520cancer%2520cells%26jtitle%3DJ.%2520Nutr.%2520Biochem.%26date%3D2006%26volume%3D17%26spage%3D689%26epage%3D696%26doi%3D10.1016%2Fj.jnutbio.2005.11.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Szliszka, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czuba, Z. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazur, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paradysz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krol, W.</span><span> </span><span class="NLM_article-title">Chalcones and dihydrochalcones augment TRAIL-mediated apoptosis in prostate cancer cells</span> <span class="citation_source-journal">Molecules</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">5336</span><span class="NLM_x">–</span> <span class="NLM_lpage">53</span><span class="refDoi"> DOI: 10.3390/molecules15085336</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.3390%2Fmolecules15085336" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2010&pages=5336-53&author=E.+Szliszkaauthor=Z.+P.+Czubaauthor=B.+Mazurauthor=A.+Paradyszauthor=W.+Krol&title=Chalcones+and+dihydrochalcones+augment+TRAIL-mediated+apoptosis+in+prostate+cancer+cells&doi=10.3390%2Fmolecules15085336"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.3390%2Fmolecules15085336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules15085336%26sid%3Dliteratum%253Aachs%26aulast%3DSzliszka%26aufirst%3DE.%26aulast%3DCzuba%26aufirst%3DZ.%2BP.%26aulast%3DMazur%26aufirst%3DB.%26aulast%3DParadysz%26aufirst%3DA.%26aulast%3DKrol%26aufirst%3DW.%26atitle%3DChalcones%2520and%2520dihydrochalcones%2520augment%2520TRAIL-mediated%2520apoptosis%2520in%2520prostate%2520cancer%2520cells%26jtitle%3DMolecules%26date%3D2010%26volume%3D15%26spage%3D5336%26epage%3D53%26doi%3D10.3390%2Fmolecules15085336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Yun, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kweon, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwon, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwang, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukhtar, H.</span><span> </span><span class="NLM_article-title">Induction of apoptosis and cell cycle arrest by a chalcone panduratin A isolated from Kaempferia pandurata in androgen-independent human prostate cancer cells PC3 and DU145</span> <span class="citation_source-journal">Carcinogenesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1454</span><span class="NLM_x">–</span> <span class="NLM_lpage">64</span><span class="refDoi"> DOI: 10.1093/carcin/bgi348</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1093%2Fcarcin%2Fbgi348" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2006&pages=1454-64&author=J.+M.+Yunauthor=M.+H.+Kweonauthor=H.+Kwonauthor=J.+K.+Hwangauthor=H.+Mukhtar&title=Induction+of+apoptosis+and+cell+cycle+arrest+by+a+chalcone+panduratin+A+isolated+from+Kaempferia+pandurata+in+androgen-independent+human+prostate+cancer+cells+PC3+and+DU145&doi=10.1093%2Fcarcin%2Fbgi348"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1093%2Fcarcin%2Fbgi348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcarcin%252Fbgi348%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DJ.%2BM.%26aulast%3DKweon%26aufirst%3DM.%2BH.%26aulast%3DKwon%26aufirst%3DH.%26aulast%3DHwang%26aufirst%3DJ.%2BK.%26aulast%3DMukhtar%26aufirst%3DH.%26atitle%3DInduction%2520of%2520apoptosis%2520and%2520cell%2520cycle%2520arrest%2520by%2520a%2520chalcone%2520panduratin%2520A%2520isolated%2520from%2520Kaempferia%2520pandurata%2520in%2520androgen-independent%2520human%2520prostate%2520cancer%2520cells%2520PC3%2520and%2520DU145%26jtitle%3DCarcinogenesis%26date%3D2006%26volume%3D27%26spage%3D1454%26epage%3D64%26doi%3D10.1093%2Fcarcin%2Fbgi348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Nozaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, K.-i.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kido, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kakumoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuura, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takaoka, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iinuma, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akao, Y.</span><span> </span><span class="NLM_article-title">Pauferrol A, a novel chalcone trimer with a cyclobutane ring from Caesalpinia ferrea mart exhibiting DNA topoisomerase II inhibition and apoptosis-inducing activity</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">8290</span><span class="NLM_x">–</span> <span class="NLM_lpage">8292</span><span class="refDoi"> DOI: 10.1016/j.tetlet.2007.09.130</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1016%2Fj.tetlet.2007.09.130" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2007&pages=8290-8292&author=H.+Nozakiauthor=K.-i.+Hayashiauthor=M.+Kidoauthor=K.+Kakumotoauthor=S.+Ikedaauthor=N.+Matsuuraauthor=H.+Taniauthor=D.+Takaokaauthor=M.+Iinumaauthor=Y.+Akao&title=Pauferrol+A%2C+a+novel+chalcone+trimer+with+a+cyclobutane+ring+from+Caesalpinia+ferrea+mart+exhibiting+DNA+topoisomerase+II+inhibition+and+apoptosis-inducing+activity&doi=10.1016%2Fj.tetlet.2007.09.130"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2007.09.130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2007.09.130%26sid%3Dliteratum%253Aachs%26aulast%3DNozaki%26aufirst%3DH.%26aulast%3DHayashi%26aufirst%3DK.-i.%26aulast%3DKido%26aufirst%3DM.%26aulast%3DKakumoto%26aufirst%3DK.%26aulast%3DIkeda%26aufirst%3DS.%26aulast%3DMatsuura%26aufirst%3DN.%26aulast%3DTani%26aufirst%3DH.%26aulast%3DTakaoka%26aufirst%3DD.%26aulast%3DIinuma%26aufirst%3DM.%26aulast%3DAkao%26aufirst%3DY.%26atitle%3DPauferrol%2520A%252C%2520a%2520novel%2520chalcone%2520trimer%2520with%2520a%2520cyclobutane%2520ring%2520from%2520Caesalpinia%2520ferrea%2520mart%2520exhibiting%2520DNA%2520topoisomerase%2520II%2520inhibition%2520and%2520apoptosis-inducing%2520activity%26jtitle%3DTetrahedron%2520Lett.%26date%3D2007%26volume%3D48%26spage%3D8290%26epage%3D8292%26doi%3D10.1016%2Fj.tetlet.2007.09.130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Qin, H.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shang, Z.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jantan, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, O. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hussain, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sher, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bukhari, S. N. A.</span><span> </span><span class="NLM_article-title">Molecular docking studies and biological evaluation of chalcone based pyrazolines as tyrosinase inhibitors and potential anticancer agents</span> <span class="citation_source-journal">RSC Adv.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">46330</span><span class="NLM_x">–</span> <span class="NLM_lpage">46338</span><span class="refDoi"> DOI: 10.1039/C5RA02995C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1039%2FC5RA02995C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosFKntr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=46330-46338&author=H.-L.+Qinauthor=Z.-P.+Shangauthor=I.+Jantanauthor=O.+U.+Tanauthor=M.+A.+Hussainauthor=M.+Sherauthor=S.+N.+A.+Bukhari&title=Molecular+docking+studies+and+biological+evaluation+of+chalcone+based+pyrazolines+as+tyrosinase+inhibitors+and+potential+anticancer+agents&doi=10.1039%2FC5RA02995C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular docking studies and biological evaluation of chalcone based pyrazolines as tyrosinase inhibitors and potential anticancer agents</span></div><div class="casAuthors">Qin, Hua-Li; Shang, Zhen-Peng; Jantan, Ibrahim; Tan, Oya Unsal; Hussain, Muhammad Ajaz; Sher, Muhammad; Bukhari, Syed Nasir Abbas</div><div class="citationInfo"><span class="NLM_cas:title">RSC Advances</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">57</span>),
    <span class="NLM_cas:pages">46330-46338</span>CODEN:
                <span class="NLM_cas:coden">RSCACL</span>;
        ISSN:<span class="NLM_cas:issn">2046-2069</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Studies on the discovery of tyrosinase enzyme inhibitors and exploration for better cytotoxic agents remain an important line in drug discovery and development.  A series of synthetic chalcones and pyrazoline derivs. was evaluated for their inhibitory effects on the diphenolase activity of mushroom tyrosinase.  The effects of these compds. on proliferation and microtubule assembly were also evaluated in seven different cancer cell lines.  The results revealed that some of the synthetic compds. showed significant inhibitory activity, with four compds. being more potent tyrosinase inhibitors than the ref. std. inhibitor kojic acid.  Several compds. were toxic to cancer cell lines.  Compd. 1a was found to possess the highest anticancer activity towards all cell lines with an IC50 in the range of 0.9-2.2 μM.  Seven of the compds. showed considerable tubulin polymn. activity at a concn. of 25 μM.  Mol. modeling studies of these synthetic compds. were performed to investigate their interactions with the tyrosinase enzyme.  The structure-activity relationship (SAR) study using in-silico anal. matched well with the in vitro tumor cell inhibitory activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsfm8YXQUkobVg90H21EOLACvtfcHk0ljxZbumee6Xmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosFKntr4%253D&md5=2498c3249d0538afed53bc0c6b79ba3d</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1039%2FC5RA02995C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5RA02995C%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DH.-L.%26aulast%3DShang%26aufirst%3DZ.-P.%26aulast%3DJantan%26aufirst%3DI.%26aulast%3DTan%26aufirst%3DO.%2BU.%26aulast%3DHussain%26aufirst%3DM.%2BA.%26aulast%3DSher%26aufirst%3DM.%26aulast%3DBukhari%26aufirst%3DS.%2BN.%2BA.%26atitle%3DMolecular%2520docking%2520studies%2520and%2520biological%2520evaluation%2520of%2520chalcone%2520based%2520pyrazolines%2520as%2520tyrosinase%2520inhibitors%2520and%2520potential%2520anticancer%2520agents%26jtitle%3DRSC%2520Adv.%26date%3D2015%26volume%3D5%26spage%3D46330%26epage%3D46338%26doi%3D10.1039%2FC5RA02995C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">de Weger, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beijnen, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schellens, J. H. M.</span><span> </span><span class="NLM_article-title">Cellular and clinical pharmacology of the taxanes docetaxel and paclitaxel – a review</span> <span class="citation_source-journal">Anti-Cancer Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">488</span><span class="NLM_x">–</span> <span class="NLM_lpage">494</span><span class="refDoi"> DOI: 10.1097/CAD.0000000000000093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1097%2FCAD.0000000000000093" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=488-494&author=V.+A.+de+Wegerauthor=J.+H.+Beijnenauthor=J.+H.+M.+Schellens&title=Cellular+and+clinical+pharmacology+of+the+taxanes+docetaxel+and+paclitaxel+%E2%80%93+a+review&doi=10.1097%2FCAD.0000000000000093"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1097%2FCAD.0000000000000093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCAD.0000000000000093%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BWeger%26aufirst%3DV.%2BA.%26aulast%3DBeijnen%26aufirst%3DJ.%2BH.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%2BM.%26atitle%3DCellular%2520and%2520clinical%2520pharmacology%2520of%2520the%2520taxanes%2520docetaxel%2520and%2520paclitaxel%2520%25E2%2580%2593%2520a%2520review%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2014%26volume%3D25%26spage%3D488%26epage%3D494%26doi%3D10.1097%2FCAD.0000000000000093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Nassar, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamel, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarimont, C.</span><span> </span><span class="NLM_article-title">Improving the decision-making process in structural modification of drug candidates: reducing toxicity</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1055</span><span class="NLM_x">–</span> <span class="NLM_lpage">64</span><span class="refDoi"> DOI: 10.1016/S1359-6446(04)03297-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1016%2FS1359-6446%2804%2903297-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=1055-64&author=A.+E.+Nassarauthor=A.+M.+Kamelauthor=C.+Clarimont&title=Improving+the+decision-making+process+in+structural+modification+of+drug+candidates%3A+reducing+toxicity&doi=10.1016%2FS1359-6446%2804%2903297-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903297-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903297-0%26sid%3Dliteratum%253Aachs%26aulast%3DNassar%26aufirst%3DA.%2BE.%26aulast%3DKamel%26aufirst%3DA.%2BM.%26aulast%3DClarimont%26aufirst%3DC.%26atitle%3DImproving%2520the%2520decision-making%2520process%2520in%2520structural%2520modification%2520of%2520drug%2520candidates%253A%2520reducing%2520toxicity%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26spage%3D1055%26epage%3D64%26doi%3D10.1016%2FS1359-6446%2804%2903297-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Bukhari, S. N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lauro, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jantan, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bifulco, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amjad, M. W.</span><span> </span><span class="NLM_article-title">Pharmacological evaluation and docking studies of α,β-unsaturated carbonyl based synthetic compounds as inhibitors of secretory phospholipase A2, cyclooxygenases, lipoxygenase and proinflammatory cytokines</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">4151</span><span class="NLM_x">–</span> <span class="NLM_lpage">4161</span><span class="refDoi"> DOI: 10.1016/j.bmc.2014.05.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1016%2Fj.bmc.2014.05.052" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=4151-4161&author=S.+N.+A.+Bukhariauthor=G.+Lauroauthor=I.+Jantanauthor=G.+Bifulcoauthor=M.+W.+Amjad&title=Pharmacological+evaluation+and+docking+studies+of+%CE%B1%2C%CE%B2-unsaturated+carbonyl+based+synthetic+compounds+as+inhibitors+of+secretory+phospholipase+A2%2C+cyclooxygenases%2C+lipoxygenase+and+proinflammatory+cytokines&doi=10.1016%2Fj.bmc.2014.05.052"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.05.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.05.052%26sid%3Dliteratum%253Aachs%26aulast%3DBukhari%26aufirst%3DS.%2BN.%2BA.%26aulast%3DLauro%26aufirst%3DG.%26aulast%3DJantan%26aufirst%3DI.%26aulast%3DBifulco%26aufirst%3DG.%26aulast%3DAmjad%26aufirst%3DM.%2BW.%26atitle%3DPharmacological%2520evaluation%2520and%2520docking%2520studies%2520of%2520%25CE%25B1%252C%25CE%25B2-unsaturated%2520carbonyl%2520based%2520synthetic%2520compounds%2520as%2520inhibitors%2520of%2520secretory%2520phospholipase%2520A2%252C%2520cyclooxygenases%252C%2520lipoxygenase%2520and%2520proinflammatory%2520cytokines%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D4151%26epage%3D4161%26doi%3D10.1016%2Fj.bmc.2014.05.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Leese, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jourdan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dohle, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimberley, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrandis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potter, B. V. L</span><span> </span><span class="NLM_article-title">Steroidomimetic Tetrahydroisoquinolines for the Design of New Microtubule Disruptors</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">5</span><span class="NLM_x">–</span> <span class="NLM_lpage">9</span><span class="refDoi"> DOI: 10.1021/ml200232c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200232c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=5-9&author=M.+P.+Leeseauthor=F.+Jourdanauthor=W.+Dohleauthor=M.+R.+Kimberleyauthor=M.+P.+Thomasauthor=R.+Baiauthor=E.+Hamelauthor=E.+Ferrandisauthor=B.+V.+L+Potter&title=Steroidomimetic+Tetrahydroisoquinolines+for+the+Design+of+New+Microtubule+Disruptors&doi=10.1021%2Fml200232c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fml200232c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200232c%26sid%3Dliteratum%253Aachs%26aulast%3DLeese%26aufirst%3DM.%2BP.%26aulast%3DJourdan%26aufirst%3DF.%26aulast%3DDohle%26aufirst%3DW.%26aulast%3DKimberley%26aufirst%3DM.%2BR.%26aulast%3DThomas%26aufirst%3DM.%2BP.%26aulast%3DBai%26aufirst%3DR.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DFerrandis%26aufirst%3DE.%26aulast%3DPotter%26aufirst%3DB.%2BV.%2BL%26atitle%3DSteroidomimetic%2520Tetrahydroisoquinolines%2520for%2520the%2520Design%2520of%2520New%2520Microtubule%2520Disruptors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D5%26epage%3D9%26doi%3D10.1021%2Fml200232c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Fawzy, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youssef, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ismail, N. S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gullbo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abouzid, K. A. M.</span><span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of Novel Curcumin Analogs with anticipated anticancer activity</span> <span class="citation_source-journal">Future Journal of Pharmaceutical Sciences</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">22</span><span class="NLM_x">–</span> <span class="NLM_lpage">31</span><span class="refDoi"> DOI: 10.1016/j.fjps.2015.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1016%2Fj.fjps.2015.06.001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2015&pages=22-31&author=I.+M.+Fawzyauthor=K.+M.+Youssefauthor=N.+S.+M.+Ismailauthor=J.+Gullboauthor=K.+A.+M.+Abouzid&title=Design%2C+synthesis+and+biological+evaluation+of+Novel+Curcumin+Analogs+with+anticipated+anticancer+activity&doi=10.1016%2Fj.fjps.2015.06.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.fjps.2015.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.fjps.2015.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DFawzy%26aufirst%3DI.%2BM.%26aulast%3DYoussef%26aufirst%3DK.%2BM.%26aulast%3DIsmail%26aufirst%3DN.%2BS.%2BM.%26aulast%3DGullbo%26aufirst%3DJ.%26aulast%3DAbouzid%26aufirst%3DK.%2BA.%2BM.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520Novel%2520Curcumin%2520Analogs%2520with%2520anticipated%2520anticancer%2520activity%26jtitle%3DFuture%2520Journal%2520of%2520Pharmaceutical%2520Sciences%26date%3D2015%26volume%3D1%26spage%3D22%26epage%3D31%26doi%3D10.1016%2Fj.fjps.2015.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Villanueva, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vultur, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somasundaram, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukunaga-Kalabis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cipolla, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wubbenhorst, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gimotty, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kee, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santiago-Walker, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letrero, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pushparajan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayden, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laquerre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathanson, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herlyn, M.</span><span> </span><span class="NLM_article-title">Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">683</span><span class="NLM_x">–</span> <span class="NLM_lpage">95</span><span class="refDoi"> DOI: 10.1016/j.ccr.2010.11.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1016%2Fj.ccr.2010.11.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=21156289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFGhsbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=683-95&author=J.+Villanuevaauthor=A.+Vulturauthor=J.+T.+Leeauthor=R.+Somasundaramauthor=M.+Fukunaga-Kalabisauthor=A.+K.+Cipollaauthor=B.+Wubbenhorstauthor=X.+Xuauthor=P.+A.+Gimottyauthor=D.+Keeauthor=A.+E.+Santiago-Walkerauthor=R.+Letreroauthor=K.+D%E2%80%99Andreaauthor=A.+Pushparajanauthor=J.+E.+Haydenauthor=K.+D.+Brownauthor=S.+Laquerreauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=K.+L.+Nathansonauthor=M.+Herlyn&title=Acquired+resistance+to+BRAF+inhibitors+mediated+by+a+RAF+kinase+switch+in+melanoma+can+be+overcome+by+cotargeting+MEK+and+IGF-1R%2FPI3K&doi=10.1016%2Fj.ccr.2010.11.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K</span></div><div class="casAuthors">Villanueva, Jessie; Vultur, Adina; Lee, John T.; Somasundaram, Rajasekharan; Fukunaga-Kalabis, Mizuho; Cipolla, Angela K.; Wubbenhorst, Bradley; Xu, Xiaowei; Gimotty, Phyllis A.; Kee, Damien; Santiago-Walker, Ademi E.; Letrero, Richard; D'Andrea, Kurt; Pushparajan, Anitha; Hayden, James E.; Brown, Kimberly Dahlman; Laquerre, Sylvie; McArthur, Grant A.; Sosman, Jeffrey A.; Nathanson, Katherine L.; Herlyn, Meenhard</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">683-695</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">BRAF is an attractive target for melanoma drug development.  However, resistance to BRAF inhibitors is a significant clin. challenge.  We describe a model of resistance to BRAF inhibitors developed by chronic treatment of BRAFV600E melanoma cells with the BRAF inhibitor SB-590885; these cells are cross-resistant to other BRAF-selective inhibitors.  Resistance involves flexible switching among the three RAF isoforms, underscoring the ability of melanoma cells to adapt to pharmacol. challenges.  IGF-1R/PI3K signaling was enhanced in resistant melanomas, and combined treatment with IGF-1R/PI3K and MEK inhibitors induced death of BRAF inhibitor-resistant cells.  Increased IGF-1R and pAKT levels in a post-relapse human tumor sample are consistent with a role for IGF-1R/PI3K-dependent survival in the development of resistance to BRAF inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgKfw2MUtmLLVg90H21EOLACvtfcHk0lhg5iSFsGehIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFGhsbjJ&md5=c535681201c592cd8941b68e8a936d0e</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2010.11.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2010.11.023%26sid%3Dliteratum%253Aachs%26aulast%3DVillanueva%26aufirst%3DJ.%26aulast%3DVultur%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DJ.%2BT.%26aulast%3DSomasundaram%26aufirst%3DR.%26aulast%3DFukunaga-Kalabis%26aufirst%3DM.%26aulast%3DCipolla%26aufirst%3DA.%2BK.%26aulast%3DWubbenhorst%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DGimotty%26aufirst%3DP.%2BA.%26aulast%3DKee%26aufirst%3DD.%26aulast%3DSantiago-Walker%26aufirst%3DA.%2BE.%26aulast%3DLetrero%26aufirst%3DR.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DK.%26aulast%3DPushparajan%26aufirst%3DA.%26aulast%3DHayden%26aufirst%3DJ.%2BE.%26aulast%3DBrown%26aufirst%3DK.%2BD.%26aulast%3DLaquerre%26aufirst%3DS.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DNathanson%26aufirst%3DK.%2BL.%26aulast%3DHerlyn%26aufirst%3DM.%26atitle%3DAcquired%2520resistance%2520to%2520BRAF%2520inhibitors%2520mediated%2520by%2520a%2520RAF%2520kinase%2520switch%2520in%2520melanoma%2520can%2520be%2520overcome%2520by%2520cotargeting%2520MEK%2520and%2520IGF-1R%252FPI3K%26jtitle%3DCancer%2520Cell%26date%3D2010%26volume%3D18%26spage%3D683%26epage%3D95%26doi%3D10.1016%2Fj.ccr.2010.11.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Li, Q.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H.-L.</span><span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of novel (E)-α-benzylsulfonyl chalcone derivatives as potential BRAF inhibitors</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">288</span><span class="NLM_x">–</span> <span class="NLM_lpage">295</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2012.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1016%2Fj.ejmech.2012.02.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2012&pages=288-295&author=Q.-S.+Liauthor=C.-Y.+Liauthor=X.+Luauthor=H.+Zhangauthor=H.-L.+Zhu&title=Design%2C+synthesis+and+biological+evaluation+of+novel+%28E%29-%CE%B1-benzylsulfonyl+chalcone+derivatives+as+potential+BRAF+inhibitors&doi=10.1016%2Fj.ejmech.2012.02.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2012.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2012.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DQ.-S.%26aulast%3DLi%26aufirst%3DC.-Y.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DH.-L.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520novel%2520%2528E%2529-%25CE%25B1-benzylsulfonyl%2520chalcone%2520derivatives%2520as%2520potential%2520BRAF%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2012%26volume%3D50%26spage%3D288%26epage%3D295%26doi%3D10.1016%2Fj.ejmech.2012.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Molnar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gyemant, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hohmann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergmann-Leitner, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molnar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deli, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Didiziapetris, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferreira, M. J.</span><span> </span><span class="NLM_article-title">Inhibition of multidrug resistance of cancer cells by natural diterpenes, triterpenes and carotenoids</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">287</span><span class="NLM_x">–</span> <span class="NLM_lpage">311</span><span class="refDoi"> DOI: 10.2174/138161206775201893</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.2174%2F138161206775201893" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=16454745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BD28XitlCruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=287-311&author=J.+Molnarauthor=N.+Gyemantauthor=M.+Tanakaauthor=J.+Hohmannauthor=E.+Bergmann-Leitnerauthor=P.+Molnarauthor=J.+Deliauthor=R.+Didiziapetrisauthor=M.+J.+Ferreira&title=Inhibition+of+multidrug+resistance+of+cancer+cells+by+natural+diterpenes%2C+triterpenes+and+carotenoids&doi=10.2174%2F138161206775201893"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of multidrug resistance of cancer cells by natural diterpenes, triterpenes and carotenoids</span></div><div class="casAuthors">Molnar, Joseph; Gyemant, Nora; Tanaka, Masaru; Hohmann, Judith; Bergmann-Leitner, Elke; Molnar, Peter; Deli, Joseph; Didiziapetris, Remigijus; Ferreira, Maria Jose Umbelino</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">287-311</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The multidrug resistance (MDR) proteins are member of the ATP-binding cassette superfamily and are present in a majority of human tumors.  Their activity is a crucial factor leading to therapeutic failure.  It is likely that compds. which inhibit the function of the MDR-efflux proteins such as MDR1 will improve the cytotoxic action of anticancer chemotherapy.  Therefore, a search for MDR reversing compds. was conducted among three classes of plant derived compds. such as diterpenes, triterpenes and carotenoids in a hope to find inhibitors without adverse effects in these natural compds.  The inhibition of efflux activity was detd. by measuring the accumulation of substrate analogs such as rhodamine in tumor cells in the presence of potential inhibitors.  Thus we detd. the effect of structurally unrelated diterpenes, triterpenes and carotenoids on reversal of multidrug resistance in MDR-1 gene-transfected L1210 mouse lymphoma cells and MDR mediated multidrug resistance of human breast cancer cells MDA-MB-231 (HTB-26) and MCF-7.  The majority of diterpenes, cycloartane triterpenes and carotenoids isolated from vegetables and medicinal plants were able to enhance rhodamine 123 accumulations of MDR-cells.  Synergistic interaction was found between epirubicin and resistance modifier terpenoids in vitro.  It is supposed that these MDR modulators bind into transmembrane domains and the action of ABC transporters is inhibited by induced conformational changes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonG2svSfe1B7Vg90H21EOLACvtfcHk0lhg5iSFsGehIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XitlCruw%253D%253D&md5=af0d0aeb6e918a841eca49ad4163c830</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.2174%2F138161206775201893&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161206775201893%26sid%3Dliteratum%253Aachs%26aulast%3DMolnar%26aufirst%3DJ.%26aulast%3DGyemant%26aufirst%3DN.%26aulast%3DTanaka%26aufirst%3DM.%26aulast%3DHohmann%26aufirst%3DJ.%26aulast%3DBergmann-Leitner%26aufirst%3DE.%26aulast%3DMolnar%26aufirst%3DP.%26aulast%3DDeli%26aufirst%3DJ.%26aulast%3DDidiziapetris%26aufirst%3DR.%26aulast%3DFerreira%26aufirst%3DM.%2BJ.%26atitle%3DInhibition%2520of%2520multidrug%2520resistance%2520of%2520cancer%2520cells%2520by%2520natural%2520diterpenes%252C%2520triterpenes%2520and%2520carotenoids%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2006%26volume%3D12%26spage%3D287%26epage%3D311%26doi%3D10.2174%2F138161206775201893" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Bukhari, S. N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jantan, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masand, V. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahajan, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sher, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naeem-ul-Hassan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amjad, M. W.</span><span> </span><span class="NLM_article-title">Synthesis of α,β-unsaturated carbonyl based compounds as acetylcholinesterase and butyrylcholinesterase inhibitors: Characterization, molecular modeling, QSAR studies and effect against amyloid β-induced cytotoxicity</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">355</span><span class="NLM_x">–</span> <span class="NLM_lpage">365</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2014.06.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1016%2Fj.ejmech.2014.06.034" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2014&pages=355-365&author=S.+N.+A.+Bukhariauthor=I.+Jantanauthor=V.+H.+Masandauthor=D.+T.+Mahajanauthor=M.+Sherauthor=M.+Naeem-ul-Hassanauthor=M.+W.+Amjad&title=Synthesis+of+%CE%B1%2C%CE%B2-unsaturated+carbonyl+based+compounds+as+acetylcholinesterase+and+butyrylcholinesterase+inhibitors%3A+Characterization%2C+molecular+modeling%2C+QSAR+studies+and+effect+against+amyloid+%CE%B2-induced+cytotoxicity&doi=10.1016%2Fj.ejmech.2014.06.034"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.06.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.06.034%26sid%3Dliteratum%253Aachs%26aulast%3DBukhari%26aufirst%3DS.%2BN.%2BA.%26aulast%3DJantan%26aufirst%3DI.%26aulast%3DMasand%26aufirst%3DV.%2BH.%26aulast%3DMahajan%26aufirst%3DD.%2BT.%26aulast%3DSher%26aufirst%3DM.%26aulast%3DNaeem-ul-Hassan%26aufirst%3DM.%26aulast%3DAmjad%26aufirst%3DM.%2BW.%26atitle%3DSynthesis%2520of%2520%25CE%25B1%252C%25CE%25B2-unsaturated%2520carbonyl%2520based%2520compounds%2520as%2520acetylcholinesterase%2520and%2520butyrylcholinesterase%2520inhibitors%253A%2520Characterization%252C%2520molecular%2520modeling%252C%2520QSAR%2520studies%2520and%2520effect%2520against%2520amyloid%2520%25CE%25B2-induced%2520cytotoxicity%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D83%26spage%3D355%26epage%3D365%26doi%3D10.1016%2Fj.ejmech.2014.06.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Bonne, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heuséle, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pantaloni, D.</span><span> </span><span class="NLM_article-title">4′,6-Diamidino-2-phenylindole, a fluorescent probe for tubulin and microtubules</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">260</span><span class="NLM_x">, </span> <span class="NLM_fpage">2819</span><span class="NLM_x">–</span> <span class="NLM_lpage">2825</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=260&publication_year=1985&pages=2819-2825&author=D.+Bonneauthor=C.+Heus%C3%A9leauthor=C.+Simonauthor=D.+Pantaloni&title=4%E2%80%B2%2C6-Diamidino-2-phenylindole%2C+a+fluorescent+probe+for+tubulin+and+microtubules"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBonne%26aufirst%3DD.%26aulast%3DHeus%25C3%25A9le%26aufirst%3DC.%26aulast%3DSimon%26aufirst%3DC.%26aulast%3DPantaloni%26aufirst%3DD.%26atitle%3D4%25E2%2580%25B2%252C6-Diamidino-2-phenylindole%252C%2520a%2520fluorescent%2520probe%2520for%2520tubulin%2520and%2520microtubules%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1985%26volume%3D260%26spage%3D2819%26epage%3D2825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 51 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Song Yi Lee, Mingyu Yang, Ji-Hye Seo, Da In Jeong, ChaeRim Hwang, Han-Jun Kim, Junmin Lee, KangJu Lee, JiHye Park, <span class="NLM_string-name hlFld-ContribAuthor">Hyun-Jong Cho</span>. </span><span class="cited-content_cbyCitation_article-title">Serially pH-Modulated Hydrogels Based on Boronate Ester and Polydopamine Linkages for Local Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">ACS Applied Materials & Interfaces</span><span> <strong>2021,</strong> <em>13 </em>
                                    (2)
                                     , 2189-2203. <a href="https://doi.org/10.1021/acsami.0c16199" title="DOI URL">https://doi.org/10.1021/acsami.0c16199</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsami.0c16199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsami.0c16199%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Applied%2520Materials%2520%2526%2520Interfaces%26atitle%3DSerially%252BpH-Modulated%252BHydrogels%252BBased%252Bon%252BBoronate%252BEster%252Band%252BPolydopamine%252BLinkages%252Bfor%252BLocal%252BCancer%252BTherapy%26aulast%3DLee%26aufirst%3DSong%2BYi%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D08092020%26date%3D22122020%26date%3D08012021%26volume%3D13%26issue%3D2%26spage%3D2189%26epage%3D2203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Mudasir Nabi Peerzada, Parvez Khan, Nashrah Sharif Khan, Fernando Avecilla, Shadab Miyan Siddiqui, Md. Imtaiyaz Hassan, <span class="NLM_string-name hlFld-ContribAuthor">Amir Azam</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Development of Small-Molecule Arylaldoxime/5-Nitroimidazole Hybrids as Potent Inhibitors of MARK4: A Promising Approach for Target-Based Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2020,</strong> <em>5 </em>
                                    (36)
                                     , 22759-22771. <a href="https://doi.org/10.1021/acsomega.0c01703" title="DOI URL">https://doi.org/10.1021/acsomega.0c01703</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.0c01703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.0c01703%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DDesign%252Band%252BDevelopment%252Bof%252BSmall-Molecule%252BArylaldoxime%25252F5-Nitroimidazole%252BHybrids%252Bas%252BPotent%252BInhibitors%252Bof%252BMARK4%25253A%252BA%252BPromising%252BApproach%252Bfor%252BTarget-Based%252BCancer%252BTherapy%26aulast%3DPeerzada%26aufirst%3DMudasir%2BNabi%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D14042020%26date%3D17072020%26date%3D01092020%26volume%3D5%26issue%3D36%26spage%3D22759%26epage%3D22771" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yingqi  Luo</span>, <span class="hlFld-ContribAuthor ">Wenhao  Wu</span>, <span class="hlFld-ContribAuthor ">Dailong  Zha</span>, <span class="hlFld-ContribAuthor ">Wenmin  Zhou</span>, <span class="hlFld-ContribAuthor ">Chengxu  Wang</span>, <span class="hlFld-ContribAuthor ">Jianan  Huang</span>, <span class="hlFld-ContribAuthor ">Shaobin  Chen</span>, <span class="hlFld-ContribAuthor ">Lihong  Yu</span>, <span class="hlFld-ContribAuthor ">Yuanzhi  Li</span>, <span class="hlFld-ContribAuthor ">Qinghui  Huang</span>, <span class="hlFld-ContribAuthor ">Jianye  Zhang</span>, <span class="hlFld-ContribAuthor ">Chao  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of novel ligustrazine-chalcone derivatives as potential anti-triple negative breast cancer agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>47 </em>, 128230. <a href="https://doi.org/10.1016/j.bmcl.2021.128230" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.128230</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.128230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.128230%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252Bligustrazine-chalcone%252Bderivatives%252Bas%252Bpotential%252Banti-triple%252Bnegative%252Bbreast%252Bcancer%252Bagents%26aulast%3DLuo%26aufirst%3DYingqi%26date%3D2021%26volume%3D47%26spage%3D128230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tarek S.  Ibrahim</span>, <span class="hlFld-ContribAuthor ">Ahmad J.  Almalki</span>, <span class="hlFld-ContribAuthor ">Amr H.  Moustafa</span>, <span class="hlFld-ContribAuthor ">Rasha M.  Allam</span>, <span class="hlFld-ContribAuthor ">Gamal El-Din A.  Abuo-Rahma</span>, <span class="hlFld-ContribAuthor ">Hussein I.  El Subbagh</span>, <span class="hlFld-ContribAuthor ">Mamdouh F.A.  Mohamed</span>. </span><span class="cited-content_cbyCitation_article-title">Novel 1,2,4-oxadiazole-chalcone/oxime hybrids as potential antibacterial DNA gyrase inhibitors: Design, synthesis, ADMET prediction and molecular docking study. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>111 </em>, 104885. <a href="https://doi.org/10.1016/j.bioorg.2021.104885" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.104885</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.104885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.104885%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DNovel%252B1%25252C2%25252C4-oxadiazole-chalcone%25252Foxime%252Bhybrids%252Bas%252Bpotential%252Bantibacterial%252BDNA%252Bgyrase%252Binhibitors%25253A%252BDesign%25252C%252Bsynthesis%25252C%252BADMET%252Bprediction%252Band%252Bmolecular%252Bdocking%252Bstudy%26aulast%3DIbrahim%26aufirst%3DTarek%2BS.%26date%3D2021%26volume%3D111%26spage%3D104885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Safyah B.  Bakare</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and anticancer evaluation of some coumarin and azacoumarin derivatives. </span><span class="cited-content_cbyCitation_journal-name">Polish Journal of Chemical Technology</span><span> <strong>2021,</strong> <em>23 </em>
                                    (2)
                                     , 27-34. <a href="https://doi.org/10.2478/pjct-2021-0013" title="DOI URL">https://doi.org/10.2478/pjct-2021-0013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2478/pjct-2021-0013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2478%2Fpjct-2021-0013%26sid%3Dliteratum%253Aachs%26jtitle%3DPolish%2520Journal%2520of%2520Chemical%2520Technology%26atitle%3DSynthesis%252Band%252Banticancer%252Bevaluation%252Bof%252Bsome%252Bcoumarin%252Band%252Bazacoumarin%252Bderivatives%26aulast%3DBakare%26aufirst%3DSafyah%2BB.%26date%3D2021%26date%3D2021%26volume%3D23%26issue%3D2%26spage%3D27%26epage%3D34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qianan  Zhang</span>, <span class="hlFld-ContribAuthor ">Guishan  Lin</span>, <span class="hlFld-ContribAuthor ">Wengui  Duan</span>, <span class="hlFld-ContribAuthor ">Shuyan  Zhao</span>, <span class="hlFld-ContribAuthor ">Jiamin  He</span>, <span class="hlFld-ContribAuthor ">Fuhou  Lei</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, Antifungal Activity and 3D‐QSAR Study of Novel (
              E
              )‐Longifolene‐Derived Tetralone Oxime Ethers. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2021,</strong> <em>6 </em>
                                    (18)
                                     , 4515-4520. <a href="https://doi.org/10.1002/slct.202100898" title="DOI URL">https://doi.org/10.1002/slct.202100898</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.202100898&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.202100898%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DSynthesis%25252C%252BAntifungal%252BActivity%252Band%252B3D%2525E2%252580%252590QSAR%252BStudy%252Bof%252BNovel%252B%252528%252BE%252B%252529%2525E2%252580%252590Longifolene%2525E2%252580%252590Derived%252BTetralone%252BOxime%252BEthers%26aulast%3DZhang%26aufirst%3DQianan%26date%3D2021%26date%3D2021%26volume%3D6%26issue%3D18%26spage%3D4515%26epage%3D4520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dinesh S.  Reddy</span>, <span class="hlFld-ContribAuthor ">Manasa  Kongot</span>, <span class="hlFld-ContribAuthor ">Amit  Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">Coumarin hybrid derivatives as promising leads to treat tuberculosis: Recent developments and critical aspects of structural design to exhibit anti-tubercular activity. </span><span class="cited-content_cbyCitation_journal-name">Tuberculosis</span><span> <strong>2021,</strong> <em>127 </em>, 102050. <a href="https://doi.org/10.1016/j.tube.2020.102050" title="DOI URL">https://doi.org/10.1016/j.tube.2020.102050</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tube.2020.102050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tube.2020.102050%26sid%3Dliteratum%253Aachs%26jtitle%3DTuberculosis%26atitle%3DCoumarin%252Bhybrid%252Bderivatives%252Bas%252Bpromising%252Bleads%252Bto%252Btreat%252Btuberculosis%25253A%252BRecent%252Bdevelopments%252Band%252Bcritical%252Baspects%252Bof%252Bstructural%252Bdesign%252Bto%252Bexhibit%252Banti-tubercular%252Bactivity%26aulast%3DReddy%26aufirst%3DDinesh%2BS.%26date%3D2021%26volume%3D127%26spage%3D102050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shijun  Su</span>, <span class="hlFld-ContribAuthor ">Mei  Chen</span>, <span class="hlFld-ContribAuthor ">Qin  Li</span>, <span class="hlFld-ContribAuthor ">Yihui  Wang</span>, <span class="hlFld-ContribAuthor ">Shuai  Chen</span>, <span class="hlFld-ContribAuthor ">Nan  Sun</span>, <span class="hlFld-ContribAuthor ">Chengwei  Xie</span>, <span class="hlFld-ContribAuthor ">Ziyou  Huai</span>, <span class="hlFld-ContribAuthor ">Yinjiu  Huang</span>, <span class="hlFld-ContribAuthor ">Wei  Xue</span>. </span><span class="cited-content_cbyCitation_article-title">Novel penta-1,4-diene-3-one derivatives containing quinazoline and oxime ether fragments: Design, synthesis and bioactivity. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>32 </em>, 115999. <a href="https://doi.org/10.1016/j.bmc.2021.115999" title="DOI URL">https://doi.org/10.1016/j.bmc.2021.115999</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2021.115999&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2021.115999%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DNovel%252Bpenta-1%25252C4-diene-3-one%252Bderivatives%252Bcontaining%252Bquinazoline%252Band%252Boxime%252Bether%252Bfragments%25253A%252BDesign%25252C%252Bsynthesis%252Band%252Bbioactivity%26aulast%3DSu%26aufirst%3DShijun%26date%3D2021%26volume%3D32%26spage%3D115999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaobo  Zhou</span>, <span class="hlFld-ContribAuthor ">Riping  Xiao</span>, <span class="hlFld-ContribAuthor ">Ming  Chen</span>, <span class="hlFld-ContribAuthor ">Li‐Ping  Bai</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Uscharin Oxime Analogues and Their Biological Evaluation as HIF‐1 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2020,</strong> <em>5 </em>
                                    (42)
                                     , 12869-12872. <a href="https://doi.org/10.1002/slct.202003586" title="DOI URL">https://doi.org/10.1002/slct.202003586</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.202003586&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.202003586%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DSynthesis%252Bof%252BUscharin%252BOxime%252BAnalogues%252Band%252BTheir%252BBiological%252BEvaluation%252Bas%252BHIF%2525E2%252580%2525901%252BInhibitors%26aulast%3DZhou%26aufirst%3DXiaobo%26date%3D2020%26date%3D2020%26volume%3D5%26issue%3D42%26spage%3D12869%26epage%3D12872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jaydeepsinh  Chavda</span>, <span class="hlFld-ContribAuthor ">Hardik  Bhatt</span>. </span><span class="cited-content_cbyCitation_article-title">Systemic review on B-RafV600E mutation as potential therapeutic target for the treatment of cancer. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>206 </em>, 112675. <a href="https://doi.org/10.1016/j.ejmech.2020.112675" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112675</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112675%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSystemic%252Breview%252Bon%252BB-RafV600E%252Bmutation%252Bas%252Bpotential%252Btherapeutic%252Btarget%252Bfor%252Bthe%252Btreatment%252Bof%252Bcancer%26aulast%3DChavda%26aufirst%3DJaydeepsinh%26date%3D2020%26volume%3D206%26spage%3D112675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Manoj Kumar  Shrivash</span>, <span class="hlFld-ContribAuthor ">Shilipi  Singh</span>, <span class="hlFld-ContribAuthor ">Akhilesh Kumar  Shukla</span>, <span class="hlFld-ContribAuthor ">Suaib  Luqman</span>, <span class="hlFld-ContribAuthor ">Jyoti  Pandey</span>, <span class="hlFld-ContribAuthor ">Krishna  Misra</span>. </span><span class="cited-content_cbyCitation_article-title">Water mediated procedure for preparation of stereoselective oximes as inhibitors of MRCK kinase. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Structure</span><span> <strong>2020,</strong> <em>1220 </em>, 128699. <a href="https://doi.org/10.1016/j.molstruc.2020.128699" title="DOI URL">https://doi.org/10.1016/j.molstruc.2020.128699</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molstruc.2020.128699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molstruc.2020.128699%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Structure%26atitle%3DWater%252Bmediated%252Bprocedure%252Bfor%252Bpreparation%252Bof%252Bstereoselective%252Boximes%252Bas%252Binhibitors%252Bof%252BMRCK%252Bkinase%26aulast%3DShrivash%26aufirst%3DManoj%2BKumar%26date%3D2020%26volume%3D1220%26spage%3D128699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mudasir Nabi  Peerzada</span>, <span class="hlFld-ContribAuthor ">Parvez  Khan</span>, <span class="hlFld-ContribAuthor ">Nashrah Sharif  Khan</span>, <span class="hlFld-ContribAuthor ">Aysha  Gaur</span>, <span class="hlFld-ContribAuthor ">Fernando  Avecilla</span>, <span class="hlFld-ContribAuthor ">Md. Imtaiyaz  Hassan</span>, <span class="hlFld-ContribAuthor ">Amir  Azam</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of morpholine based hydroxylamine analogues: selective inhibitors of MARK4/Par-1d causing cancer cell death through apoptosis. </span><span class="cited-content_cbyCitation_journal-name">New Journal of Chemistry</span><span> <strong>2020,</strong> <em>44 </em>
                                    (38)
                                     , 16626-16637. <a href="https://doi.org/10.1039/D0NJ03474F" title="DOI URL">https://doi.org/10.1039/D0NJ03474F</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0NJ03474F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0NJ03474F%26sid%3Dliteratum%253Aachs%26jtitle%3DNew%2520Journal%2520of%2520Chemistry%26atitle%3DIdentification%252Bof%252Bmorpholine%252Bbased%252Bhydroxylamine%252Banalogues%25253A%252Bselective%252Binhibitors%252Bof%252BMARK4%25252FPar-1d%252Bcausing%252Bcancer%252Bcell%252Bdeath%252Bthrough%252Bapoptosis%26aulast%3DPeerzada%26aufirst%3DMudasir%2BNabi%26date%3D2020%26date%3D2020%26volume%3D44%26issue%3D38%26spage%3D16626%26epage%3D16637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Abdelmoula  El Abbouchi</span>, <span class="hlFld-ContribAuthor ">Nabil  El Brahmi</span>, <span class="hlFld-ContribAuthor ">Marie-Aude  Hiebel</span>, <span class="hlFld-ContribAuthor ">Jérôme  Bignon</span>, <span class="hlFld-ContribAuthor ">Gérald  Guillaumet</span>, <span class="hlFld-ContribAuthor ">Franck  Suzenet</span>, <span class="hlFld-ContribAuthor ">Saïd  El Kazzouli</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of ethacrynic acid derivatives bearing sulfonamides as potent anti-cancer agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (19)
                                     , 127426. <a href="https://doi.org/10.1016/j.bmcl.2020.127426" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127426</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127426&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127426%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bethacrynic%252Bacid%252Bderivatives%252Bbearing%252Bsulfonamides%252Bas%252Bpotent%252Banti-cancer%252Bagents%26aulast%3DEl%2BAbbouchi%26aufirst%3DAbdelmoula%26date%3D2020%26volume%3D30%26issue%3D19%26spage%3D127426" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sakineh  Omidi</span>, <span class="hlFld-ContribAuthor ">Ali  Kakanejadifard</span>. </span><span class="cited-content_cbyCitation_article-title">A review on biological activities of Schiff base, hydrazone, and oxime derivatives of curcumin. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2020,</strong> <em>10 </em>
                                    (50)
                                     , 30186-30202. <a href="https://doi.org/10.1039/D0RA05720G" title="DOI URL">https://doi.org/10.1039/D0RA05720G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0RA05720G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0RA05720G%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DA%252Breview%252Bon%252Bbiological%252Bactivities%252Bof%252BSchiff%252Bbase%25252C%252Bhydrazone%25252C%252Band%252Boxime%252Bderivatives%252Bof%252Bcurcumin%26aulast%3DOmidi%26aufirst%3DSakineh%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D50%26spage%3D30186%26epage%3D30202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rossella  Fioravanti</span>, <span class="hlFld-ContribAuthor ">Stefano  Tomassi</span>, <span class="hlFld-ContribAuthor ">Elisabetta  Di Bello</span>, <span class="hlFld-ContribAuthor ">Annalisa  Romanelli</span>, <span class="hlFld-ContribAuthor ">Andrea Maria  Plateroti</span>, <span class="hlFld-ContribAuthor ">Rosaria  Benedetti</span>, <span class="hlFld-ContribAuthor ">Mariarosaria  Conte</span>, <span class="hlFld-ContribAuthor ">Ettore  Novellino</span>, <span class="hlFld-ContribAuthor ">Lucia  Altucci</span>, <span class="hlFld-ContribAuthor ">Sergio  Valente</span>, <span class="hlFld-ContribAuthor ">Antonello  Mai</span>. </span><span class="cited-content_cbyCitation_article-title">Properly Substituted Cyclic Bis-(2-bromobenzylidene) Compounds Behaved as Dual p300/CARM1 Inhibitors and Induced Apoptosis in Cancer Cells. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (14)
                                     , 3122. <a href="https://doi.org/10.3390/molecules25143122" title="DOI URL">https://doi.org/10.3390/molecules25143122</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25143122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25143122%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DProperly%252BSubstituted%252BCyclic%252BBis-%2525282-bromobenzylidene%252529%252BCompounds%252BBehaved%252Bas%252BDual%252Bp300%25252FCARM1%252BInhibitors%252Band%252BInduced%252BApoptosis%252Bin%252BCancer%252BCells%26aulast%3DFioravanti%26aufirst%3DRossella%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D14%26spage%3D3122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuanjie  Cao</span>, <span class="hlFld-ContribAuthor ">Long  Liu</span>, <span class="hlFld-ContribAuthor ">Tianzeng  Huang</span>, <span class="hlFld-ContribAuthor ">Tieqiao  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Iodine-catalyzed α,β-dehydrogenation of ketones and aldehydes generating conjugated enones and enals. </span><span class="cited-content_cbyCitation_journal-name">New Journal of Chemistry</span><span> <strong>2020,</strong> <em>44 </em>
                                    (21)
                                     , 8697-8701. <a href="https://doi.org/10.1039/D0NJ01244K" title="DOI URL">https://doi.org/10.1039/D0NJ01244K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0NJ01244K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0NJ01244K%26sid%3Dliteratum%253Aachs%26jtitle%3DNew%2520Journal%2520of%2520Chemistry%26atitle%3DIodine-catalyzed%252B%2525CE%2525B1%25252C%2525CE%2525B2-dehydrogenation%252Bof%252Bketones%252Band%252Baldehydes%252Bgenerating%252Bconjugated%252Benones%252Band%252Benals%26aulast%3DCao%26aufirst%3DYuanjie%26date%3D2020%26date%3D2020%26volume%3D44%26issue%3D21%26spage%3D8697%26epage%3D8701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaobao  Zeng</span>, <span class="hlFld-ContribAuthor ">Xin  Wang</span>, <span class="hlFld-ContribAuthor ">Yanan  Zhang</span>, <span class="hlFld-ContribAuthor ">Li  Zhu</span>, <span class="hlFld-ContribAuthor ">Yu  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">A silver-catalyzed radical ring-opening reaction of cyclopropanols with sulfonyl oxime ethers. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2020,</strong> <em>18 </em>
                                    (19)
                                     , 3734-3739. <a href="https://doi.org/10.1039/D0OB00055H" title="DOI URL">https://doi.org/10.1039/D0OB00055H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0OB00055H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0OB00055H%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DA%252Bsilver-catalyzed%252Bradical%252Bring-opening%252Breaction%252Bof%252Bcyclopropanols%252Bwith%252Bsulfonyl%252Boxime%252Bethers%26aulast%3DZeng%26aufirst%3DXiaobao%26date%3D2020%26date%3D2020%26volume%3D18%26issue%3D19%26spage%3D3734%26epage%3D3739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Meng-Yang  Chang</span>, <span class="hlFld-ContribAuthor ">Kai-Xiang  Lai</span>, <span class="hlFld-ContribAuthor ">Yu-Lun  Chang</span>. </span><span class="cited-content_cbyCitation_article-title">In(OTf)
              3
              -catalyzed intramolecular hydroarylation of α-phenylallyl β-ketosulfones – synthesis of sulfonyl 1-benzosuberones and 1-tetralones. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2020,</strong> <em>10 </em>
                                    (31)
                                     , 18231-18244. <a href="https://doi.org/10.1039/D0RA01962C" title="DOI URL">https://doi.org/10.1039/D0RA01962C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0RA01962C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0RA01962C%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DIn%252528OTf%252529%252B3%252B-catalyzed%252Bintramolecular%252Bhydroarylation%252Bof%252B%2525CE%2525B1-phenylallyl%252B%2525CE%2525B2-ketosulfones%252B%2525E2%252580%252593%252Bsynthesis%252Bof%252Bsulfonyl%252B1-benzosuberones%252Band%252B1-tetralones%26aulast%3DChang%26aufirst%3DMeng-Yang%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D31%26spage%3D18231%26epage%3D18244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiang  Li</span>, <span class="hlFld-ContribAuthor ">Qiang  Deng</span>, <span class="hlFld-ContribAuthor ">Lian  Yu</span>, <span class="hlFld-ContribAuthor ">Rui  Gao</span>, <span class="hlFld-ContribAuthor ">Zhikun  Tong</span>, <span class="hlFld-ContribAuthor ">Chenxi  Lu</span>, <span class="hlFld-ContribAuthor ">Jun  Wang</span>, <span class="hlFld-ContribAuthor ">Zheling  Zeng</span>, <span class="hlFld-ContribAuthor ">Ji-Jun  Zou</span>, <span class="hlFld-ContribAuthor ">Shuguang  Deng</span>. </span><span class="cited-content_cbyCitation_article-title">Double-metal cyanide as an acid and hydrogenation catalyst for the highly selective ring-rearrangement of biomass-derived furfuryl alcohol to cyclopentenone compounds. </span><span class="cited-content_cbyCitation_journal-name">Green Chemistry</span><span> <strong>2020,</strong> <em>22 </em>
                                    (8)
                                     , 2549-2557. <a href="https://doi.org/10.1039/C9GC04432A" title="DOI URL">https://doi.org/10.1039/C9GC04432A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9GC04432A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9GC04432A%26sid%3Dliteratum%253Aachs%26jtitle%3DGreen%2520Chemistry%26atitle%3DDouble-metal%252Bcyanide%252Bas%252Ban%252Bacid%252Band%252Bhydrogenation%252Bcatalyst%252Bfor%252Bthe%252Bhighly%252Bselective%252Bring-rearrangement%252Bof%252Bbiomass-derived%252Bfurfuryl%252Balcohol%252Bto%252Bcyclopentenone%252Bcompounds%26aulast%3DLi%26aufirst%3DXiang%26date%3D2020%26date%3D2020%26volume%3D22%26issue%3D8%26spage%3D2549%26epage%3D2557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alicja K.  Surowiak</span>, <span class="hlFld-ContribAuthor ">Stanisław  Lochyński</span>, <span class="hlFld-ContribAuthor ">Daniel J.  Strub</span>. </span><span class="cited-content_cbyCitation_article-title">Unsubstituted Oximes as Potential Therapeutic Agents. </span><span class="cited-content_cbyCitation_journal-name">Symmetry</span><span> <strong>2020,</strong> <em>12 </em>
                                    (4)
                                     , 575. <a href="https://doi.org/10.3390/sym12040575" title="DOI URL">https://doi.org/10.3390/sym12040575</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/sym12040575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fsym12040575%26sid%3Dliteratum%253Aachs%26jtitle%3DSymmetry%26atitle%3DUnsubstituted%252BOximes%252Bas%252BPotential%252BTherapeutic%252BAgents%26aulast%3DSurowiak%26aufirst%3DAlicja%2BK.%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D4%26spage%3D575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel  Petzold</span>, <span class="hlFld-ContribAuthor ">Maciej  Giedyk</span>, <span class="hlFld-ContribAuthor ">Anamitra  Chatterjee</span>, <span class="hlFld-ContribAuthor ">Burkhard  König</span>. </span><span class="cited-content_cbyCitation_article-title">A Retrosynthetic Approach for Photocatalysis. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>2020 </em>
                                    (10)
                                     , 1193-1244. <a href="https://doi.org/10.1002/ejoc.201901421" title="DOI URL">https://doi.org/10.1002/ejoc.201901421</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.201901421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.201901421%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DA%252BRetrosynthetic%252BApproach%252Bfor%252BPhotocatalysis%26aulast%3DPetzold%26aufirst%3DDaniel%26date%3D2020%26date%3D2020%26volume%3D2020%26issue%3D10%26spage%3D1193%26epage%3D1244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Farhat  Jubeen</span>, <span class="hlFld-ContribAuthor ">Aisha  Liaqat</span>, <span class="hlFld-ContribAuthor ">Misbah  Sultan</span>, <span class="hlFld-ContribAuthor ">Sania  Zafar Iqbal</span>, <span class="hlFld-ContribAuthor ">Imran  Sajid</span>, <span class="hlFld-ContribAuthor ">Farooq  Sher</span>. </span><span class="cited-content_cbyCitation_article-title">Green synthesis and biological evaluation of novel 5-fluorouracil derivatives as potent anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">Saudi Pharmaceutical Journal</span><span> <strong>2019,</strong> <em>27 </em>
                                    (8)
                                     , 1164-1173. <a href="https://doi.org/10.1016/j.jsps.2019.09.013" title="DOI URL">https://doi.org/10.1016/j.jsps.2019.09.013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jsps.2019.09.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jsps.2019.09.013%26sid%3Dliteratum%253Aachs%26jtitle%3DSaudi%2520Pharmaceutical%2520Journal%26atitle%3DGreen%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252B5-fluorouracil%252Bderivatives%252Bas%252Bpotent%252Banticancer%252Bagents%26aulast%3DJubeen%26aufirst%3DFarhat%26date%3D2019%26volume%3D27%26issue%3D8%26spage%3D1164%26epage%3D1173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ahmed H.E.  Hassan</span>, <span class="hlFld-ContribAuthor ">Sung Yeun  Yoo</span>, <span class="hlFld-ContribAuthor ">Kun Won  Lee</span>, <span class="hlFld-ContribAuthor ">Yoon Mi  Yoon</span>, <span class="hlFld-ContribAuthor ">Hye Won  Ryu</span>, <span class="hlFld-ContribAuthor ">Youngdo  Jeong</span>, <span class="hlFld-ContribAuthor ">Ji-Sun  Shin</span>, <span class="hlFld-ContribAuthor ">Shin-Young  Kang</span>, <span class="hlFld-ContribAuthor ">Seo-Yeon  Kim</span>, <span class="hlFld-ContribAuthor ">Hwi-Ho  Lee</span>, <span class="hlFld-ContribAuthor ">Boyoung Y.  Park</span>, <span class="hlFld-ContribAuthor ">Kyung-Tae  Lee</span>, <span class="hlFld-ContribAuthor ">Yong Sup  Lee</span>. </span><span class="cited-content_cbyCitation_article-title">Repurposing mosloflavone/5,6,7-trimethoxyflavone-resveratrol hybrids: Discovery of novel p38-α MAPK inhibitors as potent interceptors of macrophage-dependent production of proinflammatory mediators. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>180 </em>, 253-267. <a href="https://doi.org/10.1016/j.ejmech.2019.07.030" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.07.030</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.07.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.07.030%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRepurposing%252Bmosloflavone%25252F5%25252C6%25252C7-trimethoxyflavone-resveratrol%252Bhybrids%25253A%252BDiscovery%252Bof%252Bnovel%252Bp38-%2525CE%2525B1%252BMAPK%252Binhibitors%252Bas%252Bpotent%252Binterceptors%252Bof%252Bmacrophage-dependent%252Bproduction%252Bof%252Bproinflammatory%252Bmediators%26aulast%3DHassan%26aufirst%3DAhmed%2BH.E.%26date%3D2019%26volume%3D180%26spage%3D253%26epage%3D267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Casey J.  Maguire</span>, <span class="hlFld-ContribAuthor ">Graham J.  Carlson</span>, <span class="hlFld-ContribAuthor ">Jacob W.  Ford</span>, <span class="hlFld-ContribAuthor ">Tracy E.  Strecker</span>, <span class="hlFld-ContribAuthor ">Ernest  Hamel</span>, <span class="hlFld-ContribAuthor ">Mary Lynn  Trawick</span>, <span class="hlFld-ContribAuthor ">Kevin G.  Pinney</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of structurally diverse α-conformationally restricted chalcones and related analogues. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2019,</strong> <em>10 </em>
                                    (8)
                                     , 1445-1456. <a href="https://doi.org/10.1039/C9MD00127A" title="DOI URL">https://doi.org/10.1039/C9MD00127A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9MD00127A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9MD00127A%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bstructurally%252Bdiverse%252B%2525CE%2525B1-conformationally%252Brestricted%252Bchalcones%252Band%252Brelated%252Banalogues%26aulast%3DMaguire%26aufirst%3DCasey%2BJ.%26date%3D2019%26date%3D2019%26volume%3D10%26issue%3D8%26spage%3D1445%26epage%3D1456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Harbinder  Singh</span>, <span class="hlFld-ContribAuthor ">Jatinder Vir  Singh</span>, <span class="hlFld-ContribAuthor ">Kavita  Bhagat</span>, <span class="hlFld-ContribAuthor ">Harmandeep Kaur  Gulati</span>, <span class="hlFld-ContribAuthor ">Mohit  Sanduja</span>, <span class="hlFld-ContribAuthor ">Nitish  Kumar</span>, <span class="hlFld-ContribAuthor ">Nihar  Kinarivala</span>, <span class="hlFld-ContribAuthor ">Sahil  Sharma</span>. </span><span class="cited-content_cbyCitation_article-title">Rational approaches, design strategies, structure activity relationship and mechanistic insights for therapeutic coumarin hybrids. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2019,</strong> <em>27 </em>
                                    (16)
                                     , 3477-3510. <a href="https://doi.org/10.1016/j.bmc.2019.06.033" title="DOI URL">https://doi.org/10.1016/j.bmc.2019.06.033</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2019.06.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2019.06.033%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DRational%252Bapproaches%25252C%252Bdesign%252Bstrategies%25252C%252Bstructure%252Bactivity%252Brelationship%252Band%252Bmechanistic%252Binsights%252Bfor%252Btherapeutic%252Bcoumarin%252Bhybrids%26aulast%3DSingh%26aufirst%3DHarbinder%26date%3D2019%26volume%3D27%26issue%3D16%26spage%3D3477%26epage%3D3510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">K.P.  Rakesh</span>, <span class="hlFld-ContribAuthor ">H.K.  Kumara</span>, <span class="hlFld-ContribAuthor ">H.M.  Manukumar</span>, <span class="hlFld-ContribAuthor ">D.  Channe Gowda</span>. </span><span class="cited-content_cbyCitation_article-title">Anticancer and DNA binding studies of potential amino acids based quinazolinone analogs: Synthesis, SAR and molecular docking. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2019,</strong> <em>87 </em>, 252-264. <a href="https://doi.org/10.1016/j.bioorg.2019.03.038" title="DOI URL">https://doi.org/10.1016/j.bioorg.2019.03.038</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2019.03.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2019.03.038%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DAnticancer%252Band%252BDNA%252Bbinding%252Bstudies%252Bof%252Bpotential%252Bamino%252Bacids%252Bbased%252Bquinazolinone%252Banalogs%25253A%252BSynthesis%25252C%252BSAR%252Band%252Bmolecular%252Bdocking%26aulast%3DRakesh%26aufirst%3DK.P.%26date%3D2019%26volume%3D87%26spage%3D252%26epage%3D264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zohreh  Bakherad</span>, <span class="hlFld-ContribAuthor ">Maliheh  Safavi</span>, <span class="hlFld-ContribAuthor ">Afshin  Fassihi</span>, <span class="hlFld-ContribAuthor ">Hojjat  Sadeghi-Aliabadi</span>, <span class="hlFld-ContribAuthor ">Mohammad  Bakherad</span>, <span class="hlFld-ContribAuthor ">Hossein  Rastegar</span>, <span class="hlFld-ContribAuthor ">Jahan B.  Ghasemi</span>, <span class="hlFld-ContribAuthor ">Saghi  Sepehri</span>, <span class="hlFld-ContribAuthor ">Lotfollah  Saghaie</span>, <span class="hlFld-ContribAuthor ">Mohammad  Mahdavi</span>. </span><span class="cited-content_cbyCitation_article-title">Anti-cancer, anti-oxidant and molecular docking studies of thiosemicarbazone indole-based derivatives. </span><span class="cited-content_cbyCitation_journal-name">Research on Chemical Intermediates</span><span> <strong>2019,</strong> <em>45 </em>
                                    (5)
                                     , 2827-2854. <a href="https://doi.org/10.1007/s11164-019-03765-9" title="DOI URL">https://doi.org/10.1007/s11164-019-03765-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11164-019-03765-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11164-019-03765-9%26sid%3Dliteratum%253Aachs%26jtitle%3DResearch%2520on%2520Chemical%2520Intermediates%26atitle%3DAnti-cancer%25252C%252Banti-oxidant%252Band%252Bmolecular%252Bdocking%252Bstudies%252Bof%252Bthiosemicarbazone%252Bindole-based%252Bderivatives%26aulast%3DBakherad%26aufirst%3DZohreh%26date%3D2019%26date%3D2019%26volume%3D45%26issue%3D5%26spage%3D2827%26epage%3D2854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qingpeng  Wang</span>, <span class="hlFld-ContribAuthor ">Yan  Chen</span>, <span class="hlFld-ContribAuthor ">Guoshuai  Li</span>, <span class="hlFld-ContribAuthor ">Zhifang  Liu</span>, <span class="hlFld-ContribAuthor ">Jing  Ma</span>, <span class="hlFld-ContribAuthor ">Min  Liu</span>, <span class="hlFld-ContribAuthor ">Dacheng  Li</span>, <span class="hlFld-ContribAuthor ">Jun  Han</span>, <span class="hlFld-ContribAuthor ">Bingquan  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and evaluation of bi-functional 7-hydroxycoumarin platinum(IV) complexes as antitumor agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2019,</strong> <em>27 </em>
                                    (10)
                                     , 2112-2121. <a href="https://doi.org/10.1016/j.bmc.2019.04.009" title="DOI URL">https://doi.org/10.1016/j.bmc.2019.04.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2019.04.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2019.04.009%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bevaluation%252Bof%252Bbi-functional%252B7-hydroxycoumarin%252Bplatinum%252528IV%252529%252Bcomplexes%252Bas%252Bantitumor%252Bagents%26aulast%3DWang%26aufirst%3DQingpeng%26date%3D2019%26volume%3D27%26issue%3D10%26spage%3D2112%26epage%3D2121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guang  Huang</span>, <span class="hlFld-ContribAuthor ">Jin-Yun  Dong</span>, <span class="hlFld-ContribAuthor ">Qi-Jing  Zhang</span>, <span class="hlFld-ContribAuthor ">Qing-Qing  Meng</span>, <span class="hlFld-ContribAuthor ">Hui-Ran  Zhao</span>, <span class="hlFld-ContribAuthor ">Bao-Quan  Zhu</span>, <span class="hlFld-ContribAuthor ">Shao-Shun  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and synthesis of sulfur-containing 6-substituted 5,8-dimethoxy-1,4-naphthoquinone oxime derivatives as new and potential anti-MDR cancer agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>165 </em>, 160-171. <a href="https://doi.org/10.1016/j.ejmech.2019.01.005" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.01.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.01.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.01.005%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252Bsynthesis%252Bof%252Bsulfur-containing%252B6-substituted%252B5%25252C8-dimethoxy-1%25252C4-naphthoquinone%252Boxime%252Bderivatives%252Bas%252Bnew%252Band%252Bpotential%252Banti-MDR%252Bcancer%252Bagents%26aulast%3DHuang%26aufirst%3DGuang%26date%3D2019%26volume%3D165%26spage%3D160%26epage%3D171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gao-Feng  Zha</span>, <span class="hlFld-ContribAuthor ">Shi-Meng  Wang</span>, <span class="hlFld-ContribAuthor ">K.P.  Rakesh</span>, <span class="hlFld-ContribAuthor ">S.N.A.  Bukhari</span>, <span class="hlFld-ContribAuthor ">H.M.  Manukumar</span>, <span class="hlFld-ContribAuthor ">H.K.  Vivek</span>, <span class="hlFld-ContribAuthor ">N.  Mallesha</span>, <span class="hlFld-ContribAuthor ">Hua-Li  Qin</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel arylethenesulfonyl fluorides as potential candidates against methicillin-resistant of Staphylococcus aureus (MRSA) for overcoming multidrug resistance of bacterial infections. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>162 </em>, 364-377. <a href="https://doi.org/10.1016/j.ejmech.2018.11.012" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.11.012</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.11.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.11.012%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252Barylethenesulfonyl%252Bfluorides%252Bas%252Bpotential%252Bcandidates%252Bagainst%252Bmethicillin-resistant%252Bof%252BStaphylococcus%252Baureus%252B%252528MRSA%252529%252Bfor%252Bovercoming%252Bmultidrug%252Bresistance%252Bof%252Bbacterial%252Binfections%26aulast%3DZha%26aufirst%3DGao-Feng%26date%3D2019%26volume%3D162%26spage%3D364%26epage%3D377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gao-Fei  Pan</span>, <span class="hlFld-ContribAuthor ">Xue-Qing  Zhu</span>, <span class="hlFld-ContribAuthor ">Rui-Li  Guo</span>, <span class="hlFld-ContribAuthor ">Ya-Ru  Gao</span>, <span class="hlFld-ContribAuthor ">Yong-Qiang  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Enones and Enals via Dehydrogenation of Saturated Ketones and Aldehydes. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2018,</strong> <em>360 </em>
                                    (24)
                                     , 4774-4783. <a href="https://doi.org/10.1002/adsc.201801058" title="DOI URL">https://doi.org/10.1002/adsc.201801058</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.201801058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.201801058%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DSynthesis%252Bof%252BEnones%252Band%252BEnals%252Bvia%252BDehydrogenation%252Bof%252BSaturated%252BKetones%252Band%252BAldehydes%26aulast%3DPan%26aufirst%3DGao-Fei%26date%3D2018%26date%3D2018%26volume%3D360%26issue%3D24%26spage%3D4774%26epage%3D4783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laura E.  Kolsi</span>, <span class="hlFld-ContribAuthor ">Ana S.  Leal</span>, <span class="hlFld-ContribAuthor ">Jari  Yli-Kauhaluoma</span>, <span class="hlFld-ContribAuthor ">Karen T.  Liby</span>, <span class="hlFld-ContribAuthor ">Vânia M.  Moreira</span>. </span><span class="cited-content_cbyCitation_article-title">Dehydroabietic oximes halt pancreatic cancer cell growth in the G1 phase through induction of p27 and downregulation of cyclin D1. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2018,</strong> <em>8 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-018-34131-1" title="DOI URL">https://doi.org/10.1038/s41598-018-34131-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-018-34131-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-018-34131-1%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DDehydroabietic%252Boximes%252Bhalt%252Bpancreatic%252Bcancer%252Bcell%252Bgrowth%252Bin%252Bthe%252BG1%252Bphase%252Bthrough%252Binduction%252Bof%252Bp27%252Band%252Bdownregulation%252Bof%252Bcyclin%252BD1%26aulast%3DKolsi%26aufirst%3DLaura%2BE.%26date%3D2018%26date%3D2018%26volume%3D8%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>, <span class="hlFld-ContribAuthor ">Mengqi  Hu</span>, <span class="hlFld-ContribAuthor ">Hao  Wang</span>, <span class="hlFld-ContribAuthor ">Jiaming  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of traditional Chinese medicine monomers and their synthetic intermediates, analogs or derivatives for battling P-gp-mediated multi-drug resistance. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>159 </em>, 381-392. <a href="https://doi.org/10.1016/j.ejmech.2018.09.061" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.09.061</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.09.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.09.061%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Btraditional%252BChinese%252Bmedicine%252Bmonomers%252Band%252Btheir%2525C2%2525A0synthetic%252Bintermediates%25252C%252Banalogs%252Bor%252Bderivatives%252Bfor%252Bbattling%252BP-gp-mediated%252Bmulti-drug%252Bresistance%26aulast%3DMa%26aufirst%3DXiaodong%26date%3D2018%26volume%3D159%26spage%3D381%26epage%3D392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Meng  Wang</span>, <span class="hlFld-ContribAuthor ">Hua-Li  Qin</span>, <span class="hlFld-ContribAuthor ">Jing  Leng</span>, <span class="hlFld-ContribAuthor ">Ameeduzzafar</span>, <span class="hlFld-ContribAuthor ">Muhammad Wahab  Amjad</span>, <span class="hlFld-ContribAuthor ">Maria Abdul Ghafoor  Raja</span>, <span class="hlFld-ContribAuthor ">Muhammad Ajaz  Hussain</span>, <span class="hlFld-ContribAuthor ">Syed Nasir Abbas  Bukhari</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of new tetramethylpyrazine-based chalcone derivatives as potential anti-Alzheimer agents. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2018,</strong> <em>92 </em>
                                    (5)
                                     , 1859-1866. <a href="https://doi.org/10.1111/cbdd.13355" title="DOI URL">https://doi.org/10.1111/cbdd.13355</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.13355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.13355%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnew%252Btetramethylpyrazine-based%252Bchalcone%252Bderivatives%252Bas%252Bpotential%252Banti-Alzheimer%252Bagents%26aulast%3DWang%26aufirst%3DMeng%26date%3D2018%26date%3D2018%26volume%3D92%26issue%3D5%26spage%3D1859%26epage%3D1866" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hui  Wang</span>, <span class="hlFld-ContribAuthor ">Wenxi  Zhang</span>, <span class="hlFld-ContribAuthor ">Yatao  Cheng</span>, <span class="hlFld-ContribAuthor ">Xinyu  Zhang</span>, <span class="hlFld-ContribAuthor ">Nannan  Xue</span>, <span class="hlFld-ContribAuthor ">Gaorong  Wu</span>, <span class="hlFld-ContribAuthor ">Meng  Chen</span>, <span class="hlFld-ContribAuthor ">Kang  Fang</span>, <span class="hlFld-ContribAuthor ">Wenbo  Guo</span>, <span class="hlFld-ContribAuthor ">Fei  Zhou</span>, <span class="hlFld-ContribAuthor ">Herong  Cui</span>, <span class="hlFld-ContribAuthor ">Tao  Ma</span>, <span class="hlFld-ContribAuthor ">Penglong  Wang</span>, <span class="hlFld-ContribAuthor ">Haimin  Lei</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis and Biological Evaluation of Ligustrazine-Flavonoid Derivatives as Potential Anti-Tumor Agents. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2018,</strong> <em>23 </em>
                                    (9)
                                     , 2187. <a href="https://doi.org/10.3390/molecules23092187" title="DOI URL">https://doi.org/10.3390/molecules23092187</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules23092187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules23092187%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DDesign%25252C%252BSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252BLigustrazine-Flavonoid%252BDerivatives%252Bas%252BPotential%252BAnti-Tumor%252BAgents%26aulast%3DWang%26aufirst%3DHui%26date%3D2018%26date%3D2018%26volume%3D23%26issue%3D9%26spage%3D2187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dinesh S.  Reddy</span>, <span class="hlFld-ContribAuthor ">Manasa  Kongot</span>, <span class="hlFld-ContribAuthor ">Sandeep P.  Netalkar</span>, <span class="hlFld-ContribAuthor ">Mahantesh M.  Kurjogi</span>, <span class="hlFld-ContribAuthor ">Rakesh  Kumar</span>, <span class="hlFld-ContribAuthor ">Fernando  Avecilla</span>, <span class="hlFld-ContribAuthor ">Amit  Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and evaluation of novel coumarin-oxime ethers as potential anti-tubercular agents: Their DNA cleavage ability and BSA interaction study. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>150 </em>, 864-875. <a href="https://doi.org/10.1016/j.ejmech.2018.03.042" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.03.042</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.03.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.03.042%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bevaluation%252Bof%252Bnovel%252Bcoumarin-oxime%252Bethers%252Bas%252Bpotential%252Banti-tubercular%252Bagents%25253A%252BTheir%252BDNA%252Bcleavage%252Bability%252Band%252BBSA%252Binteraction%252Bstudy%26aulast%3DReddy%26aufirst%3DDinesh%2BS.%26date%3D2018%26volume%3D150%26spage%3D864%26epage%3D875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vijay H.  Masand</span>, <span class="hlFld-ContribAuthor ">Nahed N.E.  El-Sayed</span>, <span class="hlFld-ContribAuthor ">Mukesh U.  Bambole</span>, <span class="hlFld-ContribAuthor ">Syed A.  Quazi</span>. </span><span class="cited-content_cbyCitation_article-title">Multiple QSAR models, pharmacophore pattern and molecular docking analysis for anticancer activity of α, β-unsaturated carbonyl-based compounds, oxime and oxime ether analogues. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Structure</span><span> <strong>2018,</strong> <em>1157 </em>, 89-96. <a href="https://doi.org/10.1016/j.molstruc.2017.12.045" title="DOI URL">https://doi.org/10.1016/j.molstruc.2017.12.045</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molstruc.2017.12.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molstruc.2017.12.045%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Structure%26atitle%3DMultiple%252BQSAR%252Bmodels%25252C%252Bpharmacophore%252Bpattern%252Band%252Bmolecular%252Bdocking%252Banalysis%252Bfor%252Banticancer%252Bactivity%252Bof%252B%2525CE%2525B1%25252C%252B%2525CE%2525B2-unsaturated%252Bcarbonyl-based%252Bcompounds%25252C%252Boxime%252Band%252Boxime%252Bether%252Banalogues%26aulast%3DMasand%26aufirst%3DVijay%2BH.%26date%3D2018%26volume%3D1157%26spage%3D89%26epage%3D96" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jinmi  Zou</span>, <span class="hlFld-ContribAuthor ">Ping  Gao</span>, <span class="hlFld-ContribAuthor ">Xia  Hao</span>, <span class="hlFld-ContribAuthor ">Haoran  Xu</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Recent progress in the structural modification and pharmacological activities of ligustrazine derivatives. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>147 </em>, 150-162. <a href="https://doi.org/10.1016/j.ejmech.2018.01.097" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.01.097</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.01.097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.01.097%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Bprogress%252Bin%252Bthe%252Bstructural%252Bmodification%252Band%252Bpharmacological%252Bactivities%252Bof%252Bligustrazine%252Bderivatives%26aulast%3DZou%26aufirst%3DJinmi%26date%3D2018%26volume%3D147%26spage%3D150%26epage%3D162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ramesh  Gondru</span>, <span class="hlFld-ContribAuthor ">Ratni  Saini</span>, <span class="hlFld-ContribAuthor ">Krishnaiah  Vaarla</span>, <span class="hlFld-ContribAuthor ">Sarika  Singh</span>, <span class="hlFld-ContribAuthor ">Narsimha  Sirassu</span>, <span class="hlFld-ContribAuthor ">Rajitha  Bavantula</span>, <span class="hlFld-ContribAuthor ">Anil K.  Saxena</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Characterization of Chalcone-Pyridinium Hybrids as Potential Anti-Cancer and Anti-Microbial Agents. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2018,</strong> <em>3 </em>
                                    (5)
                                     , 1424-1431. <a href="https://doi.org/10.1002/slct.201702971" title="DOI URL">https://doi.org/10.1002/slct.201702971</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.201702971&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.201702971%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DSynthesis%252Band%252BCharacterization%252Bof%252BChalcone-Pyridinium%252BHybrids%252Bas%252BPotential%252BAnti-Cancer%252Band%252BAnti-Microbial%252BAgents%26aulast%3DGondru%26aufirst%3DRamesh%26date%3D2018%26date%3D2018%26volume%3D3%26issue%3D5%26spage%3D1424%26epage%3D1431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qixing  Li</span>, <span class="hlFld-ContribAuthor ">Pian  Zou</span>, <span class="hlFld-ContribAuthor ">Jianbo  Sun</span>, <span class="hlFld-ContribAuthor ">Li  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">O2-(2,4-dinitrophenyl)diazeniumdiolates derivatives: Design, synthesis, cytotoxic evaluation and reversing MDR in MCF-7/ADR cells. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>143 </em>, 732-744. <a href="https://doi.org/10.1016/j.ejmech.2017.11.081" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.11.081</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.11.081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.11.081%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DO2-%2525282%25252C4-dinitrophenyl%252529diazeniumdiolates%252Bderivatives%25253A%252BDesign%25252C%252Bsynthesis%25252C%252Bcytotoxic%252Bevaluation%252Band%252Breversing%252BMDR%252Bin%252BMCF-7%25252FADR%252Bcells%26aulast%3DLi%26aufirst%3DQixing%26date%3D2018%26volume%3D143%26spage%3D732%26epage%3D744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Máté  Vágvölgyi</span>, <span class="hlFld-ContribAuthor ">Ana  Martins</span>, <span class="hlFld-ContribAuthor ">Ágnes  Kulmány</span>, <span class="hlFld-ContribAuthor ">István  Zupkó</span>, <span class="hlFld-ContribAuthor ">Tamás  Gáti</span>, <span class="hlFld-ContribAuthor ">András  Simon</span>, <span class="hlFld-ContribAuthor ">Gábor  Tóth</span>, <span class="hlFld-ContribAuthor ">Attila  Hunyadi</span>. </span><span class="cited-content_cbyCitation_article-title">Nitrogen-containing ecdysteroid derivatives vs. multi-drug resistance in cancer: Preparation and antitumor activity of oximes, oxime ethers and a lactam. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>144 </em>, 730-739. <a href="https://doi.org/10.1016/j.ejmech.2017.12.032" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.12.032</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.12.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.12.032%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNitrogen-containing%252Becdysteroid%252Bderivatives%252Bvs.%252Bmulti-drug%252Bresistance%252Bin%252Bcancer%25253A%252BPreparation%252Band%252Bantitumor%252Bactivity%252Bof%252Boximes%25252C%252Boxime%252Bethers%252Band%252Ba%252Blactam%26aulast%3DV%25C3%25A1gv%25C3%25B6lgyi%26aufirst%3DM%25C3%25A1t%25C3%25A9%26date%3D2018%26volume%3D144%26spage%3D730%26epage%3D739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sujin  Park</span>, <span class="hlFld-ContribAuthor ">Eun Hye  Kim</span>, <span class="hlFld-ContribAuthor ">Jinwoo  Kim</span>, <span class="hlFld-ContribAuthor ">Seong Hwan  Kim</span>, <span class="hlFld-ContribAuthor ">Ikyon  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Biological evaluation of indolizine-chalcone hybrids as new anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>144 </em>, 435-443. <a href="https://doi.org/10.1016/j.ejmech.2017.12.056" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.12.056</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.12.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.12.056%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DBiological%252Bevaluation%252Bof%252Bindolizine-chalcone%252Bhybrids%252Bas%252Bnew%252Banticancer%252Bagents%26aulast%3DPark%26aufirst%3DSujin%26date%3D2018%26volume%3D144%26spage%3D435%26epage%3D443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hua-Li  Qin</span>, <span class="hlFld-ContribAuthor ">Jing  Leng</span>, <span class="hlFld-ContribAuthor ">Bahaa G. M.  Youssif</span>, <span class="hlFld-ContribAuthor ">Muhammad Wahab  Amjad</span>, <span class="hlFld-ContribAuthor ">Maria Abdul Ghafoor  Raja</span>, <span class="hlFld-ContribAuthor ">Muhammad Ajaz  Hussain</span>, <span class="hlFld-ContribAuthor ">Zahid  Hussain</span>, <span class="hlFld-ContribAuthor ">Syeda Naveed  Kazmi</span>, <span class="hlFld-ContribAuthor ">Syed Nasir Abbas  Bukhari</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and mechanistic studies of curcumin analog-based oximes as potential anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2017,</strong> <em>90 </em>
                                    (3)
                                     , 443-449. <a href="https://doi.org/10.1111/cbdd.12964" title="DOI URL">https://doi.org/10.1111/cbdd.12964</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.12964&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.12964%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DSynthesis%252Band%252Bmechanistic%252Bstudies%252Bof%252Bcurcumin%252Banalog-based%252Boximes%252Bas%252Bpotential%252Banticancer%252Bagents%26aulast%3DQin%26aufirst%3DHua-Li%26date%3D2017%26date%3D2017%26volume%3D90%26issue%3D3%26spage%3D443%26epage%3D449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Malledevarapura Gurumurthy  Prabhudeva</span>, <span class="hlFld-ContribAuthor ">Srinivasan  Bharath</span>, <span class="hlFld-ContribAuthor ">Achutha Dileep  Kumar</span>, <span class="hlFld-ContribAuthor ">Shivalingegowda  Naveen</span>, <span class="hlFld-ContribAuthor ">Neratur Krishnappagowda  Lokanath</span>, <span class="hlFld-ContribAuthor ">Bantaganahalli Ningappa  Mylarappa</span>, <span class="hlFld-ContribAuthor ">Kariyappa Ajay  Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">Design and environmentally benign synthesis of novel thiophene appended pyrazole analogues as anti-inflammatory and radical scavenging agents: Crystallographic , in silico modeling, docking and SAR characterization. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2017,</strong> <em>73 </em>, 109-120. <a href="https://doi.org/10.1016/j.bioorg.2017.06.004" title="DOI URL">https://doi.org/10.1016/j.bioorg.2017.06.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2017.06.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2017.06.004%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%252Band%252Benvironmentally%252Bbenign%252Bsynthesis%252Bof%252Bnovel%252Bthiophene%252Bappended%252Bpyrazole%252Banalogues%252Bas%252Banti-inflammatory%252Band%252Bradical%252Bscavenging%252Bagents%25253A%252BCrystallographic%252B%25252C%252Bin%252Bsilico%252Bmodeling%25252C%252Bdocking%252Band%252BSAR%252Bcharacterization%26aulast%3DPrabhudeva%26aufirst%3DMalledevarapura%2BGurumurthy%26date%3D2017%26volume%3D73%26spage%3D109%26epage%3D120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gao-Feng  Zha</span>, <span class="hlFld-ContribAuthor ">Hua-Li  Qin</span>, <span class="hlFld-ContribAuthor ">Bahaa G.M.  Youssif</span>, <span class="hlFld-ContribAuthor ">Muhammad Wahab  Amjad</span>, <span class="hlFld-ContribAuthor ">Maria Abdul Ghafoor  Raja</span>, <span class="hlFld-ContribAuthor ">Ahmed H.  Abdelazeem</span>, <span class="hlFld-ContribAuthor ">Syed Nasir Abbas  Bukhari</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of potential anticancer multi-targeted ligustrazine based cyclohexanone and oxime analogs overcoming the cancer multidrug resistance. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>135 </em>, 34-48. <a href="https://doi.org/10.1016/j.ejmech.2017.04.025" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.04.025</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.04.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.04.025%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bpotential%252Banticancer%252Bmulti-targeted%252Bligustrazine%252Bbased%252Bcyclohexanone%252Band%252Boxime%252Banalogs%252Bovercoming%252Bthe%252Bcancer%252Bmultidrug%252Bresistance%26aulast%3DZha%26aufirst%3DGao-Feng%26date%3D2017%26volume%3D135%26spage%3D34%26epage%3D48" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laiba  Arshad</span>, <span class="hlFld-ContribAuthor ">Md. Areeful  Haque</span>, <span class="hlFld-ContribAuthor ">Syed Nasir  Abbas Bukhari</span>, <span class="hlFld-ContribAuthor ">Ibrahim  Jantan</span>. </span><span class="cited-content_cbyCitation_article-title">An overview of structure–activity relationship studies of curcumin analogs as antioxidant and anti-inflammatory agents. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2017,</strong> <em>9 </em>
                                    (6)
                                     , 605-626. <a href="https://doi.org/10.4155/fmc-2016-0223" title="DOI URL">https://doi.org/10.4155/fmc-2016-0223</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2016-0223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2016-0223%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DAn%252Boverview%252Bof%252Bstructure%2525E2%252580%252593activity%252Brelationship%252Bstudies%252Bof%252Bcurcumin%252Banalogs%252Bas%252Bantioxidant%252Band%252Banti-inflammatory%252Bagents%26aulast%3DArshad%26aufirst%3DLaiba%26date%3D2017%26volume%3D9%26issue%3D6%26spage%3D605%26epage%3D626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bakhtyar  Sepehri</span>, <span class="hlFld-ContribAuthor ">Raouf  Ghavami</span>. </span><span class="cited-content_cbyCitation_article-title">Design new P-glycoprotein modulators based on molecular docking and CoMFA study of α, β-unsaturated carbonyl-based compounds and oxime analogs as anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Structure</span><span> <strong>2017,</strong> <em>1130 </em>, 922-928. <a href="https://doi.org/10.1016/j.molstruc.2016.10.079" title="DOI URL">https://doi.org/10.1016/j.molstruc.2016.10.079</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molstruc.2016.10.079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molstruc.2016.10.079%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Structure%26atitle%3DDesign%252Bnew%252BP-glycoprotein%252Bmodulators%252Bbased%252Bon%252Bmolecular%252Bdocking%252Band%252BCoMFA%252Bstudy%252Bof%252B%2525CE%2525B1%25252C%252B%2525CE%2525B2-unsaturated%252Bcarbonyl-based%252Bcompounds%252Band%252Boxime%252Banalogs%252Bas%252Banticancer%252Bagents%26aulast%3DSepehri%26aufirst%3DBakhtyar%26date%3D2017%26volume%3D1130%26spage%3D922%26epage%3D928" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laiba  Arshad</span>, <span class="hlFld-ContribAuthor ">Ibrahim  Jantan</span>, <span class="hlFld-ContribAuthor ">Syed Nasir Abbas  Bukhari</span>, <span class="hlFld-ContribAuthor ">Md. Areeful  Haque</span>. </span><span class="cited-content_cbyCitation_article-title">Immunosuppressive Effects of Natural α,β-Unsaturated Carbonyl-Based Compounds, and Their Analogs and Derivatives, on Immune Cells: A Review. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2017,</strong> <em>8 </em><a href="https://doi.org/10.3389/fphar.2017.00022" title="DOI URL">https://doi.org/10.3389/fphar.2017.00022</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2017.00022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2017.00022%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DImmunosuppressive%252BEffects%252Bof%252BNatural%252B%2525CE%2525B1%25252C%2525CE%2525B2-Unsaturated%252BCarbonyl-Based%252BCompounds%25252C%252Band%252BTheir%252BAnalogs%252Band%252BDerivatives%25252C%252Bon%252BImmune%252BCells%25253A%252BA%252BReview%26aulast%3DArshad%26aufirst%3DLaiba%26date%3D2017%26date%3D2017%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yoshimitsu  Hashimoto</span>, <span class="hlFld-ContribAuthor ">Hiromasa  Ishiwata</span>, <span class="hlFld-ContribAuthor ">Soko  Tachikawa</span>, <span class="hlFld-ContribAuthor ">Shintaro  Ban</span>, <span class="hlFld-ContribAuthor ">Nobuyoshi  Morita</span>, <span class="hlFld-ContribAuthor ">Osamu  Tamura</span>. </span><span class="cited-content_cbyCitation_article-title">Utilization of electron-donating α,β-unsaturated oximes: regioselective inverse 1,3-dipolar cycloaddition of nitrones. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2017,</strong> <em>53 </em>
                                    (18)
                                     , 2685-2688. <a href="https://doi.org/10.1039/C7CC00505A" title="DOI URL">https://doi.org/10.1039/C7CC00505A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7CC00505A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7CC00505A%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DUtilization%252Bof%252Belectron-donating%252B%2525CE%2525B1%25252C%2525CE%2525B2-unsaturated%252Boximes%25253A%252Bregioselective%252Binverse%252B1%25252C3-dipolar%252Bcycloaddition%252Bof%252Bnitrones%26aulast%3DHashimoto%26aufirst%3DYoshimitsu%26date%3D2017%26date%3D2017%26volume%3D53%26issue%3D18%26spage%3D2685%26epage%3D2688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jing  Leng</span>, <span class="hlFld-ContribAuthor ">Hua-Li  Qin</span>, <span class="hlFld-ContribAuthor ">Kaicheng  Zhu</span>, <span class="hlFld-ContribAuthor ">Ibrahim  Jantan</span>, <span class="hlFld-ContribAuthor ">Muhammad Ajaz  Hussain</span>, <span class="hlFld-ContribAuthor ">Muhammad  Sher</span>, <span class="hlFld-ContribAuthor ">Muhammad Wahab  Amjad</span>, <span class="hlFld-ContribAuthor ">Muhammad  Naeem-ul-Hassan</span>, <span class="hlFld-ContribAuthor ">Waqas  Ahmad</span>, <span class="hlFld-ContribAuthor ">Syed Nasir Abbas  Bukhari</span>. </span><span class="cited-content_cbyCitation_article-title">Evaluation of multifunctional synthetic tetralone derivatives for treatment of Alzheimer's disease. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2016,</strong> <em>88 </em>
                                    (6)
                                     , 889-898. <a href="https://doi.org/10.1111/cbdd.12822" title="DOI URL">https://doi.org/10.1111/cbdd.12822</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.12822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.12822%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DEvaluation%252Bof%252Bmultifunctional%252Bsynthetic%252Btetralone%252Bderivatives%252Bfor%252Btreatment%252Bof%252BAlzheimer%252527s%252Bdisease%26aulast%3DLeng%26aufirst%3DJing%26date%3D2016%26date%3D2016%26volume%3D88%26issue%3D6%26spage%3D889%26epage%3D898" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qi  Zhang</span>, <span class="hlFld-ContribAuthor ">Linjing  Zhang</span>, <span class="hlFld-ContribAuthor ">Chaojun  Tang</span>, <span class="hlFld-ContribAuthor ">Huan  Luo</span>, <span class="hlFld-ContribAuthor ">Xuediao  Cai</span>, <span class="hlFld-ContribAuthor ">Yonghai  Chai</span>. </span><span class="cited-content_cbyCitation_article-title">Cascade reaction of propargylic alcohols with hydroxylamine hydrochloride: facile synthesis of α,β-unsaturated oximes and nitriles. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2016,</strong> <em>72 </em>
                                    (44)
                                     , 6935-6942. <a href="https://doi.org/10.1016/j.tet.2016.09.010" title="DOI URL">https://doi.org/10.1016/j.tet.2016.09.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2016.09.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2016.09.010%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DCascade%252Breaction%252Bof%252Bpropargylic%252Balcohols%252Bwith%252Bhydroxylamine%252Bhydrochloride%25253A%252Bfacile%252Bsynthesis%252Bof%252B%2525CE%2525B1%25252C%2525CE%2525B2-unsaturated%252Boximes%252Band%252Bnitriles%26aulast%3DZhang%26aufirst%3DQi%26date%3D2016%26volume%3D72%26issue%3D44%26spage%3D6935%26epage%3D6942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00276/20160414/images/medium/jm-2016-00276j_0008.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00276/20160414/images/large/jm-2016-00276j_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00276&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00276/20160414/images/medium/jm-2016-00276j_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00276/20160414/images/large/jm-2016-00276j_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis Scheme of α,β-Unsaturated Carbonyl Based Compounds, Oxime, and Oxime Ether Analogs<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00276/20160414/images/large/jm-2016-00276j_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00276&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) NaOH, EtOH, room temperature; (ii) NH<sub>2</sub>OH.HCl, pyridine, ethanol, anhyd., reflux; (iii) haloalkylamine (<b>9</b>), K<sub>2</sub>CO<sub>3</sub>, acetone/DMF, anhyd., reflux.</p></p></figure><figure data-id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00276/20160414/images/medium/jm-2016-00276j_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00276/20160414/images/large/jm-2016-00276j_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Effect of selected synthetic compounds on tubulin polymerization activity at concentration of 25 μM. Results are the mean values of three experiments, <i>n</i> = 3. While vincristine and docetaxel (3 μM) were used as reference compounds. All compounds showed the inhibition of tubulin as below the horizontal line indicate tubulin inhibition; only docetaxel is above the horizontal line indicating tubulin stabilization and compounds (<b>7o</b> and <b>10o</b>) close to the horizontal line are considered to be inactive. The <i>y</i>-axis demonstrates tubulin polymerization activity measured at 15 min (arbitrary units) in the growth phase of the tubulin polymerization curve.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00276/20160414/images/large/jm-2016-00276j_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00276&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i61">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41206" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41206" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 48 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Kelland, L.</span><span> </span><span class="NLM_article-title">The resurgence of platinum-based cancer chemotherapy</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">573</span><span class="NLM_x">–</span> <span class="NLM_lpage">84</span><span class="refDoi"> DOI: 10.1038/nrc2167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1038%2Fnrc2167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=17625587" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotVKru7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=573-84&author=L.+Kelland&title=The+resurgence+of+platinum-based+cancer+chemotherapy&doi=10.1038%2Fnrc2167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The resurgence of platinum-based cancer chemotherapy</span></div><div class="casAuthors">Kelland, Lloyd</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">573-584</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The accidental discovery of the anticancer properties of cisplatin and its clin. introduction in the 1970s represent a major landmark in the history of successful anticancer drugs.  Although carboplatin - a second-generation analog that is safer but shows a similar spectrum of activity to cisplatin - was introduced in the 1980s, the pace of further improvements slowed for many years.  However, in the past several years interest in platinum drugs has increased.  Key developments include the elucidation of mechanisms of tumor resistance to these drugs, the introduction of new platinum-based agents (oxaliplatin, satraplatin and picoplatin), and clin. combination studies using platinum drugs with resistance modulators or new molecularly targeted drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTEI4HRCjxQrVg90H21EOLACvtfcHk0lhb8uCOrynYRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotVKru7c%253D&md5=9d55f600a83a19d7836a2524de20efbf</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc2167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2167%26sid%3Dliteratum%253Aachs%26aulast%3DKelland%26aufirst%3DL.%26atitle%3DThe%2520resurgence%2520of%2520platinum-based%2520cancer%2520chemotherapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D573%26epage%3D84%26doi%3D10.1038%2Fnrc2167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Lowery, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowery, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnett, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Acevedo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Secord, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Havrilesky, L.</span><span> </span><span class="NLM_article-title">Cost-effectiveness of early palliative care intervention in recurrent platinum-resistant ovarian cancer</span> <span class="citation_source-journal">Gynecol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">130</span><span class="NLM_x">, </span> <span class="NLM_fpage">426</span><span class="NLM_x">–</span> <span class="NLM_lpage">430</span><span class="refDoi"> DOI: 10.1016/j.ygyno.2013.06.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1016%2Fj.ygyno.2013.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=23769759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A280%3ADC%252BC3sjivVOrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2013&pages=426-430&author=W.+J.+Loweryauthor=A.+W.+Loweryauthor=J.+C.+Barnettauthor=M.+Lopez-Acevedoauthor=P.+S.+Leeauthor=A.+A.+Secordauthor=L.+Havrilesky&title=Cost-effectiveness+of+early+palliative+care+intervention+in+recurrent+platinum-resistant+ovarian+cancer&doi=10.1016%2Fj.ygyno.2013.06.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Cost-effectiveness of early palliative care intervention in recurrent platinum-resistant ovarian cancer</span></div><div class="casAuthors">Lowery William J; Lowery Ashlei W; Barnett Jason C; Lopez-Acevedo Micael; Lee Paula S; Secord Angeles Alvarez; Havrilesky Laura</div><div class="citationInfo"><span class="NLM_cas:title">Gynecologic oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">426-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  To determine if early palliative care intervention in patients with recurrent, platinum-resistant ovarian cancer is potentially cost saving or cost-effective.  METHODS:  A decision model with a 6 month time horizon evaluated routine care versus routine care plus early referral to a palliative medicine specialist (EPC) for recurrent platinum-resistant ovarian cancer.  Model parameters included rates of inpatient admissions, emergency department (ED) visits, chemotherapy administration, and quality of life (QOL).  From published ovarian cancer data, we assumed baseline rates over the final 6 months: hospitalization 70%, chemotherapy 60%, and ED visit 30%.  Published data from a randomized trial evaluating EPC in metastatic lung cancer were used to model odds ratios (ORs) for potential reductions in hospitalization (OR 0.69), chemotherapy (OR 0.77), and emergency department care (OR 0.74) and improvement in QOL (OR 1.07).  The costs of hospitalization, ED visit, chemotherapy, and EPC were based on published data.  Ranges were used for sensitivity analysis.  Effectiveness was quantified in quality adjusted life years (QALYs); survival was assumed equivalent between strategies.  RESULTS:  EPC was associated with a cost savings of $1285 per patient over routine care.  In sensitivity analysis incorporating QOL, EPC was either dominant or cost-effective, with an incremental cost-effectiveness ratio (ICER) <$50,000/QALY, unless the cost of outpatient EPC exceeded $2400.  Assuming no clinical benefit other than QOL (no change in chemotherapy administration, hospitalizations or ED visits), EPC remained highly cost-effective with ICER $37,440/QALY.  CONCLUSION:  Early palliative care intervention has the potential to reduce costs associated with end of life care in patients with ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQe47xmG1f2pJ6KlWarZTAzfW6udTcc2eZEZUPgUOJ6Ubntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sjivVOrtw%253D%253D&md5=b697aa90be16e33df917a6f43864214e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.ygyno.2013.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ygyno.2013.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DLowery%26aufirst%3DW.%2BJ.%26aulast%3DLowery%26aufirst%3DA.%2BW.%26aulast%3DBarnett%26aufirst%3DJ.%2BC.%26aulast%3DLopez-Acevedo%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DP.%2BS.%26aulast%3DSecord%26aufirst%3DA.%2BA.%26aulast%3DHavrilesky%26aufirst%3DL.%26atitle%3DCost-effectiveness%2520of%2520early%2520palliative%2520care%2520intervention%2520in%2520recurrent%2520platinum-resistant%2520ovarian%2520cancer%26jtitle%3DGynecol.%2520Oncol.%26date%3D2013%26volume%3D130%26spage%3D426%26epage%3D430%26doi%3D10.1016%2Fj.ygyno.2013.06.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Galluzzi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senovilla, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vitale, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michels, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martins, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kepp, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castedo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroemer, G.</span><span> </span><span class="NLM_article-title">Molecular mechanisms of cisplatin resistance</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">1869</span><span class="NLM_x">–</span> <span class="NLM_lpage">1883</span><span class="refDoi"> DOI: 10.1038/onc.2011.384</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1038%2Fonc.2011.384" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=21892204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFWrsr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2012&pages=1869-1883&author=L.+Galluzziauthor=L.+Senovillaauthor=I.+Vitaleauthor=J.+Michelsauthor=I.+Martinsauthor=O.+Keppauthor=M.+Castedoauthor=G.+Kroemer&title=Molecular+mechanisms+of+cisplatin+resistance&doi=10.1038%2Fonc.2011.384"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms of cisplatin resistance</span></div><div class="casAuthors">Galluzzi, L.; Senovilla, L.; Vitale, I.; Michels, J.; Martins, I.; Kepp, O.; Castedo, M.; Kroemer, G.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1869-1883</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Platinum-based drugs, and in particular cis-diamminedichloroplatinum(II) (best known as cisplatin), are employed for the treatment of a wide array of solid malignancies, including testicular, ovarian, head and neck, colorectal, bladder and lung cancers.  Cisplatin exerts anticancer effects via multiple mechanisms, yet its most prominent (and best understood) mode of action involves the generation of DNA lesions followed by the activation of the DNA damage response and the induction of mitochondrial apoptosis.  Despite a consistent rate of initial responses, cisplatin treatment often results in the development of chemoresistance, leading to therapeutic failure.  An intense research has been conducted during the past 30 years and several mechanisms that account for the cisplatin-resistant phenotype of tumor cells have been described.  Here, we provide a systematic discussion of these mechanism by classifying them in alterations (1) that involve steps preceding the binding of cisplatin to DNA (pre-target resistance), (2) that directly relate to DNA-cisplatin adducts (on-target resistance), (3) concerning the lethal signaling pathway(s) elicited by cisplatin-mediated DNA damage (post-target resistance) and (4) affecting mol. circuitries that do not present obvious links with cisplatin-elicited signals (off-target resistance).  As in some clin. settings cisplatin constitutes the major therapeutic option, the development of chemosensitization strategies constitute a goal with important clin. implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxTrgUhh4V17Vg90H21EOLACvtfcHk0lgNv6SBD9euVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFWrsr7E&md5=4f947e6d5b834673b819e88b06309a53</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fonc.2011.384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2011.384%26sid%3Dliteratum%253Aachs%26aulast%3DGalluzzi%26aufirst%3DL.%26aulast%3DSenovilla%26aufirst%3DL.%26aulast%3DVitale%26aufirst%3DI.%26aulast%3DMichels%26aufirst%3DJ.%26aulast%3DMartins%26aufirst%3DI.%26aulast%3DKepp%26aufirst%3DO.%26aulast%3DCastedo%26aufirst%3DM.%26aulast%3DKroemer%26aufirst%3DG.%26atitle%3DMolecular%2520mechanisms%2520of%2520cisplatin%2520resistance%26jtitle%3DOncogene%26date%3D2012%26volume%3D31%26spage%3D1869%26epage%3D1883%26doi%3D10.1038%2Fonc.2011.384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Siddik, Z. H.</span><span> </span><span class="NLM_article-title">Cisplatin: mode of cytotoxic action and molecular basis of resistance</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">7265</span><span class="NLM_x">–</span> <span class="NLM_lpage">79</span><span class="refDoi"> DOI: 10.1038/sj.onc.1206933</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1038%2Fsj.onc.1206933" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=14576837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotlajtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2003&pages=7265-79&author=Z.+H.+Siddik&title=Cisplatin%3A+mode+of+cytotoxic+action+and+molecular+basis+of+resistance&doi=10.1038%2Fsj.onc.1206933"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Cisplatin: mode of cytotoxic action and molecular basis of resistance</span></div><div class="casAuthors">Siddik, Zahid H.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">7265-7279</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cisplatin is one of the most potent antitumor agents known, displaying clin. activity against a wide variety of solid tumors.  Its cytotoxic mode of action is mediated by its interaction with DNA to form DNA adducts, primarily intrastrand crosslink adducts, which activate several signal transduction pathways, including those involving ATR, p53, p73, and MAPK, and culminate in the activation of apoptosis.  DNA damage-mediated apoptotic signals, however, can be attenuated, and the resistance that ensues is a major limitation of cisplatin-based chemotherapy.  The mechanisms responsible for cisplatin resistance are several, and contribute to the multifactorial nature of the problem.  Resistance mechanisms that limit the extent of DNA damage include reduced drug uptake, increased drug inactivation, and increased DNA adduct repair.  Origins of these pharmacol.-based mechanisms, however, are at the mol. level.  Mechanisms that inhibit propagation of the DNA damage signal to the apoptotic machinery include loss of damage recognition, overexpression of HER-2/neu, activation of the PI3-K/Akt (also known as PI3-K/PKB) pathway, loss of p53 function, overexpression of antiapoptotic bcl-2, and interference in caspase activation.  The mol. signature defining the resistant phenotype varies between tumors, and the no. of resistance mechanisms activated in response to selection pressures dictates the overall extent of cisplatin resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3k2Fki_ax2rVg90H21EOLACvtfcHk0lgNv6SBD9euVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotlajtbY%253D&md5=8520a82f029717c4352d23e4bd7166fe</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1206933&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1206933%26sid%3Dliteratum%253Aachs%26aulast%3DSiddik%26aufirst%3DZ.%2BH.%26atitle%3DCisplatin%253A%2520mode%2520of%2520cytotoxic%2520action%2520and%2520molecular%2520basis%2520of%2520resistance%26jtitle%3DOncogene%26date%3D2003%26volume%3D22%26spage%3D7265%26epage%3D79%26doi%3D10.1038%2Fsj.onc.1206933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Igney, F. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krammer, P. H.</span><span> </span><span class="NLM_article-title">Death and anti-death: tumour resistance to apoptosis</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">277</span><span class="NLM_x">–</span> <span class="NLM_lpage">88</span><span class="refDoi"> DOI: 10.1038/nrc776</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1038%2Fnrc776" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=12001989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BD38XivFGqt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=277-88&author=F.+H.+Igneyauthor=P.+H.+Krammer&title=Death+and+anti-death%3A+tumour+resistance+to+apoptosis&doi=10.1038%2Fnrc776"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Death and anti-death: tumor resistance to apoptosis</span></div><div class="casAuthors">Igney, Frederik H.; Krammer, Peter H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">277-288</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with refs.  Every cell in a multicellular organism has the potential to die by apoptosis, but tumor cells often have faulty apoptotic pathways.  These defects not only increase tumor mass, but also render the tumor resistant to therapy.  So, what are the mol. mechanisms of tumor resistance to apoptosis and how can we use this knowledge to resensitize tumor cells to cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLYsKdE8S_srVg90H21EOLACvtfcHk0lgNv6SBD9euVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XivFGqt7s%253D&md5=fa59ba8c08307cbbe71ae34f3f118222</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrc776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc776%26sid%3Dliteratum%253Aachs%26aulast%3DIgney%26aufirst%3DF.%2BH.%26aulast%3DKrammer%26aufirst%3DP.%2BH.%26atitle%3DDeath%2520and%2520anti-death%253A%2520tumour%2520resistance%2520to%2520apoptosis%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2002%26volume%3D2%26spage%3D277%26epage%3D88%26doi%3D10.1038%2Fnrc776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Holohan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Schaeybroeck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longley, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, P. G.</span><span> </span><span class="NLM_article-title">Cancer drug resistance: an evolving paradigm</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">714</span><span class="NLM_x">–</span> <span class="NLM_lpage">726</span><span class="refDoi"> DOI: 10.1038/nrc3599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1038%2Fnrc3599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=24060863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVyqurnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=714-726&author=C.+Holohanauthor=S.+Van+Schaeybroeckauthor=D.+B.+Longleyauthor=P.+G.+Johnston&title=Cancer+drug+resistance%3A+an+evolving+paradigm&doi=10.1038%2Fnrc3599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer drug resistance: an evolving paradigm</span></div><div class="casAuthors">Holohan, Caitriona; Van Schaeybroeck, Sandra; Longley, Daniel B.; Johnston, Patrick G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">714-726</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Resistance to chemotherapy and molecularly targeted therapies is a major problem facing current cancer research.  The mechanisms of resistance to 'classical' cytotoxic chemotherapeutics and to therapies that are designed to be selective for specific mol. targets share many features, such as alterations in the drug target, activation of prosurvival pathways and ineffective induction of cell death.  With the increasing arsenal of anticancer agents, improving preclin. models and the advent of powerful high-throughput screening techniques, there are now unprecedented opportunities to understand and overcome drug resistance through the clin. assessment of rational therapeutic drug combinations and the use of predictive biomarkers to enable patient stratification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrykBEUSgvv7Vg90H21EOLACvtfcHk0lgNv6SBD9euVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVyqurnE&md5=b497a823bbd968904ce1591b918d0679</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrc3599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3599%26sid%3Dliteratum%253Aachs%26aulast%3DHolohan%26aufirst%3DC.%26aulast%3DVan%2BSchaeybroeck%26aufirst%3DS.%26aulast%3DLongley%26aufirst%3DD.%2BB.%26aulast%3DJohnston%26aufirst%3DP.%2BG.%26atitle%3DCancer%2520drug%2520resistance%253A%2520an%2520evolving%2520paradigm%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2013%26volume%3D13%26spage%3D714%26epage%3D726%26doi%3D10.1038%2Fnrc3599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, L.</span><span> </span><span class="NLM_article-title">Nanoparticle delivery of pooled siRNA for effective treatment of non-small cell lung cancer</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">2280</span><span class="NLM_x">–</span> <span class="NLM_lpage">9</span><span class="refDoi"> DOI: 10.1021/mp300152v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp300152v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BC38Xotlemsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=2280-9&author=Y.+Yangauthor=Y.+Huauthor=Y.+Wangauthor=J.+Liauthor=F.+Liuauthor=L.+Huang&title=Nanoparticle+delivery+of+pooled+siRNA+for+effective+treatment+of+non-small+cell+lung+cancer&doi=10.1021%2Fmp300152v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Nanoparticle Delivery of Pooled siRNA for Effective Treatment of Non-Small Cell Lung Caner</span></div><div class="casAuthors">Yang, Yang; Hu, Yunxia; Wang, Yuhua; Li, Jun; Liu, Feng; Huang, Leaf</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2280-2289</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death.  To explore the potential of small interfering RNA (siRNA) therapy for NSCLC, we have developed anisamide-targeted LCP to efficiently deliver siRNA into the cytoplasm of sigma receptor-expressing NSCLC cells.  Targeted LCP demonstrated a 9-fold higher siRNA delivery efficiency compared to nontargeted LCP in A549 cells in vitro.  To simultaneously target multiple oncogenic mechanisms, we coformulated three siRNA sequences targeting HDM2, c-myc and VEGF oncogenes, and investigated their efficacy of cell-killing in A549 and H460 cells in vitro.  The results indicated that the pooled siRNA codelivered by the targeted LCP could effectively and simultaneously knock down HDM2, c-myc and VEGF expressions and significantly inhibit tumor cell growth.  After iv injection of mice bearing A549 xenografted tumor with Texas Red-labeled siRNA formulated in the targeted LCP, siRNA was successfully delivered to and concd. in the tumor cells.  Repeated i.v. injections of mice with pooled siRNA formulated in the targeted LCP significantly impaired NSCLC growth in vivo (p < 0.01) for both A549 and H460 tumors, demonstrating an ED50 for the treatment of ∼0.2 mg/kg in A549 tumors.  The enhanced antitumor activity is due to the fact that the silencing of HDM2/c-myc/VEGF could inhibit tumor proliferation and angiogenesis and also simultaneously induce tumor apoptosis.  Our results demonstrate that the targeted LCP is a promising vector to deliver pooled siRNA into tumors and to achieve multiple target blocking.  This is potentially a valid therapeutic modality in the gene therapy of human NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprsiDWU5lLu7Vg90H21EOLACvtfcHk0ljJwfGDao-SMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xotlemsbk%253D&md5=1d2fbf4cab7e645ba7fd9013c2020799</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fmp300152v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp300152v%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DHuang%26aufirst%3DL.%26atitle%3DNanoparticle%2520delivery%2520of%2520pooled%2520siRNA%2520for%2520effective%2520treatment%2520of%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2012%26volume%3D9%26spage%3D2280%26epage%3D9%26doi%3D10.1021%2Fmp300152v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Agarwal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, S. B.</span><span> </span><span class="NLM_article-title">Ovarian cancer: strategies for overcoming resistance to chemotherapy</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">502</span><span class="NLM_x">–</span> <span class="NLM_lpage">16</span><span class="refDoi"> DOI: 10.1038/nrc1123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1038%2Fnrc1123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=12835670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BD3sXltVSqtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=502-16&author=R.+Agarwalauthor=S.+B.+Kaye&title=Ovarian+cancer%3A+strategies+for+overcoming+resistance+to+chemotherapy&doi=10.1038%2Fnrc1123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Ovarian cancer: strategies for overcoming resistance to chemotherapy</span></div><div class="casAuthors">Agarwal, Roshan; Kaye, Stan B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">502-516</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Ovarian cancer is responsible for 4% of the deaths from cancer in women.  Treatment comprises a combination of surgery and chemotherapy, but patients typically experience disease relapse within 2 yr of the initial treatment.  Further treatment can extend survival, although relapse eventually occurs again.  A better understanding of the mechanisms that underlie this drug resistance should allow treatment to be optimized, so that substantial improvements in the outlook for women with this disease can be achieved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrU40u5eHTnk7Vg90H21EOLACvtfcHk0lilZLboWKpf5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXltVSqtr0%253D&md5=8063243f9f19e30d7a867f225efbb265</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrc1123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1123%26sid%3Dliteratum%253Aachs%26aulast%3DAgarwal%26aufirst%3DR.%26aulast%3DKaye%26aufirst%3DS.%2BB.%26atitle%3DOvarian%2520cancer%253A%2520strategies%2520for%2520overcoming%2520resistance%2520to%2520chemotherapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2003%26volume%3D3%26spage%3D502%26epage%3D16%26doi%3D10.1038%2Fnrc1123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Garofalo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosa, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bianco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tortora, G.</span><span> </span><span class="NLM_article-title">EGFR-targeting agents in oncology</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">889</span><span class="NLM_x">–</span> <span class="NLM_lpage">901</span><span class="refDoi"> DOI: 10.1517/13543776.18.8.889</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1517%2F13543776.18.8.889" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptlagsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=889-901&author=S.+Garofaloauthor=R.+Rosaauthor=R.+Biancoauthor=G.+Tortora&title=EGFR-targeting+agents+in+oncology&doi=10.1517%2F13543776.18.8.889"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR-targeting agents in oncology</span></div><div class="casAuthors">Garofalo, Sonia; Rosa, Roberta; Bianco, Roberto; Tortora, Giampaolo</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">889-901</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: The targeted therapy' has been defined as an innovative therapy designed to interfere with mol. targets playing a crit. role in tumor growth or progression.  The epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor mediating the effect of growth factors both in physiol. and pathol. conditions; aberrations in the EGFR may result in the development of a tumor phenotype.  Objective: To summarize the current state of the development of anti-EGFR drugs.  Methods: Patent literature and preclin./clin. studies about EGFR inhibitors are analyzed.  Conclusion: Some monoclonal antibodies and small-mol. tyrosine kinase inhibitors have been approved in several countries for the treatment of various human cancer types; moreover, more than ten EGFR-targeting agents are actually in advanced clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ_vZH0bm4s7Vg90H21EOLACvtfcHk0lilZLboWKpf5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptlagsbw%253D&md5=cfb4f50c4044eb45636be7999fe8a140</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1517%2F13543776.18.8.889&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.18.8.889%26sid%3Dliteratum%253Aachs%26aulast%3DGarofalo%26aufirst%3DS.%26aulast%3DRosa%26aufirst%3DR.%26aulast%3DBianco%26aufirst%3DR.%26aulast%3DTortora%26aufirst%3DG.%26atitle%3DEGFR-targeting%2520agents%2520in%2520oncology%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2008%26volume%3D18%26spage%3D889%26epage%3D901%26doi%3D10.1517%2F13543776.18.8.889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Madhusudan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganesan, T. S.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors in cancer therapy</span> <span class="citation_source-journal">Clin. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">618</span><span class="NLM_x">–</span> <span class="NLM_lpage">635</span><span class="refDoi"> DOI: 10.1016/j.clinbiochem.2004.05.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1016%2Fj.clinbiochem.2004.05.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=15234243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BD2cXltl2gtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2004&pages=618-635&author=S.+Madhusudanauthor=T.+S.+Ganesan&title=Tyrosine+kinase+inhibitors+in+cancer+therapy&doi=10.1016%2Fj.clinbiochem.2004.05.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinase inhibitors in cancer therapy</span></div><div class="casAuthors">Madhusudan, Srinivasan; Ganesan, Trivadi S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Biochemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">618-635</span>CODEN:
                <span class="NLM_cas:coden">CLBIAS</span>;
        ISSN:<span class="NLM_cas:issn">0009-9120</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Cancer is the second leading cause of death in the western world.  Despite advances in diagnosis and treatment, overall survival of patients remains poor.  Scientific advances in recent years have enhanced our understanding of the biol. of cancer.  Human protein tyrosine kinases (PTKs) play a central role in human carcinogenesis and have emerged as the promising new targets.  Several approaches to inhibit tyrosine kinase have been developed.  These agents have shown impressive anticancer effects in preclin. studies and are emerging as promising agents in the clinic.  The remarkable success of BCR-ABL tyrosine kinase inhibitor imatinib (STI571) in the treatment of chronic myeloid leukemia has particularly stimulated intense research in this field.  At least 30 inhibitors are in various stages of clin. development in cancer, and about 120 clin. trials are ongoing worldwide.  In this review, we focus on the role of tyrosine kinases in cancer and the development of specific small mol. inhibitors for therapy.  We also provide a crit. anal. of the current data on tyrosine kinase inhibitors and highlight areas for future research.  Issues with regards to the design of clin. trials with such agents are also discussed.  Innovative approaches are needed to fully evaluate the potential of these agents, and a concerted international effort will hopefully help to integrate these inhibitors in cancer therapy in the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2J3dyMJZEE7Vg90H21EOLACvtfcHk0lilZLboWKpf5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXltl2gtbY%253D&md5=ff308cde1b8cb3d2d868c8740d7422b7</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.clinbiochem.2004.05.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clinbiochem.2004.05.006%26sid%3Dliteratum%253Aachs%26aulast%3DMadhusudan%26aufirst%3DS.%26aulast%3DGanesan%26aufirst%3DT.%2BS.%26atitle%3DTyrosine%2520kinase%2520inhibitors%2520in%2520cancer%2520therapy%26jtitle%3DClin.%2520Biochem.%26date%3D2004%26volume%3D37%26spage%3D618%26epage%3D635%26doi%3D10.1016%2Fj.clinbiochem.2004.05.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Cockerill, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackey, K. E.</span><span> </span><span class="NLM_article-title">Small molecule inhibitors of the class 1 receptor tyrosine kinase family</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1001</span><span class="NLM_x">–</span> <span class="NLM_lpage">10</span><span class="refDoi"> DOI: 10.2174/1568026023393309</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.2174%2F1568026023393309" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=12171567" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BD38XmtVOitb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=1001-10&author=G.+S.+Cockerillauthor=K.+E.+Lackey&title=Small+molecule+inhibitors+of+the+class+1+receptor+tyrosine+kinase+family&doi=10.2174%2F1568026023393309"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule inhibitors of the class 1 receptor tyrosine kinase family</span></div><div class="casAuthors">Cockerill, G. Stuart; Lackey, Karen E.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Hilversum, Netherlands)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1001-1010</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  This review covers literature describing research progress in erbB family tyrosine kinase inhibition over the last year.  Excellent recent reviews are available, thus we have focussed on current developments of leading small mol. drug candidates as well as their erbB family inhibition profile.  The most advanced erbB family tyrosine kinase (TK) inhibitors are demonstrating promising anti-cancer activity in clin. trials and are discussed.  Several inhibition strategies are emerging: EGFR TK selective, irreversible TK inhibition and dual EGFR/erbB2 TK inhibitors.  While small structural differences are seen in the leading compds., the variations in their inhibition profiles and compd. properties suggest that biol. systems judge structural diversity differently.  The readers' attention is drawn to common issues of selectivity and potency generally encountered with kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBco-X2q4LCbVg90H21EOLACvtfcHk0lhpi9XS6bHMow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmtVOitb0%253D&md5=795d41584fee8792e7ca03705b73c6e3</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.2174%2F1568026023393309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026023393309%26sid%3Dliteratum%253Aachs%26aulast%3DCockerill%26aufirst%3DG.%2BS.%26aulast%3DLackey%26aufirst%3DK.%2BE.%26atitle%3DSmall%2520molecule%2520inhibitors%2520of%2520the%2520class%25201%2520receptor%2520tyrosine%2520kinase%2520family%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2002%26volume%3D2%26spage%3D1001%26epage%3D10%26doi%3D10.2174%2F1568026023393309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Yarden, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span> </span><span class="NLM_article-title">Untangling the ErbB signalling network</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">37</span><span class="refDoi"> DOI: 10.1038/35052073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1038%2F35052073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=11252954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivVWnt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=127-37&author=Y.+Yardenauthor=M.+X.+Sliwkowski&title=Untangling+the+ErbB+signalling+network&doi=10.1038%2F35052073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Untangling the ErbB signalling network</span></div><div class="casAuthors">Yarden, Yosef; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">127-137</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review, with 112 refs.  When epidermal growth factor and its relatives bind the ErbB family of receptors, they trigger a rich network of signaling pathways, culminating in responses ranging from cell division to death, motility to adhesion.  The network is often dysregulated in cancer and lends credence to the mantra that mol. understanding yields clin. benefit: over 25,000 women with breast cancer have now been treated with Herceptin, a recombinant antibody designed to block the receptor ErbB2.  Likewise, small-mol. enzyme inhibitors and monoclonal antibodies to ErbB1 are in advanced phases of clin. testing.  What can this pathway teach us about translating basic science into clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovhWL1HObvNrVg90H21EOLACvtfcHk0lhpi9XS6bHMow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivVWnt7k%253D&md5=1561a9666f77fce888be821399870cd6</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2F35052073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35052073%26sid%3Dliteratum%253Aachs%26aulast%3DYarden%26aufirst%3DY.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DUntangling%2520the%2520ErbB%2520signalling%2520network%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2001%26volume%3D2%26spage%3D127%26epage%3D37%26doi%3D10.1038%2F35052073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Han, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, H. W.</span><span> </span><span class="NLM_article-title">Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">318</span><span class="NLM_x">, </span> <span class="NLM_fpage">124</span><span class="NLM_x">–</span> <span class="NLM_lpage">34</span><span class="refDoi"> DOI: 10.1016/j.canlet.2012.01.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1016%2Fj.canlet.2012.01.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=22261334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVGns7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=318&publication_year=2012&pages=124-34&author=W.+Hanauthor=H.+W.+Lo&title=Landscape+of+EGFR+signaling+network+in+human+cancers%3A+biology+and+therapeutic+response+in+relation+to+receptor+subcellular+locations&doi=10.1016%2Fj.canlet.2012.01.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Landscape of EGFR signaling network in human cancers: Biology and therapeutic response in relation to receptor subcellular locations</span></div><div class="casAuthors">Han, Woody; Lo, Hui-Wen</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">318</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">124-134</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The epidermal growth factor receptor (EGFR) pathway is one of the most dysregulated mol. pathways in human cancers.  Despite its well-established importance in tumor growth, progression and drug-resistant phenotype over the past several decades, targeted therapy designed to circumvent EGFR has yielded only modest clin. success in cancer patients, except those with non-small cell lung cancer (NSCLC) carrying EGFR activation mutations.  However, almost all of these NSCLC patients eventually developed resistance to small mol. EGFR kinase inhibitors.  These disappointing outcomes are, in part, due to the high complexity and the interactive nature of the EGFR signaling network.  More recent compelling evidence further indicates that EGFR functionality can be dependent on its subcellular location.  In this regard, EGFR undergoes translocation into different organelles where it elicits distinctly different functions than its best known activity as a plasma membrane-bound receptor tyrosine kinase.  EGFR can be shuttled into the cell nucleus and mitochondrion upon ligand binding, radiation, EGFR-targeted therapy and other stimuli.  Nuclear EGFR behaves as transcriptional regulator, tyrosine kinase, and mediator of other physiol. processes.  The role of mitochondrial EGFR remains poorly understood but it appears to regulate apoptosis and autophagy.  While studies using patient tumors have shown nuclear EGFR to be an indicator for poor clin. outcomes in cancer patients, the impact of mitochondrial EGFR on tumor behavior and patient prognosis remains to be defined.  Most recently, several lines of evidence suggest that mislocated EGFR may regulate tumor response to therapy and that plasma membrane-bound EGFR elicits survival signals independent of its kinase activity.  In light of these recent progresses and discoveries, we will outline in this minireview an emerging line of research that uncovers and functionally characterizes several novel modes of EGFR signaling that take center stage in the cell nucleus, mitochondrion and other subcellular compartments.  We will also discuss the clin. implications of these findings in the rationale design for therapeutic strategy that overcomes tumor drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgDjdRcHam3bVg90H21EOLACvtfcHk0lhpi9XS6bHMow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVGns7c%253D&md5=e29390cd4a03e2c6d3eae1fd99202268</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2012.01.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2012.01.011%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DW.%26aulast%3DLo%26aufirst%3DH.%2BW.%26atitle%3DLandscape%2520of%2520EGFR%2520signaling%2520network%2520in%2520human%2520cancers%253A%2520biology%2520and%2520therapeutic%2520response%2520in%2520relation%2520to%2520receptor%2520subcellular%2520locations%26jtitle%3DCancer%2520Lett.%26date%3D2012%26volume%3D318%26spage%3D124%26epage%3D34%26doi%3D10.1016%2Fj.canlet.2012.01.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Barlesi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tchouhadjian, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doddoli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villani, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greillier, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleisbauer, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Astoul, P.</span><span> </span><span class="NLM_article-title">Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective</span> <span class="citation_source-journal">Fundam. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">385</span><span class="NLM_x">–</span> <span class="NLM_lpage">93</span><span class="refDoi"> DOI: 10.1111/j.1472-8206.2005.00323.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1111%2Fj.1472-8206.2005.00323.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=15910663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltFagtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2005&pages=385-93&author=F.+Barlesiauthor=C.+Tchouhadjianauthor=C.+Doddoliauthor=P.+Villaniauthor=L.+Greillierauthor=J.+P.+Kleisbauerauthor=P.+Thomasauthor=P.+Astoul&title=Gefitinib+%28ZD1839%2C+Iressa%29+in+non-small-cell+lung+cancer%3A+a+review+of+clinical+trials+from+a+daily+practice+perspective&doi=10.1111%2Fj.1472-8206.2005.00323.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: A review of clinical trials from a daily practice perspective</span></div><div class="casAuthors">Barlesi, Fabrice; Tchouhadjian, Cecile; Doddoli, Christophe; Villani, Patrick; Greillier, Laurent; Kleisbauer, Jean-Pierre; Thomas, Pascal; Astoul, Philippe</div><div class="citationInfo"><span class="NLM_cas:title">Fundamental & Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">385-393</span>CODEN:
                <span class="NLM_cas:coden">FCPHEZ</span>;
        ISSN:<span class="NLM_cas:issn">0767-3981</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Gefitinib (ZD1839) is the most widely studied targeting agent in the area of non-small-cell lung cancer (NSCLC).  Gefitinib is an orally active epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor.  In order to assess the role of gefitinib in the management of NSCLC patients, we systematically reviewed published clin. trials from a daily practice perspective.  A systematic research was made in the international medical literature.  Gefitinib demonstrated a good tolerance and an encouraging efficacy in pretreated NSCLC patients in preclin. studies.  These results were then confirmed in two phase II trials (IDEAL 1 and 2) involving more than 400 patients mostly pretreated with a platinum-contg. regimen and docetaxel.  All these results were reinforced by those of retrospective studies on patients enrolled in a compassionate use program.  Thus, two phase III trials in chemo-naive patients were initiated (INTACT 1 and 2).  Unfortunately, the use of gefitinib with std. combination chemotherapy provided no survival benefit nor response rate or progression-free survival improvement over placebo.  Furthermore, we also reviewed the results of studies interested in the characterization of predictive clin. or biol. markers for response to gefitinib and discussed the results obtained with other EGFR inhibitors.  The efficacy of gefitinib in the first-line setting of each stage of NSCLC has to be further studied through clin. trials.  Furthermore, translational studies characterizing the mol. features involved in the response to anti-EGFR-targeted therapies are needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtJIQKGI8dq7Vg90H21EOLACvtfcHk0lhpi9XS6bHMow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltFagtLw%253D&md5=40fe698dd434655696d8222111e218e1</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1111%2Fj.1472-8206.2005.00323.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1472-8206.2005.00323.x%26sid%3Dliteratum%253Aachs%26aulast%3DBarlesi%26aufirst%3DF.%26aulast%3DTchouhadjian%26aufirst%3DC.%26aulast%3DDoddoli%26aufirst%3DC.%26aulast%3DVillani%26aufirst%3DP.%26aulast%3DGreillier%26aufirst%3DL.%26aulast%3DKleisbauer%26aufirst%3DJ.%2BP.%26aulast%3DThomas%26aufirst%3DP.%26aulast%3DAstoul%26aufirst%3DP.%26atitle%3DGefitinib%2520%2528ZD1839%252C%2520Iressa%2529%2520in%2520non-small-cell%2520lung%2520cancer%253A%2520a%2520review%2520of%2520clinical%2520trials%2520from%2520a%2520daily%2520practice%2520perspective%26jtitle%3DFundam.%2520Clin.%2520Pharmacol.%26date%3D2005%26volume%3D19%26spage%3D385%26epage%3D93%26doi%3D10.1111%2Fj.1472-8206.2005.00323.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Arteaga, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, D. H.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors-ZD1839 (Iressa)</span> <span class="citation_source-journal">Curr. Opin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">491</span><span class="NLM_x">–</span> <span class="NLM_lpage">8</span><span class="refDoi"> DOI: 10.1097/00001622-200111000-00012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1097%2F00001622-200111000-00012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=11673690" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BD3MXos1Oqs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2001&pages=491-8&author=C.+L.+Arteagaauthor=D.+H.+Johnson&title=Tyrosine+kinase+inhibitors-ZD1839+%28Iressa%29&doi=10.1097%2F00001622-200111000-00012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinase inhibitors-ZD1839 (Iressa)</span></div><div class="casAuthors">Arteaga, Carlos L.; Johnson, David H.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Oncology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">491-498</span>CODEN:
                <span class="NLM_cas:coden">CUOOE8</span>;
        ISSN:<span class="NLM_cas:issn">1040-8746</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Several epithelial tumors display epidermal growth factor receptor (EGFR) overexpression (with or without EGFR gene amplification) that is often assocd. with increased prodn. of EGFR ligands.  This permits the activation of endogenous tumor EGFR via autocrine mechanisms, resulting in cellular proliferation and tumor growth.  Interruption of receptor signaling with bivalent EGFR antibodies or with small mol. inhibitors of the EGFR tyrosine kinase results in inhibition of tumor cell proliferation or viability in vitro and in vivo.  One small mol. currently undergoing preclin. and clin. investigation is ZD1839 (Iressa), a synthetic anilinoquinazoline capable of inhibiting EGFR tyrosine kinase in vitro.  The early results of clin. trials indicate this drug possesses antitumor activity in certain malignancies of the upper aerodigestive tract.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUp52ELUA8HLVg90H21EOLACvtfcHk0liG3FltzivSNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXos1Oqs7k%253D&md5=ed22721cbb3560ac54e438d363f8a59e</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1097%2F00001622-200111000-00012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00001622-200111000-00012%26sid%3Dliteratum%253Aachs%26aulast%3DArteaga%26aufirst%3DC.%2BL.%26aulast%3DJohnson%26aufirst%3DD.%2BH.%26atitle%3DTyrosine%2520kinase%2520inhibitors-ZD1839%2520%2528Iressa%2529%26jtitle%3DCurr.%2520Opin.%2520Oncol.%26date%3D2001%26volume%3D13%26spage%3D491%26epage%3D8%26doi%3D10.1097%2F00001622-200111000-00012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Barker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grundy, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godfrey, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barlow, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Healy, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodburn, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarlett, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henthorn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richards, L.</span><span> </span><span class="NLM_article-title">Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1911</span><span class="NLM_x">–</span> <span class="NLM_lpage">4</span><span class="refDoi"> DOI: 10.1016/S0960-894X(01)00344-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1016%2FS0960-894X%2801%2900344-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=11459659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltFylsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=1911-4&author=A.+J.+Barkerauthor=K.+H.+Gibsonauthor=W.+Grundyauthor=A.+A.+Godfreyauthor=J.+J.+Barlowauthor=M.+P.+Healyauthor=J.+R.+Woodburnauthor=S.+E.+Ashtonauthor=B.+J.+Curryauthor=L.+Scarlettauthor=L.+Henthornauthor=L.+Richards&title=Studies+leading+to+the+identification+of+ZD1839+%28IRESSA%29%3A+an+orally+active%2C+selective+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitor+targeted+to+the+treatment+of+cancer&doi=10.1016%2FS0960-894X%2801%2900344-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Studies leading to the identification of ZD1839 (iressa): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer</span></div><div class="casAuthors">Barker, A. J.; Gibson, K. H.; Grundy, W.; Godfrey, A. A.; Barlow, J. J.; Healy, M. P.; Woodburn, J. R.; Ashton, S. E.; Curry, B. J.; Scarlett, L.; Henthorn, L.; Richards, L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1911-1914</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">This paper describes the development of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 from a lead series of 4-anilinoquinazoline compds.  ZD1839 has suitable properties for use as a clin. effective drug and shows activity against human tumors.  In particular, the use of pharmacokinetic data in the development of ZD1839 is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvsJ1FTqEwvbVg90H21EOLACvtfcHk0liG3FltzivSNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltFylsLo%253D&md5=ebb210453ade246e43de9fd07ae1d581</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900344-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900344-4%26sid%3Dliteratum%253Aachs%26aulast%3DBarker%26aufirst%3DA.%2BJ.%26aulast%3DGibson%26aufirst%3DK.%2BH.%26aulast%3DGrundy%26aufirst%3DW.%26aulast%3DGodfrey%26aufirst%3DA.%2BA.%26aulast%3DBarlow%26aufirst%3DJ.%2BJ.%26aulast%3DHealy%26aufirst%3DM.%2BP.%26aulast%3DWoodburn%26aufirst%3DJ.%2BR.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DCurry%26aufirst%3DB.%2BJ.%26aulast%3DScarlett%26aufirst%3DL.%26aulast%3DHenthorn%26aufirst%3DL.%26aulast%3DRichards%26aufirst%3DL.%26atitle%3DStudies%2520leading%2520to%2520the%2520identification%2520of%2520ZD1839%2520%2528IRESSA%2529%253A%2520an%2520orally%2520active%252C%2520selective%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitor%2520targeted%2520to%2520the%2520treatment%2520of%2520cancer%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26spage%3D1911%26epage%3D4%26doi%3D10.1016%2FS0960-894X%2801%2900344-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Ganjoo, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakelee, H.</span><span> </span><span class="NLM_article-title">Review of erlotinib in the treatment of advanced non-small cell lung cancer</span> <span class="citation_source-journal">Biol.: Targets Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">335</span><span class="NLM_x">–</span> <span class="NLM_lpage">346</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=19707304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtVygsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2007&pages=335-346&author=K.+N.+Ganjooauthor=H.+Wakelee&title=Review+of+erlotinib+in+the+treatment+of+advanced+non-small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Review of erlotinib in the treatment of advanced non-small cell lung cancer</span></div><div class="casAuthors">Ganjoo, Kristen N.; Wakelee, Heather</div><div class="citationInfo"><span class="NLM_cas:title">Biologics: Targets & Therapy</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">335-346</span>CODEN:
                <span class="NLM_cas:coden">BTTICT</span>;
        ISSN:<span class="NLM_cas:issn">1177-5475</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press (NZ) Ltd.</span>)
        </div><div class="casAbstract">A review.  Epidermal growth factor receptor (EGFR) is a transmembrane receptor with a cytoplasmic tyrosine kinase (TK) domain present on many solid tumors including non-small cell lung cancer (NSCLC).  Once stimulated by ligand, the downstream pathway is activated leading to cell growth, survival, and carcinogenesis.  There are several methods of EGFR inhibition including monoclonal antibodies directed against the external region and small mol. inhibitors of TK domain.  Erlotinib and gefitinib are orally available small mol. EGFR TK inhibitors, with proven efficacy in NSCLC.  The most common side effects are skin toxicity and diarrhea.  Erlotinib has been shown to improve survival compared to placebo in second or third-line therapy for NSCLC.  However, erlotinib in combination with chemotherapy failed to show a survival advantage in two first-line studies which could be due to the timing of chemotherapy administration.  In general, patients with adenocarcinoma histol., female gender, Asian ethnicity, and never smokers have a better response when treated with erlotinib.  This could be related to the presence of EGFR mutations, lack of KRAS mutations, or overexpression of EGFR as measured by fluorescent in-situ hybridization (FISH) anal.  Future studies should conc. on further development of predictors of clin. benefit with erlotinib, overcoming resistance to erlotinib that develops in initial responders, as well as more effective sequencing of erlotinib with chemotherapy and combinations of the drug with other "targeted" therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkIh360NygIrVg90H21EOLACvtfcHk0liG3FltzivSNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtVygsb8%253D&md5=4980eda401551fcba54e6f9ac8da7ae9</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGanjoo%26aufirst%3DK.%2BN.%26aulast%3DWakelee%26aufirst%3DH.%26atitle%3DReview%2520of%2520erlotinib%2520in%2520the%2520treatment%2520of%2520advanced%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DBiol.%253A%2520Targets%2520Ther.%26date%3D2007%26volume%3D1%26spage%3D335%26epage%3D346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Kopper, L.</span><span> </span><span class="NLM_article-title">Lapatinib: a sword with two edges</span> <span class="citation_source-journal">Pathol. Oncol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">8</span><span class="refDoi"> DOI: 10.1007/s12253-008-9018-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1007%2Fs12253-008-9018-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=18409020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpvFyis78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=1-8&author=L.+Kopper&title=Lapatinib%3A+a+sword+with+two+edges&doi=10.1007%2Fs12253-008-9018-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Lapatinib: a sword with two edges</span></div><div class="casAuthors">Kopper, Laszlo</div><div class="citationInfo"><span class="NLM_cas:title">Pathology & Oncology Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-8</span>CODEN:
                <span class="NLM_cas:coden">POREFR</span>;
        ISSN:<span class="NLM_cas:issn">1219-4956</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Lapatinib is an oral dual tyrosine kinase inhibitor targeting EGFR1 and EGFR2 (HER2).  Phase I trials have shown that lapatinib is well tolerated, with mild diarrhea and skin rush as common adverse effects, and low cardiotoxicity.  Phase II and III trials provided evidences on clin. effectiveness in advanced or metastatic breast cancer and potential against brain metastases.  Lapatinib is active in combination with trastuzumab and in trastuzumab-resistant patients, moreover it has synergistic action with capecitabine.  Several clin. trials are in progress to explore the effectiveness of lapatinib in other combinations and against several tumor types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrf0_JyTqFmPLVg90H21EOLACvtfcHk0lhYH4E2BWCS9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpvFyis78%253D&md5=f8b3ac8f8b01092355de4b2759c1d773</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1007%2Fs12253-008-9018-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12253-008-9018-z%26sid%3Dliteratum%253Aachs%26aulast%3DKopper%26aufirst%3DL.%26atitle%3DLapatinib%253A%2520a%2520sword%2520with%2520two%2520edges%26jtitle%3DPathol.%2520Oncol.%2520Res.%26date%3D2008%26volume%3D14%26spage%3D1%26epage%3D8%26doi%3D10.1007%2Fs12253-008-9018-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Lu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blume-Jensen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, T.</span><span> </span><span class="NLM_article-title">Epidermal Growth Factor-Induced Tumor Cell Invasion and Metastasis Initiated by Dephosphorylation and Downregulation of Focal Adhesion Kinase</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">4016</span><span class="NLM_x">–</span> <span class="NLM_lpage">4031</span><span class="refDoi"> DOI: 10.1128/MCB.21.12.4016-4031.2001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1128%2FMCB.21.12.4016-4031.2001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=11359909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BD3MXktFWgtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2001&pages=4016-4031&author=Z.+Luauthor=G.+Jiangauthor=P.+Blume-Jensenauthor=T.+Hunter&title=Epidermal+Growth+Factor-Induced+Tumor+Cell+Invasion+and+Metastasis+Initiated+by+Dephosphorylation+and+Downregulation+of+Focal+Adhesion+Kinase&doi=10.1128%2FMCB.21.12.4016-4031.2001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase</span></div><div class="casAuthors">Lu, Zhimin; Jiang, Guoqiang; Blume-Jensen, Peter; Hunter, Tony</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4016-4031</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Upregulated epidermal growth factor (EGF) receptor (EGFR) expression and EGFR-induced signaling have been correlated with progression to invasion and metastasis in a wide variety of carcinomas, but the mechanism behind this is not well understood.  We show here that, in various human carcinoma cells that overexpress EGFR, EGF treatment induced rapid tyrosine dephosphorylation of focal adhesion kinase (FAK) assocd. with downregulation of its kinase activity.  The downregulation of FAK activity was both required and sufficient for EGF-induced refractile morphol. changes, detachment of cells from the extracellular matrix, and increased tumor cell motility, invasion, and metastasis.  Tumor cells with downregulated FAK activity became less adherent to the extracellular matrix.  However, once cells started reattaching, FAK activity was restored by activated integrin signaling.  Moreover, this process of readhesion and spreading could not be abrogated by further EGF stimulation.  Interruption of transforming growth factor alpha-EGFR autocrine regulation with an EGFR tyrosine kinase inhibitor led to a substantial increase in FAK tyrosine phosphorylation and inhibition of tumor cell invasion in vitro.  Consistent with this, FAK tyrosine phosphorylation was reduced in cells from tumors growing in transplanted, athymic, nude mice, which have an intact autocrine regulation of the EGFR.  We suggest that the dynamic regulation of FAK activity, initiated by EGF-induced downregulation of FAK leading to cell detachment and increased motility and invasion, followed by integrin-dependent reactivation during readhesion, plays a role in EGF-assocd. tumor invasion and metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcrBC-34ss5bVg90H21EOLACvtfcHk0lhYH4E2BWCS9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXktFWgtLw%253D&md5=1d7c09f65ed896b2dac4cb252bbce373</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1128%2FMCB.21.12.4016-4031.2001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.21.12.4016-4031.2001%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DG.%26aulast%3DBlume-Jensen%26aufirst%3DP.%26aulast%3DHunter%26aufirst%3DT.%26atitle%3DEpidermal%2520Growth%2520Factor-Induced%2520Tumor%2520Cell%2520Invasion%2520and%2520Metastasis%2520Initiated%2520by%2520Dephosphorylation%2520and%2520Downregulation%2520of%2520Focal%2520Adhesion%2520Kinase%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2001%26volume%3D21%26spage%3D4016%26epage%3D4031%26doi%3D10.1128%2FMCB.21.12.4016-4031.2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Cáceres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerrero, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martínez, J.</span><span> </span><span class="NLM_article-title">Overexpression of RhoA-GTP induces activation of the Epidermal Growth Factor Receptor, dephosphorylation of focal adhesion kinase and increased motility in breast cancer cells</span> <span class="citation_source-journal">Exp. Cell Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">309</span><span class="NLM_x">, </span> <span class="NLM_fpage">229</span><span class="NLM_x">–</span> <span class="NLM_lpage">238</span><span class="refDoi"> DOI: 10.1016/j.yexcr.2005.05.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1016%2Fj.yexcr.2005.05.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=15963982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpt1ektL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=309&publication_year=2005&pages=229-238&author=M.+C%C3%A1ceresauthor=J.+Guerreroauthor=J.+Mart%C3%ADnez&title=Overexpression+of+RhoA-GTP+induces+activation+of+the+Epidermal+Growth+Factor+Receptor%2C+dephosphorylation+of+focal+adhesion+kinase+and+increased+motility+in+breast+cancer+cells&doi=10.1016%2Fj.yexcr.2005.05.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of RhoA-GTP induces activation of the epidermal growth factor receptor, dephosphorylation of focal adhesion kinase and increased motility in breast cancer cells</span></div><div class="casAuthors">Caceres, Monica; Guerrero, Javier; Martinez, Jorge</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Cell Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">309</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">229-238</span>CODEN:
                <span class="NLM_cas:coden">ECREAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-4827</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Rho GTPases are overexpressed in human tumors and are involved in a variety of cellular processes such as organization of the actin cytoskeleton, cell-cell contact and malignant transformation.  EGFR activation plays a key role in the acquisition of motile properties in carcinoma cells, and it has been proposed that downregulation of FAK activity is one of its most relevant consequences.  In the present study, using mammary MCF-7 cells, we demonstrated that overexpression of the active form of the small GTPase RhoA induced the activation of EGFR by a phenomenon that depends on the activity of a metalloproteinase (MMP), which presumably cleaves a membrane-bound EGFR ligand.  The EGFR tyrosine phosphorylation correlates with ERK1,2 activation and the stimulation of urokinase prodn.  An aggressive mammary cell line (MDA-MB-231) that overexpresses both RhoA and EGFR in their active forms also displayed an MMP-dependent activation mechanism of EGFR.  RhoA-GTP-transfected cells showed a cortical array of F-actin, rounded morphol., reduced spreading potential and a dephosphorylation of FAK that was released by integrin-dependent fibronectin adhesion and a specific EGFR tyrosine kinase inhibitor.  Our results suggest that the MMP-dependent EGFR activation obsd. in V14 RhoA cells represents the starting point of a signaling route that promotes cell motility by activation of ERK1,2 and further enhancement of proteases prodn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohkNr-cQ1MAbVg90H21EOLACvtfcHk0lhYH4E2BWCS9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpt1ektL0%253D&md5=11166ddda07b50ac8021f01127304e36</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.yexcr.2005.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yexcr.2005.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DC%25C3%25A1ceres%26aufirst%3DM.%26aulast%3DGuerrero%26aufirst%3DJ.%26aulast%3DMart%25C3%25ADnez%26aufirst%3DJ.%26atitle%3DOverexpression%2520of%2520RhoA-GTP%2520induces%2520activation%2520of%2520the%2520Epidermal%2520Growth%2520Factor%2520Receptor%252C%2520dephosphorylation%2520of%2520focal%2520adhesion%2520kinase%2520and%2520increased%2520motility%2520in%2520breast%2520cancer%2520cells%26jtitle%3DExp.%2520Cell%2520Res.%26date%3D2005%26volume%3D309%26spage%3D229%26epage%3D238%26doi%3D10.1016%2Fj.yexcr.2005.05.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Sengupta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smitha, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santhoshkumar, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devi, S. K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sreejalekshmi, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajasekharan, K. N.</span><span> </span><span class="NLM_article-title">4-Amino-5-benzoyl-2-(4-methoxyphenylamino)thiazole (DAT1): a cytotoxic agent towards cancer cells and a probe for tubulin-microtubule system</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">145</span><span class="NLM_x">, </span> <span class="NLM_fpage">1076</span><span class="NLM_x">–</span> <span class="NLM_lpage">1083</span><span class="refDoi"> DOI: 10.1038/sj.bjp.0706276</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1038%2Fsj.bjp.0706276" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=15951833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BD2MXns1Wrsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=145&publication_year=2005&pages=1076-1083&author=S.+Senguptaauthor=S.+L.+Smithaauthor=N.+E.+Thomasauthor=T.+R.+Santhoshkumarauthor=S.+K.+C.+Deviauthor=K.+G.+Sreejalekshmiauthor=K.+N.+Rajasekharan&title=4-Amino-5-benzoyl-2-%284-methoxyphenylamino%29thiazole+%28DAT1%29%3A+a+cytotoxic+agent+towards+cancer+cells+and+a+probe+for+tubulin-microtubule+system&doi=10.1038%2Fsj.bjp.0706276"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">4-Amino-5-benzoyl-2-(4-methoxyphenylamino)thiazole (DAT1): a cytotoxic agent towards cancer cells and a probe for tubulin-microtubule system</span></div><div class="casAuthors">Sengupta, Suparna; Smitha, Sasidharan L.; Thomas, Nisha E.; Santhoshkumar, Thankaiyyan R.; Devi, Satyabhama K. C.; Sreejalekshmi, Kumaran G.; Rajasekharan, Kallikat N.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">145</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1076-1083</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Microtubule binding drugs are of special interest as they have important roles in the modulation of cellular functions and many of them act as anticancer agents.  4-Amino-5-benzoyl-2-(4-methoxyphenylamino)thiazole (DAT1) was identified as one of the active compds. from a series of diaminoketothiazoles in a cell-based screening assay to discover cytotoxic compds.  DAT1 shows cytotoxicity with GI50 values ranging from 0.05 to 1 μM in different malignant cell lines with an av. value of 0.35 μM.  It blocks mitosis in the prometaphase and metaphase stages.  In HeLa cells, DAT1 blocks the spindle function by disturbing spindle microtubule and chromosome organization.  The drug also inhibits assembly of brain microtubules and binds tubulin specifically at a single site with induction of fluorescence.  The dissocn. const. of DAT1 binding to tubulin was detd. as 2.9±1 μM at 24°.  The binding site of DAT1 on tubulin overlaps with that of the conventional colchicine-binding site.  DAT1 can thus be considered as a lead compd. of a new class of small mols. and this study can be used as a step to develop potent antimitotic agents for the control of cytoskeletal functions and cell proliferation.  It would also be an interesting probe for the structure-function studies of tubulin-microtubule system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_lBzdf_bEtbVg90H21EOLACvtfcHk0lhYH4E2BWCS9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXns1Wrsbk%253D&md5=d3bb0e7a3049cbf8a9d2a57fbdad0282</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0706276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0706276%26sid%3Dliteratum%253Aachs%26aulast%3DSengupta%26aufirst%3DS.%26aulast%3DSmitha%26aufirst%3DS.%2BL.%26aulast%3DThomas%26aufirst%3DN.%2BE.%26aulast%3DSanthoshkumar%26aufirst%3DT.%2BR.%26aulast%3DDevi%26aufirst%3DS.%2BK.%2BC.%26aulast%3DSreejalekshmi%26aufirst%3DK.%2BG.%26aulast%3DRajasekharan%26aufirst%3DK.%2BN.%26atitle%3D4-Amino-5-benzoyl-2-%25284-methoxyphenylamino%2529thiazole%2520%2528DAT1%2529%253A%2520a%2520cytotoxic%2520agent%2520towards%2520cancer%2520cells%2520and%2520a%2520probe%2520for%2520tubulin-microtubule%2520system%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2005%26volume%3D145%26spage%3D1076%26epage%3D1083%26doi%3D10.1038%2Fsj.bjp.0706276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Gray-Schopfer, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wellbrock, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span> </span><span class="NLM_article-title">Melanoma biology and new targeted therapy</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">445</span><span class="NLM_x">, </span> <span class="NLM_fpage">851</span><span class="NLM_x">–</span> <span class="NLM_lpage">857</span><span class="refDoi"> DOI: 10.1038/nature05661</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1038%2Fnature05661" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=17314971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvFGiu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=445&publication_year=2007&pages=851-857&author=V.+Gray-Schopferauthor=C.+Wellbrockauthor=R.+Marais&title=Melanoma+biology+and+new+targeted+therapy&doi=10.1038%2Fnature05661"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Melanoma biology and new targeted therapy</span></div><div class="casAuthors">Gray-Schopfer, Vanessa; Wellbrock, Claudia; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">445</span>
        (<span class="NLM_cas:issue">7130</span>),
    <span class="NLM_cas:pages">851-857</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Melanoma is a cancer that arises from melanocytes, specialized pigmented cells that are found predominantly in the skin.  The incidence of melanoma is rising steadily in western populations - the no. of cases worldwide has doubled in the past 20 years.  In its early stages malignant melanoma can be cured by surgical resection, but once it has progressed to the metastatic stage it is extremely difficult to treat and does not respond to current therapies.  Recent discoveries in cell signalling have provided greater understanding of the biol. that underlies melanoma, and these advances are being exploited to provide targeted drugs and new therapeutic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXWnhlx-AzCbVg90H21EOLACvtfcHk0lj4QmRH-obFhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvFGiu7g%253D&md5=a898105964c68ba64eca76489a703e8d</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnature05661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05661%26sid%3Dliteratum%253Aachs%26aulast%3DGray-Schopfer%26aufirst%3DV.%26aulast%3DWellbrock%26aufirst%3DC.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DMelanoma%2520biology%2520and%2520new%2520targeted%2520therapy%26jtitle%3DNature%26date%3D2007%26volume%3D445%26spage%3D851%26epage%3D857%26doi%3D10.1038%2Fnature05661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Davies, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bignell, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edkins, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clegg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teague, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woffendin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garnett, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bottomley, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dicks, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ewing, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosmidou, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menzies, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mould, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hooper, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayatilake, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gusterson, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shipley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hargrave, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard-Jones, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maitland, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chenevix-Trench, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riggins, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bigner, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmieri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cossu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, J. W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seigler, H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darrow, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paterson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wooster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratton, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Futreal, P. A.</span><span> </span><span class="NLM_article-title">Mutations of the BRAF gene in human cancer</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">417</span><span class="NLM_x">, </span> <span class="NLM_fpage">949</span><span class="NLM_x">–</span> <span class="NLM_lpage">954</span><span class="refDoi"> DOI: 10.1038/nature00766</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1038%2Fnature00766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=12068308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvVagsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=417&publication_year=2002&pages=949-954&author=H.+Daviesauthor=G.+R.+Bignellauthor=C.+Coxauthor=P.+Stephensauthor=S.+Edkinsauthor=S.+Cleggauthor=J.+Teagueauthor=H.+Woffendinauthor=M.+J.+Garnettauthor=W.+Bottomleyauthor=N.+Davisauthor=E.+Dicksauthor=R.+Ewingauthor=Y.+Floydauthor=K.+Grayauthor=S.+Hallauthor=R.+Hawesauthor=J.+Hughesauthor=V.+Kosmidouauthor=A.+Menziesauthor=C.+Mouldauthor=A.+Parkerauthor=C.+Stevensauthor=S.+Wattauthor=S.+Hooperauthor=R.+Wilsonauthor=H.+Jayatilakeauthor=B.+A.+Gustersonauthor=C.+Cooperauthor=J.+Shipleyauthor=D.+Hargraveauthor=K.+Pritchard-Jonesauthor=N.+Maitlandauthor=G.+Chenevix-Trenchauthor=G.+J.+Rigginsauthor=D.+D.+Bignerauthor=G.+Palmieriauthor=A.+Cossuauthor=A.+Flanaganauthor=A.+Nicholsonauthor=J.+W.+C.+Hoauthor=S.+Y.+Leungauthor=S.+T.+Yuenauthor=B.+L.+Weberauthor=H.+F.+Seiglerauthor=T.+L.+Darrowauthor=H.+Patersonauthor=R.+Maraisauthor=C.+J.+Marshallauthor=R.+Woosterauthor=M.+R.+Strattonauthor=P.+A.+Futreal&title=Mutations+of+the+BRAF+gene+in+human+cancer&doi=10.1038%2Fnature00766"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations of the BRAF gene in human cancer</span></div><div class="casAuthors">Davies, Helen; Bignell, Graham R.; Cox, Charles; Stephens, Philip; Edkins, Sarah; Clegg, Sheila; Teague, Jon; Woffendin, Hayley; Garnett, Mathew J.; Bottomley, William; Davis, Neil; Dicks, Ed; Ewing, Rebecca; Floyd, Yvonne; Gray, Kristian; Hall, Sarah; Hawes, Rachel; Hughes, Jaime; Kosmidou, Vivian; Menzies, Andrew; Mould, Catherine; Parker, Adrian; Stevens, Claire; Watt, Stephen; Hooper, Steven; Wilson, Rebecca; Jayatilake, Hiran; Gusterson, Barry A.; Cooper, Colin; Shipley, Janet; Hargrave, Darren; Pritchard-Jones, Katherine; Maitland, Norman; Chenevix-Trench, Georgia; Riggins, Gregory J.; Bigner, Darell D.; Palmieri, Giuseppe; Cossu, Antonio; Flanagan, Adrienne; Nicholson, Andrew; Ho, Judy W. C.; Leung, Suet Y.; Yuen, Siu T.; Weber, Barbara L.; Seigler, Hilliard F.; Darrow, Timothy L.; Paterson, Hugh; Marais, Richard; Marshall, Christopher J.; Wooster, Richard; Stratton, Michael R.; Futreal, P. Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">417</span>
        (<span class="NLM_cas:issue">6892</span>),
    <span class="NLM_cas:pages">949-954</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cancers arise owing to the accumulation of mutations in crit. genes that alter normal programs of cell proliferation, differentiation and death.  As the first stage of a systematic genome-wide screen for these genes, we have prioritized for anal. signalling pathways in which at least one gene is mutated in human cancer.  The RAS-RAF-MEK-ERK-MAP kinase pathway mediates cellular responses to growth signals.  RAS is mutated to an oncogenic form in about 15% of human cancer.  The three RAF genes code for cytoplasmic serine/threonine kinases that are regulated by binding RAS.  Here we report BRAF somatic missense mutations in 66% of malignant melanomas and at lower frequency in a wide range of human cancers.  All mutations are within the kinase domain, with a single substitution (V599E) accounting for 80%.  Mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells.  Furthermore, RAS function is not required for the growth of cancer cell lines with the V599E mutation.  As BRAF is a serine/threonine kinase that is commonly activated by somatic point mutation in human cancer, it may provide new therapeutic opportunities in malignant melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPBmhJC0GAjrVg90H21EOLACvtfcHk0lj4QmRH-obFhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvVagsLo%253D&md5=4625be53ad9a382d51b6ee753d0c17e8</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnature00766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature00766%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DH.%26aulast%3DBignell%26aufirst%3DG.%2BR.%26aulast%3DCox%26aufirst%3DC.%26aulast%3DStephens%26aufirst%3DP.%26aulast%3DEdkins%26aufirst%3DS.%26aulast%3DClegg%26aufirst%3DS.%26aulast%3DTeague%26aufirst%3DJ.%26aulast%3DWoffendin%26aufirst%3DH.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DBottomley%26aufirst%3DW.%26aulast%3DDavis%26aufirst%3DN.%26aulast%3DDicks%26aufirst%3DE.%26aulast%3DEwing%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DK.%26aulast%3DHall%26aufirst%3DS.%26aulast%3DHawes%26aufirst%3DR.%26aulast%3DHughes%26aufirst%3DJ.%26aulast%3DKosmidou%26aufirst%3DV.%26aulast%3DMenzies%26aufirst%3DA.%26aulast%3DMould%26aufirst%3DC.%26aulast%3DParker%26aufirst%3DA.%26aulast%3DStevens%26aufirst%3DC.%26aulast%3DWatt%26aufirst%3DS.%26aulast%3DHooper%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DJayatilake%26aufirst%3DH.%26aulast%3DGusterson%26aufirst%3DB.%2BA.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DShipley%26aufirst%3DJ.%26aulast%3DHargrave%26aufirst%3DD.%26aulast%3DPritchard-Jones%26aufirst%3DK.%26aulast%3DMaitland%26aufirst%3DN.%26aulast%3DChenevix-Trench%26aufirst%3DG.%26aulast%3DRiggins%26aufirst%3DG.%2BJ.%26aulast%3DBigner%26aufirst%3DD.%2BD.%26aulast%3DPalmieri%26aufirst%3DG.%26aulast%3DCossu%26aufirst%3DA.%26aulast%3DFlanagan%26aufirst%3DA.%26aulast%3DNicholson%26aufirst%3DA.%26aulast%3DHo%26aufirst%3DJ.%2BW.%2BC.%26aulast%3DLeung%26aufirst%3DS.%2BY.%26aulast%3DYuen%26aufirst%3DS.%2BT.%26aulast%3DWeber%26aufirst%3DB.%2BL.%26aulast%3DSeigler%26aufirst%3DH.%2BF.%26aulast%3DDarrow%26aufirst%3DT.%2BL.%26aulast%3DPaterson%26aufirst%3DH.%26aulast%3DMarais%26aufirst%3DR.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26aulast%3DWooster%26aufirst%3DR.%26aulast%3DStratton%26aufirst%3DM.%2BR.%26aulast%3DFutreal%26aufirst%3DP.%2BA.%26atitle%3DMutations%2520of%2520the%2520BRAF%2520gene%2520in%2520human%2520cancer%26jtitle%3DNature%26date%3D2002%26volume%3D417%26spage%3D949%26epage%3D954%26doi%3D10.1038%2Fnature00766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Wan, P. T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garnett, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roe, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niculescu-Duvaz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Project, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barford, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span> </span><span class="NLM_article-title">Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">855</span><span class="NLM_x">–</span> <span class="NLM_lpage">867</span><span class="refDoi"> DOI: 10.1016/S0092-8674(04)00215-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1016%2FS0092-8674%2804%2900215-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=15035987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivVyksLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2004&pages=855-867&author=P.+T.+C.+Wanauthor=M.+J.+Garnettauthor=S.+M.+Roeauthor=S.+Leeauthor=D.+Niculescu-Duvazauthor=V.+M.+Goodauthor=C.+G.+Projectauthor=C.+M.+Jonesauthor=C.+J.+Marshallauthor=C.+J.+Springerauthor=D.+Barfordauthor=R.+Marais&title=Mechanism+of+Activation+of+the+RAF-ERK+Signaling+Pathway+by+Oncogenic+Mutations+of+B-RAF&doi=10.1016%2FS0092-8674%2804%2900215-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF</span></div><div class="casAuthors">Wan, Paul T. C.; Garnett, Mathew J.; Roe, S. Mark; Lee, Sharlene; Niculescu-Duvaz, Dan; Good, Valerie M.; Project, Cancer Genome; Jones, C. Michael; Marshall, Christopher J.; Springer, Caroline J.; Barford, David; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">855-867</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Over 30 mutations of the B-RAF gene assocd. with human cancers have been identified, the majority of which are located within the kinase domain.  Here the authors show that of 22 B-RAF mutants analyzed, 18 have elevated kinase activity and signal to ERK in vivo.  Surprisingly, three mutants have reduced kinase activity towards MEK in vitro but, by activating C-RAF in vivo, signal to ERK in cells.  The structures of wild type and oncogenic V599EB-RAF kinase domains in complex with the RAF inhibitor BAY43-9006 show that the activation segment is held in an inactive conformation by assocn. with the P loop.  The clustering of most mutations to these two regions suggests that disruption of this interaction converts B-RAF into its active conformation.  The high activity mutants signal to ERK by directly phosphorylating MEK, whereas the impaired activity mutants stimulate MEK by activating endogenous C-RAF, possibly via an allosteric or transphosphorylation mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYiQicwc1xVLVg90H21EOLACvtfcHk0lhOwrKqf2jkQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivVyksLw%253D&md5=4cc020056c64e514286c000666da1972</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2804%2900215-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252804%252900215-6%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DP.%2BT.%2BC.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DRoe%26aufirst%3DS.%2BM.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DGood%26aufirst%3DV.%2BM.%26aulast%3DProject%26aufirst%3DC.%2BG.%26aulast%3DJones%26aufirst%3DC.%2BM.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26aulast%3DBarford%26aufirst%3DD.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DMechanism%2520of%2520Activation%2520of%2520the%2520RAF-ERK%2520Signaling%2520Pathway%2520by%2520Oncogenic%2520Mutations%2520of%2520B-RAF%26jtitle%3DCell%26date%3D2004%26volume%3D116%26spage%3D855%26epage%3D867%26doi%3D10.1016%2FS0092-8674%2804%2900215-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puzanov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Dwyer, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grippo, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span> </span><span class="NLM_article-title">Inhibition of Mutated, Activated BRAF in Metastatic Melanoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">809</span><span class="NLM_x">–</span> <span class="NLM_lpage">819</span><span class="refDoi"> DOI: 10.1056/NEJMoa1002011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1056%2FNEJMoa1002011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=20818844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVyksb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=809-819&author=K.+T.+Flahertyauthor=I.+Puzanovauthor=K.+B.+Kimauthor=A.+Ribasauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=P.+J.+O%E2%80%99Dwyerauthor=R.+J.+Leeauthor=J.+F.+Grippoauthor=K.+Nolopauthor=P.+B.+Chapman&title=Inhibition+of+Mutated%2C+Activated+BRAF+in+Metastatic+Melanoma&doi=10.1056%2FNEJMoa1002011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of mutated, activated BRAF in metastatic melanoma</span></div><div class="casAuthors">Flaherty, Keith T.; Puzanov, Igor; Kim, Kevin B.; Ribas, Antoni; McArthur, Grant A.; Sosman, Jeffrey A.; O'dwyer, Peter J.; Lee, Richard J.; Grippo, Joseph F.; Nolop, Keith; Chapman, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">809-819</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: The identification of somatic mutations in the gene encoding the serine-threonine protein kinase B-RAF (BRAF) in the majority of melanomas offers an opportunity to test oncogene-targeted therapy for this disease.  Methods: We conducted a multicenter, phase 1, dose-escalation trial of PLX4032 (also known as RG7204), an orally available inhibitor of mutated BRAF, followed by an extension phase involving the max. dose that could be administered without adverse effects (the recommended phase 2 dose).  Patients received PLX4032 twice daily until they had disease progression.  Pharmacokinetic anal. and tumor-response assessments were conducted in all patients.  In selected patients, tumor biopsy was performed before and during treatment to validate BRAF inhibition.  Results: A total of 55 patients (49 of whom had melanoma) were enrolled in the dose-escalation phase, and 32 addnl. patients with metastatic melanoma who had BRAF with the V600E mutation were enrolled in the extension phase.  The recommended phase 2 dose was 960 mg twice daily, with increases in the dose limited by grade 2 or 3 rash, fatigue, and arthralgia.  In the dose-escalation cohort, among the 16 patients with melanoma whose tumors carried the V600E BRAF mutation and who were receiving 240 mg or more of PLX4032 twice daily, 10 had a partial response and 1 had a complete response.  Among the 32 patients in the extension cohort, 24 had a partial response and 2 had a complete response.  The estd. median progression-free survival among all patients was more than 7 mo.  Conclusions: Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwq1fkvEjfyLVg90H21EOLACvtfcHk0lhOwrKqf2jkQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVyksb3M&md5=80f70df0ac490828a42e6c7c0b40067f</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1002011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1002011%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DP.%2BJ.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DGrippo%26aufirst%3DJ.%2BF.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26atitle%3DInhibition%2520of%2520Mutated%252C%2520Activated%2520BRAF%2520in%2520Metastatic%2520Melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D809%26epage%3D819%26doi%3D10.1056%2FNEJMoa1002011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Chapman, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauschild, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haanen, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ascierto, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larkin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dummer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Testori, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorigan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jouary, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schadendorf, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Day, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkwood, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eggermont, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreno, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span> </span><span class="NLM_article-title">Improved survival with vemurafenib in melanoma with BRAF V600E mutation</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">2507</span><span class="NLM_x">–</span> <span class="NLM_lpage">16</span><span class="refDoi"> DOI: 10.1056/NEJMoa1103782</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1056%2FNEJMoa1103782" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=21639808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosVeitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=2507-16&author=P.+B.+Chapmanauthor=A.+Hauschildauthor=C.+Robertauthor=J.+B.+Haanenauthor=P.+Asciertoauthor=J.+Larkinauthor=R.+Dummerauthor=C.+Garbeauthor=A.+Testoriauthor=M.+Maioauthor=D.+Hoggauthor=P.+Loriganauthor=C.+Lebbeauthor=T.+Jouaryauthor=D.+Schadendorfauthor=A.+Ribasauthor=S.+J.+O%E2%80%99Dayauthor=J.+A.+Sosmanauthor=J.+M.+Kirkwoodauthor=A.+M.+Eggermontauthor=B.+Drenoauthor=K.+Nolopauthor=J.+Liauthor=B.+Nelsonauthor=J.+Houauthor=R.+J.+Leeauthor=K.+T.+Flahertyauthor=G.+A.+McArthur&title=Improved+survival+with+vemurafenib+in+melanoma+with+BRAF+V600E+mutation&doi=10.1056%2FNEJMoa1103782"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Improved survival with vemurafenib in melanoma with BRAF V600E mutation</span></div><div class="casAuthors">Chapman, Paul B.; Hauschild, Axel; Robert, Caroline; Haanen, John B.; Ascierto, Paolo; Larkin, James; Dummer, Reinhard; Garbe, Claus; Testori, Alessandro; Maio, Michele; Hogg, David; Lorigan, Paul; Lebbe, Celeste; Jouary, Thomas; Schadendorf, Dirk; Ribas, Antoni; O'Day, Steven J.; Sosman, Jeffrey A.; Kirkwood, John M.; Eggermont, Alexander M. M.; Dreno, Brigitte; Nolop, Keith; Li, Jiang; Nelson, Betty; Hou, Jeannie; Lee, Richard J.; Flaherty, Keith T.; McArthur, Grant A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2507-2516</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Phase 1 and 2 clin. trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation.  METHODS: We conducted a phase 3 randomized clin. trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation.  Patients were randomly assigned to receive either vemurafenib (960 mg orally twice daily) or dacarbazine (1000 mg per square meter of body-surface area i.v. every 3 wk).  Coprimary end points were rates of overall and progression-free survival.  Secondary end points included the response rate, response duration, and safety.  A final anal. was planned after 196 deaths and an interim anal. after 98 deaths.  RESULTS: At 6 mo, overall survival was 840/ (95% confidence interval [CI], 78 to 89) in the vemurafenib group and 64% (95% CI, 56 to 73) in the dacarbazine group.  In the interim anal. for overall survival and final anal. for progression-free survival, vemurafenib was assocd. with a relative redn. of 63% in the risk of death and of 74% in the risk of either death or disease progression, as compared with dacarbazine (P < 0.001 for both comparisons).  After review of the interim anal. by an independent data and safety monitoring board, crossover from dacarbazine to vemurafenib was recommended.  Response rates were 48% for vemurafenib and 5% for dacarbazine.  Common adverse events assocd. with vemurafenib were arthralgia, rash, fatigue, alopecia, keratoacanthoma or squamous-cell carcinoma, photosensitivity, nausea, and diarrhea; 38% of patients required dose modification because of toxic effects.  CONCLUSIONS: Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4NFxmTaDz97Vg90H21EOLACvtfcHk0lhOwrKqf2jkQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosVeitbs%253D&md5=1a4b4f963221888dc63f620e87408070</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1103782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1103782%26sid%3Dliteratum%253Aachs%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DHaanen%26aufirst%3DJ.%2BB.%26aulast%3DAscierto%26aufirst%3DP.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DTestori%26aufirst%3DA.%26aulast%3DMaio%26aufirst%3DM.%26aulast%3DHogg%26aufirst%3DD.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DLebbe%26aufirst%3DC.%26aulast%3DJouary%26aufirst%3DT.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Day%26aufirst%3DS.%2BJ.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DKirkwood%26aufirst%3DJ.%2BM.%26aulast%3DEggermont%26aufirst%3DA.%2BM.%26aulast%3DDreno%26aufirst%3DB.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DNelson%26aufirst%3DB.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26atitle%3DImproved%2520survival%2520with%2520vemurafenib%2520in%2520melanoma%2520with%2520BRAF%2520V600E%2520mutation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D2507%26epage%3D16%26doi%3D10.1056%2FNEJMoa1103782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Lehnert, M.</span><span> </span><span class="NLM_article-title">Multidrug resistance in human cancer</span> <span class="citation_source-journal">J. Neuro-Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">239</span><span class="NLM_x">–</span> <span class="NLM_lpage">43</span><span class="refDoi"> DOI: 10.1007/BF01052927</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1007%2FBF01052927" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=7760101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A280%3ADyaK2M3otVSmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1994&pages=239-43&author=M.+Lehnert&title=Multidrug+resistance+in+human+cancer&doi=10.1007%2FBF01052927"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Multidrug resistance in human cancer</span></div><div class="casAuthors">Lehnert M</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neuro-oncology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">239-43</span>
        ISSN:<span class="NLM_cas:issn">0167-594X</span>.
    </div><div class="casAbstract">Resistance to cytotoxic chemotherapy continues to be a major obstacle to more effective treatment of human cancers.  A particular problem in clinical cancer chemotherapy is the phenomenon of simultaneous resistance of cancers to a variety of unrelated cytotoxic agents.  Such resistance to multiple drugs is observed much more often than resistance to individual compounds.  A similar experimental phenomenon has been termed multidrug resistance or MDR.  Much has been learned in recent years about molecular mechanisms which can lead to MDR in cancer cells and a number of studies has been performed to evaluate the clinical relevance of such mechanisms.  In particular, P-glycoprotein-associated MDR (MDR1) has received a lot of attention.  This review will discuss (i) some principal aspects of drug resistance in cancer with particular emphasis on MDR1; (ii) available data on drug resistance mechanisms in brain tumors; and (iii) our current knowledge on the putative role of P-glycoprotein in the blood-brain barrier.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR51BMNng4S_ty3lHz94U-GfW6udTcc2eYcL2AgSYoZ_bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2M3otVSmtw%253D%253D&md5=b8ef6c87aa932a1be90be81e1f230b1e</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1007%2FBF01052927&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF01052927%26sid%3Dliteratum%253Aachs%26aulast%3DLehnert%26aufirst%3DM.%26atitle%3DMultidrug%2520resistance%2520in%2520human%2520cancer%26jtitle%3DJ.%2520Neuro-Oncol.%26date%3D1994%26volume%3D22%26spage%3D239%26epage%3D43%26doi%3D10.1007%2FBF01052927" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Gottesman, M. M.</span><span> </span><span class="NLM_article-title">How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal Foundation Award Lecture</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">747</span><span class="NLM_x">–</span> <span class="NLM_lpage">54</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1993&pages=747-54&author=M.+M.+Gottesman&title=How+cancer+cells+evade+chemotherapy%3A+sixteenth+Richard+and+Hinda+Rosenthal+Foundation+Award+Lecture"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26atitle%3DHow%2520cancer%2520cells%2520evade%2520chemotherapy%253A%2520sixteenth%2520Richard%2520and%2520Hinda%2520Rosenthal%2520Foundation%2520Award%2520Lecture%26jtitle%3DCancer%2520Res.%26date%3D1993%26volume%3D53%26spage%3D747%26epage%3D54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Sahu, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balbhadra, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choudhary, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohli, D. V.</span><span> </span><span class="NLM_article-title">Exploring pharmacological significance of chalcone scaffold: a review</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">209</span><span class="NLM_x">–</span> <span class="NLM_lpage">25</span><span class="refDoi"> DOI: 10.2174/092986712803414132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.2174%2F092986712803414132" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=22320299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1ygtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=209-25&author=N.+K.+Sahuauthor=S.+S.+Balbhadraauthor=J.+Choudharyauthor=D.+V.+Kohli&title=Exploring+pharmacological+significance+of+chalcone+scaffold%3A+a+review&doi=10.2174%2F092986712803414132"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring pharmacological significance of chalcone scaffold: a review</span></div><div class="casAuthors">Sahu, N. K.; Balbhadra, S. S.; Choudhary, J.; Kohli, D. V.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-225</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Chalcones (1,3-diaryl-2-propen-1-ones) and their heterocyclic analogs, belong to the flavonoid family, which possess a no. of interesting biol. properties such as antioxidant, cytotoxic, anticancer, antimicrobial, antiprotozoal, antiulcer, antihistaminic and anti-inflammatory activities.  Several pure chalcones have been approved for clin. use or tested in humans.  Clin. trials have shown that these compds. reached reasonable plasma concn. and are well-tolerated.  For this reason they are an object of continuously growing interest amongst the scientists.  However, much of the pharmacol. potential of chalcones is still not utilized.  The purpose of this review is to provide an overview of the pharmacol. activity of naturally occurring and synthetic chalcones.  This review highlights more recent pharmacol. screening of these compds., their mechanisms of action and relevant structure-activity relationships.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxOy69N3sXULVg90H21EOLACvtfcHk0liw0N5qyUU9IQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1ygtbo%253D&md5=65b8fd77d6156b5de7bcc8f46740ff70</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.2174%2F092986712803414132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986712803414132%26sid%3Dliteratum%253Aachs%26aulast%3DSahu%26aufirst%3DN.%2BK.%26aulast%3DBalbhadra%26aufirst%3DS.%2BS.%26aulast%3DChoudhary%26aufirst%3DJ.%26aulast%3DKohli%26aufirst%3DD.%2BV.%26atitle%3DExploring%2520pharmacological%2520significance%2520of%2520chalcone%2520scaffold%253A%2520a%2520review%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2012%26volume%3D19%26spage%3D209%26epage%3D25%26doi%3D10.2174%2F092986712803414132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Bukhari, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jantan, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unsal Tan, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sher, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naeem-Ul-Hassan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, H. L.</span><span> </span><span class="NLM_article-title">Biological activity and molecular docking studies of curcumin-related alpha,beta-unsaturated carbonyl-based synthetic compounds as anticancer agents and mushroom tyrosinase inhibitors</span> <span class="citation_source-journal">J. Agric. Food Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">5538</span><span class="NLM_x">–</span> <span class="NLM_lpage">47</span><span class="refDoi"> DOI: 10.1021/jf501145b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jf501145b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2014&pages=5538-47&author=S.+N.+Bukhariauthor=I.+Jantanauthor=O.+Unsal+Tanauthor=M.+Sherauthor=M.+Naeem-Ul-Hassanauthor=H.+L.+Qin&title=Biological+activity+and+molecular+docking+studies+of+curcumin-related+alpha%2Cbeta-unsaturated+carbonyl-based+synthetic+compounds+as+anticancer+agents+and+mushroom+tyrosinase+inhibitors&doi=10.1021%2Fjf501145b"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjf501145b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjf501145b%26sid%3Dliteratum%253Aachs%26aulast%3DBukhari%26aufirst%3DS.%2BN.%26aulast%3DJantan%26aufirst%3DI.%26aulast%3DUnsal%2BTan%26aufirst%3DO.%26aulast%3DSher%26aufirst%3DM.%26aulast%3DNaeem-Ul-Hassan%26aufirst%3DM.%26aulast%3DQin%26aufirst%3DH.%2BL.%26atitle%3DBiological%2520activity%2520and%2520molecular%2520docking%2520studies%2520of%2520curcumin-related%2520alpha%252Cbeta-unsaturated%2520carbonyl-based%2520synthetic%2520compounds%2520as%2520anticancer%2520agents%2520and%2520mushroom%2520tyrosinase%2520inhibitors%26jtitle%3DJ.%2520Agric.%2520Food%2520Chem.%26date%3D2014%26volume%3D62%26spage%3D5538%26epage%3D47%26doi%3D10.1021%2Fjf501145b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Pati, H. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimmock, J. R.</span><span> </span><span class="NLM_article-title">Cytotoxic thiol alkylators</span> <span class="citation_source-journal">Mini-Rev. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">131</span><span class="NLM_x">–</span> <span class="NLM_lpage">9</span><span class="refDoi"> DOI: 10.2174/138955707779802642</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.2174%2F138955707779802642" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=131-9&author=H.+N.+Patiauthor=U.+Dasauthor=R.+K.+Sharmaauthor=J.+R.+Dimmock&title=Cytotoxic+thiol+alkylators&doi=10.2174%2F138955707779802642"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.2174%2F138955707779802642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955707779802642%26sid%3Dliteratum%253Aachs%26aulast%3DPati%26aufirst%3DH.%2BN.%26aulast%3DDas%26aufirst%3DU.%26aulast%3DSharma%26aufirst%3DR.%2BK.%26aulast%3DDimmock%26aufirst%3DJ.%2BR.%26atitle%3DCytotoxic%2520thiol%2520alkylators%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26spage%3D131%26epage%3D9%26doi%3D10.2174%2F138955707779802642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Maydt, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Spirt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muschelknautz, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahl, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, T. J.</span><span> </span><span class="NLM_article-title">Chemical reactivity and biological activity of chalcones and other alpha,beta-unsaturated carbonyl compounds</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">711</span><span class="NLM_x">–</span> <span class="NLM_lpage">8</span><span class="refDoi"> DOI: 10.3109/00498254.2012.754112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.3109%2F00498254.2012.754112" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2013&pages=711-8&author=D.+Maydtauthor=S.+De+Spirtauthor=C.+Muschelknautzauthor=W.+Stahlauthor=T.+J.+Muller&title=Chemical+reactivity+and+biological+activity+of+chalcones+and+other+alpha%2Cbeta-unsaturated+carbonyl+compounds&doi=10.3109%2F00498254.2012.754112"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.3109%2F00498254.2012.754112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F00498254.2012.754112%26sid%3Dliteratum%253Aachs%26aulast%3DMaydt%26aufirst%3DD.%26aulast%3DDe%2BSpirt%26aufirst%3DS.%26aulast%3DMuschelknautz%26aufirst%3DC.%26aulast%3DStahl%26aufirst%3DW.%26aulast%3DMuller%26aufirst%3DT.%2BJ.%26atitle%3DChemical%2520reactivity%2520and%2520biological%2520activity%2520of%2520chalcones%2520and%2520other%2520alpha%252Cbeta-unsaturated%2520carbonyl%2520compounds%26jtitle%3DXenobiotica%26date%3D2013%26volume%3D43%26spage%3D711%26epage%3D8%26doi%3D10.3109%2F00498254.2012.754112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Peng, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span> </span><span class="NLM_article-title">Characterization of a novel curcumin analog P1 as potent inhibitor of the NF-kappaB signaling pathway with distinct mechanisms</span> <span class="citation_source-journal">Acta Pharmacol. Sin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">939</span><span class="NLM_x">–</span> <span class="NLM_lpage">50</span><span class="refDoi"> DOI: 10.1038/aps.2013.2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1038%2Faps.2013.2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=23603982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVGktrjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=939-50&author=Y.+M.+Pengauthor=J.+B.+Zhengauthor=Y.+B.+Zhouauthor=J.+Li&title=Characterization+of+a+novel+curcumin+analog+P1+as+potent+inhibitor+of+the+NF-kappaB+signaling+pathway+with+distinct+mechanisms&doi=10.1038%2Faps.2013.2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of a novel curcumin analog P1 as potent inhibitor of the NF-κB signaling pathway with distinct mechanisms</span></div><div class="casAuthors">Peng, Yan-min; Zheng, Jian-bin; Zhou, Yu-bo; Li, Jia</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">939-950</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Aim: Curcumin has shown promising anticancer activity, which relies on its inhibition on NF-κB pathway.  In this study, we characterized the pharmacol. profile of a novel curcumin analog P1 and elucidate the related mechanisms.  Methods: HEK293/NF-κB cells, stably transfected with an NF-κB-responsive luciferase reporter plasmid, were generated for high-throughput screen (HTS).  Eight cancer cell lines, including PC3, COLO 205, HeLa cells etc. were tested.  Cell viability was assessed using the sulforhodamine B (SRB) assays.  Cell apoptosis was evaluated using FACS, immunocytochem., and Western blotting.  H2-DCFDA and MitoSOX Red were used to detect cellular and mitochondrial reactive oxygen species (ROS).  The mitochondrial function was evaluated using mitochondrial oxygen consumption assay.  Results: P1, a tropinone curcumin, was found in HTS targeting the NF-κB pathway.  Its IC50 value in inhibition of TNF-α-induced NF-κB activation was 0.8 μmol/L, whereas its IC50 values in inhibiting the growth of A549 and HeLa cells were 1.24 and 0.69 μmol/L, resp., which was 20- to 30-fold more potent than curcumin.  The inhibition of P1 on the NF-κB pathway was further addressed in HeLa cells.  The compd. up to 10 μmol/L did not affect the binding of NF-κB to DNA, but markedly inhibited NF-κB nuclear translocation, IκB degrdn. and IκB kinase phosphorylation.  The compd. (1 and 3 μmol/L) concn.-dependently induced ROS generation, whereas curcumin up to 20 μmol/L had no effect.  P1-induced ROS generation was mainly localized in mitochondria, and reversed by NAC.  Moreover, the compd. significantly enhanced TNF-α-induced apoptosis.  Conclusion: P1 is a novel curcumin analog with potent anticancer activities, which exerts a distinct inhibition on the NF-κB pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrACH-zytJoj7Vg90H21EOLACvtfcHk0ljtGnrsTXYK2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVGktrjI&md5=92649400225e5c44217954fcf4203923</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Faps.2013.2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Faps.2013.2%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DY.%2BM.%26aulast%3DZheng%26aufirst%3DJ.%2BB.%26aulast%3DZhou%26aufirst%3DY.%2BB.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DCharacterization%2520of%2520a%2520novel%2520curcumin%2520analog%2520P1%2520as%2520potent%2520inhibitor%2520of%2520the%2520NF-kappaB%2520signaling%2520pathway%2520with%2520distinct%2520mechanisms%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2013%26volume%3D34%26spage%3D939%26epage%3D50%26doi%3D10.1038%2Faps.2013.2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Jung, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, H.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, W.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, K.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. H. Y.</span><span> </span><span class="NLM_article-title">Isoliquiritigenin induces apoptosis by depolarizing mitochondrial membranes in prostate cancer cells</span> <span class="citation_source-journal">J. Nutr. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">689</span><span class="NLM_x">–</span> <span class="NLM_lpage">696</span><span class="refDoi"> DOI: 10.1016/j.jnutbio.2005.11.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1016%2Fj.jnutbio.2005.11.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=16517140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BD28XpvFGisr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2006&pages=689-696&author=J.+I.+Jungauthor=S.+S.+Limauthor=H.+J.+Choiauthor=H.+J.+Choauthor=H.-K.+Shinauthor=E.+J.+Kimauthor=W.-Y.+Chungauthor=K.-K.+Parkauthor=J.+H.+Y.+Park&title=Isoliquiritigenin+induces+apoptosis+by+depolarizing+mitochondrial+membranes+in+prostate+cancer+cells&doi=10.1016%2Fj.jnutbio.2005.11.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Isoliquiritigenin induces apoptosis by depolarizing mitochondrial membranes in prostate cancer cells</span></div><div class="casAuthors">Jung, Jae In; Lim, Soon Sung; Choi, Hyun Ju; Cho, Han Jin; Shin, Hyun-Kyung; Kim, Eun Ji; Chung, Won-Yoon; Park, Kwang-Kyun; Park, Jung Han Yoon</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nutritional Biochemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">689-696</span>CODEN:
                <span class="NLM_cas:coden">JNBIEL</span>;
        ISSN:<span class="NLM_cas:issn">0955-2863</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Isoliquiritigenin (ISL), a simple chalcone deriv., 4,2',4'-trihydroxychalcone, found in licorice, shallot and bean sprouts, has been reported to have chemoprotective effects.  To examine the effects of ISL on the growth of prostate cancer cells, we cultured MAT-LyLu (MLL) rat and DU145 human prostate cancer cells with various concns. (0-20 μmol/L) of ISL.  Treatment of the cells with increasing concns. of ISL led to dose-dependent decreases in the viable cell nos. in both DU145 and MLL cells (P<.05).  Hoechst 33258 dye staining of condensed nuclei and annexin V binding to surface phosphatidylserine revealed increased nos. of apoptotic cells after ISL treatment.  Western blot anal. revealed that ISL increased the levels of membrane-bound Fas ligand (FasL), Fas, cleaved caspase-8, truncated Bid (tBid), Bax and Bad in DU145 cells (P<.05).  Isoliquiritigenin increased the percentage of cells with depolarized mitochondrial membranes, in a concn.-dependent manner (P<.05).  Isoliquiritigenin induced the release of cytochrome c and Smac/Diablo from the mitochondria into the cytoplasm (P<.05).  Isoliquiritigenin dose-dependently increased the levels of cleaved caspase-9, caspase-7, caspase-3 and poly(ADP-ribose) polymerase (P<.05).  The present results indicate that ISL inhibits prostate cancer cell growth by the induction of apoptosis, which is mediated through mitochondrial events, which are assocd. with an evident disruption of the mitochondrial membrane potential, and the release of cytochrome c and Smac/Diablo, and the activation of caspase-9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomeWjZMwPxxrVg90H21EOLACvtfcHk0ljtGnrsTXYK2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpvFGisr0%253D&md5=3649aa6519f562bce7b93c69664ab032</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.jnutbio.2005.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jnutbio.2005.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DJung%26aufirst%3DJ.%2BI.%26aulast%3DLim%26aufirst%3DS.%2BS.%26aulast%3DChoi%26aufirst%3DH.%2BJ.%26aulast%3DCho%26aufirst%3DH.%2BJ.%26aulast%3DShin%26aufirst%3DH.-K.%26aulast%3DKim%26aufirst%3DE.%2BJ.%26aulast%3DChung%26aufirst%3DW.-Y.%26aulast%3DPark%26aufirst%3DK.-K.%26aulast%3DPark%26aufirst%3DJ.%2BH.%2BY.%26atitle%3DIsoliquiritigenin%2520induces%2520apoptosis%2520by%2520depolarizing%2520mitochondrial%2520membranes%2520in%2520prostate%2520cancer%2520cells%26jtitle%3DJ.%2520Nutr.%2520Biochem.%26date%3D2006%26volume%3D17%26spage%3D689%26epage%3D696%26doi%3D10.1016%2Fj.jnutbio.2005.11.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Szliszka, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czuba, Z. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazur, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paradysz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krol, W.</span><span> </span><span class="NLM_article-title">Chalcones and dihydrochalcones augment TRAIL-mediated apoptosis in prostate cancer cells</span> <span class="citation_source-journal">Molecules</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">5336</span><span class="NLM_x">–</span> <span class="NLM_lpage">53</span><span class="refDoi"> DOI: 10.3390/molecules15085336</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.3390%2Fmolecules15085336" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2010&pages=5336-53&author=E.+Szliszkaauthor=Z.+P.+Czubaauthor=B.+Mazurauthor=A.+Paradyszauthor=W.+Krol&title=Chalcones+and+dihydrochalcones+augment+TRAIL-mediated+apoptosis+in+prostate+cancer+cells&doi=10.3390%2Fmolecules15085336"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.3390%2Fmolecules15085336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules15085336%26sid%3Dliteratum%253Aachs%26aulast%3DSzliszka%26aufirst%3DE.%26aulast%3DCzuba%26aufirst%3DZ.%2BP.%26aulast%3DMazur%26aufirst%3DB.%26aulast%3DParadysz%26aufirst%3DA.%26aulast%3DKrol%26aufirst%3DW.%26atitle%3DChalcones%2520and%2520dihydrochalcones%2520augment%2520TRAIL-mediated%2520apoptosis%2520in%2520prostate%2520cancer%2520cells%26jtitle%3DMolecules%26date%3D2010%26volume%3D15%26spage%3D5336%26epage%3D53%26doi%3D10.3390%2Fmolecules15085336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Yun, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kweon, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwon, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwang, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukhtar, H.</span><span> </span><span class="NLM_article-title">Induction of apoptosis and cell cycle arrest by a chalcone panduratin A isolated from Kaempferia pandurata in androgen-independent human prostate cancer cells PC3 and DU145</span> <span class="citation_source-journal">Carcinogenesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1454</span><span class="NLM_x">–</span> <span class="NLM_lpage">64</span><span class="refDoi"> DOI: 10.1093/carcin/bgi348</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1093%2Fcarcin%2Fbgi348" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2006&pages=1454-64&author=J.+M.+Yunauthor=M.+H.+Kweonauthor=H.+Kwonauthor=J.+K.+Hwangauthor=H.+Mukhtar&title=Induction+of+apoptosis+and+cell+cycle+arrest+by+a+chalcone+panduratin+A+isolated+from+Kaempferia+pandurata+in+androgen-independent+human+prostate+cancer+cells+PC3+and+DU145&doi=10.1093%2Fcarcin%2Fbgi348"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1093%2Fcarcin%2Fbgi348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcarcin%252Fbgi348%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DJ.%2BM.%26aulast%3DKweon%26aufirst%3DM.%2BH.%26aulast%3DKwon%26aufirst%3DH.%26aulast%3DHwang%26aufirst%3DJ.%2BK.%26aulast%3DMukhtar%26aufirst%3DH.%26atitle%3DInduction%2520of%2520apoptosis%2520and%2520cell%2520cycle%2520arrest%2520by%2520a%2520chalcone%2520panduratin%2520A%2520isolated%2520from%2520Kaempferia%2520pandurata%2520in%2520androgen-independent%2520human%2520prostate%2520cancer%2520cells%2520PC3%2520and%2520DU145%26jtitle%3DCarcinogenesis%26date%3D2006%26volume%3D27%26spage%3D1454%26epage%3D64%26doi%3D10.1093%2Fcarcin%2Fbgi348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Nozaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, K.-i.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kido, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kakumoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuura, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takaoka, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iinuma, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akao, Y.</span><span> </span><span class="NLM_article-title">Pauferrol A, a novel chalcone trimer with a cyclobutane ring from Caesalpinia ferrea mart exhibiting DNA topoisomerase II inhibition and apoptosis-inducing activity</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">8290</span><span class="NLM_x">–</span> <span class="NLM_lpage">8292</span><span class="refDoi"> DOI: 10.1016/j.tetlet.2007.09.130</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1016%2Fj.tetlet.2007.09.130" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2007&pages=8290-8292&author=H.+Nozakiauthor=K.-i.+Hayashiauthor=M.+Kidoauthor=K.+Kakumotoauthor=S.+Ikedaauthor=N.+Matsuuraauthor=H.+Taniauthor=D.+Takaokaauthor=M.+Iinumaauthor=Y.+Akao&title=Pauferrol+A%2C+a+novel+chalcone+trimer+with+a+cyclobutane+ring+from+Caesalpinia+ferrea+mart+exhibiting+DNA+topoisomerase+II+inhibition+and+apoptosis-inducing+activity&doi=10.1016%2Fj.tetlet.2007.09.130"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2007.09.130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2007.09.130%26sid%3Dliteratum%253Aachs%26aulast%3DNozaki%26aufirst%3DH.%26aulast%3DHayashi%26aufirst%3DK.-i.%26aulast%3DKido%26aufirst%3DM.%26aulast%3DKakumoto%26aufirst%3DK.%26aulast%3DIkeda%26aufirst%3DS.%26aulast%3DMatsuura%26aufirst%3DN.%26aulast%3DTani%26aufirst%3DH.%26aulast%3DTakaoka%26aufirst%3DD.%26aulast%3DIinuma%26aufirst%3DM.%26aulast%3DAkao%26aufirst%3DY.%26atitle%3DPauferrol%2520A%252C%2520a%2520novel%2520chalcone%2520trimer%2520with%2520a%2520cyclobutane%2520ring%2520from%2520Caesalpinia%2520ferrea%2520mart%2520exhibiting%2520DNA%2520topoisomerase%2520II%2520inhibition%2520and%2520apoptosis-inducing%2520activity%26jtitle%3DTetrahedron%2520Lett.%26date%3D2007%26volume%3D48%26spage%3D8290%26epage%3D8292%26doi%3D10.1016%2Fj.tetlet.2007.09.130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Qin, H.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shang, Z.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jantan, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, O. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hussain, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sher, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bukhari, S. N. A.</span><span> </span><span class="NLM_article-title">Molecular docking studies and biological evaluation of chalcone based pyrazolines as tyrosinase inhibitors and potential anticancer agents</span> <span class="citation_source-journal">RSC Adv.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">46330</span><span class="NLM_x">–</span> <span class="NLM_lpage">46338</span><span class="refDoi"> DOI: 10.1039/C5RA02995C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1039%2FC5RA02995C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosFKntr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=46330-46338&author=H.-L.+Qinauthor=Z.-P.+Shangauthor=I.+Jantanauthor=O.+U.+Tanauthor=M.+A.+Hussainauthor=M.+Sherauthor=S.+N.+A.+Bukhari&title=Molecular+docking+studies+and+biological+evaluation+of+chalcone+based+pyrazolines+as+tyrosinase+inhibitors+and+potential+anticancer+agents&doi=10.1039%2FC5RA02995C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular docking studies and biological evaluation of chalcone based pyrazolines as tyrosinase inhibitors and potential anticancer agents</span></div><div class="casAuthors">Qin, Hua-Li; Shang, Zhen-Peng; Jantan, Ibrahim; Tan, Oya Unsal; Hussain, Muhammad Ajaz; Sher, Muhammad; Bukhari, Syed Nasir Abbas</div><div class="citationInfo"><span class="NLM_cas:title">RSC Advances</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">57</span>),
    <span class="NLM_cas:pages">46330-46338</span>CODEN:
                <span class="NLM_cas:coden">RSCACL</span>;
        ISSN:<span class="NLM_cas:issn">2046-2069</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Studies on the discovery of tyrosinase enzyme inhibitors and exploration for better cytotoxic agents remain an important line in drug discovery and development.  A series of synthetic chalcones and pyrazoline derivs. was evaluated for their inhibitory effects on the diphenolase activity of mushroom tyrosinase.  The effects of these compds. on proliferation and microtubule assembly were also evaluated in seven different cancer cell lines.  The results revealed that some of the synthetic compds. showed significant inhibitory activity, with four compds. being more potent tyrosinase inhibitors than the ref. std. inhibitor kojic acid.  Several compds. were toxic to cancer cell lines.  Compd. 1a was found to possess the highest anticancer activity towards all cell lines with an IC50 in the range of 0.9-2.2 μM.  Seven of the compds. showed considerable tubulin polymn. activity at a concn. of 25 μM.  Mol. modeling studies of these synthetic compds. were performed to investigate their interactions with the tyrosinase enzyme.  The structure-activity relationship (SAR) study using in-silico anal. matched well with the in vitro tumor cell inhibitory activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsfm8YXQUkobVg90H21EOLACvtfcHk0ljBNNKzSVG7Eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosFKntr4%253D&md5=2498c3249d0538afed53bc0c6b79ba3d</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1039%2FC5RA02995C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5RA02995C%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DH.-L.%26aulast%3DShang%26aufirst%3DZ.-P.%26aulast%3DJantan%26aufirst%3DI.%26aulast%3DTan%26aufirst%3DO.%2BU.%26aulast%3DHussain%26aufirst%3DM.%2BA.%26aulast%3DSher%26aufirst%3DM.%26aulast%3DBukhari%26aufirst%3DS.%2BN.%2BA.%26atitle%3DMolecular%2520docking%2520studies%2520and%2520biological%2520evaluation%2520of%2520chalcone%2520based%2520pyrazolines%2520as%2520tyrosinase%2520inhibitors%2520and%2520potential%2520anticancer%2520agents%26jtitle%3DRSC%2520Adv.%26date%3D2015%26volume%3D5%26spage%3D46330%26epage%3D46338%26doi%3D10.1039%2FC5RA02995C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">de Weger, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beijnen, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schellens, J. H. M.</span><span> </span><span class="NLM_article-title">Cellular and clinical pharmacology of the taxanes docetaxel and paclitaxel – a review</span> <span class="citation_source-journal">Anti-Cancer Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">488</span><span class="NLM_x">–</span> <span class="NLM_lpage">494</span><span class="refDoi"> DOI: 10.1097/CAD.0000000000000093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1097%2FCAD.0000000000000093" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=488-494&author=V.+A.+de+Wegerauthor=J.+H.+Beijnenauthor=J.+H.+M.+Schellens&title=Cellular+and+clinical+pharmacology+of+the+taxanes+docetaxel+and+paclitaxel+%E2%80%93+a+review&doi=10.1097%2FCAD.0000000000000093"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1097%2FCAD.0000000000000093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCAD.0000000000000093%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BWeger%26aufirst%3DV.%2BA.%26aulast%3DBeijnen%26aufirst%3DJ.%2BH.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%2BM.%26atitle%3DCellular%2520and%2520clinical%2520pharmacology%2520of%2520the%2520taxanes%2520docetaxel%2520and%2520paclitaxel%2520%25E2%2580%2593%2520a%2520review%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2014%26volume%3D25%26spage%3D488%26epage%3D494%26doi%3D10.1097%2FCAD.0000000000000093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Nassar, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamel, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarimont, C.</span><span> </span><span class="NLM_article-title">Improving the decision-making process in structural modification of drug candidates: reducing toxicity</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1055</span><span class="NLM_x">–</span> <span class="NLM_lpage">64</span><span class="refDoi"> DOI: 10.1016/S1359-6446(04)03297-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1016%2FS1359-6446%2804%2903297-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=1055-64&author=A.+E.+Nassarauthor=A.+M.+Kamelauthor=C.+Clarimont&title=Improving+the+decision-making+process+in+structural+modification+of+drug+candidates%3A+reducing+toxicity&doi=10.1016%2FS1359-6446%2804%2903297-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903297-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903297-0%26sid%3Dliteratum%253Aachs%26aulast%3DNassar%26aufirst%3DA.%2BE.%26aulast%3DKamel%26aufirst%3DA.%2BM.%26aulast%3DClarimont%26aufirst%3DC.%26atitle%3DImproving%2520the%2520decision-making%2520process%2520in%2520structural%2520modification%2520of%2520drug%2520candidates%253A%2520reducing%2520toxicity%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26spage%3D1055%26epage%3D64%26doi%3D10.1016%2FS1359-6446%2804%2903297-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Bukhari, S. N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lauro, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jantan, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bifulco, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amjad, M. W.</span><span> </span><span class="NLM_article-title">Pharmacological evaluation and docking studies of α,β-unsaturated carbonyl based synthetic compounds as inhibitors of secretory phospholipase A2, cyclooxygenases, lipoxygenase and proinflammatory cytokines</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">4151</span><span class="NLM_x">–</span> <span class="NLM_lpage">4161</span><span class="refDoi"> DOI: 10.1016/j.bmc.2014.05.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1016%2Fj.bmc.2014.05.052" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=4151-4161&author=S.+N.+A.+Bukhariauthor=G.+Lauroauthor=I.+Jantanauthor=G.+Bifulcoauthor=M.+W.+Amjad&title=Pharmacological+evaluation+and+docking+studies+of+%CE%B1%2C%CE%B2-unsaturated+carbonyl+based+synthetic+compounds+as+inhibitors+of+secretory+phospholipase+A2%2C+cyclooxygenases%2C+lipoxygenase+and+proinflammatory+cytokines&doi=10.1016%2Fj.bmc.2014.05.052"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.05.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.05.052%26sid%3Dliteratum%253Aachs%26aulast%3DBukhari%26aufirst%3DS.%2BN.%2BA.%26aulast%3DLauro%26aufirst%3DG.%26aulast%3DJantan%26aufirst%3DI.%26aulast%3DBifulco%26aufirst%3DG.%26aulast%3DAmjad%26aufirst%3DM.%2BW.%26atitle%3DPharmacological%2520evaluation%2520and%2520docking%2520studies%2520of%2520%25CE%25B1%252C%25CE%25B2-unsaturated%2520carbonyl%2520based%2520synthetic%2520compounds%2520as%2520inhibitors%2520of%2520secretory%2520phospholipase%2520A2%252C%2520cyclooxygenases%252C%2520lipoxygenase%2520and%2520proinflammatory%2520cytokines%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D4151%26epage%3D4161%26doi%3D10.1016%2Fj.bmc.2014.05.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Leese, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jourdan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dohle, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimberley, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrandis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potter, B. V. L</span><span> </span><span class="NLM_article-title">Steroidomimetic Tetrahydroisoquinolines for the Design of New Microtubule Disruptors</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">5</span><span class="NLM_x">–</span> <span class="NLM_lpage">9</span><span class="refDoi"> DOI: 10.1021/ml200232c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200232c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=5-9&author=M.+P.+Leeseauthor=F.+Jourdanauthor=W.+Dohleauthor=M.+R.+Kimberleyauthor=M.+P.+Thomasauthor=R.+Baiauthor=E.+Hamelauthor=E.+Ferrandisauthor=B.+V.+L+Potter&title=Steroidomimetic+Tetrahydroisoquinolines+for+the+Design+of+New+Microtubule+Disruptors&doi=10.1021%2Fml200232c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fml200232c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200232c%26sid%3Dliteratum%253Aachs%26aulast%3DLeese%26aufirst%3DM.%2BP.%26aulast%3DJourdan%26aufirst%3DF.%26aulast%3DDohle%26aufirst%3DW.%26aulast%3DKimberley%26aufirst%3DM.%2BR.%26aulast%3DThomas%26aufirst%3DM.%2BP.%26aulast%3DBai%26aufirst%3DR.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DFerrandis%26aufirst%3DE.%26aulast%3DPotter%26aufirst%3DB.%2BV.%2BL%26atitle%3DSteroidomimetic%2520Tetrahydroisoquinolines%2520for%2520the%2520Design%2520of%2520New%2520Microtubule%2520Disruptors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D5%26epage%3D9%26doi%3D10.1021%2Fml200232c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Fawzy, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youssef, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ismail, N. S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gullbo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abouzid, K. A. M.</span><span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of Novel Curcumin Analogs with anticipated anticancer activity</span> <span class="citation_source-journal">Future Journal of Pharmaceutical Sciences</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">22</span><span class="NLM_x">–</span> <span class="NLM_lpage">31</span><span class="refDoi"> DOI: 10.1016/j.fjps.2015.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1016%2Fj.fjps.2015.06.001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2015&pages=22-31&author=I.+M.+Fawzyauthor=K.+M.+Youssefauthor=N.+S.+M.+Ismailauthor=J.+Gullboauthor=K.+A.+M.+Abouzid&title=Design%2C+synthesis+and+biological+evaluation+of+Novel+Curcumin+Analogs+with+anticipated+anticancer+activity&doi=10.1016%2Fj.fjps.2015.06.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.fjps.2015.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.fjps.2015.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DFawzy%26aufirst%3DI.%2BM.%26aulast%3DYoussef%26aufirst%3DK.%2BM.%26aulast%3DIsmail%26aufirst%3DN.%2BS.%2BM.%26aulast%3DGullbo%26aufirst%3DJ.%26aulast%3DAbouzid%26aufirst%3DK.%2BA.%2BM.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520Novel%2520Curcumin%2520Analogs%2520with%2520anticipated%2520anticancer%2520activity%26jtitle%3DFuture%2520Journal%2520of%2520Pharmaceutical%2520Sciences%26date%3D2015%26volume%3D1%26spage%3D22%26epage%3D31%26doi%3D10.1016%2Fj.fjps.2015.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Villanueva, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vultur, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somasundaram, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukunaga-Kalabis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cipolla, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wubbenhorst, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gimotty, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kee, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santiago-Walker, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letrero, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pushparajan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayden, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laquerre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathanson, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herlyn, M.</span><span> </span><span class="NLM_article-title">Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">683</span><span class="NLM_x">–</span> <span class="NLM_lpage">95</span><span class="refDoi"> DOI: 10.1016/j.ccr.2010.11.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1016%2Fj.ccr.2010.11.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=21156289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFGhsbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=683-95&author=J.+Villanuevaauthor=A.+Vulturauthor=J.+T.+Leeauthor=R.+Somasundaramauthor=M.+Fukunaga-Kalabisauthor=A.+K.+Cipollaauthor=B.+Wubbenhorstauthor=X.+Xuauthor=P.+A.+Gimottyauthor=D.+Keeauthor=A.+E.+Santiago-Walkerauthor=R.+Letreroauthor=K.+D%E2%80%99Andreaauthor=A.+Pushparajanauthor=J.+E.+Haydenauthor=K.+D.+Brownauthor=S.+Laquerreauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=K.+L.+Nathansonauthor=M.+Herlyn&title=Acquired+resistance+to+BRAF+inhibitors+mediated+by+a+RAF+kinase+switch+in+melanoma+can+be+overcome+by+cotargeting+MEK+and+IGF-1R%2FPI3K&doi=10.1016%2Fj.ccr.2010.11.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K</span></div><div class="casAuthors">Villanueva, Jessie; Vultur, Adina; Lee, John T.; Somasundaram, Rajasekharan; Fukunaga-Kalabis, Mizuho; Cipolla, Angela K.; Wubbenhorst, Bradley; Xu, Xiaowei; Gimotty, Phyllis A.; Kee, Damien; Santiago-Walker, Ademi E.; Letrero, Richard; D'Andrea, Kurt; Pushparajan, Anitha; Hayden, James E.; Brown, Kimberly Dahlman; Laquerre, Sylvie; McArthur, Grant A.; Sosman, Jeffrey A.; Nathanson, Katherine L.; Herlyn, Meenhard</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">683-695</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">BRAF is an attractive target for melanoma drug development.  However, resistance to BRAF inhibitors is a significant clin. challenge.  We describe a model of resistance to BRAF inhibitors developed by chronic treatment of BRAFV600E melanoma cells with the BRAF inhibitor SB-590885; these cells are cross-resistant to other BRAF-selective inhibitors.  Resistance involves flexible switching among the three RAF isoforms, underscoring the ability of melanoma cells to adapt to pharmacol. challenges.  IGF-1R/PI3K signaling was enhanced in resistant melanomas, and combined treatment with IGF-1R/PI3K and MEK inhibitors induced death of BRAF inhibitor-resistant cells.  Increased IGF-1R and pAKT levels in a post-relapse human tumor sample are consistent with a role for IGF-1R/PI3K-dependent survival in the development of resistance to BRAF inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgKfw2MUtmLLVg90H21EOLACvtfcHk0lj2mpMwU5z9uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFGhsbjJ&md5=c535681201c592cd8941b68e8a936d0e</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2010.11.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2010.11.023%26sid%3Dliteratum%253Aachs%26aulast%3DVillanueva%26aufirst%3DJ.%26aulast%3DVultur%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DJ.%2BT.%26aulast%3DSomasundaram%26aufirst%3DR.%26aulast%3DFukunaga-Kalabis%26aufirst%3DM.%26aulast%3DCipolla%26aufirst%3DA.%2BK.%26aulast%3DWubbenhorst%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DGimotty%26aufirst%3DP.%2BA.%26aulast%3DKee%26aufirst%3DD.%26aulast%3DSantiago-Walker%26aufirst%3DA.%2BE.%26aulast%3DLetrero%26aufirst%3DR.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DK.%26aulast%3DPushparajan%26aufirst%3DA.%26aulast%3DHayden%26aufirst%3DJ.%2BE.%26aulast%3DBrown%26aufirst%3DK.%2BD.%26aulast%3DLaquerre%26aufirst%3DS.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DNathanson%26aufirst%3DK.%2BL.%26aulast%3DHerlyn%26aufirst%3DM.%26atitle%3DAcquired%2520resistance%2520to%2520BRAF%2520inhibitors%2520mediated%2520by%2520a%2520RAF%2520kinase%2520switch%2520in%2520melanoma%2520can%2520be%2520overcome%2520by%2520cotargeting%2520MEK%2520and%2520IGF-1R%252FPI3K%26jtitle%3DCancer%2520Cell%26date%3D2010%26volume%3D18%26spage%3D683%26epage%3D95%26doi%3D10.1016%2Fj.ccr.2010.11.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Li, Q.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H.-L.</span><span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of novel (E)-α-benzylsulfonyl chalcone derivatives as potential BRAF inhibitors</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">288</span><span class="NLM_x">–</span> <span class="NLM_lpage">295</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2012.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1016%2Fj.ejmech.2012.02.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2012&pages=288-295&author=Q.-S.+Liauthor=C.-Y.+Liauthor=X.+Luauthor=H.+Zhangauthor=H.-L.+Zhu&title=Design%2C+synthesis+and+biological+evaluation+of+novel+%28E%29-%CE%B1-benzylsulfonyl+chalcone+derivatives+as+potential+BRAF+inhibitors&doi=10.1016%2Fj.ejmech.2012.02.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2012.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2012.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DQ.-S.%26aulast%3DLi%26aufirst%3DC.-Y.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DH.-L.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520novel%2520%2528E%2529-%25CE%25B1-benzylsulfonyl%2520chalcone%2520derivatives%2520as%2520potential%2520BRAF%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2012%26volume%3D50%26spage%3D288%26epage%3D295%26doi%3D10.1016%2Fj.ejmech.2012.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Molnar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gyemant, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hohmann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergmann-Leitner, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molnar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deli, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Didiziapetris, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferreira, M. J.</span><span> </span><span class="NLM_article-title">Inhibition of multidrug resistance of cancer cells by natural diterpenes, triterpenes and carotenoids</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">287</span><span class="NLM_x">–</span> <span class="NLM_lpage">311</span><span class="refDoi"> DOI: 10.2174/138161206775201893</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.2174%2F138161206775201893" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=16454745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=1%3ACAS%3A528%3ADC%252BD28XitlCruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=287-311&author=J.+Molnarauthor=N.+Gyemantauthor=M.+Tanakaauthor=J.+Hohmannauthor=E.+Bergmann-Leitnerauthor=P.+Molnarauthor=J.+Deliauthor=R.+Didiziapetrisauthor=M.+J.+Ferreira&title=Inhibition+of+multidrug+resistance+of+cancer+cells+by+natural+diterpenes%2C+triterpenes+and+carotenoids&doi=10.2174%2F138161206775201893"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of multidrug resistance of cancer cells by natural diterpenes, triterpenes and carotenoids</span></div><div class="casAuthors">Molnar, Joseph; Gyemant, Nora; Tanaka, Masaru; Hohmann, Judith; Bergmann-Leitner, Elke; Molnar, Peter; Deli, Joseph; Didiziapetris, Remigijus; Ferreira, Maria Jose Umbelino</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">287-311</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The multidrug resistance (MDR) proteins are member of the ATP-binding cassette superfamily and are present in a majority of human tumors.  Their activity is a crucial factor leading to therapeutic failure.  It is likely that compds. which inhibit the function of the MDR-efflux proteins such as MDR1 will improve the cytotoxic action of anticancer chemotherapy.  Therefore, a search for MDR reversing compds. was conducted among three classes of plant derived compds. such as diterpenes, triterpenes and carotenoids in a hope to find inhibitors without adverse effects in these natural compds.  The inhibition of efflux activity was detd. by measuring the accumulation of substrate analogs such as rhodamine in tumor cells in the presence of potential inhibitors.  Thus we detd. the effect of structurally unrelated diterpenes, triterpenes and carotenoids on reversal of multidrug resistance in MDR-1 gene-transfected L1210 mouse lymphoma cells and MDR mediated multidrug resistance of human breast cancer cells MDA-MB-231 (HTB-26) and MCF-7.  The majority of diterpenes, cycloartane triterpenes and carotenoids isolated from vegetables and medicinal plants were able to enhance rhodamine 123 accumulations of MDR-cells.  Synergistic interaction was found between epirubicin and resistance modifier terpenoids in vitro.  It is supposed that these MDR modulators bind into transmembrane domains and the action of ABC transporters is inhibited by induced conformational changes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonG2svSfe1B7Vg90H21EOLACvtfcHk0ljuF3A6JfAweQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XitlCruw%253D%253D&md5=af0d0aeb6e918a841eca49ad4163c830</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.2174%2F138161206775201893&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161206775201893%26sid%3Dliteratum%253Aachs%26aulast%3DMolnar%26aufirst%3DJ.%26aulast%3DGyemant%26aufirst%3DN.%26aulast%3DTanaka%26aufirst%3DM.%26aulast%3DHohmann%26aufirst%3DJ.%26aulast%3DBergmann-Leitner%26aufirst%3DE.%26aulast%3DMolnar%26aufirst%3DP.%26aulast%3DDeli%26aufirst%3DJ.%26aulast%3DDidiziapetris%26aufirst%3DR.%26aulast%3DFerreira%26aufirst%3DM.%2BJ.%26atitle%3DInhibition%2520of%2520multidrug%2520resistance%2520of%2520cancer%2520cells%2520by%2520natural%2520diterpenes%252C%2520triterpenes%2520and%2520carotenoids%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2006%26volume%3D12%26spage%3D287%26epage%3D311%26doi%3D10.2174%2F138161206775201893" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Bukhari, S. N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jantan, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masand, V. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahajan, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sher, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naeem-ul-Hassan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amjad, M. W.</span><span> </span><span class="NLM_article-title">Synthesis of α,β-unsaturated carbonyl based compounds as acetylcholinesterase and butyrylcholinesterase inhibitors: Characterization, molecular modeling, QSAR studies and effect against amyloid β-induced cytotoxicity</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">355</span><span class="NLM_x">–</span> <span class="NLM_lpage">365</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2014.06.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;key=10.1016%2Fj.ejmech.2014.06.034" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2014&pages=355-365&author=S.+N.+A.+Bukhariauthor=I.+Jantanauthor=V.+H.+Masandauthor=D.+T.+Mahajanauthor=M.+Sherauthor=M.+Naeem-ul-Hassanauthor=M.+W.+Amjad&title=Synthesis+of+%CE%B1%2C%CE%B2-unsaturated+carbonyl+based+compounds+as+acetylcholinesterase+and+butyrylcholinesterase+inhibitors%3A+Characterization%2C+molecular+modeling%2C+QSAR+studies+and+effect+against+amyloid+%CE%B2-induced+cytotoxicity&doi=10.1016%2Fj.ejmech.2014.06.034"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.06.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.06.034%26sid%3Dliteratum%253Aachs%26aulast%3DBukhari%26aufirst%3DS.%2BN.%2BA.%26aulast%3DJantan%26aufirst%3DI.%26aulast%3DMasand%26aufirst%3DV.%2BH.%26aulast%3DMahajan%26aufirst%3DD.%2BT.%26aulast%3DSher%26aufirst%3DM.%26aulast%3DNaeem-ul-Hassan%26aufirst%3DM.%26aulast%3DAmjad%26aufirst%3DM.%2BW.%26atitle%3DSynthesis%2520of%2520%25CE%25B1%252C%25CE%25B2-unsaturated%2520carbonyl%2520based%2520compounds%2520as%2520acetylcholinesterase%2520and%2520butyrylcholinesterase%2520inhibitors%253A%2520Characterization%252C%2520molecular%2520modeling%252C%2520QSAR%2520studies%2520and%2520effect%2520against%2520amyloid%2520%25CE%25B2-induced%2520cytotoxicity%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D83%26spage%3D355%26epage%3D365%26doi%3D10.1016%2Fj.ejmech.2014.06.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Bonne, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heuséle, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pantaloni, D.</span><span> </span><span class="NLM_article-title">4′,6-Diamidino-2-phenylindole, a fluorescent probe for tubulin and microtubules</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">260</span><span class="NLM_x">, </span> <span class="NLM_fpage">2819</span><span class="NLM_x">–</span> <span class="NLM_lpage">2825</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=260&publication_year=1985&pages=2819-2825&author=D.+Bonneauthor=C.+Heus%C3%A9leauthor=C.+Simonauthor=D.+Pantaloni&title=4%E2%80%B2%2C6-Diamidino-2-phenylindole%2C+a+fluorescent+probe+for+tubulin+and+microtubules"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBonne%26aufirst%3DD.%26aulast%3DHeus%25C3%25A9le%26aufirst%3DC.%26aulast%3DSimon%26aufirst%3DC.%26aulast%3DPantaloni%26aufirst%3DD.%26atitle%3D4%25E2%2580%25B2%252C6-Diamidino-2-phenylindole%252C%2520a%2520fluorescent%2520probe%2520for%2520tubulin%2520and%2520microtubules%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1985%26volume%3D260%26spage%3D2819%26epage%3D2825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i56"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00276">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_25442"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b00276">10.1021/acs.jmedchem.6b00276</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">HPLC analytical chromatograms of respective most active purified compounds (<b>7f</b>, <b>7o</b>, <b>8af</b>, and <b>8ag</b>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00276/suppl_file/jm6b00276_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00276/suppl_file/jm6b00276_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00276/suppl_file/jm6b00276_si_001.pdf">jm6b00276_si_001.pdf (491.04 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00276/suppl_file/jm6b00276_si_002.csv">jm6b00276_si_002.csv (1.76 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b00276&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-7%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b00276%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b00276" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                1MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a6d99887aa2c4","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
